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Neisseria meningitidis is a Gram negative bacterium that commonly colonizes the
nasopharyngeal mucosa of 10% of the population at any given time. Infrequently it
invades to cause life threatening septicaemia and/or meningitis. I have used microar-
ray technology to study the repertoire of meningococcal gene expression in the course
of prolonged incubation in human plasma and blood, with the aim of identifying genes
that are progressively up-regulated during sepsis, especially those encoding surface
antigens. I hypothesize that any surface exposed gene products that are expressed at
a higher level in the bloodstream than on the mucosal surface, where immune selec-
tion pressure drives antigenic diversity, should be less variable, and so, attractive as
cross-protective vaccine candidates.
In my thesis research I explored experimental methods for modelling meningococ-
cal bacteraemia ex vivo. I characterised the transcriptional response of a serogroup B
strain of N. meningitidis during prolonged incubation (up to 4 hours) in fresh frozen
non-bactericidal plasma from two individuals. Subsequently the meningococcal tran-
scriptome was examined during incubation in fresh, anticoagulated non-bactericidal
whole human blood for different periods up to 4 hours, using microarrays and real-
time PCR technology.
The cellular localisation of proteins encoded by genes confirmed to be significantly
differentially expressed in plasma and/or blood, both by microarray technology and
by real-time PCR, was explored using bioinformatic resources, and those predicted
(or established) to be surface-exposed were brought forward for further evaluation.
Amongst these, I selected genes up-regulated in bacteria incubated in plasma and/or
5
blood, but down-regulated (according to data previously obtained) for organisms
isolated from an experimental system modelling the nasopharyngeal carriage state,
for examination of sequence diversity. Using serogroup B meningococcal strains of
established (multi locus sequence type) diversity; I have used direct sequencing to
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1.1 The genus Neisseria
The genus Neisseria consists of Gram-negative proteobacteria that all colonise mu-
cosa. Hosts range from humans (ten species including the only pathogenic species
Neisseria meningitidis and Neisseria gonorrhoeae and the commensal Neisseria lac-
tamica) to animals (five species) (Dent, 1982; Barrett & Sneath, 1994). All human
Neisserial species colonise the nasopharynx except N. gonorrhoeae, which resides in
the urogenital tract. Disease caused by meningococci or gonococci results in very
different symptoms, even though the two species are closely related. Infection by
N. gonorrhoeae leads to local inflammation of the urogenital tract (gonorrhoea), but
rarely leads to systematic spread (disseminated disease). In contrast N. meningi-
tidis, usually an asymptomatic coloniser of the nasopharyngeal mucosa, occasionally
causes invasive disease, which although infrequent, may result in fatal septicaemia or
meningitis, or both.
1.2 N. meningitidis
N. meningitidis is an aerobic Gram-negative diplococcus. The vast majority of strains
isolated from cases of invasive disease are encapsulated, whereas strains isolated from
asymptomatic carriers are commonly unencapsulated (Claus et al., 2002; Caugant
et al., 2007). Humans are the only natural host for meningococci. The host-specificity
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is linked to meningococcal surface structures, such as pili, which interact exclusively
with human surface receptors for binding and invasion (Rudel et al., 1995; Ka¨llstro¨m
et al., 1997). In addition, meningococcal iron-uptake systems are mainly able to
scavenge iron from human iron transport proteins (Schryvers & Gonzalez, 1989).
1.2.1 Classification
Traditionally N. meningitidis strains have been classified according to antigenic dif-
ferences in their surface structures. Serological tests divide strains into serogroups
(polysaccharide capsule), serotypes (PorB, class 2 or 3 outer membrane proteins
(OMPs)), serosubtypes (PorA, class 1 OMPs) and immunotypes (lipo-oligosaccharide
(LOS)) (Frasch et al., 1985). Thirteen serogroups are recognised (A, B, C, D, 29E,
H, I, K, L, W135, X, Y and Z) based on the chemical composition of the polysac-
charide capsule. The majority of cases of invasive disease are associated with the five
serogroups A, B, C, W135 and Y. There are 21 serotypes characterised by variants
in surface epitopes in class 2 or 3 (PorB) OMPs, of which two (2 and 15) have been
particularly associated with invasive disease (Tzeng & Stephens, 2000). Strains can
be further divided into serosubtypes based on antigenic variation in PorA. However,
this protein is not expressed in all strains (Newcombe et al., 1998). Meningococci can
be classified into thirteen immunotypes (L1–L13) defined by heterogeneity in LOS
structures. Three of these (L3, 7, 9) are particularly associated with invasive disease
(Achtman et al., 1992; Scholten et al., 1994; Tzeng & Stephens, 2000). While sero-
logical methods based on surface structures have proved valuable in, for example, the
delineation of outbreaks, they have some disadvantages. Recognition is limited to
serological variants included in the panel of monoclonal antibodies used, and between
20 and 60% of serogroup B and C strains are non-typeable for PorB (Sacchi et al.,
1998). Both the serotype and serosubtype can be more reliably deduced from the
nucleotide sequence of the genes. Of more fundamental importance, meningococcal
outer membrane structures are under immune selection by the host, and subject to
high frequency phase and antigenic variation. They are therefore of limited use for
studies of the evolution of the meningococcal population.
Chapter 1: General introduction 25
For studies of meningococcal population structure and epidemiology, molecular
typing methods such as Multi Locus Enzyme Electrophoresis (MLEE) and Multi
Locus Sequence Typing (MLST) are more suitable. MLEE is based on the elec-
trophoretic mobility of metabolic enzymes on a starch gel (Selander et al., 1986).
Each strain is assigned an electrophoretic subtypes (ET) profile. The method has
successfully been employed to identify meningococcal hyperinvasive lineages (Kertesz
et al., 1998). However, MLEE gives only an indirect measure of the genotype and
differences in sequence that do not give rise to structural changes will not be de-
tected. Additionally, the technique is highly labour intensive and standardisation be-
tween laboratories is difficult. Fortunately, MLST overcomes the problems associated
with MLEE. MLST is based on the sequencing of internal fragments of seven house-
keeping genes, followed by assignment of each sequence to a specific allele (Maiden
et al., 1998). MLST has enough resolution and discrimination to be used in epidemi-
ological surveillance. A large collection of N. meningitidis MLST data is stored in a
public database that can be assessed and interrogated through a webpage interface
(http://pubmlst.org/neisseria) (Jolley et al., 2004).
1.2.2 Genomics
The full sequencing of several Neisserial genomes has opened up the possibility of per-
forming comparative genomics. To date, the genome sequences of seven N. meningi-
tidis strains have been published; Z2491 (serogroup A), MC58 (serogroup B), FAM18
(serogroup C) and 053442 (serogroup C), and three carriage strains (serogroup W135,
29E and non-typeable) (Tettelin et al., 2000; Parkhill et al., 2000; Bentley et al., 2007;
Peng et al., 2008; Schoen et al., 2008). The genomes of strains MC58, FAM18 and
Z2491 differ by approximately 10%, with the major structural differences found in
so-called islands of horizontally transferred (IHT) DNA. The genome sequences of
the commensal N. lactamica strain ST-640 (http://www.sanger.ac.uk/Projects/
N_lactamica/), as well as the pathogenic N. gonorroheae strain FA1090 are also avail-
able for comparison (Lewis et al., 2003). Sequencing of additional Neisserial strains
continually adds additional genes to the Neisserial gene bank, indicative of an open
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pan-genome, a common characteristic of organisms that readily take up foreign DNA
(Medini et al., 2005). Genome comparisons of N. meningitidis isolates have shown
that genes encoding meningococcal virulence factors can be found both in disease
and carriage associated isolates (Schoen et al., 2008). Genomotyping methods, based
on hybridisation to microarrays, have been used to compare the genetic material of
non-sequenced Neisserial strains to any of the sequence strains (Stabler et al., 2005;
Hotopp et al., 2006; Snyder & Saunders, 2006; Schoen et al., 2008).
1.2.3 Epidemiology
1.2.3.1 Invasive disease
The annual incidence of meningococcal disease in non-epidemic settings is between 0.5
and 10 per 100,000 persons, but can under epidemics in the so called “meningitis belt”
in sub-Saharan Africa reach incidences of 1,000 per 100,000. World-wide, serogroups
A, B and C have been responsible for 90% of cases of meningococcal disease, with
serogroup A causing the most cases in Africa.
Pandemics, until now mainly caused by N. meningitidis serogroup A, occur in
irregular cycles every 5–12 years in the sub-Saharan area from Senegal to Ethiopia.
The epidemics usually last for 2–3 years, with 75% of disease affecting those under
the age of 15. The case rate peaks at the end of the dry season and wanes during
the rainy season (Greenwood et al., 1984). Between 1998 and 2003 most serogroup A
disease in Africa was caused by sequence types ST-5 and ST-7 (Nicolas et al., 2005).
Meningococcal disease caused by serogroup W135 has been relatively uncommon,
but major outbreaks of serogroup W135 meningococcal disease have occurred, for
example among Hajj pilgrims in 2000 (Taha et al., 2000) and in Burkina Faso in
2002 (Teyssou & Rouzic, 2007). Other serogroups have the potential to emerge as
significant problems; for example serogroup X in Niger (Djibo et al., 2003) and Ghana
(Gagneux et al., 2002).
In the developed world serogroups B and C are responsible for most disease. In
Europe, serogroups B and C are responsible for 90% of cases, while in the United
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States they account for around 70% of disease, with N. meningitidis serogroup Y
accounting for a large proportion of the remaining cases (Rosenstein et al., 1999).
A relatively small number of sequence types are associated with serogroup B and C
invasive disease, so called hyperinvasive lineages. A large European survey conducted
between 2000–2002 identified around 1,000 discrete STs among disease isolates, but
only ten STs were predominant and accounted for half of the cases. The five most
common clonal complexes were ST-8, ST-11, ST-32, ST-41/44 and ST-269 (Brehony
et al., 2007). In Europe, the clonal complexes ST-32, ST-41/44 and ST-269 are
generally associated with serogroup B, whereas ST-11 and ST-8 are largely associated
with serogroup C. During the same period ST-11, ST-41/44 and ST-269 were the most
common clonal complexes in the UK, but the proportion of ST-11 strains has since
decreased following the introduction of a national vaccination programme against
serogroup C disease (in 1999) (Gray et al., 2006; Brehony et al., 2007). Today, most
of the meningococcal disease in the UK is caused by serogroup B (87% in 2003/2004),
although the total number of cases has decreased since the late 1990s. The most
common serogroup B strain, B:4:P1.4 phenotype, was responsible for 17% of the
disease in 2003/2004 (Gray et al., 2006).
Serogroup B and C meningococci are less frequently associated with epidemics than
serogroup A. Epidemics (otherwise termed hyperendemics) due to N. meningitidis
serogroup B (MenB) have occurred in, for example Brazil (Costa et al., 1991; Sacchi
et al., 1992), Cuba (Sierra et al., 1991) and Norway (Bøvre et al., 1977; Bøvre &
Gedde-Dahl, 1980) and recently in New Zealand (Wilson et al., 1995). Epidemics
with serogroup B have been long-lived, persisting for 5 to 10 years or longer. In the
New Zealand epidemic, starting in 1991, the incidence peaked in 1997 at 16.9 per
100,000 and stayed high with an average of 14 per 100,000 (Baker et al., 2001) until
the nation-wide introduction of a tailor-made vaccine in 2004 that reduced disease to
previous endemic levels (Oster et al., 2005). An increase in serogroup C meningococcal
disease in the United Kingdom during the 1990s prompted the introduction of a
new vaccine. The increase in disease was due to a strain of the C:2a phenotype
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belonging to the hypervirulent lineage ST-11 clonal complex associated with invasive
disease and rarely recovered from asymptomatic carriers. Strains belonging to this
hyperinvasive lineage have been involved in several outbreaks and are associated with
increased mortality (Swartley et al., 1997; Kertesz et al., 1998; Kriz et al., 1999; Pe´rez-
Trallero et al., 2002). Introduction of routine vaccination with glycoconjugate vaccines
raised concerns about a possible increase in disease caused by other serogroups not
covered by vaccine, such as serogroup B strains. Capsular switching, as the result of
replacement of the siaD gene through transformation and recombination, is known
to occur in N. meningitidis, and this would be a mechanism for the bacteria to
escape the host’s immune response (Swartley et al., 1997). In epidemiological data
of meningococcal disease (until season 2003/2004), no evidence has been seen for
an increase of serogroup B cases caused by B:2a in the UK, or indeed by any other
serogroup B strains (Trotter et al., 2006b). However, in the winter of 2008/2009 an
increase in the number of cases of invasive MenB disease has been observed in the
UK (Health protection agency, 2009).
1.2.3.2 Asymptomatic carriage
The carriage rate of N. meningitidis in the population is around 10% at any given
time, although rates exceeding 40% have been recorded in, for example, military
recruits in high-density living (Andersen et al., 1998). The meningococcal carriage
rate increases through childhood and peaks in adolescence. In young children below
the age of five, colonisation of nasopharyngeal mucosa by commensal Neisseria species,
such as N. lactamica, is six times more common than carriage by N. meningitidis
(Gold et al., 1978; Cartwright et al., 1987; Bennett et al., 2005). Colonisation with
N. lactamica is thought to offer cross-protective immunity to N. meningitidis (Oliver
et al., 2002; Bennett et al., 2005). Introduction of vaccines aimed at prevention
of invasive disease can also affect carriage. After the introduction of the conjugate
polysaccharide C vaccine in the UK, there was a marked decrease in carriage of N.
meningitidis serogroup C strains expressing high levels of capsule, particularly strains
of the hyperinvasive ST-11 type, both in vaccinated and unvaccinated individuals.
Chapter 1: General introduction 29
No significant decrease was detected in carriage of serogroup C strains expressing low
levels of the polysaccharide capsule (Maiden et al., 2008).
1.2.4 Meningococcal disease
The annual global burden of meningococcal disease in non-epidemic settings is ap-
proximately 500,000 cases with overall mortality of about 10%. The highest incidence
of invasive disease is in children of less than four years, with a second peak in ado-
lescents (Stephens et al., 2007). In Europe and the USA, the highest incidence is in
infants below one year of age, and the case fatality is also higher in this age group.
Meningococcal disease incidence follows a seasonal pattern, with the highest numbers
of cases recorded during late winter. Higher incidence of disease is also correlated
with low humidity, poor living conditions, smoking, viral infections and close contact
with infected individuals, such as family members. Invasive disease with N. menin-
gitidis is most commonly manifested as septicaemia and/or meningitis (Brandtzaeg
& van Deuren, 2002). In its mildest form, almost certainly underdiagnosed, disease
is characterised by a transient bacteremic illness that resolves spontaneously in 1
to 2 days. In its most serious form there is fulminant septicaemia associated with
multisystem involvement (affecting 5–15% of patients) and a high mortality. The
case fatality of meningococcal disease in industrialised countries is 5–15% (up to 40%
for septicaemia), but higher in developing countries with less advanced healthcare
(Goldacre et al., 2003). Of the survivors, between 10–20% are left with permanent
disability, such as loss of limbs, deafness or mental retardation (Danzig, 2004). Clin-
ical signs of meningococcal disease include fever and altered mental status. Patients
often complain of severe headache, limb pain, nausea, vomiting and photophobia. A
characteristic of fulminant meningococcal sepsis, in cases with or without meningitis,
is the development of skin haemorrhages (petechiae, purpura) (van Deuren et al.,
2000). Where bacteria invade the cerebrospinal fluid (CSF) from the bloodstream by
traversing the blood brain barrier (BBB), the result is meningitis.
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1.2.5 Meningococcal pathogenesis
In most individuals in whom the respiratory tract epithelium (nasopharyngeal and
tonsillar mucosa) is colonised with N. meningitidis, the condition is entirely asymp-
tomatic. However, for reasons poorly understood N. meningitidis occasionally invades
the mucosa and enters the bloodstream to cause life threatening septicaemia and/or
meningitis. This process consists of multiple stages. First the host must be exposed
to the meningococcus. This is then followed by invasion of the nasopharyngeal epithe-
lium, survival and proliferation in the bloodstream to cause bacteraemia and finally
the crossing of the BBB (from the blood stream or directly from the nasopharynx)
to the CSF by some bacteria, resulting in meningitis. Important meningococcal vir-
ulence factors at different stages of disease include the polysaccharide capsule, LOS
and pili.
Meningococci are spread between humans in aerosol droplets or by direct contact
with respiratory secretions from asymptomatic carriers. The polysaccharide capsule is
thought to offer protection to N. meningitidis during transmission (Berger & Do¨ring,
1969). Colonisation of the nasopharyngeal mucosa by N. meningitidis is generally a
transient event, but can in some individuals result in systemic meningococcal disease.
Bacteria initially attach to form micro-colonies on the mucosal surface, interacting
exclusively with non-ciliated cells (Stephens et al., 1983; Merz & So, 2000). Stud-
ies using cultured epithelial cells or nasopharyngeal explants suggest that the ini-
tial adhesion of meningococci to host cells is mediated through interactions between
meningococcal type IV pili (Tfp) and the host receptor CD46 (Ka¨llstro¨m et al., 1997;
Nassif et al., 1997; Merz & So, 2000). However, piliated meningococci can interact
with erythrocytes, lacking detectable CD46, suggesting involvement of additional host
cell receptors. Pilin can be modified by O-glycosylation mediated by proteins PglA–
D (Power et al., 2000), but it is unclear if glycosylation is important for host cell
binding or other virulent properties (Virji et al., 1993b; Marceau et al., 1998). Pilin
mediated binding of the meningococcus to CD46 has been shown to induce intracel-
lular signalling in the host cell, triggering an increase in free calcium in the cytosol
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that regulates cellular processes (Ka¨llstro¨m et al., 1998). After initial adherence, the
meningococcus down-regulates pilus and the polysaccharide capsule and this is fol-
lowed by closer adherence to the host cells (Pujol et al., 1997). Down-regulation of
the capsule is thought to make the meningococcus more adherent (Stephens et al.,
1993), and this is supported by the observation that the capsule is generally found to
be expressed at lower levels or to be completely absent in colonising strains (Caugant
et al., 2007). Absence of the polysaccharide capsule may either be due to phase-
variation of key genes, or to the presence of a capsule null locus (cnl). Retraction
of pilus is also essential for intimate adhesion to host cells. pilT mutants, unable to
retract pilus, are incapable of intimate adherence to host cells (Pujol et al., 1999).
Down-regulation of pili and capsule facilitates the interaction between meningococcal
OMPs and host cells. Sialylated LOS has also been shown to inhibit meningococcal
binding through OMPs such as opacity proteins (de Vries et al., 1996). The phase
variable opacity proteins (Opa and Opc) contribute to both the adhesion and inva-
sion of host cells (Virji et al., 1993a). Receptors for opacity proteins on the host
cells, facilitating adhesion and invasion, are thought to be CD66 family receptors and
heparan sulphate proteoglycans (Virji et al., 1996; de Vries et al., 1998). However, it
is worth noting that the attachment through opacity proteins may not be essential.
Pujol et al. (1997) presented some evidence for this by showing that a ∆opa/∆opc
strain could adhere and form intimate adhesion to a polarized monolayer, in vitro,
suggesting that the attachment may be mediated through some other surface protein.
Some evidence also suggests a role for LOS in adhesion to host cells (Porat et al.,
1995; Song et al., 2000).
Only a small proportion of individuals infected with N. meningitidis go on to de-
velop invasive disease. Initial invasion is thought to occur by invasion of host cells by
meningococci on the mucosal surface through endocytosis and crossing the epithelium
to the blood stream (Merz & So, 2000). Specific risk factors for invasive disease are
not entirely clear but are likely to be a combination of environmental factors as well
as host and bacterial genetics. Invasive meningococcal disease has been correlated
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with certain age groups (young children and teenagers) and immunocompromised in-
dividuals (although not HIV), as well as factors that disturb the mechanical barrier
of the nasopharyngeal epithelium such as smoking and viral illnesses (Trotter et al.,
2006a). There is also some genetic predisposition, such as relatively rare deficiencies
in components of the complement pathways as well as more common polymorphisms
in genes of the immune system (discussed in Section 1.2.5.1). Invasiveness is also as-
sociated with the infecting strain, some meningococcal strains being more commonly
associated with disease than others (Salit et al., 1984; Caugant et al., 2007). Bac-
terial factors that function in invasion include IgA1 protease, which is only found in
pathogenic Neisseria species (Mulks & Plaut, 1978). The protease has been found to
be expressed at higher levels in invasive isolates of meningococci than non-invasive
isolates (Vitovski et al., 1999). The IgA1 protease cleaves host IgA1 antibodies and
has, for example, been observed to cleave PorA specific IgA1 antibodies bound to the
meningococcal surface (Vidarsson et al., 2005). IgA1 protease also cleaves many other
proteins (Vitovski & Sayers, 2007). By cleaving Lysosomal-associated membrane pro-
tein 1 (LAMP1) in the phagosome IgA1 protease has been found to contribute to
intracellular survival in epithelial cells (Lin et al., 1997). After invasion of the ep-
ithelium, meningococci have been shown to reside within subepithelial tissue (Read
et al., 1995) and have also been observed deep in tonsillar tissue (Sim et al., 2000).
Plasminogen, a component of the fibrinolytic system, can after activation cleave com-
ponents of the extracellular matrix. Binding of plasminogen to the bacterial surface
has been shown to increase bacterial invasiveness (La¨hteenma¨ki et al., 2005). Three
meningococcal proteins, DnaK, enolase and peroxidase, have been suggested to act
as binding partners of plasminogen on the bacterial surface (Knaust et al., 2007).
In the blood stream a pre-requisite for meningococcal survival is the presence of
a polysaccharide capsule that protects bacteria from the host immune system (Vo-
gel et al., 1997; Estabrook et al., 1998; Kahler et al., 1998; Geoffroy et al., 2003).
However, in a few cases unencapsulated strains have caused meningococcal disease
in previously healthy individuals (Hoang et al., 2005; Findlow et al., 2007). Find-
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low et al. (2007) also demonstrated that an unencapsulated strain recovered from
an infected individual showed serum resistance comparable to that of a capsulated
reference strain. Increased virulence during bacterial growth in the blood stream is
also associated with expression of meningococcal LOS, as strains with disruptions in
genes involved in synthesis of LOS, especially of the inner core, are less virulent in
animal infection models and are sensitive to serum killing (Kahler et al., 1998; Sun
et al., 2000; Geoffroy et al., 2003; Plant et al., 2006). Additionally, acquisition of iron
or biosynthesis of amino acids has been associated with meningococcal survival in the
blood stream (Sun et al., 2000).
From the blood stream (or directly from the nasopharynx) meningococci can invade
the meninges to cause meningitis, by crossing the BBB through the transcellular route
or via the choroid plexuses (reviewed in Nassif & So (1995)). In tissue from a fatal
case of meningococcal meningitis, meningococci were attached both to endothelial
cells in the BBB and the choroid plexus (Pron et al., 1997). The bacteria probably
traverse the BBB by stimulating endocytosis on the blood side by the cells composing
the membrane and release into the CSF on the other side (Nassif, 1999). In vitro,
the polysaccharide capsule has been shown to be important for intracellular survival
in human brain microvascular endothelial cells (Nikulin et al., 2006; Spinosa et al.,
2007).
1.2.5.1 Innate and adaptive host responses to the meningococcus
Host responses to the presence of meningococci involve the activation of the com-
plement system, activation of inflammatory responses (chemokines and cytokines)
and activation of coagulation and fibrinolysis. In this section, humoral immune re-
sponses to N. meningitidis will be discussed. Cellular immune responses, probably
playing a smaller role in protection to N. meningitidis, will be discussed in Chapter
6. The complement system is required for protection against N. meningitidis, and
defence against invasive meningococcal disease is primarily mediated through bacte-
ricidal antibodies and complement. As a consequence, individuals with deficiencies in
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certain components of the complement system, such as properdin and C6–C9, as well
as individuals with immunoglobulin deficiencies, are at increased risk of developing
meningococcal disease (Emonts et al., 2003). Complement is activated on the sur-
face of the meningococcus by one or more of the three initial complement-activating
pathways; the classical, alternative or lectin pathway. Proteins on the meningococcal
surface interact with components of the complement cascade, altering their function-
ality. An overview of the three complement pathways with some of the interaction
points is shown in Figure 1.1.
Most of the complement mediated killing of meningococci is initiated by the
antibody-dependent classical pathway (Goldschneider et al., 1969), activated by bind-
ing of bactericidal antibodies to structures on the bacterial surface. Serogroup B
capsular polysaccharide is poorly immunogenic and Welsch & Granoff (2007) have
shown that exogenous serogroup B polysaccharide, in most cases, does not inhibit
whole blood bactericidal activity, suggesting that bactericidal antibodies in blood are
mainly directed against other meningococcal surface structures. However, studies
have also indicated that deposition of complement on the meningococcal surface is
independent of IgG antibodies to MenB (Drogari-Apiranthitou et al., 2002).
Activation of the alternative and lectin pathways is also evident in response to
stimulation with meningococci. During in vitro incubation of MenB in human serum
considerable amounts of activated factor B (Bb), a serum factor of the alternative
pathway, is produced (Drogari-Apiranthitou et al., 2002). Individuals with deficien-
cies in properdin or factor D, activators of the alternative pathway, are more sus-
ceptible to meningococcal disease as well as presenting with more severe symptoms,
which suggest that a functional alternative pathway is an important component in
protection (Sprong et al., 2006). The initial step in the lectin pathway is mediated by
the human serum protein mannose binding lectin (MBL), which has been shown to
bind Opa and PorB on the meningococcal surface (Estabrook et al., 2004). Binding
of MBL to the meningococcal surface accelerates complement activation and thereby
serum killing of N. meningitidis, as well as inducing interactions with phagocytotic
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cells (Jack et al., 2001a,b). MBL deficiency and specific sequence polymorphisms in
the gene encoding MBL have been associated with meningococcal disease (Bax et al.,
1999; Hibberd et al., 1999), findings which suggest that the lectin pathway is also
important for control of meningococcal disease.
Activation of all three complement pathways results in the cleavage of C3 de-
posited on the bacterial surface. The same levels of C3 surface-deposition, as well as
degradation of C3 to iC3b fragments and C3b molecules on the bacterial surface, have
been observed for serum-sensitive and serum-resistant bacterial strains (Jarvis, 1994).
The deposition of C3b (probably bound to Opa (Lewis et al., 2008)) and iC3b on the
bacterial surface has surprisingly not been shown to be inhibited by capsule, LOS or
porins (Drogari-Apiranthitou et al., 2002). Both C3b and iC3b can also function as an
opsonin, mediating uptake of the bacteria by phagocytotic cells (opsonophagocytosis).
The last step in the complement cascade is the formation of the C5b–9 complement
complex (membrane attack complex (MAC)), which following insertion in the outer
membrane results in lysis of the bacteria. The polysaccharide capsule may protect
the meningococcus from correct insertion of MAC, which is required for efficient lysis
of the bacteria. The rate of MAC formation on the MenB surface has been found to
be higher in bactericidal than non-bactericidal sera, but correct insertion rather than
amounts of MAC seem to be most important for effective bacterial killing (Drogari-
Apiranthitou et al., 2002). Individuals with deficiencies in components of the terminal
complement complex are more susceptible to meningococcal disease, but may suffer
from a less fulminant form (Bartholomew & Shanahan, 1990), emphasising the con-
tribution that activation of host defence mechanisms makes to symptomatic illness.
In these individuals, killing of meningococci is possibly mediated through phagocyto-
sis (Ross et al., 1987). Meningococci modulate steps in the complement cascade by
binding negative regulators to surface structures. C4bp, an inhibitor of both the clas-
sical and lectin pathways, binds to the surface of meningococci in a PorA dependent
manner (Jarva et al., 2005). Factor H (fH), a negative regulator of the alternative
pathway, has been shown to interact with the meningococcal protein NMB1870 on
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the meningococcal surface (Madico et al., 2006). Binding of fH to the meningococcal
surface is associated with increased resistance to complement mediated killing and
increased survival in blood (Haralambous et al., 2006; Schneider et al., 2006). Ad-
ditionally, polymorphisms in the fH gene that lead to decreased levels of factor H in
human blood plasma have been correlated with increased susceptibility to meningo-
coccal disease (Haralambous et al., 2006). NMB1870 is one of the five components
of an experimental MenB vaccine formulation developed by Novartis (Giuliani et al.,
2006) (Section 1.4.1).
Activation of proinflammatory (and antiinflammatory) responses in the host is con-
trolled by Toll like receptors (TLR). N. meningitidis primarily interacts with TLR2
and TLR4. The meningococcal surface protein PorB has been shown to interact di-
rectly with host cell TLR2 (Massari et al., 2006). LOS has been shown to be the main
ligand for TLR4 (Zughaier et al., 2004). However, a LOS-deficient meningococcal
strain has also been shown to activate TLR4-dependent proinflammatory responses,
indicating that additional surface structures interact with TLR4 (Plant et al., 2007).
TLRs are important in innate host defences, but uncontrolled proinflammatory ac-
tivation is detrimental for the host and is one of the hallmarks of fulminant sepsis.
For example, expression levels of tumour necrosis factor (TNF)-α, induced by endo-
toxin (LOS), is correlated with death of patients during sepsis (Waage et al., 1987).
Interleukin (IL)-6 is up-regulated in all meningococcal disease patients, but levels
have been found to be significantly higher in non-survivors than survivors (Waage
et al., 1989). High levels of IL-10, a suppressor of proinflammatory cytokine produc-
tion, have also been associated with fatality in meningococcal sepsis (Lehmann et al.,
1995).
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1.2.6 Models of meningococcal disease
Animal models Animal models are useful for exploration of some of the aspects of
meningococcal pathogenesis, but none of the available animal models can capture its
full complexity, with disease progression from mucosal carriage to septicaemia and/or
meningitis. Models of meningococcal disease include: the mouse intra-peritoneal
(i.p.) challenge model, the infant rat i.p. infection model, intranasal infection models
and infection models using humanized mice. These have mainly been used to model
invasive disease in the blood stream. Recent development of transgenic mouse models,
expressing human surface receptor CD46 (Johansson et al., 2005) or human transferrin
(Zarantonelli et al., 2007), may improve the modelling of meningococcal bacteraemia.
In vitro and ex vivo models In vitro and ex vivo models have also been used to
explore specific aspects of meningococcal disease. Human primary or immortalised
cell lines have been used to model the interactions between the bacteria and cell types
encountered by N. meningitidis during different stages of infection. Models to repli-
cate steps in nasopharyngeal colonisation or invasion include cultured epithelial cells
or ex vivo tissue explants (Stephens et al., 1983; Virji et al., 1992; Read et al., 1995).
Transcriptional changes in response to interactions between meningococci and human
cells have been studied in both the host (Bonnah et al., 2004; Plant et al., 2004) and
the bacteria (Grifantini et al., 2002b; Dietrich et al., 2003) (Section 1.3). Aspects
of invasive meningococcal disease can be modelled using animal models (discussed
above), as well as cultured immune cells, and in an ex vivo whole blood assay (WBA)
(Heist et al., 1922; Ison et al., 1995) as well as in serum or plasma. Heist et al. (1922)
developed the WBA as a simple means for studying bactericidal activity against
meningococci. They incubated bacteria in fresh anti-coagulated blood and monitored
bacterial survival by counting colony forming units (CFU) at intervals. A minority
of individuals’ blood allowed bacterial proliferation. Using this assay they defined
the terms ‘non-killer’ and ‘killer’ as individuals whose blood respectively supported
or failed to support the growth of meningococci. Setting aside this labour intensive
assay, Goldschneider et al. (1969) developed what has become the gold standard in
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evaluation of host/meningococcal interaction, the serum bactericidal assay (SBA).
In this assay, heat-inactivated1 serum is incubated with appropriate target strains
and complement from various sources2, and the serum bactericidal titre for each un-
known serum is expressed as the reciprocal of the lowest serum dilution yielding a 50%
killing as compared to time zero. SBA has become the established way of determin-
ing the efficiency of meningococcal vaccines, with a titre of 1:4 considered protective.
Ison et al. (1995), concerned at the loss of information inherent in tests of serum
rather than of whole blood, revived Heist’s WBA method, and demonstrated indi-
vidual differences in susceptibility to meningococcal infection not reflected in SBA.
Individuals with a negative SBA to MenB, i.e. non-bactericidal, can still have a
positive WBA, i.e. limited meningococcal survival in whole blood (Ison et al., 1999;
Welsch & Granoff, 2007), pointing to the importance of MenB killing by phagocy-
tosis (antibody-dependent and/or independent). Peripheral blood mononuclear cells
have been used to study, for example, phagocytosis of the bacteria. Using such cells
Kalmusova et al. (2000) showed that invasive meningococcal strains were able to sur-
vive within vacuoles in monocytes/macrophages whereas non-invasive strains were
quickly killed. Using mutant strains of bacteria, surface structures important for
stimulation of monocytes or protection from phagocytosis have been identified. For
example, sialyation of LOS (Unkmeir et al., 2002) and the surface protein NhhA have
been suggested to protect the bacteria from phagocytosis (Sjo¨linder et al., 2008).
Entry of N. meningitidis into the CSF requires adhesion to endothelial cells and
crossing of the BBB, and these processes have been mimicked in vitro using endothelial
and more recently meningeal cells (Christodoulides et al., 2002). Adhesion to the
BBB has been shown to require the expression of PilC, the adhesive tip of the type
IV pilus (Pron et al., 1997). Using such models meningococci have been shown to
be encapsulated during passage of the cells and intracellular growth (Nikulin et al.,
2006).
1To remove endogenous complement
2Now conventionally human or baby rabbit
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1.3 Transcriptomic studies of infectious disease
Exploring the complex interactions between pathogen and host on a genome-wide
scale can increase our understanding of the genes and pathways that are linked to
infection and invasion of the host, and may be used as a tool to discover new virulence
genes, vaccine candidates and drug targets. Microarray technology, developed in
the mid-1990s at Stanford University, can be used to determine the genome-wide
transcriptional profile of an organism (Schena et al., 1995). Microarrays are based
on the hybridisation of fluorescently labelled targets (one- or two-colour) to gene
specific probes on a surface, with the objective to determine the absolute or relative
abundance of gene transcripts in the respective samples. Other applications of DNA
microarrays include the assessment of gene copy number (array-CGH) (Pinkel et al.,
1998), genotyping (Behr et al., 1999), single nucleotide polymorphisms (SNP) analysis
(Hacia et al., 1999) and for detection of DNA-protein interactions (ChIP-chip) (Ren
et al., 2000).
Microarray technology has been extensively used in the prokaryote field to probe
differences due to gene mutations (Thompson et al., 2002; Beliaev et al., 2002; Se-
bert et al., 2002). Microarrays have also been used to explore, for example, bacterial
responses to different perturbations, interactions with host cells, invasive disease or
responses to environments mimicking some specific condition encountered by the bac-
teria during infection (Ye et al., 2000; Smoot et al., 2001; Fisher et al., 2002; Grifantini
et al., 2002b; Phadtare et al., 2002; Bina et al., 2003). The first two micro (macro)
array papers published in the bacterial field explored the response of Escherichia coli
to rich or minimal media (Tao et al., 1999) and the drug-induced transcriptome of
Mycobacterium tuberculosis (Wilson et al., 1999). The sequencing of the first com-
plete meningococcal genome in the year 2000 opened up the possibility of performing
functional genomics studies for N. meningitidis, such as transcriptomic studies using
microarrays (Tettelin et al., 2000). Several groups have used microarrays to study
the changes in transcriptional profile when N. meningitidis has been subjected to,
for example, iron depletion (Grifantini et al., 2003), heat-shock (Guckenberger et al.,
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2002), and co-culture with human cells (Grifantini et al., 2002b; Dietrich et al., 2003).
Grifantini et al. (2002b) studied the changes in gene expression at four time-points
(30, 60, 120 and 180 min) for three different MenB strains (MC58, 2996, and BZ83)
when they adhered to epithelial cells. They found differentially regulated genes (N
= 347) mainly to be associated with adhesion, host-pathogen cross talk, amino acid
biosynthesis, DNA metabolism. Dietrich et al. (2003) carried out similar experiments,
comparing differential gene expression of an unencapsulated mutant of MC58 when
adherent to epithelial or endothelial cells, using oligo-based microarrays. They found
significant changes in gene expression for 72 and 48 genes, respectively. More than 200
meningococcal genes were found to be iron-regulated, including known iron-regulated
genes such as tbpA and tbpB, but also novel genes such as NMB1436–38 (Grifantini
et al., 2003). Microarrays have also been used to characterise genes with hypothetical
function (Grifantini et al., 2004).
Host cell responses induced by stimulation with N. meningitidis have also been
studied using microarray technology. The major gene expression changes in response
to stimulation with meningococci involve the up-regulation of inflammatory factors.
Up-regulation of genes involved in inflammatory processes, as well as cell prolifera-
tion, have been observed when epithelial cells are stimulated by piliated meningococci
(Linhartova et al., 2006). Stimulation of human primary monocytes with a similar
load of heat-killed wild-type N. meningitidis or a LOS mutant resulted in differen-
tial regulation of 4689 and 72 genes, respectively (Øvstebø et al., 2008), indicating
that LOS is the main activator of gene expression changes in response to exposure
to dead bacteria. At 100-fold higher load the N. meningitidis LOS deficient strain
induced differential regulation of the same magnitude as the wild-type strain, indi-
cating a dose response in the stimulatory effect by other surface exposed bacterial
factors. However, Øvstebø et al. found several genes, including IFN-β, which were
specifically up-regulated upon stimulation of monocytes with wild-type meningococci.
Co-incubation of N. meningitidis with whole human blood resulted in up-regulation of
174 genes, including IL-6 and TNF-α, an activator of inflammatory responses (Pathan
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et al., 2004). Meningeal cells, stimulated with secreted meningococcal proteins or co-
incubated with live bacteria, expressed genes encoding the inflammatory factors IL-6,
a major pyrogen, and IL-8 at higher levels (Wells et al., 2001; Robinson et al., 2004).
In addition to changes in immune responses, Bonnah et al. (2004) showed that ad-
hesion of N. meningitidis to human epithelial cells induced changes in expression of
host genes involved in iron homeostasis, indicative of an iron starved state. This is
consistent with another study, in which Larson et al. (2004) showed that when N.
meningitidis is incubated with human epithelial cells, degradation of host cell ferritin
is increased, providing an iron source for the bacteria.
1.4 Meningococcal vaccines
The severity of meningococcal disease as well as the economic cost of health care (in-
tensive care and long-term care for survivors) has prompted huge efforts to develop
preventive measures. Vaccines based on purified capsule polysaccharides have been
available since the 1960s for the pathogenic serogroups A, C, Y, and W135. Their ma-
jor drawback is minimal efficacy in infants and children under 2 years old, at greatest
risk of disease, with the exception of serogroup A polysaccharide that offers protection
from about three months of age. Although inducing a good immune response in older
individuals, protection is of limited longevity. Vaccine boosters have been tested as a
way of offering longer lasting protection, but these are not feasible for all serogroups.
For example, serogroup C capsular polysaccharide preparations cause immuno hypo-
responsiveness upon repeated administration (Granoff et al., 1998). To overcome the
limitations with the earlier vaccines, protein-conjugated polysaccharide vaccines have
been developed where the capsular polysaccharides are chemically conjugated to a
protein. The serogroup C glycoconjugated polysaccharide vaccine is effective in in-
fants and can induce a strong response after only a single dose (Richmond et al., 1999a;
Cartwright et al., 2001). The protein conjugated polysaccharide induces a T-cell de-
pendent response, and therefore gives rise to memory T-cells, leading to a long-term
protective effect (Richmond et al., 1999a,b) with efficient boosting. Glycoconjugated
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vaccines have also been developed for improved prevention of meningococcal disease
caused by serogroups A, Y and W135 (Pace & Pollard, 2007). As explained in the next
section, however, there is no comparable glycoconjugate vaccine to prevent serogroup
B infections, and a radically different approach is needed for this major challenge.
1.4.1 Serogroup B vaccines
The capsular polysaccharide of MenB is virtually non-immunogenic in humans, due to
it chemical identity to a human neuronal surface carbohydrate, α-(2→8)-linked poly
N-acetyl neuraminic acid (Finne et al., 1983), and therefore the vaccine strategies
used for the other pathogenic serogroups are not applicable to MenB. In attempts to
increase immunogenicity, the group B polysaccharide has been complexed with OMPs
or conjugated to a protein carrier, with limited improvements (Zollinger et al., 1979;
Jennings & Lugowski, 1981). There are however concerns that inducing an immune
response through such strategies could trigger autoimmunity (Fusco et al., 1998).
Trials have been conducted with N-propionylated capsular polysaccharide (Jennings
et al., 1986, 1987; Ha¨yrinen et al., 1995; Pon et al., 1997), which might circumvent
the possibility of inducing self-reactive antibodies. N-propionylated modified capsular
structures were evaluated in a phase I clinical trials (Bruge et al., 2004), but failed to
induce protective antibodies to meningococcal strains.
Instead of basing vaccines on the polysaccharide capsule, other strategies have
been employed for protection against serogroup B strains. These include the use
of various immunogenic surface exposed proteins, as well as formulations of outer
membrane vesicles (OMVs), which naturally contain a variety of OMPs, LOS and
periplasmic proteins (Danzig, 2004; Vaughan et al., 2006).
1.4.1.1 Lipooligosaccharide
N. meningitidis LOS, also referred to as endotoxin, is a potent activator of the im-
mune system. Several approaches have been taken in attempts to create an effective
LOS vaccine. Due to the toxicity of native LOS, elicited by the lipid A moiety of
the molecule, modified detoxified structures have been constructed, which have been
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tested for their potential to induce a protective immune response. Conjugation of
either oligosaccharide structures (Verheul et al., 1993) or truncated LOS inner core
structures (Cox et al., 2005) to proteins have been tested as a way of increasing the
immunogenicity. In the study by Verheul et al. (1993) antibodies to the protein but
not to LPS were induced in mice, whereas Cox et al. (2005) previously showed that
bactericidal antibodies could be induced to the inner core structure of LOS coupled
via the lipid A region. A monoclonal antibody raised to an inner core epitope of
LOS, conserved in 26 of 34 MenB strains tested (except immunotypes L2, L4, L5,
L6), bound to the meningococcal surface (Plested et al., 1999), and was able to confer
protection against experimental meningococcaemia in a rat model, but only to strains
expressing truncated LOS glycoforms (Plested et al., 2003). Peptide mimetics of LOS
structures have also been investigated as a way of inducing protection (Tiwana et al.,
2005), but have failed to induce complement-mediated serum bactericidal activity to
MenB.
1.4.1.2 Surface exposed proteins
Surface exposed proteins or combinations of several OMPs are currently the most
promising candidates for a broad range, if not universal, MenB vaccine. Proteins
accessible on the meningococcal surface during colonisation and invasive disease have
the potential to induce a host immune response (Zollinger et al., 1974). A large pro-
portion of the bactericidal antibodies in meningococcal patients are directed towards
the abundant OMP PorA. The protein has variable expression among strains (van der
Ende et al., 1995) and highly variable surface exposed loops (Feavers et al., 1996),
which have hampered the development of universally protective vaccine preparations
based on PorA. Antigenic variability (or variable surface expression) is a general
problem besetting many meningococcal surface exposed proteins.
OMPs which have been explored as vaccine antigens include TbpA (Ferron et al.,
1992), NspA (Martin et al., 1997), H.8 (Bhattacharjee et al., 1990) and factor H
binding protein (NMB1870) (Masignani et al., 2003). Surface exposed proteins which
are induced in response to conditions mimicking environments in the human host are
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likely to be good candidates for inclusion in protein based vaccines. Such proteins
include those induced under conditions of low iron-availability (Banerjee-Bhatnagar
& Frasch, 1990), commonly encountered by N. meningitidis in the host. Studies have
investigated the potential of several surface exposed iron uptake proteins to induce
bactericidal antibodies that provides protection to meningococcal disease. Isolated
transferrin binding proteins, TbpA and TbpB, have both been shown to induce an
immune response (Ferron et al., 1992; Ala′Aldeen et al., 1994). Antisera raised against
one TbpB type have been demonstrated to induce cross-reactive antibodies that bind
to the surface and kill a diverse set of strains (Rokbi et al., 1997). Both recombi-
nant TbpA and TbpB have been shown to induce protection to meningococci in a
mouse model (West et al., 2001). In mice TbpB were found to induce a stronger
bactericidal activity than TbpA, but on the other hand, bactericidal antibodies to
TbpA were found to be more cross-reactive. Formulations of TbpB have been tested
in phase I clinical trials, but immunogenicity of the protein was limited in humans
(Danve et al., 1998). Other proteins that have reached clinical trials include NspA, a
conserved meningococcal outer membrane protein, which provided protection against
experimental infection in mice (Martin et al., 1997). However, a vaccine compris-
ing recombinant (unfolded) NspA, although inducing bactericidal antibodies in mice,
failed to induce bactericidal antibodies in adult volunteers in a clinical trial, possibly
due to loss of antigenic epitopes in the linearised protein (Halperin et al., 2007).
The completion of the whole genome sequence of the MenB strain MC58 in 2000
heralded the move into the post-genomic era of vaccine development (Tettelin et al.,
2000). Pizza et al. (2000) used genome information to identify a large number of puta-
tive surface exposed proteins, which were expressed and tested in mice for their ability
to induce an immune response. Their actual cellular location was tested by flow cy-
tometry on whole cell meningococci. This approach was termed ‘reverse vaccinology’
by Rappuoli (2000). From the study by Pizza et al. (2000) a set of proteins was iden-
tified for investigation of their potential as vaccines. Others have used the genomic
information combined with new ‘omics’ technologies to identify putative immuno-
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genic surface antigens. Proteins that have been investigated include the conserved
surface accessible protein NMB0035 (Arenas et al., 2008); the lipoproteins NMB1126
(Niebla et al., 2006) and NMB0928 (Delgado et al., 2007); and the surface protein
NMB1468 identified by a proteomic approach (Hsu et al., 2008). Others include a
meningococcal OMP named LP2086 (identical to factor H binding protein), which
has been explored for its vaccine potential (Fletcher et al., 2004), and shown to offer
protection in experimental models of disease (Pillai et al., 2005).
In general, efforts to design vaccines that induce immunity against bacterial surface
proteins have met with some drawbacks, including importantly (a) that they do not
seem to induce as good immunity in children under 2 years of age (the group most af-
fected by disease) as in adults, and (b) that many surface exposed proteins show a high
degree of variability between different strains, through mutation or phase variation,
and therefore a vaccine based on these will not give universal protection. Additionally,
for many OMPs, abundance and accessibility on the surface of the bacteria have been
found to be variable among strains. During all stages of colonisation and infection
N. meningitidis adapts to the changing environment within the host and evades the
immune system by for example phase-variation (due to for example slipped strand mi-
spairing) leading to antigenic variation of proteins, and variable expression of surface
antigens. Many putative phase-variable genes have been identified in the genome of
MenB (Saunders et al., 2000). Examples of such genes include the pilin gene pilE the
expression of which has been found to be regulated by phase-variation (Pinner et al.,
1991), and that undergoes phase variation in invasive disease (Rytko¨nen et al., 2004).
Introduction of repeats in the coding region of genes due to phase variation can also
result in frame shifts, which lead to non-functional truncated gene products (Jonsson
et al., 1991) or peptides with varied immunoepitopes. In addition, transcription levels
of genes can differ between Neisseria species or meningococcal strains due to other
processes. Variable gene expression is often a result of genomic variants in up-stream
regions of the gene, such as insertion elements resulting in novel activator binding
sites or different strength promoters. An example of the latter is the observed two
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fold higher expression of the lst gene, encoding a LOS sialyl transferase, in gonococci
in comparison to levels in meningococci (Packiam et al., 2006). Uria et al. (2008)
showed that insertion of an IS1301 element between the capsular biosynthesis locus
and the capsular export locus in a MenC strain led to increased expression of adjacent
genes and resulted in resistance to killing by bactericidal antibodies induced to the
MenC conjugate vaccine as well as other surface structures.
Problems with presenting the antigens in their native form have also hampered
attempts to develop vaccines from OMPs. This could be solved by expressing the
antigens on the surface of OMVs.
One investigational OMP vaccine developed by Novartis Vaccines, which has
passed through phase II clinical trials, shows promising results both in adults and tod-
dlers (Miller et al., 2008; Snape, 2008). The vaccine is based on recombinant surface
exposed proteins NadA (NMB1994) and two fusion proteins, NMB2132–NMB1030
and NMB2091–NMB1870 (Giuliani et al., 2006).
1.4.1.3 Outer membrane vesicles (OMVs)
N. meningitidis sheds OMVs (blebs) containing OMPs, LOS and periplasmic pro-
teins, which have similar immunostimulatory effects to live bacteria. OMVs isolated
from bacterial cultures and appropriately detoxified can be used as vaccines (Fredrik-
sen et al., 1991). The vaccines developed so far have been more appropriate for use in
strain-specific situations such as clonal outbreaks, rather than in a routine immunisa-
tion programme aimed at preventing disease caused by all MenB strains. They have
been well tolerated and have been used in response to outbreaks of MenB disease
in Norway (Bjune et al., 1991) and Cuba (Sierra et al., 1991). Convincing efficacy
data derive from recent experience in New Zealand, where a recent epidemic has been
controlled using an OMV vaccine based on the epidemic strain NZ98/254. The vac-
cine was used in mass-vaccination of the population under the age of twenty (Oster
et al., 2005). However, immunodominance of a few hypervariable surface proteins, in
particular PorA, limits the capacity of OMVs to confer a broad immunity against a
wide range of strains. OMVs with modified expression of surface proteins have been
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investigated as a way to increase both immunogenicity and strain coverage. OMVs
isolated from two strains constructed to express three alleles each of different PorAs
(Claassen et al., 1996), have been found to induce bactericidal antibodies in mice.
The hexavalent OMV preparation has been demonstrated to induce bactericidal an-
tibodies to the meningococcal strains covered by the PorA types in infants (94%)
after four doses (Cartwright et al., 1999) and in children (16-100%) after three doses
(de Kleijn et al., 2000). Over-expression of the factor H binding protein NMB1870 on
OMVs induced broader protection against meningococci than both the protein alone
or wild type OMVs (Hou et al., 2005). O′Dwyer et al. (2004) investigated the use of
OMVs from commensal Neisseria as vectors for presenting meningococcal antigens in
their native form on the surface of OMVs and showed that such OMVs, expressing
the vaccine antigen NspA, induced bactericidal antibodies in mice.
1.4.1.4 Live-attenuated vaccines
Live-attenuated vaccines have been used to combat disease caused by for example
Salmonella enterica (Tacket et al., 2000), and have been suggested as a potential
strategy for a MenB vaccine (Tang et al., 1999). Sun et al. (2000) identified genes
essential for meningococcal growth in the blood stream of infant rats. The ability
of two of the attenuated mutant strains (∆siaD∆metH and ∆siaD∆rfaF ) to induce
an immune response were tested in mice, and were shown to be well tolerated, in-
duce bactericidal antibodies and confer protection to subsequent challenge with wild
type meningococci, both homologues and heterologous strains (Li et al., 2004). The
meningococcus is strictly a human pathogen, so results in mice are not necessarily
highly predictive of the response in humans, and should be interpreted with caution.
Vaccines developed using this strategy will naturally require substantial tests of safety
before being approved by regulatory authorities.
1.4.1.5 Commensal Neisseria
Since naturally occurring nasopharyngeal colonisation with N. lactamica induces a
cross-protective immune response to meningococci, intra-nasal vaccination based on
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live N. lactamica has been suggested (Oliver et al., 2002; Li et al., 2006). OMVs iso-
lated from non-pathogenic N. lactamica have also been tested as a vaccine (Gorringe
et al., 2005; Finney et al., 2008), but failed to induce bactericidal antibodies to MenB
strains in mice.
1.5 Hypothesis and aims
1.5.1 Hypothesis
Vaccine strategies that have successfully reduced the incidence of group C meningo-
coccal disease have had their primary effect through eliciting bactericidal plasma
antibody, but have also had a secondary effect through reduction of nasopharyngeal
colonisation and carriage (Maiden et al., 2008). However, anti-colonisation strategies
to prevent invasive bacterial infection are inherently risky. While a vaccine that tar-
gets structures expressed by bacteria on the nasopharyngeal epithelial surface may
effectively reduce the incidence of meningococcal disease by reducing colonisation,
there remains a risk of occasional invasive infection which can only be neutralised
by antibodies in the bloodstream. Significant perturbation of meningococcal ecology
with an anti-colonisation vaccine may indeed, in the long run, turn out to be detri-
mental, as the vaccine-induced immune response may promote the survival of resistant
strains expressing alternative antigens or down-regulating antigen expression. For ex-
ample, an invasive strain of N. meningitidis has been identified that lacks the immuno-
dominant surface antigen PorA due to a mutation (Newcombe et al., 1998). While
some meningococcal genes expressed during bacteraemia will be as highly expressed
by organisms in the nasopharynx, others will be up- or down-regulated in response to
the major changes in bacterial environment that follows invasion. Gene products that
are expressed more strongly in the blood stream than in the nasopharynx are partic-
ularly attractive candidates for inclusion in a vaccine, as they should be less subject
to immune selection. A major problem besetting most proposed meningococcal vacci-
nation strategies based on OMPs has been the propensity of the organism to undergo
antigenic variation, importantly driven by immune selection pressure (Martin et al.,
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2000). However septicaemia is, from the organism’s perspective, a non-productive
end point of meningococcal infection, an evolutionary dead-end from which bacteria
do not survive to contribute to the genetic diversity of the species in the nasopharynx
of present or future hosts. Therefore, selection pressures operating principally in the
bloodstream are less likely to lead to the evolution of vaccine-resistant organisms if
their targets are the products of genes expressed largely or solely in the bloodstream.
I hypothesize that any surface exposed gene products that are expressed at a
higher level in the bloodstream than on the mucosal surface, where immune selec-
tion pressure drives antigenic diversity, should be less variable, and so, attractive as
cross-protective vaccine candidates. In the absence of a satisfactory animal model of
meningococcal septicaemia, I have chosen to explore the repertoire of meningococcal
gene expression in the course of prolonged incubation in human plasma and blood.
In this thesis the transcriptome of MenB in ex vivo models of septicaemia will be
compared to the transcriptional pattern during nasopharyngeal carriage, with the
objective of identifying genes expressed largely or solely in the bloodstream. Any
such genes that encode a predicted or known surface exposed protein will be explored
for their vaccine candidacy.
1.5.2 Aims
• to characterise the expression profile of N. meningitidis in models of human
septicaemia
• to identify candidate genes which are relatively up-regulated during septicaemia
compared to conditions mimicking the carriage state
• to explore cross-protective vaccine candidacy of any surface exposed proteins
encoded by such genes
Chapter 2
Materials and methods
2.1 Bacterial strains and growth conditions
2.1.1 Bacterial growth conditions
Neisseria strains were routinely propagated on GC (gonococcal) agar (Difco) supple-
mented with 1% Vitox (sGC) at 37◦C in 5% CO2. Neisseria strains were grown in
Mueller-Hinton (MH) broth supplemented with 1% Vitox (sMH) at 37◦C in an orbital
incubator at 180 rpm. All experiments with N. meningitidis strains were carried out
in a biosafety level 3 containment laboratory.
2.1.2 Bacterial strains
Bacterial strains utilised in this work are listed in Table 2.1.
Table 2.1: Neisseria meningitidis strains used in this project
Strain Sequence
type
Clonal complex Designation Disease Country
MC58 74 ST-32 complex/ ET-5
complex
B:15:P1.7,16-2 – UK
BZ 169 32 ST-32 complex/ ET-5
complex
B:P1.5-2,16 invasive † Netherlands
H44/76 32 ST-32 complex/ ET-5
complex
B:P1.7,16 invasive † Norway
BZ 83 34 ST-32 complex/ ET-5
complex
B:P1.5-2,10 invasive † Netherlands
SWZ 107 35 ST-35 complex B:P1.ND,ND invasive † Switzerland
NG H38 36 – B:P1.ND,3 carrier Norway
Continued on next page . . .
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Table 2.1 – continued from previous page
Strain Sequence
type
Clonal complex Designation Disease Country
BZ 232 38 ST-37 complex B:P1.ND,2 invasive † Netherlands
NG 6/88 13 ST-269 complex B:P1.ND,1 invasive † Norway
NG F26 14 ST-269 complex B:P1.ND,16 carrier Norway
BZ 198 41 ST-41/44 complex/
Lineage 3
B:P1.7-2,4 invasive † Netherlands
NG H15 43 ST-41/44 complex/
Lineage 3
B:P1.19,15-2 carrier Norway
NG H36 47 ST-41/44 complex/
Lineage 3
B:P1.5-1,2-2 carrier Norway
BZ 147 48 ST-41/44 complex/
Lineage 3
B:P1.ND,ND invasive † Netherlands
297-0 49 ST-254 complex B:P1.ND,15 carrier Chile
1000 20 ST-18 complex B:P1.ND,ND invasive † Russia
528 4802 ST-18 complex B:P1.5-1,10 invasive ‡ Poland
NG P165 – ST-11/ ET-37 complex N.D. – –
MO1-
240185
11 ST-11 complex/ ET-37
complex
B:2a:P1.5,10-8 – UK
90/18311 11 ST-11 complex/ ET-37
complex
C:P1.5,2-1 – UK
BZ 133 1 ST-1 complex/subgroup
I/II
B:P1.7,16 invasive † Netherlands
F6124 5 ST-5 complex/
subgroup III
A:P1.20,9 invasive † Chad
NG E28 26 – B:4:- carrier Norway
2996 – – B:2b:P1.2 – –
†: Unspecified/other; ‡: Meningitis and septicaemia
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2.2 Reagents and Kits
Reagents and kits used in this work are described in Table 2.2. Chemicals not listed
in the table below were obtained from Sigma or BDH. Solutions were sterilised by
autoclaving at 121◦C for 15 min. Heat labile reagents were manually filter-sterilised
or filtered using a vacuum manifold and 0.22 µm nitrocellulose filters (Millipore).
Table 2.2: Description of reagents and kits
Reagent Supplier
1 kb DNA ladder Invitrogen
5×First strand buffer Invitrogen
10× REact 2 buffer Invitrogen
BigDye v3.1 Applied Biosystems
Cy3 dCTPs Fluorlink Amersham Biosciences
Cy5 dCTPs Fluorlink Amersham Biosciences
DNA polymerase I Large (Klenow) fragment Invitrogen
dNTPs Invitrogen
DTT Invitrogen
Fast RNApro Blue kit QBiogene
Fetal Bovine Serum Gibco
GC agar Difco
HotStar Taq DNA polymerase Qiagen
MH broth Oxoid
Min Elute PCR purification kit Qiagen
Molecular-grade DNAse I (Units) Invitrogen
QIAquick gel extraction kit Qiagen
N. meningitidis antiserum group B Difco Laboratories
Random hexamer primers MWG Biotech
RNA 6000 Nano chip and reagents Agilent
RNAprotect bacterial reagent Qiagen
RNAse OUT Invitrogen
RNAse-Free DNase Set Qiagen
RNeasy Min Elute kit Qiagen
RNeasy kit Qiagen
SuperScript III reverse transcriptase (200U/µl) Invitrogen
TaqMan Universal PCR MasterMix Applied Biosystems
TaqMan Primers Applied Biosystems
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2.3 Polymerase chain reaction (PCR) and DNA
sequencing
2.3.1 PCR
PCR was carried out in a final volume of 30 µl containing 1 µl DNA, 0.75 U HotStar
Taq DNA polymerase (Qiagen), 0.2 mM dNTPs, 1×PCR buffer with 1.5 mM MgCl2
and 15 pmol of each primer. To increase the stringency of primer binding 10% DMSO
was added to reactions. Reactions were performed in a DNA Engine thermal cycler
(BioRad). PCR amplification of DNA was carried out as follows. The first cycle
consisted of 15 min activation of Taq polymerase at 95◦C, 1 min of denaturation at
94◦C, annealing at 52◦C for 1 min and extension at 72◦C for 2 min. The subsequent
29 cycles contained denaturation for 1 min at 94◦C, annealing for 1 min at 52◦C and
extension at 72◦C for 2 min. The final cycle consisted of extension at 72◦C for 10
min. After amplification by PCR the gene specific fragments were checked on a 1.5%
agarose gel (Section 2.4) using TAE (0.04 M Tris acetate, 0.001 M EDTA, pH 8.0) as
a buffer and their size compared to the corresponding product from reference strain
MC58. Table 2.3 lists all primers used in the project, which were synthesized by
MWG-Biotech. Primers used in PCR reactions for amplification of genomic regions
for sequencing were designed to bind in flanking regions ∼100–200 base pairs (bp)
outside the open reading frame (orf). The primer pairs used in these amplification
reactions were designed to match both the genomic sequence of MC58 as well as
homologues regions in FAM18 and Z2491 genomes where possible.
2.3.2 Precipitation of amplified products
PCR products were cleaned by polyethylene glycol (PEG) precipitation. PCR prod-
ucts were mixed with 20% PEG/2.5 M NaCl solution to achieve a final concentration
of 10.9% PEG and 1.37 M NaCl. The mixture was incubated for 30 min at room
temperature (RT) followed by centrifugation at 2750 g for 1 hr (4◦C). Pelleted prod-
ucts were further cleaned with 70% Ethanol. Remaining ethanol was removed by an
inverse spin for 1 min at 500 g. PCR products were re-dissolved in molecular-grade
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water.
Table 2.3: Primers used in PCR reactions




















All primer used in sequencing reactions, if different from primers used during standard
PCR reaction (Table 2.3), are listed in Table 2.4. Sequencing reactions were performed
in 96-well format plates using BigDye v3.1 reaction kit (Applied Biosystems). The
sequencing reaction mixture contained 1 µl DNA (PCR product, precipitated as in
Section 2.3.2), 1.5 pmol gene-specific primer (forward or reverse direction) and 2 µl
BigDye enzyme. The sequencing reaction was carried out in a DNAEngine thermal
cycler (BioRad) as follows. The first cycle consisted of 1 sec at 96◦C, 10 sec at 96◦C,
5 sec at 50◦C and 2 min at 60◦C. The subsequent 29 cycles contained 10 sec at 96◦C,
5 sec at 50◦C and 2 (4) min at 60◦C. Products were cleaned by precipitation as fol-
lows. A mixture of 31 µl H2O and 64 µl 95% ethanol was added to each well. The
plate was incubated in the dark for 15 min at RT followed by centrifugation at 2750
g for 1 hr at 4◦C to precipitate products. The pellets were washed with 150 µl 70%
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Ethanol. Remaining ethanol was removed by an inverse spin for 1 min at 500 g. The
plate was kept at 4◦C until sequencing. The sequencing was run on an ABI3730XL
sequencer (Sequencing unit, Department of Zoology, University of Oxford). The se-
quencing trace files generated from each run were checked manually and necessary
corrections were made to the sequence-call-errors. Each gene was sequenced on both
strands, and in some cases using primers internal to the open reading frame. DNA
and protein sequence alignments were carried out using the web based ClustalW pro-
gramme (Larkin et al., 2007). Sequences were further analysed using the programme
Molecular Evolutionary Genetics Analysis (MEGA) (Tamura et al., 2007).
Table 2.4: Primers used in sequencing, if different from primers in Table 2.3













Nucleic acids were size-fractionated by agarose gel electrophoresis containing 0.5
µg/ml ethidium bromide and 1×TAE (0.04 M Tris acetate, 0.001 M EDTA, pH 8.0)
buffer. Samples were mixed with 0.17 volumes of 6×loading dye, loaded into sample
wells and typically electrophoresed at 80–120 volts. The nucleic acids was visualised
by placing the gel on a UV transilluminator using instant Polaroid black and white
film to record the image.
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2.4.1 RNA analysis by capillary gel electrophoresis
1 µl RNA samples were analysed on a RNA 6000 Nano Chip (Agilent) using an Agilent
2100 Bioanalyzer as per manufacturer’s instructions (Agilent, Palo Alto, CA) to check
quality of isolated RNA. The intensity of 23s and 16s rRNA peaks in relation to a
standard was used for RNA quantification, and the ratio between the peak-intensities
(23s/16s) used as a control of RNA quality. For RNA without degradation a 23s/16s
ratio within the range of 1.4–2 is expected dependent on RNA extraction method
and organism. Any contaminating eukaryote RNA in the sample could be detected
by peaks in regions corresponding to 28s or 18s rRNA.
2.4.2 Purification of DNA from agarose gels
DNA fragments were visualised by fluorescence of added ethidium bromide, under
UV transillumination (302 nm), and excised from gels using a clean scalpel blade.
DNA was purified from the agarose using a QIAquick gel extraction kit according to
the manufacturer’s instructions (Qiagen, UK).
2.5 Extraction of nucleic acids
2.5.1 Isolation of chromosomal DNA
Neisseria strains were grown over night on sGC agar plates. The bacteria were har-
vested from a single plate and chromosomal DNA isolated using a standard phe-
nol/chloroform method (Sambrook et al., 1989).
2.5.2 Extraction of total RNA
For isolation of total bacterial RNA a bacterial pellet was re-suspended in 1 ml
RNApro solution (QBiogen), the solution added to a tube containing Lysis matrix
B, and cells lysed by the use of a FastPrep Instrument (QBiogen). Total RNA was
isolated using protocol from Fast RNApro Blue kit supplier (QBiogen). RNA sam-
ples were further cleaned on a RNA MinElute column or an RNeasy column using on
column DNase I treatment following the manufacturer’s instructions (Qiagen).
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2.6 Nucleic acid manipulations
2.6.1 Quantification of nucleic acid concentration
Quantification of RNA and DNA samples were performed by checking the absorbance
at 260 nm using a NanoDrop 1000 instrument (NanoDrop Technologies, Wilmington,
DE). The purity of the RNA or DNA was determined by A260/A280 and A260/A230.
For pure DNA and RNA samples the A260/A280 should be 1.8 and 2.0, respectively.
2.7 Microarray procedures
2.7.1 Microarray slides and pre-processing procedures
A pan-Neisseria microarray acquired from the Bacterial microarray group at the St
George’s hospital was used. The microarray has been designed to cover the genome
sequence of three strains of N. meningitidis and one strain of N. gonorrhoeae (Stabler
et al., 2005). N. meningitidis serogroup B strain MC58 was used as the base strain
for the design of the microarray, and therefore all genes from this strain are spotted
on the microarray. The MC58 genes were used as a reference to identify any unique or
divergent genes in strains FAM18 (MenC), Z2491 (MenA), FA1090 (N. gonorrhoeae).
Each gene in the gene pool was amplified by PCR, with each product designed to give
minimal cross hybridisation to other genes in the pool. There are 2907 genes from
MC58, 343 from Z2491, 125 from FAM18 and 404 from FA1090 on the microarray.
Quality controlled PCR products are spotted in duplicate on coated glass slides.
Before hybridisation microarray slides were pre-hybridised in 3.5×SSC, 0·1% SDS, and
10 mg/ml BSA at 65◦C for 20 min before washing in distilled water and a subsequent
1 min wash in isopropanol. The slides were dried by centrifugation at 1500 rpm for 5
min, and stored in a dust-free box for less than 1 hr until hybridisation.
2.7.2 Labelling of total RNA
Complementary DNA (cDNA) was synthesised from 5–10 µg of total RNA using Su-
perScript III reverse transcriptase (Invitrogen) and random hexamer primers (MWG
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Biotech) and labelled directly with either Cy3- or Cy5-dCTP (Amersham Biosciences)
as below. In a 0.5 ml microfuge tube 5–10 µg of total RNA was mixed with 3 µg of
random hexamers (3 µg/µl, Invitrogen) and made up to a total volume of 11 µl with
RNase free water (Qiagen). The sample was incubated in a heat block at 75◦C for 5
min and then snap cooled on ice, followed by a brief centrifugation in a microfuge. The
reverse transcription reaction mix was prepared by combining 5 µl 5×First Strand
Buffer, 2.5 µl of 100 mM DTT, 2.3 µl dNTPs (5 mM dA/G/TTP, 2 mM dCTP),
1.7 µl Cy3- or Cy5-dCTP, and 2.5 µl SuperScript III (200 U/µl). This reaction mix
is sufficient for one labelling reaction. The reaction was incubated in dark for 10
min at 25◦C followed by incubation at 42◦C for 90 min. Cy3- and Cy5- labelled
samples were mixed and purified using a MinElute kit following the manufacturer’s
instructions (Qiagen). The mixture was eluted in 14.9 µl H2O.
2.7.3 Labelling of genomic DNA
Genomic DNA isolated from stationary phase organisms was fragmented by sonication
to obtain sizes between 500-3000 bp. The fragmentation was confirmed by separation
on a agarose gel as per Section 2.4. For genomotyping experiments 2 µg was labelled
with either Cy5-dCTP or Cy3-dCTP using Klenow fragment (Invitrogen) and ran-
dom hexamer primers (MWG Biotech). For gene expression experiments, in which
genomic DNA was used as a common reference, 0.5 µg genomic DNA was labelled
with Cy3-dCTP using Klenow fragment (Invitrogen) and random hexamer primers
(MWG Biotech). In a 0.5 ml microfuge tube 0.5-2 µg DNA was mixed with 3 µg
of random hexamers (3 µg/µl, Invitrogen) and made up to a total volume of 41.5 µl
with molecular biology grade water. The sample was incubated in a heat block at
95 ◦C for 5 min and then snap cooled on ice, followed by a brief centrifugation in a
microfuge. The labelling reaction was prepared by combining 5 µl 10×REact 2 buffer,
1 µl dNTPs (5 mM dA/G/TTP, 2 mM dCTP), 1.5 µl Cy3- or Cy5-dCTP and 1 µl
Klenow fragment (3–9 U/µl). This reaction mix is sufficient for one labelling reac-
tion. The reaction was incubated in dark for 120 min at 37◦C. Cy3- and Cy5- labelled
samples were mixed and purified using a MinElute kit following the manufacturer’s
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instructions (Qiagen). The mixture was eluted in 14.9 µl H2O.
2.7.4 Hybridisation and post-hybridisation washes
The mixture of test and reference samples in 14.9 µl H2O was combined with filtered
solutions of 4.6 µl 20×SSC and 2.0 µl 3·6% SDS to achieve a final 23 µl hybridiza-
tion solution of 4×SSC, 0·3% SDS. Mixed test and reference samples in hybridisation
solution (4×SSC, 0·3% SDS) were denatured at 95◦C for 2 min followed by a brief
centrifugation. The solution was hybridised to a microarray slide under a 22×22mm
Lifterslip (Eyrie Scientific). Arrays were incubated in a humidified hybridisation
chamber (Corning) placed in a water bath at 65◦C for 16–20 hours. Following hy-
bridisation the slides were washed once in 1×SSC, 0·06% SDS at 65◦C with agitation
for 2 min followed by two washes in 0.06×SSC with agitation for 2 min. Slides were
dried by centrifugation in a 50 ml Falcon tube at 1500 rpm for 5 min. Slides were
kept in the dark in a dust-free box until scanning.
2.7.5 Scanning and image processing
Microarrays were scanned using a GenePix 4000B laser scanner (Axon Instruments),
and fluorescence signals analysed using GenePix Pro 6.1 software (Axon Instruments).
Technically flawed spots were removed either automatically by the GenePix software
or through manual examination of the array images, and these spots were flagged as
‘poor’ in the GenePix results files.
2.7.6 Pre-processing and statistical analysis of gene expres-
sion data
Data points with a low intensity compared to background (signal-to-noise ratio of
≤3) in both channels (and on all arrays) were flagged as poor. Spots on the array
that did not pass the initial quality control and filtering procedure on all arrays were
down-weighted (0.1) during normalisation and in the following analysis steps. The
intensity of each spot was background corrected, each microarray normalised, and the
correlation between technical replicates (duplicate spots on each array) calculated us-
ing methods implemented in ‘Linear models for microarray data’ (Limma) (Smyth,
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2004). For background correction the method ‘normexp’ was used. This method gives
the lowest false discovery rate and additionally has the advantage of not giving neg-
ative values after adjustment (Ritchie et al., 2007). For experiments using genomic
DNA as a common reference each slide was normalised to median log2 ratios. Mi-
croarray data from cDNA: cDNA experiments were normalised using locally weighted
scatterplot smoothing (Lowess/Loess). Linear models as implemented in the Limma
package (Smyth, 2004) for the statistical software R (R Development Core Team,
2008), were used to identify differentially expressed genes. Control spots on the array
were removed before fitting the model. P-values were adjusted for multiple testing
to control false discovery rate (FDR) using the Benjamini and Hochberg step down
correction (Benjamini & Hochberg, 1995). Genes with an adjusted P-value of ≤0.01
or ≤0.05 (dependent on the experiment) and with a fold change of at least 1.5 are
reported as significantly different between conditions or time-points.
2.7.7 Pre-processing and statistical analysis of genomotyping
data
Data flagged as absent in GenePix were filtered out, local background (for each spot)
intensity was subtracted from the spot intensity and each microarray slide was nor-
malised to median log2 ratios. The designation of genes in each strain as present,
divergent or absent/highly divergent was achieved using Genomotyping Analysis by
Charlie Kim (GACK) (Kim et al., 2002). The GACK software uses the normal dis-
tribution to calculate a value of estimated probability of presence (EPP) for each
gene on the array. A gene is designated as present (1) if the calculated EPP is 100%,
as divergent (0) if the calculated EPP is between 0% and 100% and as absent (-1)
if the calculated EPP is 0%. Genes in strain MO1-240185 which were identical (or
similar) to genes found in MenA strain Z2491 and/or MenC strain FAM18 could also
be determined since pan-Neisseria arrays (Section 2.7.1) were used in all experiments.
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Figure 2.1: Illustration of how data points
(black) in a two-dimensional space are pro-
jected down orthogonally onto the first prin-
cipal component. The red points indicate the
projection on the component: the position of
the projected points on the principal compo-
nent is equivalent to the score of the obser-
vation for component one. Figure adaptated
with permission from Rantalainen (2008)
2.7.8 Visualisation (dimensionality reduction) and gene set
enrichment analysis
Hierarchical clustering of data on gene or sample level was performed in R using the
function hclust() . Principal component analysis (PCA) (Figure 2.1) of microarray
data was performed in R using the function prcomp() . Heat maps were constructed
using functions in the R-package gplots, available as part of the gregmisc add-on
package bundle (Warnes, 2003). Gene set enrichment analysis to detect differential
regulation of groups of genes was performed using the ‘Gene set enrichment analysis
(GSEA)’ software (Mootha et al., 2003) or the function geneSetTest() available in
the R-package Limma (Smyth, 2004).
2.8 Reverse transcription (RT) PCR for quantifi-
cation of transcripts
2.8.1 Semi-quantified RT-PCR
OneStep RT-PCR kit (Qiagen) was used according to manufacturer’s instructions
to confirm expression of a selected set of genes which were differentially expressed
in microarray analysis. RNA samples from each time-point were reverse transcribed
using random hexamer primers, and the resulting cDNA amplified with gene-specific
primers. The resulting products were separated in 2% agarose gels stained with
ethidium bromide. The intensity of bands on the gel image was quantified using
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ImageQuant software (GE Health Care/Molecular Dynamics). Ratios were calculated
for each comparison of interest by dividing the median intensities in the bands on the
gel. Primers used are listed in Table 2.5.
Table 2.5: Primers used in semi-quantified RT-PCR





2.8.2 Comparative real-time RT-PCR (TaqMan analysis)
Before analysis, the RNA was digested 2×15 min with DNase I on an RNeasy col-
umn (Qiagen) to remove contaminating genomic DNA. cDNA was synthesised from
total bacterial RNA using SuperScript III reverse transcriptase and random hexamer
primers (Invitrogen). The RNA was primed with 50 ng random primer per 1 µg of
total RNA. For each gene-specific primer and each sample, the TaqMan reaction was
performed using 5 ng of input RNA, both for cDNA (reverse transcribed from total
RNA) and with total RNA, examined to detect any signal attributable to contam-
inating DNA. Three biological replicates were assayed for each time-point in blood,
and four technical replicates of the TaqMan reaction were performed for each sam-
ple. The primers were designed and manufactured using Assay-by-Design (Applied
Biosystems) and primers and reporters are listed in Table 2.6 and Table 2.7, respec-
tively. Reporter dye and quencher were FAM and NFQ, respectively. All data were
normalised to the expression of 16s rRNA or two genes found to be relatively stable
in the microarray experiment (NMB0108 and NMB0184). The data were analysed
using the comparative CT (threshold cycle) method, in which the amount of target
normalised to 16s rRNA (in this case) and relative to a ‘calibrator’ is given by 2−44CT
(Applied Biosystems, 1997). Standard deviations were calculated as described by
Bookout & Mangelsdorf (2003).
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Table 2.7: Reporter sequences for TaqMan analysis
















2.9 Ex vivo infection models
2.9.1 Plasma assay
Fresh frozen plasmas (FFP) that were used in microarray studies were kindly provided
by HPA Porton Down and the Department of Haematology at St Mary’s Hospital.
All other blood plasmas used during this project were collected from adult volunteers
(informed consent). For microarray experiments N. meningitidis strain MO1-240185
was propagated for 4 hr on sGC agar plates. The cells were harvested into cell culture
medium RPMI 1640 (Sigma) to an OD600 of approximately 5. An initial load of 1–
5×107 cfu/ml was added to 20 ml plasma for the 60 min time-point and to 10–20
ml plasma for the 240 min time-point. The same inocula were used for growth in
RPMI 1640 (Sigma) supplemented with 10% heat inactivated (hI) FBS. At time-
points 60 and 240 min after inoculation an aliquot of the cultures was added to 4
times ice cold medium kept on ice. Bacteria were harvested by centrifugation and
RNA was isolated as described in Section 2.5.2. RNA was isolated from at least four
independent experiments. To assess the number of viable bacteria aliquots of plasma
Chapter 2: Materials and methods 66
were removed at various time-points, 100 µl of appropriate dilutions were plated in
triplicate on sGC agar. Results were expressed compared to time zero.
2.9.2 Human blood infection model
Fresh blood for the study was collected from adult volunteers (informed consent) into
heparinised tubes. Blood was maintained at 37◦C with 5% CO2, for less than 20 min,
until the time course was initiated. The whole blood assay method was adopted from
Ison et al. (1995). Briefly, about ten colonies of N. meningitidis from an overnight
sGC agar plate were sub-cultured onto a fresh sGC agar plate and incubated for 4
hours at 37◦C with 5% CO2. The cells were harvested into cell culture medium RPMI
1640 (Sigma) to an OD600 of approximately 1–5. Heparinised blood was inoculated
with 1–5×107 cfu/ml of meningococci and incubated on a rocking platform at 37◦C
with 5% CO2. To assess the number of viable bacteria, aliquots of blood removed at
various time-points, and 100 µl of appropriate dilutions in triplicate were plated on
sGC agar. Results were expressed compared to time zero.
2.9.2.1 Recovery of bacterial RNA from blood
At time-points 0, 20, 40, 60, 90 and 240 min after inoculation, aliquots of infected
blood were added to 4 volumes 5% Saponin (Sigma) in ice cold RPMI 1640 and
incubated for 10 min to lyse human cells. The lysate was mixed with RNAprotect
bacterial reagent (Qiagen) and cells were harvested by centrifugation at 3500 g for
10 min. The RNA was isolated from the corresponding pellet as described in Section
2.5.2.
2.9.2.2 Biochemical analysis of blood
At the start of a WBA experiment (Section 2.9.2) and at time-points up to 240
min post-infection with meningococci, aliquots of blood were removed for analysis
of a number of different constituents. As a control, uninfected blood incubated and
treated identically was also included in the analysis. Analysis was performed by the
Clinical Biochemistry unit at St Mary’s Hospital, London. For analysis of levels of
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glucose and lactate 200-400 µl of blood was added to microtainer tube containing
sodium fluoride and potassium oxalate and the cells were collected by centrifugation.
For analysis of complement (C3, C4 and total haemolytic complement) and iron,
400-500 µl blood was added to a serum-separating microtainer tube and the cells
collected by centrifugation. All the samples were kept on ice until analysis. Samples
that were going to be analysed for total haemolytic complement were stored at -80◦C
until analysis. For analysis of blood gases, 600 µl blood was collected in a 1 ml capped
syringe and analysed at once in a blood-gas machine (Rapidlab 865).
2.10 pH effect on N. meningitidis
About ten colonies of N. meningitidis strain MC58 from an overnight sGC agar plate
were sub-cultured onto a fresh sGC agar plate and incubated for 4 hours at 37◦C
with 5% CO2. Meningococci from solid agar were harvested into 3 ml of Muller-
Hinton broth supplemented with IsoVitalex (sMH) to an OD600 of 1. The cells were
harvested by centrifugation and the bacterial pellet was re-suspended in sMH buffered
with 50mM HEPES and adjusted to a pH of 7.4. The culture was further split into
two batches, and pH adjusted to either 7.4 or 7.8 using KOH. The pH of the medium
was adjusted with KOH solution rather than NaOH to avoid extra sodium ions,
which stress cells at high pH (Gerchman et al., 1993). Bacteria were cultured for 20
min at 37◦C with 5% CO2. 5 ml of each liquid culture were added to 2 volumes of
RNAprotect bacterial reagent (Qiagen) and the bacteria harvested by centrifugation.
RNA was isolated and processed as described in Section 2.5.2. RNA isolated from 6
independent experiments (biological replicates) were analysed using microarrays, as
described in Section 2.7.
2.11 Bioinformatic analysis
Public databases containing previously published protein and DNA sequences were
searched using the BLAST program (Altschul et al., 1990). Multiple alignments of
nucleotide and amino acid sequences were performed using the web based ClustalW
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with default settings (Larkin et al., 2007). The amino acid sequence was deduced
in silico from the nucleotide sequence using the Expasy translate tool (http://www.
expasy.ch/tools/dna.html) or using tools available in MEGA software (Tamura
et al., 2007). TEXshade was used to visualise alignments and representations of
protein characteristics and structure (Beitz, 2000). The MC58 (serogroup B), Z2491
(serogroup A) and FAM18 (serogroup C) genomes were interrogated using genome
information in the NCBI database (http://www.ncbi.nlm.nih.gov/genomes).
Table 2.8: TIGR main role categories
Amino acid biosynthesis Biosynthesis of cofactors, prosthetic groups and carriers
Cell envelope Cellular processes
Central intermediary metabolism DNA metabolism
Energy metabolism Fatty acid and phospholipid metabolism
Conserved hypothetical proteins Mobile and extrachromosomal element functions
Protein fate Protein synthesis
Purines, pyrimidines, nucleosides and nucleotides
biosynthesis
Regulatory functions
Transcription Transport and binding proteins
Unassigned Unknown function
Proteins were divided into functional groups according to their annotation in the
Comprehensive Microbial Resource at ‘The Institute for Genomic Research’ (TIGR)
(Peterson et al., 2001). All TIGR main role categories are listed in Table 2.8. For
predictions of cellular location of proteins PSORTb v2.0 (Gardy et al., 2005) and
PLSpred (Bhasin et al., 2005) were used. For predictions of signal peptides the
SignalP 3.0 server was used (Nielsen et al., 1997; Bendtsen et al., 2004), and for
determining the presence and location of twin-arginine signal peptide cleavage sites
TatP was used (Bendtsen et al., 2005b). Lipoproteins were predicted using LipoP
(Juncker et al., 2003), and non-classically secreted proteins with SecretomeP (Bendt-
sen et al., 2005a). Secondary structures were predicted using Jnet secondary struc-
ture prediction algorithm (Cuff & Barton, 2000). For prediction of transmembrane
α-helices either THMMM (Krogh et al., 2001) or TMpred (http://www.ch.embnet.
org/software/TMPRED_form.html) were used. For prediction of transmembrane β-
barrels either BOMP (Berven et al., 2004) or PRED-TMBB (Bagos et al., 2004a,b)
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were used.
2.12 Genetic nomenclature
MC58 genes are denominated by the letters NMB followed by a four digit number. In
this thesis genes will be annotated by their common name and NMB ID in the first
occurrence in each chapter, and thereafter only referred to by their common name.

Chapter 3
MenB growth and corresponding changes
in human blood
To model the scenario in na¨ıve hosts, blood from adults with absent bactericidal
activity to the meningococcal strains under investigation was used in all microarray
studies presented in this thesis. In this chapter is described how whole blood samples
from adults were tested, to find individuals whose blood could sustain meningococcal
growth (i.e. ‘non-killers’). Any changes in composition of ‘non-killer’ and ‘killer’
blood samples during incubation with or without the addition of bacteria were also
determined. These results were used to explain some of the transcriptional responses
to in vitro growth in blood (Chapter 6).
3.1 Introduction
During septicaemia, immune defences, both innate and adaptive, are activated along
with inflammatory factors. Host immune responses during meningococcal disease
have been discussed in Section 1.2.5.1. The hallmark of meningococcal disease is
the uncontrolled production of inflammatory factors, such as the pro-inflammatory
cytokine TNF-α, which contribute to septic shock through activation of immune cells
and the pro-coagulant system, leading to the high mortality. Increases in plasma
lactate are commonly observed in patients with severe sepsis and this increase has
been correlated with poor outcome (Bakker et al., 1991). The observed increase in
plasma lactate was initially suggested to be an effect of tissue hypoxia, but has in
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more recent studies been linked to effects of cytokines and local inflammation (Gore
et al., 1996; Gutierrez & Wulf, 1996).
3.1.1 In vitro (ex vivo) models of meningococcal sepsis
Experimental systems exploiting serum bactericidal activity (Goldschneider et al.,
1969) or whole blood killing (Heist et al., 1922; Ison et al., 1995) have been used
to model meningococcal survival or killing in the bloodstream (Section 1.2.6). Heist
et al. (1922) coined the terms ‘non-killer’ and ‘killer’ to described individuals whose
blood respectively supported or failed to support the growth of meningococci in whole
blood.
In vitro models that have been used to mimic events during septicaemia include
the incubation of whole bacteria or bacterial components, such as LOS, in whole
blood or co-incubated with isolated blood cells. Several groups have studied the
effects of incubating meningococci, or adding bacterial factors, in whole blood or
plasma, mainly focusing on immune and inflammatory responses (Ison et al., 1995;
Gagnon et al., 1998; Padro´n et al., 1999; Hellerud et al., 2008). Cytokine release
during incubation of meningococci in whole blood has been shown to be similar to
responses in patients with meningococcal sepsis (Nolte et al., 2002), indicating the
relevance of this assay for modelling meningococcal sepsis.
In the developed world meningococcal disease is most common in children under the
age of five (Gray et al., 2006; Caro et al., 2007), who generally do not have protective
antibodies against N. meningitidis. In this chapter whole blood collected from adult
donors was tested in the whole blood assay to find individuals whose blood could
sustain meningococcal growth. In addition, changes to a number of components of
blood (from ‘killers’ or ‘non-killers’) were determined during incubation in vitro either
with or without meningococci.
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3.2 Results
3.2.1 Growth of meningococci in blood from adult donors
5–10% of adults in the UK are ‘non-killers’ of one or several N. meningitidis strains:
that is, the bacteria proliferate in their anti-coagulated whole blood (Ison et al. un-
published). To identify such individuals the survival of MenB strains was initially
tested in plasma and/or blood samples donated by twenty adult volunteers. Survival
was determined by serial dilution of plasma or blood followed by plating out (100
µl) in triplicate for quantitative determination of CFU (Section 2.9.2). Time-points
between 0 to 240 min were explored to determine the behaviour of MenB when incu-
bated over time in blood or plasma. Two individuals (A and B) were found to have
essentially absent or low bactericidal activity against the test strain of N. meningitidis
in both whole blood and plasma. Survival of MenB strain MC58 in non-bactericidal
whole blood (A and B) in contrast to survival in bactericidal whole blood (donors C
and D) is shown in Figure 3.1.
In fulminant meningococcal sepsis, numbers of bacteria in blood have been deter-
mined to be 104–105 cfu per ml using quantitative direct plating procedures (Zwahlen
& Waldvogel, 1984). In a later study, the copy number of meningococcal DNA in
blood was found to be 105–5×108 with a median of 2×107 during fulminant meningo-
coccal septicaemia (Øvstebø et al., 2004), indicating potentially higher bacterial loads
than determined by plating methods. In the whole blood assay an addition of 109
cfu per ml bacteria at the start of the experiment was found to overwhelm the killing
capacity of the blood (donor F) (Figure 3.2). A substantially increased survival was
observed using 109 cfu per ml bacteria in comparison to an initial load of 107 cfu per
ml bacteria (survival at 90 min 535.48% versus 1.26%). For all studies, the initial in-
oculum of bacteria was therefore kept to the minimum sufficient to allow the isolation
of enough RNA for a microarray profiling experiments (Chapter 5 and 6).
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Donor B Donor C Donor D





























Figure 3.1: Growth of MenB strain MC58 in blood from donor A (‘non-killer’), A +
bactericidal plasma (E), B (‘non-killer’), C (‘killer’) and D (‘killer’). Graph 1 shows the
survival or killing of MenB in blood from donor A, A + bactericidal plasma (E), C and
D (assay day 2). Graph 2 shows the survival of MenB in blood from donor B (assay day
3). Note that the time scale are different in graph A and B. An initial load of 107 cfu
per ml meningococci were added to heparinised blood followed by incubation. CFUs were
determined by plating out appropriate dilutions on solid sGC agar. Error bars represent
standard deviations of technical replicates (measuring error).
















Figure 3.2: The initial load of meningococci affects the bacterial survival over time in
blood. At an initial load of 1.6×109 cfu per ml (solid line) the bacteria survived up to 180
min in blood from this individual (donor F), whereas at a lower initial load (2.7×106 cfu per
ml, dashed line) bacteria were killed. Error bars represent standard deviations of technical
replicates within assays.
3.2.2 Changes to blood upon infection with meningococci
Since blood composition (carbohydrates, electrolytes) may affect bacterial growth, dif-
ferent constituents of blood were measured using a blood-gas machine or biochemical
tests (Section 2.9.2.2). Analyses of blood samples from four individuals, two non-
bactericidal (A and B) and two bactericidal (C and D) to MenB strain MC58, were
performed before the start of the experiment, and during incubation in vitro at time-
points until 240 min. These measurements were performed on blood infected with
meningococci, as well as on uninfected blood, otherwise treated identically. Growth
of meningococci in blood samples from the four individuals are shown in Figure 3.1.
To evaluate if there were any differences dependent on whether MC58 was growing or
being killed, blood samples collected from donor A was mixed with ∼10% bactericidal
plasma (E), which rendered the blood sample bactericidal (Figure 3.1 (1)).
At the start of the experiments all results were within the normal clinical range for
the parameters measured, and most of the measured entities, including iron and sev-
eral electrolytes, stayed within the physiological range during the time course (Tables
3.2 – 3.3). Comparison of physiological changes in bactericidal and non-bactericidal
blood samples during the course of the assay did not indicate any relationship between
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meningococcal growth and changes in measured entities. For example, no significant
change was detected in total levels of complement C3 in blood samples upon incu-
bation with meningococci over a 90 or 240 min time period, independent of whether
the blood was bactericidal or non-bactericidal to N. meningitidis. This shows, as
expected, that C3 is abundantly available in blood and not exhausted during a 240
min WBA, even while meningococci are killed. Levels of soluble total haemolytic
complement (THC) were measured at 0, 90 and 240 min in blood samples from three
individuals (Donor A, B and C). None of the measured values were outside the normal
reference range (23–46 U/ml) for the assay. Levels of extracellular iron in blood did
not noticeably change during the course of the experiment. In addition, no significant
change was observed in levels of potassium, a marker of haemolysis (Jay & Provasek,
1993), suggesting that this was negligible in the course of a 240 min experiment. Over
a 240 min incubation of blood samples, there were significant changes in the concen-
tration of blood glucose and lactate (Figure 3.3). Over the time course blood lactate
increased, while plasma glucose decreased. The initial changes, up to 90 min, are
most likely independent of bacterial growth since the same change was observed in
both infected and uninfected blood samples (Table 3.1). In blood samples containing
overwhelming levels of bacteria (fast-growing meningococci) (B, assay 3) (Figure 3.1
(2)), a decrease in the level of lactate was observed between 90 and 240 min.
Table 3.1: Changes in levels of glucose and lactate over time during incubation in vitro of
infected or uninfected blood samples from all individuals. Levels are given as mean mmol/l
with errors given as standard deviations (in parenthesis).
Time (min) Infected blood Uninfected blood
Glucose 0 5.08 (0.35) 5.40 (0.63)
90 3.72 (0.27) 3.98 (0.28)
240 0.98 (0.71) 1.95 (0.07)
Lactate 0 1.88 (0.68) 2.13 (0.86)
90 4.06 (0.89) 4.70 (0.93)
240 4.90 (4.22) 8.75 (0.07)
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Donor C (infected) Donor C (uninfected) Donor D (infected)












































Figure 3.3: Changes in levels of glucose and lactate in blood samples over time.
Data for glucose are shown at the top and data for lactate at the bottom in the figure.
All solid symbols show data from experiment for blood samples infected with bacteria, and
open symbols show data from experiments for blood samples without bacteria (uninfected).
Blood glucose levels decreased over time, whereas blood lactate levels increased, with the
exception of data at 240 min in one assay (donor B (solid blue square)). Red lines show the
normal reference range in blood for this particular analytical method
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Table 3.2: Changes in nutrients and complement in blood upon in vitro incubation for
90 or 240 min with MenB bacteria (strain MC58) added (infected) or without added bac-
teria (uninfected). Heparinised whole blood was collected from killers or non-killers of
meningococci: individual A (non-killer), individual B (non-killer), individual C (killer) and
individual D (mild killer). In some assays using blood from individual A bactericidal plasma
from a killer was added to the blood (A + E). Blood was inoculated with 107 cfu per ml
of MC58 and incubated up to 240 min. All data for time-point 0 min is taken before the
addition of bacteria. Groups of rows shaded in the same colour (grey or white) represent












A 1 0 N.D. 6.1 3.0 0.86
A 1 40 N.D. 5.3 4.2 0.91
A 1 60 N.D. 4.8 4.6 0.89
A 1 90 N.D. 4.3 6.1 0.90
A + MC58 1 40 N.D. 5.1 4.0 0.91
A + MC58 1 60 N.D. 4.5 4.4 0.91
A + MC58 1 90 N.D. 3.8 5.5 0.90
A + MC58 2 0 20 4.9 2.3 0.86
A + MC58 2 40 19.8 4.5 3 0.84
A + MC58 2 60 21.2 4.2 3.4 0.84
A + MC58 2 90 22 3.5 4.2 0.84
A + E (10%) + MC58 2 0 18.2 4.9 2.1 0.86
A + E (10%) + MC58 2 40 17.7 4.7 2.7 0.88
A + E (10%) + MC58 2 60 18.8 4.4 3.2 0.86
A + E (10%) + MC58 2 90 19.5 3.8 3.8 0.88
A 4 0 20.8 4.6 2.7 1.00 ≤11∗
A 4 90 22.4 3.7 4.9 0.99 34
A 4 240 25 1.9 8.8 1.05 33
A + MC58 4 90 21.8 3.4 4.9 1.00 30
A + MC58 4 240 24.5 1.2 7.9 1.06 26
A + E (10%) + MC58 4 0 20 4.7 2.6 1.04 38
A + E (10%) + MC58 4 90 20.1 3.6 4.6 1.01 32
A + E (10%) + MC58 4 240 23.1 1.8 8.9 1.07 30
B + MC58 3 0 15.1 5.5 1.5 1.00 26
B + MC58 3 90 15.6 3.7 2.8 0.98 34
B + MC58 3 240 17.2 0.1 0 1.02 29
C 2 0 16.6 5.6 1.2 1.04
C 2 40 17 5.1 2.3 1.02
C 2 60 17.5 4.7 3 1.03
C 2 90 18.7 4.1 3.9 1.00
C + MC58 2 40 17.4 5 2.4 1.01
C + MC58 2 60 19.5 4.5 3.2 1.04
C + MC58 2 90 20.1 3.9 4 1.01
C 3 0 20.5 5.3 1.6 1.08 41
Continued on next page . . .
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C 3 90 21.7 3.8 4.5 1.08
C 3 240 24.8 2 8.7 1.07
C + MC58 3† 90 20.7 3.5 3.9 1.08 42
C + MC58 3† 240 23.3 0.8 2.8 1.11 36
D + MC58 2 0 7.9 5.4 0.9 0.83
D + MC58 2 40 8.4 5.1 1.6 0.82
D + MC58 2 60 9.1 4.8 2.1 0.80
D + MC58 2 90 9.2 4.3 2.8 0.81
Reference ranges: Glucose: 3.9-6.1 mmol/l, Lactate: 0.5-2.2 mmol/l, C3: 0.75-1.35,
CH50: 23-46 U/ml. ∗ Failed assay. † In this assay MC58 survived in donor C’s blood.
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3.2.3 The effect of blood pH on the meningococcal transcrip-
tome
The median pH of freshly drawn heparinised blood samples was 7.4 and increased to
7.54 at 90 min upon incubation at 37◦C with 5% CO2, as determined by measurement
in a blood-gas machine (Section 3.2.2). In some cases the pH change was more
dramatic with an increase at 90 min to 7.7. This shift towards more alkaline pH was
observed both in infected and uninfected blood samples indicating that the addition
of bacteria did not contribute to the increase (Figure 3.4). At 240 min there was a
decrease in pH in blood, and a significant difference was observed between infected
and uninfected blood samples (Figure 3.4). During growth on glucose meningococci
produce acetate that decreases the pH of the growth medium (Leighton et al., 2001),














Figure 3.4: pH of blood samples from four different individuals, at 0, 90 and 240 min post
collection. The pH of blood was measured using a blood-gas machine. White boxes depict
pH in blood samples infected with meningococci, and grey boxes depict pH in uninfected
blood samples. Red lines show the normal reference range in blood, for this particular
analytical method
Since the pH of blood was found to increase (in a few cases) upon in vitro incuba-
tion, transcriptional changes induced by subtle differences in pH were assessed to rule
out any major effects on the meningococcal transcriptome. Attempts to consistently
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buffer pH in blood samples during in vitro incubation with meningococci were not
successful, so the meningococcal transcriptional changes in response to differences in
pH were instead determined in buffered standard broth culture. MenB strain MC58
was sub-cultured from liquid culture (pH 7.4) into broth with a pH of 7.4 or 7.8
and further incubated for 20 min before isolation of RNA as per Section 2.10. Mi-
croarray technology was used to analyse the gene expression of meningococci at pH
7.8 versus 7.4 (as described in Section 2.7). A direct comparison (cDNA vs. cDNA
hybridisation) was performed. The microarray data were analysed as described in
Section 2.7.6. The shift in pH from 7.4 to 7.8 did not induce any major changes in
the meningococcal gene expression. Six genes, all down-regulated, were found to be
significantly differentially expressed with a fold change of ≥1.5 and a P-value of ≤0.01
after multiple testing correction (Table 3.4). All of the differentially expressed genes,
except rplD, have previously been shown to be involved in responses to nitric oxide
or anaerobic growth.
Table 3.4: Differentially expressed meningococcal genes in response to growth at pH 7.8
versus 7.4 in sMH broth
ID Name Annotation Fold change P-value*
NMB0143 rplD 50S ribosomal protein L4 -3.03 1.61E-03
NMB0577 NosR-related protein -1.61 9.17E-09
NMB0578 nosD copper ABC transporter, periplasmic
copper-binding protein
-1.52 6.24E-06
NMB1622 norB nitric oxide reductase -1.95 3.69E-05
NMB1623 aniA major anaerobically induced outer mem-
brane protein
-1.75 6.24E-06
NMB1624 nirV hypothetical protein -1.82 7.04E-07
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
3.3 Discussion
To be able to model the transcriptional response of N. meningitidis in blood or plasma
in a na¨ıve host, individuals whose blood sustained meningococcal survival had to be
identified. By screening blood samples from twenty adult volunteers, two individuals
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were found to have virtually absent bactericidal activity against strain MC58, using
an initial load of bacteria of 107 cfu/ml.
An initial addition of 109 cfu/ml meningococci into blood at the start of the exper-
iment overwhelmed the killing capacity of the blood system. To model septicaemia
realistically it was essential to add an initial load of meningococci as close as possible
to a clinically relevant load of bacteria in sepsis. Using quantitative direct plating pro-
cedures the number of bacteria in fulminant meningococcal sepsis has been suggested
to be 104–105 cfu per ml (Zwahlen & Waldvogel, 1984), while using more recently
developed nucleotide based methods, copies of meningococcal DNA have been found
to be even higher, between 105 and 5×108 with a median of 2×107 copies per ml
during fulminant meningococcal septicaemia (Øvstebø et al., 2004). It is necessary
to design experiments so that enough RNA can be extracted for expression analysis,
while keeping the bacterial load on an as realistic level as possible. In our experi-
mental setup an initial load of 1–5×107 cfu per ml blood (in 5–10 ml of blood) was
enough to isolate sufficient amounts of RNA.
To ascertain that no major changes occurred in blood constituents during in vitro
incubation of infected or uninfected bactericidal or non-bactericidal blood samples,
analytes were followed over 240 min time courses, representing the planned time
course for the gene expression experiments later carried out (Chapter 6). Levels of
complement C3 and soluble THC (CH50) were measured to determine if any difference
could be observed between bactericidal and non-bactericidal blood. Neither C3 nor
soluble THC changed during the time course, irrespective of whether the blood sample
was bactericidal or non-bactericidal. C3 is present in substantial concentrations in the
blood, which may explain why no difference could be observed. Furthermore, Jarvis
(1994) previously showed that C3 binds to the surface of bacteria in equal amounts,
regardless of whether the strain is serum-sensitive or serum-resistant. Difference in
bacteriolysis of meningococci has been suggested to be independent of the amount
of deposited complement on the surface, but instead to be associated with correct
insertion of the MAC complex in the surface of the bacteria (Drogari-Apiranthitou
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et al., 2002). During the time course in whole blood, a change was observed in
blood glucose (decreased) and in blood lactate (increased). In assays with the fastest
bacterial growth, levels of lactate were found to first increase, but then decrease to the
240 min time-point, indicating that bacteria utilised the available lactate as an energy
source when a limited amount of glucose was available in the blood. Metabolism of
glucose to lactate (1:2 ratio) has previously been observed during in vitro incubation
of erythrocytes (Gomperts, 1967; Sullivan & Stern, 1983, 1984). Haji-Michael et al.
(1999) observed increased lactate levels when whole blood was stimulated with LPS,
and suggested that the production of lactate may be a by-product of inflammation.































Figure 3.5: Gene expression of pH responsive genes in blood over the time course
In some of the whole blood assays in this study, the pH of blood samples increased
during the time course. N. gonorrhoeae autolysis has been observed at pH over 8
(Elmros et al., 1976), but, pH in blood never exceeded 7.8 in the experiments presented
here. To ascertain that the increased pH of blood did not induce a major shift in
gene expression, the meningococcal transcriptional profile in response to incubation
at pH 7.8 was determined in comparison to bacteria grown at the physiological pH
7.4. MenB subjected to mildly alkaline pH was shown to respond by down-regulation
of a very limited set of genes (N = 6). The expression of five of these genes during
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meningococcal growth in blood is shown in Figure 3.5. NMB0577, aniA and NMB1623
were down-regulated also in blood at one or more time-points (Chapter 6). On the
other hand, expression of aniA (NMB1623) and NMB1623 increased to 20 min (the
time-point explored in the pH experiment) during growth in blood.
Chapter 4
Genomotyping of MenB strains used in
genome-wide transcriptional studies
In this chapter MenB strains that were used in microarray studies were genomotyped.
The microarrays that were used in genome-wide transcriptional studies (Chapter 5
and Chapter 6) are based on MenB strain MC58, and since MenB strain MO1-240185
was used in the studies in Chapter 5, the difference in gene content between the two
strains was determined. This study was also performed to assess how well MenB
strain MO1-240185 was represented on the microarray.
4.1 Introduction
4.1.1 Genomotyping
Genomotyping methods, based on hybridisation to microarrays, can be used to com-
pare the genetic material of bacterial strains. Genomotyping can be used to identify
absent or highly divergent genes (a distinction cannot be made) in the so-called ‘test’
strain compared to the ‘reference’ strain. Detection is limited to genes represented
on the microarray, and the method can not be used for discovery of novel genetic
material. Genomotyping has been used to compare Neisserial strains to any of the
meningococcal genome sequence strains (Bille et al., 2005; Stabler et al., 2005; Ho-
topp et al., 2006; Snyder & Saunders, 2006). These, and other studies, have shown
that many of the genes encoding meningococcal so-called virulence factors can be
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found not only in both disease and carriage-associated isolates of N. meningitidis
(Schoen et al., 2008), but also in the non-pathogenic N. lactamica (Snyder & Saun-
ders, 2006). A few genomic elements have however only been identified in invasive
strains of meningococci, including the phage Nf1 associated with hypervirulent lin-
eages (Bille et al., 2005). The phage is thought to contribute to virulence by changing
transmission rates in certain age groups.
Data are presented on the difference in gene content, as determined by genomo-
typing, between N. meningitidis serogroup B strains MC58 and MO1-240185. MenB
strain MO1-240185 was used in the plasma infection model discussed in Chapter 5
and MenB strain MC58 was used in the blood infection model discussed in Chapter
6.
4.2 Results
4.2.1 Genomic composition of MenB strain MO1-240185
Differences in gene content between MenB strains MC58 (B:15:P1.7,16-2) and MO1-
240185 (B:2A:P1.5-10-8), used in the plasma transcriptome study (Chapter 5), were
determined by hybridisation of differentially labelled genomic DNA to a pan-Neisseria
microarray (described in Section 2.7.1). This array is based on strain MC58 genes
but also contains meningococcal genes from serogroup C strain FAM18 and serogroup
A strain Z2491. The strain MO1-240185 belongs to the ST-11 clonal complex (a
hypervirulent lineage associated with invasive disease) and may therefore be expected
to have similarity to other strains belonging to this clonal complex, which include the
MenC sequence strain FAM18.
Dye-swap experiments were performed to control for possible differences in in-
corporation of fluorescently labelled Cy5-dCTP and Cy3-dCTP. Normalised log2 ra-
tios from microarrays were analysed using the software GACK, which calls genes as
either absent (‘-1’), divergent (‘0’) or present (‘1’) (Kim et al., 2002) (Section 2.7.7).
Using this approach three IHTs present in the MC58 genome, but absent in FAM18
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and Z2491 genomes, were also called as absent in MenB strain MO1-240185. The list
of genes called as ‘absent’ by GACK (N = 165) was compared to a list of stipulated
MC58 specific genes from Bentley et al. (2007). Eighty-nine out of the ninety-five
genes listed were represented in the microarray data after quality control, and of
these, all except five were found to be absent from strain M01-240185. This suggests
that genes absent in MenB strain MO1-240185 are found specifically in the MenB se-
quence strain MC58. Data obtained for MenB strain MO1-240185 were compared to
publically available genomotyping data for fifty-three Neisseria strains in comparison
to MC58 DNA obtained by Hotopp et al. (2006). Hierarchical clustering analysis was
performed using average linkage and a distance metric based on correlation (1–Pearson
correlation), using microarray data collected for strain MO1-240185 and data from
Hotopp et al. (2006) (Figure A.1). This analysis indicated that strain MO1-240185 is
similar to strains of the ‘mCGH-3’ type defined by Hotopp et al. (2006), which also
includes MenC sequence strain FAM18. The meningococcal strains in this cluster all
contain the so called IHT-E region, as does MO1-240185 (Figure 4.1).
Genes in MC58















Figure 4.1: Log2 ratios for genes on the microarray covering the so called Neisserial
IHT-E region found in MenC reference strain FAM18. Genomic DNA from all strains
was compared to the serogroup B reference strain MC58. Grey lines represent data from
Neisserial strains in cluster ‘mCGH-3’ (data from Hotopp et al. (2006)). Data for strain
MO1-240185, collected in this study, is depicted in red. Each point in the graph represents
a gene on the pan-Neisseria microarray. Genes also present in the genome of strain MC58
(MenB) are indicated in the graph.
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4.3 Discussion
Comparison of the gene content of MO1-240185 and MC58 revealed that 91% of the
genes are shared, i.e. not called as absent by the GACK software. The majority of the
genes that were included among the absent genes in MO1-240185 compared to MC58
were genes with hypothetical function or genes in IHT regions. Strain MO1-240185
belongs to the same clonal complex, ST-11/E-37, as the serogroup C strain FAM18,
which is represented on the microarray used. As expected, MenB strain MO1-240185
contained several genes found in the FAM18 genome sequence, and hybridised to 68
out of the 125 MenC specific spots on the microarray.
In conclusion, the strain MO1-240185 is comparable to strain MC58 and well
represented on the pan-Neisseria microarrays used in the genome-wide transcriptional
studies.
Chapter 5
Genome-wide transcriptional profiling of
serogroup B meningococci in plasma
In this chapter the transcriptional profiling of MenB, upon incubation in whole human
non-bactericidal plasma, is presented. The changes in the meningococcal transcrip-
tome were determined by using microarrays. Genes of particular interest were those
encoding surface exposed proteins which were up-regulated in this experimental sys-
tem.
5.1 Introduction
A vaccine based on surface exposed antigenic proteins represents one potential strat-
egy for achieving an effective cross-protective MenB vaccine (discussed in Section
1.4.1.2). Meningococcal genes encoding surface exposed proteins that are up-regulated
during infection, or in conditions mimicking in vivo bacterial growth, are attractive
candidates for inclusion in such a vaccine. The objective of the study presented in this
chapter was to identify MenB genes encoding known or putative surface exposed pro-
teins, which were relatively or exclusively up-regulated during incubation in plasma,
a simple model of bacteraemia, compared to models of colonisation.
5.1.1 Bacterial growth and survival in serum or plasma
In vitro growth of bacteria in serum or plasma can be used to model bacterial growth
in the blood stream of the host. N. meningitidis killing by the human host is primarily
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mediated through the action of complement to which the bacteria are exposed during
in vitro incubation in either serum or plasma. N. meningitidis surface structures that
are associated with increased survival in human serum include the polysaccharide
capsule, LOS and surface proteins that interact with human immune defence pro-
teins; for example factor H binding protein encoded by NMB1870 (Vogel et al., 1997;
Kahler et al., 1998; Madico et al., 2006). Studies utilising mutagenesis with tagged
transposons have also revealed the importance of de novo biosynthesis of purine nu-
cleotides and amino acids as well as up-take of iron for bacterial survival both during
in vitro growth in serum and in animal models of systemic infection (Wang et al.,
1996; Fuller et al., 1999; Sun et al., 2000; Samant et al., 2008). Specific genes that are
important for meningococcal survival during infection are discussed in greater detail
in Chapter 6, as many of them are foremost relevant for bacterial growth in blood.
5.1.2 Microarray studies
Genome-wide transcriptional profiling has been extensively used to study the re-
sponses of bacteria to a broad range of biological conditions, both in vivo and in
vitro (Ye et al., 2000; Smoot et al., 2001; Fisher et al., 2002; Grifantini et al., 2002b;
Phadtare et al., 2002; Bina et al., 2003). Transcriptional changes in response to
plasma or serum exposure have been determined for several human pathogens in-
cluding Yersinia pestis (Chauvaux et al., 2007) and Klebsiella pneumoniae (Hsieh
et al., 2008). Up-regulated genes included those involved in iron acquisition, thiamine
biosynthesis and purine/pyrimidine metabolism. The meningococcal transcriptome
in normal human serum (NHS) has previously been explored by Dove et al. (2003)
and Kurz et al. (2003). Dove et al. (2003) compared the transcriptional changes in
strain Z5463 (serogroup A) upon incubation in 25% NHS for 6 hr to those in meningo-
cocci incubated in heat inactivated (hI) serum for 6 hr. The most highly differentially
expressed gene was NMA1686, a serogroup A orthologue to MenB gene NMB1475,
encoding a hypothetical protein that may be involved in universal stress responses.
Kurz et al. (2003) investigated the transcriptional changes induced in meningococci
upon growth in 100% NHS for 30 min compared to growth in phosphate buffered
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saline (PBS) and found 279 genes to be differentially expressed including those en-
coding proteins involved in categories such as metabolism, transport and translation.
Twenty-three of the up-regulated genes encoded known or predicted OMPs, including
NMB0586 and NMB1966, encoding components of a Mn2+/Zn2+ and a L-glutamate
transporter respectively (Monaco et al., 2006; Lim et al., 2008).
In the study presented in this chapter meningococcal gene expression profiles were
determined at 60 and 240 min, during incubation in non-bactericidal plasma. The
same time-series was studied for meningococci grown in liquid laboratory medium to
attempt to identify changes specific to exposure to components of the plasma. The
reason for doing a time-series (although sparse) was to explore temporal changes in
gene expression upon meningococcal growth in plasma. Two different experimental
designs were evaluated; either gene expression in plasma in relation to growth in
laboratory medium or in relation to an initial starting point. In these experiments
plasma from two individuals were used due to limited availability from each donor.
The reason for using plasma rather than blood in the study in this chapter was that
plasma studies are easier to standardise than those in blood, as plasma can be stored
and used in a set of experiments over time, and that work in plasma is experimentally
simpler. In addition, isolation of RNA from bacteria in blood initially proved difficult,
and could only be accomplished after extensive testing of different methods. Results
from transcriptional profiling during growth in plasma are presented below, with a
particular emphasis on genes up-regulated in this growth condition that may encode
surface exposed proteins.
5.2 Results
Most adults in the UK have naturally acquired bactericidal antibodies to a range
of MenB strains, and accordingly are classified as ‘killers’ in the serum bactericidal
and/or the whole blood assays (further discussed in Chapter 1 and 3). So as to be
able to determine genome-wide transcriptional changes during growth in non-immune
individuals, plasma samples from adult volunteers and fresh frozen plasma, acquired
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through external collaborators (Section 2.9.1), were screened to identify those that
could sustain meningococcal growth. The MenB strain MO1-240185 (B:2a:P1.5-10-
8) and MenB reference strain MC58 (B:15:P1.7,16-2) were incubated in fresh frozen
plasma (FFP) from two different adult individuals, using an initial inoculum of 107
cfu/ml. The growth characteristics of each of the strains in fresh frozen plasma from
individual 1 (FFP 1) and individual 2 (FFP 2) are shown in Figure 5.1. Each plasma
sample supported the sustained growth of strain MO1-240185, but they differed in
their ability to support growth of strain MC58. In FFP 1 neither substantial growth
nor killing of strain MC58 was observed over 3 hr. On the other hand, FFP 2 was
bactericidal to strain MC58. This confirms that bactericidal antibodies to surface
structures other than the capsular polysaccharide are of importance for controlling
growth of MenB in the circulation. The strain MO1-240185, used in all gene expres-
sion studies presented in this chapter, belongs to the ST-11 clonal complex, a hy-
pervirulent lineage responsible for several outbreaks of meningococcal disease. These
outbreaks have mainly been associated with serogroup C meningococci. A serogroup
C strain of the 2a phenotype belonging to this clonal complex was associated with
the increase in meningococcal disease in UK in the 1990s (discussed on page 27), and
there is concerns that serogroup B strains of the same phenotype could also emerge as
a threat. Therefore studies into the pathogenicity of MenB strains of this phenotype,
such as MO1-240185, are important. Plasma from these two individuals (FFP 1 and
FFP 2) was used in the genome-wide transcriptional profiling studies presented in the
following sections.
In all studies RNA was isolated from bacteria at 60 and 240 min post-inoculation
(as described in Sections 2.5.2 and 2.9.1) and the transcriptional profile at each time-
point analysed using pan-Neisseria microarrays (Section 2.7). The quantity of RNA
obtained from meningococci was determined by measuring the absorbance at 260
nm (A260) using a Nanodrop spectrophotometer (Section 2.6.1). The purity of the
RNA was determined by the A260/A280 ratio. In order to further assess the quality
of the RNA, samples were separated on a non-denaturing 1% agarose gel (Section















Figure 5.1: Growth over time of MenB strains MO1-240185 and MC58 in fresh frozen
plasma from two donors. Data of growth in FFP 1 are shown in orange and data of growth
in FFP 2 are shown in dark grey. Data for strain MO1-240185 are represented by a solid
line and data for strain MC58 by a dashed line. Number of bacteria at time-point 0 min,
60 min and 180 min were determined by serial dilution and spreading out in triplicate
(technical replicates) on solid support for CFU count. In both FFP 1 and FFP 2 growth of
strain MO1-240815 and strain MC58 differed. Error bars represent standard deviations of
technical replicates.
2.4). On a non-denaturing gel two bands corresponding to 23S rRNA and 16S rRNA
are visible (Figure 5.2). The 23S rRNA band should be more intense than the 16S
rRNA band in intact good quality RNA (at a ratio of 1.5–2:1). Isolated RNA samples
were reverse transcribed to cDNA, labelled with Cy5-dCTP and co-hybridised with
Cy3-dCTP labelled MC58 genomic DNA (gDNA) to pan-Neisseria microarray slides
featuring probes representing the whole meningococcal gene complement of strains

















1 2 3 4 5 Figure 5.2: Agarose gel image of total RNA
isolated from MO1-240185 incubated in fresh
frozen plasma (FFP 1) or medium. RNA sam-
ples were further treated with DNase I and
cleaned up on an RNeasy column before mi-
croarray analysis. Lane 1: FFP 1 60 min;
lane 2: Medium 60 min; lane 3: FFP 1 240
min; lane 4: Medium 240 min; lane 5: 1µg
rRNA E. coli. Arrows indicate the 16S and
23S rRNA subunits.
In the microarray experiments described in this chapter, a common reference de-
sign was used which facilitated comparison between all time-points and conditions.
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In all experiments MC58 genomic DNA (gDNA) was used as the reference sample,
hybridising to all MenB specific spots on the microarray. The use of gDNA as a com-
mon reference has been described and discussed by Kim et al. (2002) and Gadgil et al.
(2005). A representative microarray image of a cDNA versus gDNA hybridisation is
shown in Figure 5.3. Microarray data were analysed as outlined in Section 2.7.6.
Briefly, data collected from microarrays were pre-processed to remove spots with low
fluorescent intensity across all microarray slides. Ratio data were normalised to me-
dian log2 ratios per slide. Normalised data were analysed by means of moderated
t-statistics and an empirical Bayes variance adjustment as implemented in the R-
package Limma, to find differentially expressed genes (Smyth, 2004; R Development
Core Team, 2008). A gene was considered to be significantly differentially expressed
between classes when the change was ≥ ±1.5-fold at a FDR of 5% (meaning that less
than 5% of the selected genes are expected to be false positives).
Figure 5.3: A representative microarray image of a cDNA versus gDNA hybridisation.
Fluorescently labelled samples were hybridised overnight to a pan-Neisseria microarray.
In the following sections, experiments involving FFP 1 and FFP 2 will be described
separately. In experiment one, using FFP 1, the gene expression profile of bacteria
incubated in plasma was compared to that of bacteria incubated over the same period
of time in cell culture medium (Section 5.2.1). In experiment two, using FFP 2,
the transcriptional profile of bacteria incubated for different periods in plasma was
compared to bacterial gene expression at time-point 0 min (Section 5.2.2).
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5.2.1 Transcriptional profile in FFP 1 in relation to gene ex-
pression in medium
The gene expression profile of MenB strain MO1-240185 in FFP 1 was compared to
bacteria incubated in growth medium RPMI 1640 supplemented with 10% hI fetal
bovine serum (medium) in a parallel experiment. The growth of MO1-240185 in
plasma was comparable to growth in medium over a 240 min experiment (Figure














Figure 5.4: Growth over time of MenB strain MO1-240185 in plasma and medium. The
solid orange line shows growth in FFP 1 and the black dashed line shows growth in medium
after 0, 60 and 240 min incubation. The graph depicts the mean of three assays for time-
point 60 min and six assays for time-point 240 min. Error bars represent standard deviations
of biological replicates. The growth rate was comparable for meningococcal strain MO1-
240185 in plasma and medium.
of plasma or medium. In a representative gel image of RNA samples (Figure 5.2),
the two visible bands correspond to 23S rRNA and 16S rRNA, respectively. RNA of
sufficient quality and quantity for microarray analysis could be isolated from MenB
incubated in both FFP 1 and medium (twenty samples in total). These samples were
hybridised onto microarrays (as outlined in Section 2.7). Taking into account the
duplicates on the microarray slides, 10 data points were obtained per condition for
each gene.
After pre-processing of microarray data, PCA (described in Section 2.7.8), a
data dimension reduction method, was performed using gene expression data (mean-
centred) from all genes of good quality to provide a multivariate overview of similar-
ities between samples (from plasma and medium) and for a low dimensional visual-
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Figure 5.5: PCA of data collected for meningococci incubated in FFP 1 or medium.
PCA, with mean-centering, was performed using gene expression data for MC58 genes on
microarrays hybridised with RNA from FFP 1 or medium. Data from plasma (FFP 1) are
depicted by yellow filled circles, and data from medium are depicted by grey filled diamonds.
The smaller symbols represent data from time-point 60 min and the larger symbols represent
data from time-point 240 min. The data points in the red rectangle represent samples from
assay-day one.
isation of the expression profiles. The score plot of the first two PCA components,
showing each assay as one point, is shown in Figure 5.5. Separation in the second PCA
component reflects both time (as most samples isolated at 60 and 240 min separate
along this component) and growth condition (as data at 240 min for meningococci in
either plasma or medium separate along the second component as well). At 240 min,
growth condition (plasma or medium) had a greater influence on the transcriptional
profile than at 60 min. PCA analysis of the data indicated that microarray data
collected for RNA samples isolated on day one (symbols enclosed in rectangle, see
Figure 5.5) were different to microarray data for isolation day two to six. However,
exclusion of data from day one in the statistical analysis aimed at finding differentially
expressed genes, did not significantly alter the results. Therefore, samples from all
RNA isolation days were included in the further analysis presented in this chapter.
The genes that contributed most to this separation along the first component (indicat-
ing large contribution to the pattern seen in Figure 5.5) were NMB0398, NMB0434,
NMB0577–79, NMB0810 and norM (NMB0812). The gene norM encodes an eﬄux
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protein that previously has been shown to protect Neisseria from the toxic effect of
cationic compounds (Rouquette-Loughlin et al., 2003). NMB0810, encoding a puta-
tive transcriptional regulator, most likely regulates the expression of norM. NMB0577
has previously been shown to be regulated by FNR (fumarate and nitrate reduction
regulator) upon oxygen-restriction (Bartolini et al., 2006).
Statistical analysis was performed using the Limma package (Section 5.2) to find
differences in gene expression between meningococci in plasma and medium. A total of
208 genes was found to be differentially expressed (fold-change ≥1.5, FDR of ≤0.05)
in plasma at 60 min compared to medium. Of these, 74 genes were up-regulated
(Supplementary table B.1) and 134 genes were down-regulated (Supplementary table
B.2). After 240 min incubation, 260 genes were found to be differentially expressed
in plasma compared to medium, using the same inclusion criteria as for the 60 min
time-point. There was an even distribution between up-regulated (N = 126) and
down-regulated genes (N = 134) at this time-point (Supplementary tables B.3 – B.4).
Comparing the differentially expressed genes at 60 and 240 min, it was immediately
72 2 124
60 min 240 min
113 21 113
60 min 240 min
Figure 5.6: Differentially expressed genes at 60 and 240 min in FFP 1 compared to
medium. In the figure up-regulated genes are shown to the left and down-regulated genes
are shown to the right. The 21 down-regulated genes shared between the two time-points
(labelled in red) are listed in Supplementary table B.5.
clear that the transcriptional profiles were different (Figure 5.6). Only two of the
up-regulated genes were found to be shared between the two time-points: cysD-
1 (NMB1154) involved in sulphur metabolism and mtrF (NMB1719) involved in
protection against hydrophobic agents (Veal & Shafer, 2003). Twenty-one genes were
consistently down-regulated in plasma (Supplementary table B.5), including genes
belonging to the FrpC operon. Another notable category of differentially expressed
Chapter 5: Genome-wide transcriptional profiling of meningococci in plasma 100
genes shared between the two time-points, was those encoding proteins involved in
chaperone activities, such as dnaK (NMB0554) and grpE (NMB0661).
5.2.1.1 The nature of genes differentially expressed in plasma com-
pared to medium
Exploration of sets of genes sharing a common functionality may give clues about
biological processes that are important under a certain growth state or condition.
Therefore, genes differentially expressed upon growth in FFP 1 were divided into
functional categories according to designations established at TIGR (Peterson et al.,
2001). In addition, gene set enrichment analysis using the GSEA software (Mootha
et al., 2003; Subramanian et al., 2005) was used to determine whether any of the TIGR
functional role categories (TFRC) were significantly enriched among the plasma-
responding genes (i.e. among up-regulated genes). In GSEA analysis, genes are
ranked according to the expression difference between two classes. A non-parametric
test is then used to assess whether the null hypothesis can be rejected, the null hypoth-
esis being that the rank ordering of genes is random with regard to the pre-defined
gene sets (e.g. functional categories). Any gene sets with high rank order, overrep-
resented at the top (or bottom) of the list, are correlated with the phenotype. To
assess the statistical significance, a permutation test was used to calculate a global
P-value, which was then corrected for FDR to give a q-value (a FDR q-value ≤0.25
is considered significant by Mootha et al. (2003)). Results from GSEA can give an
indication of categories of genes that may be important. However, permutations over
phenotypes are more effective for larger groups (N ≥7 suggested by (Mootha et al.,
2003)), so result from GSEA analysis here should be interpreted with some caution.
A large proportion of the genes found to be up-regulated at 60 min are annotated
as hypothetical or unassigned proteins (Figure 5.7 (1)). The second largest group of
genes contained members involved in central intermediary metabolism. In the GSEA
analysis, genes encoding functions categorised as central intermediary metabolism
and biosynthesis of cofactors, prosthetic groups and carriers (FDR q-value ≤0.10),
were significantly enriched and associated with increased expression during meningo-
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Figure 5.7: Differentially expressed genes at 60 (1) and 240 min (2) in FFP 1 compared
to medium divided into functional categories, according to their TIGR designations. Up-
regulated genes are depicted by light-grey bars and down-regulated genes by green bars.
Numbers shown on the Y-axis represent the percentage each category constitutes of the
total number of either up- or down-regulated genes. Columns: A. Amino acid biosyn-
thesis, B. Biosynthesis of cofactors, prosthetic groups, and carriers, C. Cell envelope, D.
Cellular processes, E. Central intermediary metabolism, F. DNA metabolism, G. Energy
metabolism, H. Fatty acid and phospholipid metabolism, I. Hypothetical proteins, J. Mo-
bile and extrachromosomal element functions, K. Protein fate, L. Protein synthesis, M.
Purines, pyrimidines, nucleosides, and nucleotides biosynthesis, N. Regulatory functions,
O. Transcription, P. Transport and binding proteins, Q. Unassigned, R. Unknown function.
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coccal growth in plasma compared to medium at 60 min. At 240 min many of the
genes found to be up-regulated encoded proteins involved in energy metabolism (Fig-
ure 5.7 (2)) and this category was also significantly enriched (FDR q-value = 0.05) in
GSEA analysis. Genes annotated in the three TFRCs protein synthesis, transcription
and protein fate, were common among the down-regulated genes following 240 min
incubation in plasma. This may indicate a slower growth of meningococci in plasma
compared to medium, although this was not reflected in CFUs at 240 min (Figure
5.4). In GSEA analysis the same three categories were found to be associated with
up-regulation in the medium-grown meningococci (FDR q-value ≤0.11).
5.2.1.2 Known or putative surface exposed proteins
Genes found to be up-regulated in plasma were divided into categories according
to predicted (or known) cellular locations, based on experimental data or in silico
predictions. Algorithms: PSORTb, PSLpred and the bioinformatics tools available
at CBS (http://www.cbs.dtu.dk/services) were used as laid out in Section 2.11
for in silico predictions. All MC58 genes that encoded a protein with a signal peptide
or which were attributed as encoding non-cytoplasmic proteins are listed in Table 5.1.
Genes encoding proteins that have been identified in preparations of OM or OMVs,
or experimentally confirmed to be on the surface of the bacteria are also included in
Table 5.1. Fifty such genes were up-regulated in these experiments.
The gene NMB1971, encoding a predicted OMP, was up-regulated at 60 min
in plasma. NMB1971 has previously been found to be up-regulated in an in vitro
model of colonisation (Grifantini et al., 2002b), and a NMB1971 knock-out strain has
been shown to be attenuated in an infant rat model of infection (Sun et al., 2000).
Taken together these results suggest an important function for the gene product in
meningococcal survival in vivo or in virulence. NMB0787 and NMB0995, the products
of which have previously been shown to be surface exposed on intact meningococci by
flow cytometry (following 2 hr adherence to epithelial cells) (Grifantini et al., 2002b),
were up-regulated at 60 min during growth in plasma. The gene cysK (NMB0763),
up-regulated at 60 min, encodes a protein that has been identified in both OM and
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OMVs preparations (Ferrari et al., 2006; Williams et al., 2007), suggesting a possible
surface exposed location despite that the protein is predicted to be located in the
cytoplasm using prediction algorithms.
Of the genes up-regulated at 240 min during growth in plasma, mapA (NMB0390),
nspA (NMB0663), nadA (NMB1994)1, mspA (NMB1998), NMB1144, NMB1624 and
NMB2050, all encode proteins with a known or predicted outer membrane loca-
tion. The products of nadA and mspA are both annotated as auto-transporter ad-
hesin/invasins and have been shown to be involved in adherence to epithelial cells
(Capecchi et al., 2005; Turner et al., 2006). NadA has also been shown to medi-
ate adherence to monocytes and macrophages (Franzoso et al., 2008). NadA is one
of five components of a experimental meningococcal vaccine (Giuliani et al., 2006).
NMB1220, up-regulated at 240 min, encodes a protein that is not predicted to be
located in the meningococcal OM, but, which in previous studies has been shown to
be exposed on the meningococcal surface (Pizza et al., 2000). This protein was found
to function as a ligand for the class A macrophage scavenger receptor (Peiser et al.,
2006).
In proteomic studies, meningococcal proteins not predicted to be located in the
outer membrane have been identified in OM preparations (Williams et al., 2007).
Seventeen of the genes up-regulated at 240 min encode proteins identified in the
OM fraction by Williams et al. (2007). These genes included gdhA (NMB1710) and
NMB1035. gdhA encodes a NADP-specific glutamate dehydrogenase (described on
page 107). NMB1035, encoding a putative lipoprotein with unknown function, has
previously been shown to be up-regulated in response to MenB incubation in normal
human serum for 30 min when compared to bacteria incubated in PBS (Kurz et al.,
2003).
1The common name of NMB1994, nadA, is shared with NMB0394 (nadA) encoding a quinolinate
synthetase, but the denomination nadA in this thesis will hereafter refer to NMB1994.
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5.2.1.3 Virulence factors
Tettelin et al. (2000) identified 104 established or putative determinants of meningo-
coccal virulence. The major N. meningitidis virulence factors are capsule, LOS and
the type IV pilus. None of the genes associated with these surface structures were
up-regulated in plasma-grown organisms. Genes associated with biosynthesis and
transport of the polysaccharide capsule were found to be down-regulated following
60 min incubation in plasma, but the genes were still expressed at reasonable high
levels (signal intensity in comparison to gDNA). A gene (pglB (NMB1820)) encoding
a protein involved in pilin glycosylation was found to be up-regulated at 60 min. A
mutant in pglB has previously been shown to be more sensitive to killing in serum.
The increased sensitivity was not found to be linked to decreased pilin glycosylation,
but was instead attributed to a decrease in expression of the polysaccharide capsule
(Kahler et al., 2001). Three of Tettelin’s genes (NMB0995, bfrA (NMB1206) and
nadA), were up-regulated in plasma-grown organisms. NMB0995, up-regulated at 60
min, encodes a macrophage infectivity potentiator-related protein. The other two
genes (bfrA, encoding bacterioferritin A, and nadA) were up-regulated at 240 min.
5.2.1.4 Meningococcal adaptation to the plasma environment
Genes involved in bacterial metabolic functions were affected by growth in plasma.
Such genes included those involved in amino acid biosynthesis, energy metabolism
and associated with responses to oxygen availability.
Amino acid biosynthesis and acquisition Amino acids are essential for many
cellular processes - e.g. protein synthesis, peptidoglycan cross-linking (alanine) and
nitrogen transfer (glutamate, glutamine) (Hebeler & Young, 1976; Boehlein et al.,
1994). Biosynthesis of amino acids has been shown to be important for bacterial
survival at sites where their availability is limited (Wang et al., 1996; Fuller et al.,
1999; Sun et al., 2000). In some pathogens, limitation of amino acids has been shown
to induce the expression of virulence associated genes (Wagner & Mulks, 2006). For
example, N. meningitidis has been reported to require L-glutamic acid, L-arginine,
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glycine, L-serine and (for some strains) L-cysteine under laboratory growth condi-
tions (Catlin, 1973). Using genomic information Baart et al. (2007) predicted that
N. meningitidis is most likely able to synthesise all amino acids, with the possible
exception of serine. Ten genes encoding products functioning in biosynthesis of ei-
ther the aromatic, aspartate family, glutamate family or pyruvate family of amino
acids have previously been identified as essential to allow sustained bacteraemia in
an infant rat model (Sun et al., 2000). Four of the genes (aroG (NMB0307), aroE
(NMB0358), ilvD-2 (NMB1188) and gdhA) found in the study by Sun et al. (2000)
were up-regulated during incubation in plasma. The gene aroE, encoding a shiki-
mate 5-dehydrogenase, was up-regulated at 60 min. The three other genes were
up-regulated at the 240 min time-point: ilvD-2, encoding a dihydroxy-acid dehy-
dratase; aroG, encoding a phospho-2-dehydro-3-deoxyheptonate aldolase; and gdhA,
encoding a NADP-specific glutamate dehydrogenase. An additional eight genes as-
sociated with synthesis of amino acids (cysK, dapE (NMB1530), ilvE (NMB0337),
ilvD-1 (NMB1150), leuC (NMB1036), proB (NMB1069), argD (NMB1371), argF
(NMB1573)) were up-regulated in plasma-grown meningococci at either 60 or 240
min. Genes up-regulated at 240 min were primarily associated with degradation or
synthesis of glutamate (argD, argF, proB, gdhA) and branched chained amino acids
(ilvE, ilvD-1, leuC ). In addition, several genes encoding transporters of amino acids
were up-regulated during growth in plasma (presented in the following paragraphs).
The gene gdhA, up-regulated at 240 min in bacteria grown in plasma is involved in
glutamate metabolism and synthesis, and its gene product, an L-glutamate dehydro-
genase, converts 2-oxoglutarate and NH+4 to L-glutamate (or the reverse reaction). At
the same time-point amtB (NMB0615), encoding an ammonium transporter, was up-
regulated. Ammonia can be used as a nitrogen source by bacteria and can be utilised
in the synthesis of, for example, L-glutamate. The transcription of gdhA has been
shown to be initiated from two separate promoters (Pagliarulo et al., 2004). The gene
gdhR (NMB1711), encoding the transcriptional regulator that activates transcription
of gdhA from one of its two promoters, was also up-regulated in plasma at 240 min.
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Pagliarulo et al. (2004) showed that the transcriptional activation of gdhA by GdhR
can be repressed by the binding of 2-oxoglutarate to the promoter, which results in
blockage of activator binding. GdhR has also been shown to regulate the transcription
of the operon NMB1966–1962, encoding components of a L-glutamate transporter,
which has been suggested to function at low sodium levels (Monaco et al., 2006).
The operon was not significantly differentially expressed in plasma, but instead gltS
(NMB0085), involved in L-glutamate uptake at higher sodium concentrations, was
up-regulated in plasma-grown organisms. Genes (NMB0787–89) encoding a putative
ATP-binding cassette (ABC) transporter of polar amino acids were up-regulated at
60 min, suggesting that there may be free amino acids available for uptake, at least
initially. Alternatively, up-regulation of these genes may suggest that there is a lack
of amino acids in plasma which the bacteria respond to by increasing expression of
amino acid transport systems. NMB0787–89 have been shown to be up-regulated by
growth in L-glutamine (Friedrich et al., 2007), which may indicate that L-glutamine,
the most abundant amino acid in plasma (Tsai & Huang, 1999), is transported by
this ABC transporter. Research in gonococci suggests that the substrate-binding
component, encoded by NMB0787 in MC58, is essential for bacterial viability (Du &
Arvidson, 2006).
At the later time-point during incubation in plasma, putP (NMB0402) (encoding a
sodium/proline symporter) was found to be up-regulated. L-proline can be degraded
by the gene product of putA (NMB0401) (also up-regulated at 240 min) to 1-pyrroline-
5-carboxylate and further to L-glutamate. These transcriptional changes point to a
requirement of L-glutamate by the later time-point in plasma. However, it may be
that differential regulation of genes associated with L-glutamine and L-glutamate
results from differences in glutamine and glutamic acid concentrations in plasma and
culture medium RPMI 1640.
In a study by Grifantini et al. (2002a) genes involved in sulphur metabolism and
acquisition were found to be induced when N. meningitidis, but not N. lactamica,
adhered to epithelial cells. Up-regulation of these genes results in increased synthesis
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of the sulphur-containing amino acids cysteine and methionine, the universal start
of proteins. Genes involved in sulphur metabolism, including cysD-1 and cysN-1
(NMB1153), were here up-regulated at 60 min.
At the 240 min time-point many of the induced genes belong to the functional
category energy metabolism (significant by GSEA analysis) (Figure 5.7 (2)). The en-
richment of this TFRC was apparently related to an increase in oxidative phosphory-
lation, since up-regulation was observed for genes encoding the NADH dehydrogenase
I (nuo genes), ubiquinol-cytochrome c reductase (pet genes), succinate dehydrogenase
(sdh genes) and cytochrome cbb3 oxidase (fix genes). This suggests an increase in
energy requirement at later time-points in plasma. Up-regulation could also indicate
either increased levels of the ferric uptake repressor (Fur) (Fur can also function as
an activator) and/or available iron as both Fur and iron-replete conditions previously
have been shown to induce expression of these genes (Delany et al., 2006). Genes
encoding the ATP synthase F1 and an electron transfer flavoprotein were, however,
down-regulated.
Neisseria primarily degrades glucose through the pentose phosphate or the Entner-
Doudoroff pathway (Morse & Hebeler, 1978). The tricarboxylic acid (TCA) cycle
is generally not active until glucose is exhausted in the medium or the cells reach
stationary phase of growth. Nine genes encoding proteins involved in the TCA cycle
were up-regulated at 240 min, suggesting that the bacteria utilised the TCA cycle for
energy production.
Iron uptake Iron uptake is important for meningococcal survival in the human
host (Rohde & Dyer, 2003). During growth in vivo, meningococci can sequester
iron from the human iron binding proteins transferrin (Schryvers & Morris, 1988b),
pre-dominant in serum, and lactoferrin, found mainly on mucosal surfaces and at
sites of infection (Schryvers & Morris, 1988a). The two genes, tbpA (NMB0461) and
tbpB (NMB0460), encoding the transferrin binding protein, were not up-regulated at
either time-point upon growth in plasma in comparison to growth in medium. The
gene NMB0034, encoding a putative high-affinity iron transporter, was, however, up-
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regulated in plasma-grown organisms at 60 min. This gene has previously been shown
to be up-regulated under iron-depleted conditions (Grifantini et al., 2003). After 240
min incubation in plasma, genes encoding proteins involved in iron uptake were found
to be down-regulated. These included genes encoding the transferrin binding protein
and the lactoferrin binding protein (lbpA (NMB1540) and lbpB (NMB1541)). Delany
et al. (2006) used microarrays to identify genes induced by both iron and Fur, or by
the transcriptional regulator alone. 20 of the genes up-regulated in plasma at 240
min were found by Delany et al. to be induced both by iron and Fur. An additional
seven genes (up-regulated during growth in plasma) are induced only by Fur. This
suggests that levels of available iron and of the regulator Fur were higher in plasma
than in medium at this time-point.
Responses to changes in oxygen availability After 240 min incubation, up-
regulated genes included mapA and aniA (NMB1623). Both genes have previously
been shown to be positively regulated by FNR under oxygen-limiting conditions (Bar-
tolini et al., 2006). The gene mapA encodes a surface exposed 85 kDa maltose phos-
phorylase involved in catalysing the cleavage of maltose to glucose and β-glucose-
1-phosphate, the latter subsequently converted into β-D-glucose-6-phosphate by a
β-phosphoglucomutase, encoded by pgmB (NMB0391). β-D-glucose-6-phosphate can
be used for energy utilisation in the pentose phosphate or the Entner-Doudoroff path-
way. A mapA knock-out strain was found to have a 3-log reduction in blood survival
in a mouse model of infection compared to wild-type (Bartolini et al., 2006). The
gene aniA encodes a nitrite reductase that degrades nitrite to nitric oxide (NO). Be-
sides positive regulation by FNR, aniA is negatively regulated by the NO-sensitive
repressor NsrR (encoded by NMB0437) (Rock et al., 2007; Heurlier et al., 2008).
This gene was found to be up-regulated at 60 min during growth in plasma. Two
other genes, dnrN (NMB1365) and NMB1624, which were up-regulated at 240 min
in plasma, have also been reported to be negatively controlled by NsrR (Rock et al.,
2007; Heurlier et al., 2008). The gene NMB1624, transcribed down-stream of aniA,
has similarity to nirV genes and may have a nitrite reductase function and dnrN
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is similar to proteins functioning in protection against NO damage (Heurlier et al.,
2008).
5.2.1.5 Stress induced responses and cell detoxification
Genes encoding proteins involved in responses to oxidative stress or other general
stresses have previously been associated with survival in animal models of infection
and in vitro/ex vivo infection models (Herbert et al., 2002; Bron et al., 2004). Some
of the genes up-regulated during growth in plasma encode chaperones involved in
protein folding or degradation. clpA (NMB0836), up-regulated at 60 min, encodes
the ATP binding subunit of a two-component ATP-dependent Clp protease which
contributes to the elimination of damaged or aggregated proteins (Singh et al., 2000).
The product of dsbB (NMB1649), up-regulated at 240 min, plays a critical role in
returning DsbA, involved in disulphide bond formation of periplasmic proteins, to its
active state (Whitley & von Heijne, 1993).
Other meningococcal transcriptional changes at 240 min that might be a re-
sponse to stresses encountered by the bacteria during growth in plasma included
up-regulation of the operon NMB1436–38, as well as a putative transcriptional regu-
lator (encoded by NMB1891), known to be responsive to various stresses. Products
of NMB1436–38 have been shown to be involved in meningococcal responses to ox-
idative stress (Grifantini et al., 2004). Deletion of the operon NMB1436–38 resulted
in a strain with increased sensitivity to killing by polymorphonuclear leukocytes and
impairment in growth in the blood stream of adult mice (Grifantini et al., 2004).
NMB1891 has previously been shown to be up-regulated in heat-shock (Guckenberger
et al., 2002). The MenB gene has sequence similarity to the xenobiotic response el-
ement (XRE) family of transcriptional regulators, which has been reported to be
involved in responses to a wide variety of stresses including acidic pH (Tran et al.,
2005), salt (Pflu¨ger et al., 2007), nitrogen availability (Veit et al., 2006) and radiation
(Liu et al., 2003).
Eﬄux proteins protect bacteria from the effects of toxic compounds, such as anti-
bacterial factors secreted by host cells. Genes significantly induced during growth
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in plasma included farA (NMB0318) and mtrF, both encoding eﬄux proteins. In
addition, a putative drug/metabolite transporter (encoded by NMB1459) was up-
regulated at 60 min.
5.2.1.6 Proteins with putative or hypothetical function
Forty-three percent of the genes in strain MC58 are annotated as hypothetical proteins
or proteins with unknown function. The products of more than one quarter (53 out
of 200) of MenB-specific genes up-regulated during growth in plasma are annotated
as hypothetical proteins, emphasising that many genes associated with virulence are
still poorly characterised.
Two such genes up-regulated at 60 min have previously been observed to have
elevated expression upon exposure to serum (NMB0260) (Kurz et al., 2003) or in
contact with epithelial cells (NMB0305) (Grifantini et al., 2002b). Three of the genes
up-regulated at 240 min (NMB0228, NMB0252 and NMB1590), have previously been
reported to be differentially expressed upon incubation in NHS versus PBS (Kurz
et al., 2003). During meningococcal growth in FFP 1, NMB0277 and NMB0776 were
up-regulated at 60 min or 240 min respectively. A sequence repeat found in the up-
stream regions of both these genes has been suggested to be involved in transcriptional
induction on host cell contact (Deghmane et al., 2003; Morelle et al., 2003). However,
Morelle et al. (2003) showed that neither of the genes is necessary for attachment
to host cells. NMB0277 is annotated as the virulence factor MviN, due to sequence
similarity to the mouse virulence family (MVF) of proteins, and its gene product may
function in drug eﬄux. NMB0776 is similar to the gly1 gene identified in gonococci,
encoding a protein of unknown function which, when mutated, results in strains
with decreased cytotoxicity to host cells (Arvidson et al., 1999). The genes up-
regulated at 60 min also included NMB1532, encoding a protein with a putative
haemerythrin, oxygen-binding, domain. Interestingly, a Staphylococcus aureus protein
with a haemerythrin domain has been shown to be involved in bacterial adaptation
to low oxygen environments (Throup et al., 2001).
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Figure 5.8: Agarose gel image of products from semi-quantitative RT-PCR using RNA
isolated from meningococci incubated in FFP 1 (P) or medium (M) for 60 and 240 min
(Section 5.2.1). Samples were separated on a 2% agarose gel, with a 1 kb ladder. Samples
in lane 1–4 were amplified using primers specific for fetA. Samples in lane 5–6 were amplified
using primers specific for NMB0995. Height of bars in graph corresponds to the median
intensity of each band as determined by quantification with ImageQuant software.
5.2.1.7 Validation of microarray data
Expression of two of the genes found to be differentially expressed upon growth in FFP
1 from the microarray study was validated by semi-quantitative RT-PCR (Section
2.8.1). These were NMB0995 and fetA (NMB1988) (encoding an iron-regulated outer
membrane protein). fetA was down-regulated in plasma at 240 min (compared to
all other conditions and time-points) and NMB0995 was up-regulated in plasma at
60 min (compared to all other conditions and time-points). For gene NMB0995, the
ratio in median intensity was 1.21 between the product amplified from an aliquot of
RNA isolated from plasma-grown bacteria at 60 min and the product amplified from
an aliquot of RNA isolated from medium grown bacteria at 60 min. For gene fetA the
median intensity for the product from RNA isolated from plasma at 240 min was 0.76
of the median intensity for RNA isolated from medium grown organisms at 240 min,
and ∼ 0.8 compared to median intensity for products amplified from RNA recovered
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from bacteria in either plasma or medium at 60 min time-point.
5.2.2 Transcriptional profile in FFP 2 in comparison to time-
point 0 min
The transcriptional profile after incubation for 60 and 240 min in FFP 2 was compared
to that at time-point zero. RNA was isolated at 0, 60 and 240 min from four indepen-
dent experiments. The quantity of RNA that could be extracted from meningococci
in FPP 2 was 10–20 µg. The quality of the isolated RNA was determined by separa-
tion on an agarose gel (Section 2.4). Each of the isolated RNA samples were analysed
on microarrays.
Processing of microarray data and statistical analysis to find differentially expressed
genes was performed as described in Section 5.2. Meningococcal gene expression in
plasma at 60 and 240 min post-inoculation was compared to transcription at time-
point zero. Following 60 min incubation in FFP 2, 378 genes were differentially
expressed with a fold-change of ≥1.5 and a FDR of ≤0.05. Applying the same cut
off, 199 genes were found to be differentially expressed at 240 min (Supplementary
tables B.6–B.9). Of the differentially expressed genes, 108 were shared between the
two time-points in plasma (Figure 5.9, Supplementary table B.10). Genes that were
found to be up-regulated at both time-points included NMB0787–89, encoding a
putative amino acid transporter; leuD (NMB1034) and leuC, involved in biosynthesis
of branched chain amino acids; and NMB1040, an outer membrane protein with an
unknown function. These genes will be presented in greater detail in subsequent
sections.
To explore the functional roles of genes associated with meningococcal growth in
plasma, genes differentially expressed in response to bacterial growth in FFP 2 were
divided into categories according to their TIGR designations (Figure 5.10), and the
microarray data were analysed using the GSEA software (described on page 100) to
test for significantly overrepresented TFRCs. Meningococcal growth in plasma at 60
min was associated with an enrichment of genes (with higher expression than at t =
0 min) that are involved in the following TFRCs: purines, pyrimidines, nucleosides
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Figure 5.9: Venn diagram of genes differentially expressed in FFP 2 at 60 and 240 min
compared to the 0 min time-point. Up-regulated genes are shown to the left and down-
regulated genes are shown to the right in the figure. Genes that were up- or down-regulated
at both time-points in FFP 2 are listed in Supplementary table B.10.
and nucleotides biosynthesis; protein synthesis; protein fate; transcription; biosyn-
thesis of cofactors, prosthetic groups and carriers; hypothetical proteins; and DNA
metabolism (FDR q-value ≤0.25). Genes involved in energy metabolism and cellular
processes were associated with up-regulation at t = 0 min (FDR q-value ≤0.194)
compared to 60 min during growth in FFP 2, indicating a down-regulation of genes
in those TFRCs at 60 min. None of the TFRCs were found to be over-represented
among genes with increased expression at 240 min. However, genes annotated in
the category transcription were significantly enriched (FDR q-value 0.058) among
genes up-regulated at time-point 0 min (in relation to the 240 min time-point), which
suggest that transcription was reduced at the later time-point in FFP 2.



























































Figure 5.10: Differentially expressed genes at 60 (1) and 240 min (2) in FFP 2 compared to
time zero divided into functional categories, according to TIGR designations. Up-regulated
genes are depicted by light-grey bars and down-regulated genes by green bars. Numbers
shown on the Y-axis represent the percentage each category constitutes of the total number
of either up- or down-regulated genes. Columns: A. Amino acid biosynthesis, B. Biosynthe-
sis of cofactors, prosthetic groups, and carriers, C. Cell envelope, D. Cellular processes, E.
Central intermediary metabolism, F. DNA metabolism, G. Energy metabolism, H. Fatty
acid and phospholipid metabolism, I. Hypothetical proteins, J. Mobile and extrachromo-
somal element functions, K. Protein fate, L. Protein synthesis, M. Purines, pyrimidines,
nucleosides, and nucleotides biosynthesis, N. Regulatory functions, O. Transcription, P.
Transport and binding proteins, Q. Unassigned, R. Unknown function.
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5.2.2.1 Known or putative surface exposed proteins
Genes found to be up-regulated in plasma were divided into categories according
to predicted (or known) cellular locations, based on experimental confirmations or
in silico predictions. Several different prediction algorithms were used to form a
consensus about cellular location (Section 2.11). All MC58 genes found to encode a
protein with a signal peptide or which were attributed as encoding proteins located
in the periplasm or the outer membrane, are listed in Table 5.2. In addition, genes
encoding proteins that have been identified in preparations of OM or OMVs, or
experimentally confirmed to be on the surface of the bacteria are also included in
Table 5.2. Sixty-six such genes were up-regulated in these experiments.
Seven genes (NMB0866, NMB0872, NMB1533, NMB1961, NMB1962, NMB1966
and NMB1977) encoding proteins predicted to have an outer membrane location,
were up-regulated at 60 min in plasma. The protein encoded by NMB0872 contains
tetratricopeptide repeat (TPR) domains, commonly involved in protein–protein inter-
actions (Blatch & La¨ssle, 1999). A surface exposed autotransported serine protease
A (AspA) (encoded by NMB1969), was up-regulated at the 240 min time-point. Re-
active antibodies to AspA have been detected in acute sera from patients (Turner
et al., 2002). Three more genes up-regulated at the 240 min time-point encode pro-
teins with a known or predicted surface location. They were NMB0293, encoding
a TonB-dependent receptor; mapA, encoding an outer membrane located maltose
phosphorylase; and mlp (NMB1898), encoding a lipoprotein. Interestingly, the gene
mapA was also up-regulated at 240 min during incubation in FFP 1 in comparison
to medium. Three genes (NMB0821, NMB1040 and NMB1073), encoding proteins
with a predicted outer membrane location, were up-regulated at both time-points in
plasma. Additionally, NMB0787 and NMB0995, which were both consistently up-
regulated during incubation in FFP 2, have previously been established by Grifantini
et al. (2002b), using flow cytometry, to encode surface located products.
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5.2.2.2 Virulence factors
The expression of meningococcal virulence factors identified by Tettelin et al. (2000)
(described in Section 5.2.1.3) during growth in plasma were explored. Genes involved
in biosynthesis or transport of the polysaccharide capsule were found to be down-
regulated upon incubation in FFP 2, but were still expressed at reasonably high levels
(compared to common reference). Eight of the Tettelin genes were found to be up-
regulated compared to t = 0 at either or both time-points in plasma. These included
lst (NMB0922), encoding an alpha-2,3-sialyltransferase and NMB0995, encoding a
putative macrophage infectivity potentiator-related protein, as well as three genes
(lgtF (NMB1704), rfaK (NMB1705) and lgtA (NMB1929)), which encode proteins
involved in synthesis of LOS (up-regulated at 60 min). Genes up-regulated at 60
min also included pglF (NMB0596), encoding a putative O-antigen ligase involved in
glycosylation of pilin (Power et al., 2006). A pglF mutant has increased sensitivity
to cationic antimicrobial peptides (CAMPs) (Tzeng et al., 2005a).
5.2.2.3 Meningococcal adaptations to incubation in FFP 2
Initial responses at 60 min included up-regulation of genes involved in protein syn-
thesis and protein fate, indicating an initial adaptation to the environment. Genes
involved in protein synthesis were over-represented among plasma-responding genes
(using GSEA) at 60 min. The genes that contributed most to the enrichment of
this category were infB (NMB1643) (encoding a translation initiator) and two genes
(prfC (NMB0626) and prfA (NMB1686)) encoding peptide release factors 1 and 3,
respectively.
Amino acids are essential in many processes in the cell and biosynthesis of amino
acids are important for bacterial pathogenesis (described in greater detail in Sec-
tion 5.2.1.4). During incubation in FFP 2, several of the genes up-regulated at 60
and 240 min were associated with biosynthesis of branched-chain amino acids (va-
line, leucine and isoleucine), including the genes leuD and leuC. These genes en-
code the small and large subunit of an isopropylmalate isomerase that forms part
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of the leucine-biosynthesis pathway. At 240 min, genes such as aspC (NMB0540)
and tyrB (NMB1678), involved in biosynthesis of aromatic amino acids, were also
up-regulated. Both these genes encode aminotransferases functioning mainly in the
breakdown of amino acids. Besides genes associated with amino acid biosynthesis,
genes encoding amino acid transporters were also found to be up-regulated. The
operon NMB0787–89, encoding an amino acid ABC transporter that may specifically
bind polar amino acids, was up-regulated at both time-points in plasma. Similarly,
at both time-points, genes encoding proteins involved in L-glutamate transport were
up-regulated. NMB1966, encoding a component of a L-glutamate ABC transporter,
was up-regulated at 60 min and gltS, encoding a sodium/glutamate symporter, was
found to be up-regulated at 240 min (also up-regulated at 240 min in FFP 1).
As with meningococcal responses to growth in FFP 1 (described on page 108),
genes up-regulated at 60 and 240 min during growth in FFP 2 included some involved
in sulphur metabolism (involved in the synthesis of S-adenosylmethionine (SAM), me-
thionine and N-formylmethionyl-tRNA) and sbp (NMB1017) involved in acquisition
of sulphate (up-regulated at 240 min).
Samant et al. (2008) have previously identified de novo biosynthesis of purine and
pyrimidine to be essential for bacterial growth in serum. After 60 min growth in
plasma three genes (purA (NMB0815), purK (NMB1019) and purM (NMB1252)) in-
volved in purine biosynthesis were found to be up-regulated. Analysis of the microar-
ray data with the function geneSetTest() in the Limma package (Smyth, 2004),
which implements an alternative approach to gene set enrichment analysis, using
moderated t-statistics for each gene from the statistical analysis as input values, in-
dicated that genes involved in purine biosynthesis were significantly more likely to be
up-regulated in plasma at 60 min than at time-point 0 min (P-value = 0.00186).
Energy metabolism and exploitation of nutrient sources Gene expression
changes at the later time-point during incubation in plasma indicate that nutrient
sources may have become limited, or alternatively that increased energy was required
due to increased bacterial growth. Up-regulation was, for example, observed for relA
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(NMB1735), encoding a protein that mediates accumulation of (p)ppGpp in response
to nutrient-limitation. N. gonorrhoeae RelA-dependent accumulation of (p)ppGpp
occurs under amino acid, energy source and phosphate starvation (Fisher et al., 2005).
Additionally, comparison of the expression of genes involved in energy metabolism at
60 and 240 min (Section 5.2.3) revealed significant up-regulation of genes encod-
ing proteins involved in the TCA cycle. Genes (NMB0388 and gluP (NMB0535))
encoding putative transporters of carbon sources (maltose and glucose/galactose re-
spectively) were induced over the time course in plasma. Genes involved in exploita-
tion of alternative carbohydrate sources such as maltose were also found to be up-
regulated over time during growth in plasma. At 240 min NMB0470, encoding a
C4-dicarboxylate transporter, was also found to be up-regulated. This protein is
thought to transport 2-oxoglutarate and/or malate, which can be used for energy
utilisation in the TCA cycle. The gene has previously been found to be up-regulated
during exposure to serum (Kurz et al., 2003). A C4-dicarboxylate permease has previ-
ously been shown to be up-regulated when Pasteurella multocida is grown in medium
supplemented with haemoglobin (Paustian et al., 2002).
At the 240 min time-point, several of the up-regulated genes encoded proteins in-
volved in biosynthesis of the cofactor thiamine (thiC (NMB2040), thiO (NMB2068),
thiE (NMB2069) and thiG (NMB2071)), a possible response to amino acid availabil-
ity. Thiamine acts as a co-enzyme in steps in the TCA cycle and the pentose phos-
phate pathway, as well as in metabolism of branched-chain amino acids. Differential
regulation of thiC, involved in thiamine biosynthesis, has previously been observed in
Yersinia pestis, when incubated in plasma as compared to broth (Chauvaux et al.,
2007).
Iron acquisition and metabolism Genes encoding proteins involved in iron up-
take, including lbpAB and hmbR (NMB1668), were down-regulated at 60 min in
comparison to expression at 0 min. However, seven of the genes (NMB0316–17,
NMB0821, NMB0861–62, NMB0865–66) that were up-regulated at 60 min during
growth in plasma have previously been found to have increased expression under
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iron limiting conditions and to be under transcriptional regulation by Fur (Grifantini
et al., 2003). Between 60 and 240 min, genes involved in iron uptake were found to
be induced (Section 5.2.3).
Stress-induced functions Following 60 min incubation in plasma, genes encoding
chaperones were up-regulated. These included prlC (NMB0214), encoding oligopepti-
dase A; lon (NMB1231), encoding an ATP-dependent protease; and clpX (NMB1372),
encoding the ATP-binding subunit of an ATP-dependent protease.
Polyamines have been shown to be involved in many processes in the cell, for
example protection to oxidative damage (Shah & Swiatlo, 2008). Shah et al. (2008)
previously found that potD, encoding the binding-domain of a polyamine transporter,
is highly up-regulated in a murine model of pneumococcal bacteraemia. In this
study, the genes potB (NMB0611) and potC (NMB0612), encoding components of
a polyamine transporter, were found to be up-regulated at 60 min.
Eﬄux proteins play a role in the protection of bacteria from toxic compounds.
Following 60 min incubation in plasma, NMB0393, encoding a multidrug resistance
protein thought to confer protection to quaternary ammonium compounds, was found
to be up-regulated.
Bacteria respond to hyperosmolarity by increasing influx of potassium, a process
followed by an increase in glutamate synthesis (genes required for synthesis were up-
regulated between 60 and 240 min time-points) to counteract the high level of cations
(Dinnbier et al., 1988). After the initial phases K+ is transported out of the cell
by KefB or other non-specific eﬄux pumps (Kempf & Bremer, 1998). The gene trkA
(NMB1614), encoding a potassium transport system, was found to be up-regulated at
60 min during incubation in plasma in this study. Chen et al. (2004) previously showed
that the Vibrio vulnificus TrkA protein is involved in serum resistance, which was
attributed to its ability to counterbalance the change in osmotic pressure occurring
as a result of insertion of MAC. Up-regulation of trkA during growth in FFP 2 could
reflect a general bacterial response to changes in osmolarity, but alternatively could
be a response to counteract insertion of MAC.
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The gene dnrN (described in Section 5.2.1.4), shown to be under NsrR transcrip-
tional repression by Heurlier et al. (2008), was up-regulated in plasma-grown organ-
isms at 240 min. This may indicate that meningococci were subjected to oxygen
limitation or nitric oxide at the later time-point in plasma. The products of the
operon NMB1436–38 involved in meningococcal protection to oxidative stress were,
however, up-regulated at 240 min, although this may be related protection to iron
toxicity rather than oxidative stress (Grifantini et al., 2004). NsrR also represses the
transcription of norB (NMB1622), when nitric oxide levels are low. In gonococci,
norB has been shown to be repressed by an additional regulator, with features of a
member of the ArsR family of transcriptional regulators (Isabella et al., 2008). Is-
abella et al. (2008) showed that the binding of the ArsR regulator, to its binding site
in the norB up-stream region, can be abolished by the binding of the regulator Fur
to the same site. An orthologue of the gonococcal arsR gene, NMB0398, was found
to be up-regulated following 240 min incubation in plasma.
5.2.2.4 Regulatory proteins
Only a few transcriptional regulators have been characterised in N. meningitidis and
relatively few genes, encoding putative regulatory proteins, were found to be differen-
tially expressed during growth in plasma. At 60 min three of the up-regulated genes
(phoQ/misS (NMB0594), NMB1561, NMB2055) and three of the down-regulated
genes (NMB1049, NMB1303, NMB1843) encode putative or established transcrip-
tional regulators. phoQ/misS encodes a sensor histidine kinase, which together with
the product from NMB0595 (the DNA-binding response regulator) makes up a two-
component regulatory system, one of only four that have been identified in the N.
meningitidis strain MC58 genome. This has been suggested to respond to levels of
Mg2+ (Johnson et al., 2001), although this has subsequently been called into ques-
tion (Tzeng et al., 2006). A knock-out mutation of NMB0595 resulted in attenuated
growth in mice (Newcombe et al., 2004), which may relate to changes in the LOS
inner core structure observed for the mutant (Tzeng et al., 2006). The transcrip-
tional profile of an NMB0595 mutant under laboratory conditions has been reported
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both by Newcombe et al. (2004) and Tzeng et al. (2008). Fourteen of the genes that
these authors found to be down-regulated, were up-regulated at 60 min in FFP 2,
perhaps induced in response to activation of the two-component system. NMB1843,
here found to be down-regulated during plasma growth, has previously been shown to
be up-regulated in contact with endothelial cells (Dietrich et al., 2003), and confirmed
to repress transcription of nadA (Schielke et al., 2008). Differentially expressed genes
at 240 min included three genes encoding transcriptional regulators, one up-regulated
(relA) and two down-regulated (NMB0398, lrp (NMB1650)). lrp encodes a protein
with similarity to members of the family of leucine-responsive regulatory proteins. In
E. coli Lrp is a global regulator that regulates the expression of genes involved, for
example, in metabolism of amino acids and peptide transport (Calvo & Matthews,
1994), but the functionality of Lrp may not be the same in other bacterial species
(Lintner et al., 2008). In E.coli Lrp has been shown to repress the expression of
metK, the gene product of which is important for the synthesis of SAM (Newman
et al., 1998). During incubation in plasma, metK (NMB1799) was up-regulated after
240 min, which may suggest a similar regulation in meningococci. However, genes
under regulation of Lrp in N. meningitidis have not yet been determined.
5.2.2.5 Hypothetical genes and proteins with putative functions
At both time-points in plasma a large proportion of the differentially expressed genes
is categorised into the groups hypothetical proteins or unassigned (70 in total). A
few of the genes with a putative function based on sequence similarity, or genes that
have previously been observed to be differentially regulated in meningococcal growth
under other environmental conditions, are described below.
Two genes up-regulated at 60 min in plasma, NMB0292 and NMB0438, may be
involved in responses to changes in oxygen availability, as their products incorporate
domains involved in such processes. NMB0292 encodes a protein with a putative
nitroreductase domain and the NMB0438 gene product has a haemerythrin domain,
which is commonly associated with oxygen binding.
Some of the genes that were up-regulated at 60 min have previously been observed
Chapter 5: Genome-wide transcriptional profiling of meningococci in plasma 127
to be differentially expressed in other in vitro infection models. creA (NMB1335),
suhB (NMB1347) and NMB1912 have previously been found to be up-regulated on
contact with epithelial cells (Grifantini et al., 2002b; Deghmane et al., 2003; Morelle
et al., 2003). creA and suhB both have regulatory elements in their upstream region,
which have been suggested to be associated with gene regulation in response to contact
with host cells (Deghmane et al., 2003; Morelle et al., 2003). NMB1336, up-regulated
at 60 min during growth in plasma, has previously been found to be up-regulated
upon exposure to serum (Kurz et al., 2003).
Some of the up-regulated genes annotated as encoding hypothetical proteins have
sequence similarity to transporters. NMB0531, encoding a putative transporter of
the Na+/H+ NhaC family type and NMB1426, encoding a protein with similarities
to Mn2+/Fe2+ transporters, were up-regulated at 60 min. At 240 min NMB0213,
encoding a putative ion channel, was up-regulated. This type of ion channel has been
shown to provide protection to hypoosmotic shock (Pivetti et al., 2003).
5.2.3 Progressively regulated genes during growth in FFP or
medium
To determine meningococcal responses to longer incubation in human plasma or
medium, microarray data collected for the 240 min time-point were compared to
data collected for the 60 min time-point. Separate analysis was performed for each
of the three growth conditions (FFP 1, FFP 2 or medium). The overlap between
the differentially expressed genes from each comparison is shown in the Venn dia-
gram in Figure 5.11. Fifty-eight of the up-regulated genes were only found to be
up-regulated during incubation in plasma (FFP 1 and FFP 2). All genes that were
found to be up-regulated in FFP 1 and/or FFP 2 at 240 min versus 60 min are listed
in Supplementary table B.11. Many of the up-regulated genes from 60 to 240 min,
during incubation in plasma, may reflect changes in nutrient availability. Growth in
plasma was associated with up-regulation of genes involved in the TCA cycle (Figure
5.12). Under growth in broth or medium in vitro, Neisseria primarily degrades glucose
via the Entner-Doudoroff (80%) or the pentose phosphate pathway (20%) (Morse &
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Figure 5.11: Venn diagram of differentially expressed genes at 240 min versus 60 min
in plasma (FFP 1 or FFP 2) or medium. Up-regulated genes are shown to the left and
down-regulated genes to the right in the figure. Fifty-eight meningococcal genes (number
coloured in red) were up-regulated in both FFP 1 and FFP 2.
Hebeler, 1978). The TCA cycle is generally not active until glucose is exhausted in the
medium or the cells reach the stationary phase of growth. Eight of the up-regulated
genes, that were specifically up-regulated in plasma-grown organisms, encode proteins
in the TCA cycle, including four genes (NMB0948–51), encoding subunits of succi-
nate dehydrogenase, a membrane-bound enzyme that converts succinate to fumarate
under aerobic growth. sdhA (NMB0950) and sdhC (NMB0948) have been shown by
Mellin et al. (2007) to be under transcriptional regulation by nrrF, a Fur-repressed
small RNA (sRNA), and to be expressed under iron-depleted conditions. Genes that
were specifically up-regulated in plasma from 60 to 240 min also included three encod-
ing transporters: gluP a putative glucose/galactose transporter; lctP (NMB0543) a
lactate permease; and amtB a putative ammonium transporter. Increased expression
of lctP may suggest that the meningococcus utilises lactate as an energy source at
the later time-point during growth in plasma. In the cell, lactate can be degraded to
pyruvate, which can be used in amino acid biosynthesis or in the TCA cycle. Pyruvate
can be converted to phosphoenol pyruvate, which can be used in sialic acid synthesis
together with N-acetyl-mannosamine (ManNAc). Expression of the lactate permease
has previously been shown to be important for nasopharyngeal colonisation (Exley
et al., 2005a), as well as survival in the bloodstream (Exley et al., 2005b). The gene
gluP, found to be up-regulated in plasma, has previously been found to be progres-
sively up-regulated when meningococci interact with epithelial cells (Grifantini et al.,
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2002b). The observed up-regulation of a putative ammonium transporter suggests
that the meningococcus has an increased need for nitrogen at later time-points in
plasma. Up-regulation was also observed for gdhA, encoding a protein engaged in
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Figure 5.12: Up-regulated genes in plasma or medium at 240 min versus 60 min mapped
to pathways for metabolism of nitrogen and L-glutamate, and related to the TCA cycle.
Yellow boxes indicate genes that were up-regulated in both FFP 1 and FFP 2. Grey boxes
indicate genes that were up-regulated in FFP 1. Green boxes indicate genes that were up-
regulated in FFP 2. Genes coloured in red were also found to be progressively up-regulated
during growth in medium. The diamond shape indicates a positive regulator and the oval
shape indicates a transporter.
Meningococcal genes involved in iron-utilisation were also found to be up-regulated
over time during growth in both plasma and medium. However, a few of these genes
were only found to be differentially expressed in plasma-grown organisms, including
hemO (NMB1669) that encodes a haem oxygenase involved in the extraction of iron
from haem. Haem can be transported across the N. meningitidis membrane by the
haemoglobin receptor (HmbR) or HpuA/B (not present in the MC58 genome) in a
TonB-dependent manner (Stojiljkovic et al., 1995). Uptake of haem can also occur
independently of TonB, using an unknown mechanism (Desai et al., 2000). The gene
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encoding the haemoglobin receptor was found to be progressively up-regulated during
growth in FFP 2.
5.3 Discussion
In this chapter the transcriptional profile of a MenB strain MO1-240185 was deter-
mined in a model of infection in a non-immune (‘non-killer’) individual. This model
was realised by incubating MenB organisms at 37◦C in plasma samples (FFP 1 and
FFP 2) and determining bacterial transcriptional changes.
In the first set of experiments, the gene expression of MenB strain MO1-240185 in
FFP 1 was compared to the gene expression of MenB in cell culture medium with an
addition of fetal bovine serum, since meningococci showed similar growth under these
two conditions. The gene expression profiles of meningococci incubated in plasma or
medium were similar at the 60 min time-point. By 240 min the difference in gene
expression between meningococci in plasma or medium was greater, despite similar
growth characteristics of strain MO1-240185 in plasma and medium. In the second
study, the gene expression in FFP 2 was compared to the gene expression of bacteria
recovered from solid agar at time-point 0 min. The gene expression changes in this
study were most dramatic at 60 min. However, it should be noted that the two FFPs
differ in composition, as indicated by their different killing of strain MC58 (Figure
5.1). Since the same common reference sample (gDNA) was used in each of the
microarray hybridisations it is possible in principle to make a number of comparisons
between time-points and conditions. Unfortunately, direct comparison of data from
the two studies could not be accomplished due to relatively high inter-experimental
variation, a problem frequently encountered in microarray experiments. Instead lists
of differentially expressed genes under each condition were compared to find genes
that consistently respond to exposure to plasma.
The study presented in this chapter was partly designed to be a proof of principle
for later work in whole human blood (presented in Chapter 6), to find optimal con-
ditions for growth and to explore the isolation of meningococcal RNA from human
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biological fluids. The advantages of using plasma rather than blood are that studies
in plasma are easier to standardise. For example, plasma can be stored, unlike blood
that has to be used directly after collection. It is therefore possible to use plasma
collected on one occasion in a set of experiments. A difficulty in gene expression
studies is finding a suitable reference condition. In this study the gene expression
of meningococci incubated in plasma was compared to either of two reference con-
ditions: medium supplemented with hI fetal bovine serum or to a time-point 0 min
(initial inoculum). In other similar studies rich broth (Hsieh et al., 2008; Chauvaux
et al., 2007), heat-inactivated serum (Dove et al., 2003) or culture medium (Kurz
et al., 2003) have been used as reference conditions. In Chapter 6, in which the
genome-wide transcriptional changes in whole human blood are presented, the sec-
ond experimental design was chosen, i.e. meningococcal gene expression in blood was
compared to expression at a time-point 0 min as well as between sampling points in
the time course.
In this chapter MenB strain MO1-240185 was used in all microarray experiments.
The primarily reason for using this strain rather then MenB sequence strain MC58
(represented on the microarray) was that MO1-240185 (but not MC58) survived in
plasma available to us at the time of the experiments. In microarray experiments
in blood (Chapter 6) MenB strain MC58 was used as this strain survived in blood
samples from the two individuals used in that study (donors A and B).
5.3.1 Global impact of growth in plasma on meningococci
First, genes encoding surface exposed proteins identified to be up-regulated in this
genome-wide transcriptional study are discussed, as identification of such genes was
the primary objective of the study presented in this chapter. Second, the general
themes in changes to the meningococcal transcriptome upon incubation in plasma
are discussed.
Surface exposed proteins The primary aim of the work presented in this chap-
ter was to identify genes expressed during infection that might be exposed on the
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surface of the bacteria. Genes encoding surface exposed proteins that are specifically
up-regulated during infection identify candidates for inclusion in a MenB vaccine
(described in detail in Section 1.4.1.2). In the study presented here, several genes
encoding known or putative surface exposed proteins were found to be up-regulated
during meningococcal growth in plasma in relation to different control conditions (Ta-
ble 5.1 and Table 5.2). Meningococcal growth in either FFP 1 or FFP 2 resulted in
up-regulation of NMB0787 and NMB0995, encoding surface exposed proteins (Gri-
fantini et al., 2002b), by 60 min. Both these genes were also up-regulated at the
later time-point (240 min) in FFP 2. Both these genes were previously observed to
be up-regulated in contact with epithelial cells (Grifantini et al., 2002b). Five of the
genes encoding putative surface exposed proteins (gltS, mapA, argD, NMB1437 and
petA (NMB2053)) were found to be up-regulated by the later time-point (240 min)
in both plasma samples. NMB1035 encodes a putative lipoprotein, which has been
identified in preparations of outer membrane proteins (Williams et al., 2007) and was
up-regulated at 60 min in FFP 2 and at 240 min in FFP 1. The gene nspA, encoding
an outer membrane protein that previously has been identified as a vaccine candidate
(Martin et al., 1997), was up-regulated at 240 min after incubation in FFP 1.
An aim of this study was to explore the differences in meningococcal gene ex-
pression in a model of bacteraemia compared to the gene expression in a model of
colonisation, to identify genes encoding surface exposed proteins that respond in par-
ticular to conditions to which meningococci are exposed in the blood stream. Despite
several attempts to isolate RNA from meningococci adherent to epithelial cells, bac-
terial RNA could not be recovered of sufficient quality and quantity for microarray
analysis. Data were therefore compared to microarray data from two studies in which
the meningococcal transcriptional profile in contact with cultured epithelial cells has
been characterised (Grifantini et al., 2002b; Dietrich et al., 2003). Genes that encode
proteins that may have a cellular location in the periplasm or outer membrane, and
that are down-regulated at some time-point in contact with cells, are listed in Ta-
ble 5.3. Genes that were found to be up-regulated during meningococcal growth in
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plasma, but which were down-regulated when meningococci adhered to epithelial cells
included mapA, dnaK, purA, rplY (NMB0876), bfrA, NMB1220, NMB1533, mspA
and hslO (NMB2000).
Some of the genes, encoding (known or putative) surface-exposed proteins, which
were up-regulated during incubation in plasma were not reported to be differentially
expressed upon attachment to epithelial cells in the studies by Grifantini et al. (2002b)
and Dietrich et al. (2003). These genes included NMB0821, NMB0866, NMB1040,
NMB1073, mlp, NMB1961, aspA and nadA. NadA is one of the five components of
a experimental MenB protein based vaccine (Giuliani et al., 2006). The sequence
variability of mapA, NMB1040 and NMB1961 is explored using direct sequencing
from a collection of meningococcal strains in Chapter 7.
Surface structures Genes encoding proteins involved in capsular polysaccharide
synthesis and export to the bacterial surface were found to be down-regulated in FFP
1 at 60 min in comparison to medium; however the genes were still expressed at high
levels. A few genes encoding other meningococcal surface structures were, however,
up-regulated during growth in plasma, for example, three genes involved in LOS
biosynthesis (up-regulated at 60 min in FFP 2). Glycosylation of pilin has previously
been shown to protect meningococci from CAMPs and serum killing (Kahler et al.,
2001; Tzeng et al., 2005a). In response to incubation in both FFP 1 and FFP 2 genes
involved in pilin glycosylation were found to be up-regulated at 60 min.
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Meningococcal adaptation to growth in plasma For a general overview of
meningococcal responses to growth in plasma, data were analysed using the GSEA
software (Mootha et al., 2003). Following incubation of MenB in both plasma sam-
ples (FFP 1 and FFP 2) for 60 min, genes in the TFRCs biosynthesis of cofactors,
prosthetic groups and carriers were overrepresented among plasma-responding genes.
The subset of genes in the category that contributed mostly to the enrichment was in-
volved in porphyrin metabolism, including the genes cysG-1 (NMB1156) and cysG-2
(NMB1194), encoding siroheme synthases; hemC (NMB0539), encoding a porpho-
bilinogen deaminase; and hemH (NMB0718), encoding a ferrochelatase. The TFRC
central intermediary metabolism was specifically overrepresented in microarray data
from FFP 1 at 60 min. Upon incubation in FFP 2 six additional TFRCs were found
to be enriched at 60 min: purines, pyrimidines, nucleosides and nucleotides; protein
synthesis; protein fate; transcription; hypothetical proteins; and DNA metabolism.
Performing the same analysis for data from the 240 min time-points one TFRC en-
ergy metabolism was found to be enriched among the up-regulated genes only during
incubation in FFP 1. In each respective reference condition (meningococci grown in
medium and the time-point 0 min) genes involved in transcription were found to be
significantly enriched among up-regulated genes, indicating down-regulation of this
TFRC at 240 min in both plasma (FFP 1 and FFP 2). This suggests a slowing of
growth in plasma, although this was not yet reflected in the CFU counts at 240 min.
In meningococci incubated in medium (at 240 min) two more TFRCs - protein fate
and protein synthesis - were found to be significantly enriched among up-regulated
genes in relation to bacteria in FFP 1, which may also relate to changes in growth
phase in plasma. GSEA analysis has provided some interesting results as presented
and discussed here. However, it should be noted that the sample numbers in this
study are somewhat limited, and results should be treated with caution. To confirm
the GSEA results a larger study would be necessary, but this was not feasible for
the project presented here. Nonetheless the results should be indicative of the major
trends in the data.
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During incubation in FFP 1 NMB0034, encoding a putative high-affinity iron trans-
porter, was up-regulated at 60 min compared to organisms grown in medium. In
general, however, incubation of meningococci in plasma did not result in a significant
up-regulation of iron-responsive genes, such as those encoding iron-uptake systems.
Instead, genes including fetA and tbpAB were down-regulated during growth in FFP
1 at 240 min, as well as at 60 min in FFP 2. These genes have previously been
found to be down-regulated in iron-replete versus iron-depleted conditions in mi-
croarray experiments performed by Grifantini et al. (2003). In the FFP 1 study, the
down-regulation of these genes might be explained by the release of iron into the
plasma through bacterial lysis, or through release of bound iron from proteins such
as transferrin, or alternatively by the consumption of iron in the medium after 240
min incubation. For example fetA was also found to be down-regulated after 240 min
incubation in plasma compared to the 60 min time-point in FFP 1, which suggests
that the effects seen were the result of increased availability of iron in plasma, rather
than its consumption by the media-grown organisms to which the transcriptome was
compared. In the FFP 2 study, the down-regulation of these genes at 60 min may
perhaps be explained by the iron-replete status of the bacteria at the start of the
experiment.
During growth in plasma, genes associated with responses to lower oxygen ten-
sion were up-regulated both in comparison to medium and to t = 0. After 60 min
incubation in plasma, two of the genes (NMB0438 and NMB1532) found to be up-
regulated encode proteins with a haemerythrin domain, commonly associated with
oxygen binding. Other proteins with this domain have been shown to be involved
in bacterial adaptations to exposure to low oxygen environments (Throup et al.,
2001). During incubation in FFP 1, two genes (mapA and aniA), previously shown
by Bartolini et al. (2006) to be regulated by FNR under micro-aerobic conditions,
were up-regulated in comparison to incubation in medium. Bacteria in FFP 1 and
medium were cultured under identical conditions, and showed similar growth rates,
so the oxygen availability should have been comparable. Britigan et al. (1985) have
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previously shown that growth of N. gonorrhoeae in the presence of serum consider-
ably increases bacterial oxygen consumption. Therefore the induction of these genes
might be explained by the fact that meningococci in plasma consume oxygen more
rapidly than in medium, possibly due to higher levels of oxidative phosphorylation,
as indicated by up-regulation of energy metabolism genes at 240 min in FFP 1.
Amino acid synthesis is necessary for bacterial survival in the host (Wang et al.,
1996; Fuller et al., 1999; Sun et al., 2000). In this study, meningococcal growth in
plasma was associated with differential regulation of genes involved in amino acid
biosynthesis, underlining the importance of these genes in infection. The major tran-
scriptional changes observed for this group of genes occurred at 240 min during incu-
bation in FFP 1 and at both time-points during incubation in FFP 2.
Other processes that previously have been found to be important during bacterial
growth in infection models include sulphur metabolism (Grifantini et al., 2002a) and
de novo nucleotide biosynthesis (Samant et al., 2008). In the present studies using
FFP 1 and FFP 2, genes involved in sulphur metabolism and acquisition were found to
be up-regulated, at 60 min during incubation in FFP 1 and at 60 and 240 min during
incubation in FFP 2. Up-regulation of these genes results in increased synthesis of
sulphur containing amino acids, such as methionine.
In a recent study by Samant et al. (2008) all mutants attenuated in growth in
serum were shown to map to genes involved in de novo biosynthesis of purine and
pyrimidine. Consistent with this finding, meningococcal genes involved in purine
biosynthesis were found to be up-regulated at 60 min during incubation in FFP 2
compared to the start position at t = 0 (bacteria grown on solid nutrient agar).
In this study time-responsive genes were also established by comparing the gene ex-
pression at the late to the early time-point upon meningococcal incubation in plasma.
Comparison of the gene expression profiles at 60 and 240 min in either plasma (FFP 1
and FFP 2) or medium revealed up-regulation of fifty-eight genes specific for plasma-
grown organisms. Many of these may be up-regulated as a response to changes in
nutrient availability. Genes encoding components of the TCA cycle were found to
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be progressively up-regulated, including acnB (NMB1572) encoding a bifunctional
aconitate hydratase 2. This gene is known to be sensitive to iron-depletion in E. coli
(Varghese et al., 2003). Genes encoding proteins for uptake of haem iron (hmbR and
hemO) were also found to be progressively up-regulated during meningococcal growth
in plasma (FFP 2). Up-regulation of genes involved in up-take of lactate (lctP) and
alternative sugar sources, as well as the TCA cycle, indicates that glucose was not
the main source of energy at the later time-point in plasma.
5.3.2 Conclusions
The transcriptional response of MenB strain MO1-240185 to incubation in non-
bactericidal human plasma from two individuals has been characterised. This model
has provided an initial platform for studying meningococcal transcription as bacteria
proliferate in the bloodstream, a basis for understanding aspects of the pathogenesis
of meningococcal sepsis.
In the studies presented in this chapter genes encoding surface exposed proteins,
or putatively surface exposed proteins, were identified amongst genes up-regulated in
plasma. These proteins represent potential vaccine targets. The sequence variability
of three of these proteins (mapA, NMB1040 and NMB1961) are presented in Chapter
7.
In the next phase of my project, this work was refined so as to be able to study
meningococcal gene expression in non-bactericidal fresh human blood. In experiments
mimicking bacterial infections, reference conditions are invariably difficult. Based on
experiments in plasma, I decided to include additional time-points in the blood study
(Chapter 6) to improve the monitoring of meningococcal transcriptional responses,
thereby improving characterisation of temporal expression patterns.
Chapter 6
Genome-wide transcriptional profiling of
Neisseria meningitidis serogroup B in
blood
In this chapter the gene expression of meningococci in the whole blood ex vivo model
of sepsis is presented. Genes of particular interest were those, encoding surface ex-
posed proteins, which were up-regulated in this experimental system. In Chapter
5 meningococcal transcriptional changes upon incubation in plasma were discussed.
Incubating bacteria in plasma to model septicaemia has the obvious drawback of ig-
noring potentially important interactions of meningococci with cellular constituents of
blood. In young children, with no or low bactericidal activity to meningococci, cellu-
lar immune responses may be of great importance, and this can be modelled with the
use of fresh anti-coagulated non-bactericidal whole human blood. The model is more
complex than plasma due to the presence of cells as well as a richer microenvironment,
with metabolic changes over time induced by both the human and bacterial cells. The
complexity of the system makes the experimental procedures and standardisation of
the experiments harder to achieve, compared to the plasma model.
6.1 Introduction
Killing of N. meningitidis in its human host is mainly due to complement-mediated
processes, discussed in Section 1.2.5.1. However, in young children serum bactericidal
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activity is generally low, even after recent meningococcal infection (Pollard et al.,
1999). Cellular immunity is correspondingly important in limiting disease in young
children. Additionally, individuals with poor serum bactericidal activity against N.
meningitidis can still show phagocytic activity, either opsonic or non-opsonic (Welsch
& Granoff, 2007). Since cellular immunity through phagocytic activity may be im-
portant for control of bacterial growth, especially in individuals without bactericidal
antibodies, it is of interest to study the transcriptional changes that occur in bacteria
propagated in blood compared to transcriptional changes in plasma (Chapter 5).
6.1.1 Components of blood and cellular and humoral immune
responses
While N. meningitidis is predominantly an extracellular bacterium, it can adhere
to and invade human host cells, and survive within cells. On the mucosal surface,
and when crossing the blood-brain barrier, the meningococcus interacts with epithe-
lial and endothelial cells and encounters phagocytotic cells such as macrophages. In
the bloodstream meningococci come in contact with erythrocytes and leukocytes.
N. meningitidis in blood is primarily killed by complement-mediated bactericidal
effects, but also by antibody dependent and independent phagocytosis (Estabrook
et al., 1998). Both host and bacterial factors may modulate the susceptibility of the
bacterium to phagocytosis. For example host receptors for lipo-oligosaccharide (LOS)
may be important for effective phagocytosis of meningococci, since a LOS-deficient
mutant strain is less susceptible to phagocytosis (Uronen-Hansson et al., 2004), but
this could potentially also be an effect of changes in cell surface-exposed lipoproteins
or membrane composition in the mutant (Steeghs et al., 2001). Heyderman et al.
(1999) previously showed that incubation of meningococci in vitro in whole blood
stimulates activation of neutrophils, leading to increased phagocytosis of the bacte-
ria. Stimulation of whole blood with N. meningitidis or isolated OMVs increases the
production of reactive oxygen species (ROS) (Mirlashari et al., 2002). ROS stimulate
the recruitment of phagocytic cells, but can also kill bacteria directly after phagocy-
tosis.
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Meningococcal septicaemia is characterised by high levels of cytokines such as
tumour necrosis factor (TNF)-α, a pro-inflammatory factor, and interleukin (IL)-6,
IL-8 and IL-10 (Waage et al., 1987, 1989; Lehmann et al., 1995). A similar pattern of
cytokine release is observed in vitro, on incubation of meningococci in whole human
blood (Ison et al., 1995). Expression of chemokines, regulators of leukocyte traffic,
during meningococcaemia has been shown to relate to the amount of detectable LOS
in the blood stream (Schall & Bacon, 1994; Møller et al., 2005). N. meningitidis sheds
OMVs in large quantities during growth in blood, which contribute to the overwhelm-
ing immune response during meningococcal sepsis (Devoe & Gilchrist, 1973). OMVs
contain LOS, OMPs, periplasmic proteins and probably some entrapped cytoplasmic
proteins (Williams et al., 2007). During growth in blood, bacteria are also exposed
to factors secreted by cells, such as antibacterial proteins and peptides. Neutrophils
secrete the antimicrobial factors lactoferrin, bactericidal/permeability-increasing pro-
tein, serprocidins, cathelicidins and defensins; whereas platelets secrete antimicrobial
effectors (platelet microbicidal proteins), which target the bacterial cytoplasmic mem-
brane (Levy, 2000).
6.1.2 Bacterial genes associated with survival in in vivo and
ex vivo models of sepsis
Encapsulation protects bacteria, such as meningococci, from both bactericidal and
phagocytotic killing during growth in the bloodstream (Read et al., 1996; Vogel
et al., 1996). Genes associated with several functional categories, such as amino
acid biosynthesis, iron uptake and regulatory function, have also been demonstrated
to be important for N. meningitidis survival in the bloodstream. Studies in other
bacteria have also demonstrated the importance of genes associated with metabolism
in adaptation to new environments during growth in vivo. A few of these categories
are discussed below.
Lipooligosaccharide expression LOS, also referred to as endotoxin, is a potent
stimulant of the immune system (Brandtzaeg et al., 1989). Mutant meningococci
with disruption of genes involved in LOS biosynthesis, or in genes involved in its
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sialyation, are attenuated in the bloodstream or during growth in serum (Vogel et al.,
1996; Sun et al., 2000; Li et al., 2004). Attenuation associated with disruption of genes
functioning in LPS biosynthesis has also been reported for other organisms, including
E. coli K1 (Gonzalez et al., 2001) and P. multocida (Harper et al., 2003). Knock-
out of the E. coli gene rfaL, encoding an O antigen ligase, resulted in attenuation
in systemic infection in an infant rat model (Gonzalez et al., 2001). Mutants in
either the P. multocida gene dcaA, encoding a phosphoethanolamine transferase, or
pm1294, encoding a heptosyl transferase, were demonstrated to result in attenuation
in a mouse septicaemia model (Harper et al., 2003).
Iron uptake and transport systems Iron is an essential co-factor in the cell,
but can be toxic at high levels. Iron is therefore sequestered to iron binding proteins.
Most of the available iron in the human host is bound to proteins such as transfer-
rin or lactoferrin, which results in low levels of free iron for bacteria to utilise. Low
levels of free iron in the host can be seen as a bacteriostatic factor since it limits
bacterial growth (Weinberg, 1984). However, most bacterial species have developed
ways of scavenging iron bound to human proteins and genes involved in iron or haem
uptake and utilisation are essential for bacterial survival in vivo (Li et al., 2005). The
meningococcus encodes several systems for uptake of various forms of bound iron, in-
cluding transferrin binding proteins (TbpA and TbpB) (Schryvers & Morris, 1988a),
lactoferrin binding proteins (LbpA and LbpB) (Schryvers & Morris, 1988b) and a
haemoglobin receptor (HmbR) (Stojiljkovic et al., 1995). N. meningitidis, an obligate
human pathogen, only binds iron from human forms of transferrin and lactoferrin
(Schryvers & Gonzalez, 1989). In order to establish meningococcal sepsis in animal
models, an additional iron source is required (human transferrin or iron dextran)
(Oftung et al., 1999). Haemoglobin is normally only found within cells, but may be
released during lysis of erythrocytes. A N. meningitidis hmbR (NMB1668) mutant
has previously been shown to be attenuated in the infant rat model, indicating that
uptake of haemoglobin may be of importance during bacterial growth in the blood-
stream (Stojiljkovic et al., 1995). N. meningitidis strains with disruptions in any
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of the genes encoding the TonB system (tonB (NMB1730), exbB (NMB1729), exbD
(NMB1728)) have also been found to be attenuated in their ability to cause bacter-
aemia in an infant rat model (Sun et al., 2000). The TonB system, located in the inner
membrane, is required for utilisation of transferrin, lactoferrin and haemoglobin (Sto-
jiljkovic & Srinivasan, 1997), and functions by transducing the energy that induces
conformational changes in TonB-dependent outer membrane transporters.
In addition to iron, bacteria require other nutrients (e.g. amino acids, oligopep-
tides) that they must acquire from their environment. Sun et al. (2000) isolated
eight meningococcal mutants attenuated in an infant rat bacteraemia model that
mapped to genes encoding transporters including: NMB0792, a sodium: dicarboxy-
late/sulphate transporter; NMB1240, an ATP-binding component of an ABC trans-
porter; NMB1362, a putative oxalate/formate antiporter; NMB1612, a substrate-
binding protein of a polar amino acid transport system; and NMB1515, a putative
transporter. Additionally, meningococci with disabling mutations in the NMB1966
operon, encoding a L-glutamate transporter, have previously been found to be atten-
uated in growth in the bloodstream (Chow, 2006; Monaco et al., 2006).
Amino acid biosynthesis Synthesis of amino acids is important for bacterial sur-
vival during growth in body sites where exogenous sources of amino acids are limited,
such as in the bloodstream. On the other hand, blood is fairly rich in peptides that
may be absorbed and degraded by the bacterium. Biosynthesis of branched amino
acids (isoleucine, leucine and valine) has been demonstrated to be important for
several pathogens during in vivo growth, including Actinobacillus pleuropneumoniae
(Fuller et al., 1999), Pseudomonas aeruginosa (Wang et al., 1996) and M. tubercu-
losis (Hondalus et al., 2000). S. enterica requires synthesis of aromatic amino acids
for survival in vivo (Gu¨nel-Ozcan et al., 1997; Sebkova et al., 2008). Amino acid
biosynthesis has also been shown to be important during meningococcal bacteraemia.
Eleven out of seventy-three attenuated genes identified by screening insertional mu-
tants in an infant rat bacteraemia model were associated with amino acid biosynthesis,
including genes involved in biosynthesis of branched amino acids (ilvI (NMB1577),
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ilvD (NMB1188)), aromatic amino acids (aroB (NMB1814), aroC (NMB1680), aroD
(NMB1446), aroE (NMB0358), aroG (NMB0307)) and glutamate (gdhA (NMB1710))
(Sun et al., 2000).
Nucleotide biosynthesis De novo nucleotide biosynthesis is important for bacte-
rial survival in animal models of disease, as well as during in vitro growth in serum.
N. meningitidis with a transposon insertion in purL, involved in purine biosynthesis,
was attenuated in growth compared to wild-type in an infant rat model of disease
(Sun et al., 2000). Mutations in E. coli, S. typhimurium and Bacillus anthracis re-
sulting in an attenuated phenotype in heat-inactivated human serum were all found
to map to genes involved in either purine or pyrimidine ribonucleotide biosynthesis
(Samant et al., 2008). Mutations of genes involved in de novo purine or pyrimidine
biosynthesis in P. multocida (Harper et al., 2003) and E. coli (Li et al., 2005) have
also been reported to result in attenuation in septicaemia models.
Stress induced functions and cell detoxification During growth in blood mi-
crobes are subjected to environmental stresses such as the action of reactive oxygen
species released by phagocytic cells. Deletions in bacterial genes encoding chaperones
or other proteins involved in protection against oxidative damage or environmental
stresses have previously been found to result in virulence attenuation in animal models
of sepsis. Polissi et al. (1998) found that disruptions of genes encoding transporters
of polyamines, which act as antioxidants in the bacterial cell, led to attenuation in
growth of Streptococcus pneumoniae in the blood stream. Studies in E. coli (Gonzalez
et al., 2001) and Haemophilus influenzae (Rosadini et al., 2008) have indicated that
dsbA, which is involved in disulphide bond formation (Whitley & von Heijne, 1993),
is important for survival and infection in vivo. The H. influenzae gene dsbB, encod-
ing the second component of the DsbA–B system, has also been demonstrated to be
required for bacteraemia in an animal model (Herbert et al., 2002). The meningococ-
cal operon NMB1436–38, encoding proteins involved in protection against oxidative
stress, may be important for growth in the bloodstream since a mutant is attenu-
ated in a mouse model of infection (Grifantini et al., 2004). Genes important for H.
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influenzae bacteraemia in the infant rat model of human invasive disease included
a putative zinc protease involved in degradation of proteins and peptides (Herbert
et al., 2002). In addition, genes encoding oxidoreductases have been shown to be
required for septicaemia caused by E. coli (Li et al., 2005).
Miscellaneous genes important for meningococcal survival in vivo Other
genes that have been found to be important for meningococcal survival in the blood-
stream include NMB0345, encoding a putative a cell-binding factor; ntrY (NMB0114),
encoding a nitrogen regulation protein (Sun et al., 2000); phoP/misS (NMB0595),
encoding the DNA binding part of a two-component system (Newcombe et al., 2004);
and luxS (NMB1981), encoding a S-ribosylhomocysteinase (Winzer et al., 2002). Sun
et al. (2000) identified seventy-three such N. meningitidis genes by screening inser-
tional mutants in vivo in an infant rat model, of which sixteen encoded hypothetical
proteins, including NMB0840 and NMB1564 (both discussed later in this chapter).
6.1.3 Bacterial transcriptional changes in ex vivo or animal
models of sepsis
One early study of meningococcal gene expression used the strategy of differential flu-
orescence induction (DFI) developed by Valdivia & Falkow (1996) (using modified or-
ganisms with inserted promoter–GFP constructs) to evaluate genes up-regulated in a
whole blood model (at 5 hr) (Webb, 2001). Genes found to respond the most to growth
in blood (as determined by changes in fluorescence) were pilMNOPQ (NMB1808–
12), pilC1 (NMB1847), NMB1449, frpC (NMB1415), groEL (NMB1972) and groES
(NMB1973).
Functional genomics (transcriptomics, proteomics etc.) technologies, like microar-
rays, can be used to study the global responses of bacteria in models of infection.
Genome-wide transcriptional changes in the course of septicaemia (ex vivo or in vivo)
have been studied in a few pathogens, including group A Streptococcus (GAS) (Gra-
ham et al., 2005), S. pneumoniae (Orihuela et al., 2004) and P. multocida (Boyce
et al., 2002). Such studies have revealed adaptive transcriptional changes during
bacteraemia that confer apparent survival advantages.
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Graham et al. (2005) determined the repertoire of gene expression of GAS in
human blood at 30, 60 and 90 min in comparison to 0 min. They found genes
involved in purine biosynthesis to be highly up-regulated during growth in blood,
with the three most strongly up-regulated genes involved in purine biosynthesis. Gene
expression peaked at 30 min indicating an involvement in the early adaptation to the
environment. Several genes encoding membrane transporters were found to be up-
regulated during growth in blood, including systems for transport of manganese, zinc
and iron. Over time the most significant group of changing genes were those encoding
cofactors. Down-regulated genes over the time course included those involved in
glycolysis, which they attribute to the high levels of nutrients in blood, and in cell
envelope biogenesis (including peptidoglycan biosynthesis), which they suggest relates
to decreased growth rate in blood.
Orihuela et al. (2004) recovered S. pneumoniae RNA from the blood of mice with
severe experimentally-induced sepsis. In comparison to bacteria grown in rich broth,
transcriptional changes included up-regulation of genes involved in biosynthesis of
purine and folic acid and those encoding manganese and zinc transporters. These
authors’ microarray data further underline the importance of biosynthesis of purines
during growth in blood. No genes involved in transport of iron were found to be
up-regulated in this system.
Boyce et al. (2002) found sixteen P. multocida genes to be consistently up-regulated
during sepsis in poultry, in comparison to growth in rich medium. Up-regulated genes
included asnA, encoding an ammonia-dependent asparagine synthetase; purH, in-
volved in purine biosynthesis; and gdhA, encoding a glutamate dehydrogenase. Boyce
et al. (2002) observed limited overlap between P. multocida genes found to be differ-
entially expressed in septicaemia and genes that had previously been demonstrated
to respond to growth under iron limitation.
So far no studies have been published in which genome-wide transcriptional changes
in N. meningitidis have been determined in the course of septicaemia, either in in
vivo or in ex vivo models. In this chapter I present the genome-wide transcriptional
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profile of a MenB strain during culture in whole human blood, an ex vivo model
of bacteraemia. To model the scenario in na¨ıve hosts, representing young children,
meningococci were incubated in non-bactericidal whole human blood. Genes of partic-
ular interest were those, encoding surface exposed proteins, which were up-regulated
in this experimental system.
6.2 Results
Blood samples from a total of 20 adult volunteers were screened for the ability to sus-
tain growth of MenB strain MC58. Two of the adult blood donors tested in this whole
blood assay (WBA) (Section 2.9.2) were found to have almost no bactericidal activity
to strain MC58. The growth characteristics of strain MC58 in non-bactericidal blood
from individual A (female) and B (male) are shown in Figure 6.1 (these are the same
donor A and B as in Chapter 3). The survival of MC58 in blood from these two indi-
viduals varied slightly between assays, but in most assays a 10-fold to 100-fold increase
in bacterial number was observed during a 240 min time course. In contrast, during
incubation of meningococci in blood from a ‘killer’, no bacteria were detectable by 60
min. Thirty ml of fresh non-bactericidal heparinised pre-prandial blood samples from
adult donors were infected with meningococcal strain MC58 (B:15:P1.7,16-2) in late
exponential phase of growth, at an initial inoculum of 107 cfu per ml, and incubated
for up to 240 min. At the starting point, and up to 240 min post-infection, changes
in the blood biochemistry were measured (data presented in Section 3.2.2). At 20,
40, 60, 90 and 240 min post-infection, bacterial RNA was isolated from the blood of
donor A, following differential lysis of human cells, for a genome-wide transcriptional
study as described in Section 2.9.2. The time course experiment was replicated on
six separate occasions over a period of two months. For analysis of a subset of genes
using comparative real-time RT-PCR, RNA isolated from meningococci incubated in
blood from both donor A and B were used (Section 6.2.4). RNA was isolated from
bacteria in blood using the method described in Section 2.9.2, and the quality of
the isolated RNA was determined by analysis on a Bioanalyzer (described in Section
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Figure 6.1: Survival of MenB strain MC58 in blood from donor A and donor B up to 240
min. Data presented for each individual are from one representative whole blood assay, with
CFUs determined at different time-points. An initial load of 107 cfu per ml was added to
heparinised blood followed by incubation up to 240 min. CFUs were determined by plating
out appropriate dilutions in triplicate on solid sGC agar. Error bars represent standard
deviations of technical replication.
2.4.1) (Figure 6.2). In the genome-wide transcriptional study, blood from only donor
A was used for two main reasons: firstly, due to the cost of performing microarray
studies and secondly, that insufficient amounts of RNA for microarray analysis could
be isolated from bacteria incubated in blood from donor B.
6.2.1 MenB transcriptome in blood from donor A
RNA isolated from meningococci incubated in blood from donor A was reverse tran-
scribed, fluorescently labelled and hybridised to pan-Neisseria microarrays as de-
scribed in Section 2.7. Genomic DNA isolated from strain MC58 was used as a
common reference in all hybridisations. Data collected from microarrays were filtered
to remove spots with low intensity on all microarray slides and normalised to median
log2 ratios on each slide. After pre-processing and normalisation of the data, statis-
tical analysis was carried out using Bayesian linear models, as implemented in the
software package Limma (Smyth, 2004), to identify differentially expressed genes (see
Section 2.7.6 for details). A gene was considered to be significantly changed between
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Figure 6.2: Bacterial RNA samples isolated from blood were analysed on an Agilent
2100 Bioanalyzer using RNA 6000 Nano assay chip. Abundance is given as fluorescence
(relative to an RNA ladder) and plotted against migration time that has been converted
into a nucleotide (nt) estimate of product size relative to an RNA ladder. To the left is an
electropherogram of RNA isolated from meningococci in blood from individual A at the 20
min time-point and to the right is an electropherogram of RNA isolated from meningococci
in blood from individual B at the 90 min time-point. The peak at 25 nt represents the
marker added to all samples. Peaks at 1800 nt may represent contaminating human rRNA
(18S) in the samples.
conditions or time-points when the change was ≥ ±1.5-fold at a FDR of ≤0.01. The
data were further analysed using gene enrichment methods that determine the signif-
icant differential regulation of a set of genes, rather than gene-by-gene. Two different
methods were used for gene enrichment: the GSEA software developed by Mootha
et al. (2003) (described on pages 100 and 135) or the function geneSetTest() avail-
able in the R-package Limma developed by Smyth (2004). PCA, a data dimension
reduction method, was performed using gene expression data (mean-centred) from
all genes of good quality to provide a multivariate overview of similarities between
samples and for a low dimensional visualisation of the expression profiles (Section
2.7.8). The first two PCA components are shown in the score plot in Figure 6.3.
The microarray data separated in space along the first PCA component according to
time-point in blood (samples from later time-points are further to the left along the
first component) and along the second PCA component according to experimental
condition (incubation in blood or at t = 0 bacteria re-suspended in RPMI 1640 cul-
ture medium). Microarray data collected for time-points 20, 40 and 60 min during
growth in blood had similar overall transcription profiles, indicated by the fact that
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all samples from these time-points cluster in the bottom right corner in Figure 6.3.
































Figure 6.3: Principal component analysis of the gene expression in blood or on solid agar
using data from all MC58 genes on all microarray slides. The PCA score plot reveal a
separation of the time-points in blood along the first component (from right to left: early
to late time-points), which points to differences in their overall transcriptional profile. Each
symbol represents one biological replicate (five to six biological replicates per time-point).
PCA component 1 explains 33.3% and PCA component 2 explains 16.8% of the variance in
the data.
6.2.2 Nature of differentially expressed genes in comparison
to time-point 0 min
Data presented in the following sections represent the comparison of the gene ex-
pression profile during incubation in blood to the gene expression profile at 0 min.
Transcriptional changes between time-points or in relation to an early time-point in
blood (t = 20 min) are presented in Section 6.2.3. In all of the comparisons, up-
regulated meningococcal genes encoding known or putative surface exposed proteins
will first be described, as identification of such proteins were the primary aim of this
project.
At all time-points (20, 40, 60, 90 and 240 min) during ex vivo culture in blood, an
extensive remodelling of the meningococcal transcriptome was observed, compared to
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the transcriptional profile of bacteria at the time of inoculation. Using the inclusion
criteria, 1135 genes (50% of the genome) were found to be differentially expressed at
one or more time-points in response to exposure to human blood relative to time-
point 0 min. All differentially expressed genes, grouped by their TIGR designations
(Peterson et al., 2001), are listed in Appendix C (Tables C.1–C.17). At each time-
point, there was a relatively even distribution between up- and down-regulated genes.
The proportion of differentially expressed genes that are associated with each TFRC
is listed in Table 6.1. Most of the genes up-regulated in blood were associated with
the following TFRCs: hypothetical proteins; protein synthesis; energy metabolism;
and transport and binding proteins. The same categories, with the exception of
protein synthesis, were also most common among the down-regulated genes. At 20
min, a large proportion of the up-regulated genes encode proteins involved in energy
metabolism, at a much higher level than at later time-points. One plausible expla-
nation for this up-regulation may be an initial energy requirement for adaptation
to the new environment. At 90 min, there was a relative increase compared to the
earlier time-points in transcription of genes encoding proteins involved in biosynthe-
sis of cofactors, prosthetic groups and carriers, components of central intermediary
metabolism and regulatory functions. The proportion of the up-regulated genes asso-
ciated with either DNA metabolism (6.62%) or cell envelope (5.96%) was increased at
the 240 min time-point. Analysis was performed using the GSEA software (Mootha
et al., 2003) to find TFRCs that were significantly associated with differential regula-
tion during incubation in blood. Categories with a FDR q-value of ≤ 0.25 (the cut-off
suggested by Mootha et al. (2003)) are listed in Table 6.2. None of the TFRCs were
found to be significantly enriched among genes with higher expression at the 90 and
240 min time-points than at 0 min.
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Table 6.1: Differentially expressed genes in blood versus time-point 0 min categorised
into functional groups according to their TIGR designations. Numbers listed in the table
(%) gives the proportion of each TFRC among up- or down-regulated at each time-point.
Underlined numbers indicate categories found at a higher proportion among up- or down-
regulated genes at specific time-points during incubation in blood, than the total proportion
in the MC58 genome (column two).















Amino acid biosynthesis 3.42 5.56 6.54 7.63 6.63 2.65
Biosynthesis of cofactors, prosthetic
groups and carriers
4.08 2.96 2.31 2.97 8.84 5.96
Cell envelope 5.39 2.96 4.62 3.39 4.42 5.96
Cellular processes 5.92 1.85 3.85 1.69 2.76 4.64
Central intermediary metabolism 1.75 1.11 2.31 2.12 3.87 1.99
DNA metabolism 4.43 3.70 3.08 3.39 3.31 6.62
Energy metabolism 7.15 11.85 8.85 7.20 4.42 6.62
Fatty acid and phospholipid
metabolism
1.36 1.48 1.54 2.12 1.10 0.99
Conserved hypothetical proteins 14.12 10.37 14.23 11.86 20.44 13.25
Mobile and extrachromosomal element
functions
3.20 – – – 1.10 4.97
Protein fate 3.24 2.96 6.92 6.36 5.52 2.65
Protein synthesis 5.39 22.59 15.77 17.37 4.97 3.97
Purines, pyrimidines, nucleosides and
nucleotides biosynthesis
1.80 2.59 3.85 3.81 2.76 2.98
Regulatory functions 2.37 1.85 1.54 1.69 2.76 2.32
Transcription 1.71 4.81 3.85 4.66 2.21 1.66
Transport and binding proteins 5.52 6.30 6.15 5.93 6.63 5.63
Unassigned 23.24 11.85 10.77 12.71 12.71 21.52
Unknown function 5.92 5.19 3.85 5.08 5.52 5.63
Down-regulated
Amino acid biosynthesis 3.42 1.74 1.81 1.17 1.03 3.88
Biosynthesis of cofactors, prosthetic
groups and carriers
4.08 0.87 0.90 1.17 0.68 1.83
Cell envelope 5.39 1.74 2.26 2.33 3.77 4.11
Cellular processes 5.92 9.57 9.05 9.34 9.25 7.76
Central intermediary metabolism 1.75 1.30 1.36 1.17 1.37 1.37
DNA metabolism 4.43 1.74 2.26 2.33 3.08 3.88
Energy metabolism 7.15 13.04 12.22 10.12 9.93 11.64
Fatty acid and phospholipid
metabolism
1.36 0.43 – 0.39 1.37 1.60
Conserved hypothetical proteins 14.12 15.65 11.76 14.79 12.33 10.73
Continued on next page . . .
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Table 6.1 – continued from previous page














Mobile and extrachromosomal element
functions
3.20 1.30 1.81 1.56 2.40 1.14
Protein fate 3.24 2.17 1.36 1.17 1.71 2.74
Protein synthesis 5.39 0.43 0.45 0.39 0.34 6.85
Purines, pyrimidines, nucleosides and
nucleotides biosynthesis
1.80 0.43 0.90 0.78 1.03 1.60
Regulatory functions 2.37 4.35 3.62 3.50 5.14 3.20
Transcription 1.71 0.87 0.90 0.78 0.68 1.60
Transport and binding proteins 5.52 9.13 9.05 8.17 6.16 5.94
Unassigned 23.24 28.70 32.58 33.07 32.88 25.57
Unknown function 5.92 6.52 7.69 7.78 6.85 4.57
Table 6.2: TFRCs significantly enriched (FDR q-value of ≤ 0.25), using GSEA analysis,










Biosynthesis and biosynthesis of cofactors, prosthetic groups and car-
riers
√








Categories that were found to be significant during blood at 20, 40 and/or 60 min in comparison
to gene expression at time-point 0 min are indicated by a tick (
√
)
6.2.2.1 Surface structures and surface exposed proteins
During incubation in blood, transcriptional profiles of genes encoding components
of the cell envelope were found to alter substantially, suggesting that the surface of
the organism was undergoing extensive re-modelling. There was a complex sequence
of changes, for example, in the expression of genes involved in pilus biogenesis –
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Figure 6.4: Heat map (Section 2.7.8) visualising gene expression of genes associated with
LOS and polysaccharide capsule at time-points 20 to 240 min during incubation in blood,
relative to expression at the 0 min time-point. Values represent log2 ratios.
an initial increase in expression, followed in many cases by subsequent waning. An
overview of gene expression (in relation to time-point 0 min) of all genes annotated in
TIGR subrole category biosynthesis and degradation of surface polysaccharides and
lipopolysaccharides, is shown in Figure 6.4. Two separate clusters can be seen in the
figure, one representing the early time-points (20–60 min) and one representing the
later time-points (90 and 240 min). The separation corresponds mainly to increased
expression of seven genes (lipAB, galE-1, rfbA-1, rfbA-2, rfbB-1 and rfbB-2 ) and
decreased expression of the capsule biosynthesis genes (Figure 6.5) at the later time-
points. Surprisingly, none of the genes involved in capsule biosynthesis and surface
expression were found to be significantly up-regulated in this experimental system
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Figure 6.5: Transcriptional profiles over time of genes involved in biosynthesis (left) and
export to the surface (right) of the capsular polysaccharide in comparison to the common
reference (gDNA).
(Supplementary table C.3), although their expression was slightly elevated at early
time-points (20 and 40 min) (Figure 6.5). At all time-points, genes the products of
which are required for biosynthesis of the capsular polysaccharide were expressed at
high absolute levels, emphasising an important caveat in interpretation: if capsular
genes, or any other genes, are already highly expressed at time 0 min, no change may
be detected. This does not of course mean that such genes are necessarily expressed
at low level in blood.
In bacteria incubated in blood, lst (NMB0922), encoding the sialyl-transferase
responsible for sialylation of LOS, was found to be up-regulated at 20 to 60 min.
Loss of LOS sialyation in meningococci, due to a knock out of lst, is associated with
a 50% increase in serum sensitivity (Kahler et al., 1998). At this point, it has not
been confirmed that up-regulation of lst correlates with actual increased sialylation.
Several other genes associated with the capsule, LOS or surface structures were found
to be significantly up-regulated in response to incubation in blood. These included
two genes involved in inner core LOS biosynthesis: lgtF (NMB1704), up-regulated
at 20 min and rfaK (NMB1705), up-regulated at 20, 40 and 90 min. As well as
a phosphoglucomutase (encoded by pgm (NMB0790)) involved in for example LOS
biosynthesis, which was up-regulated at 40 and 60 min. The gene lipB (NMB0083)
(responsible for proper translocation and surface expression of lipidated capsule poly-
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mer) was up-regulated at 60 and 90 min.
Known or putative surface proteins with increased expression in blood–
grown organisms Genes found to be up-regulated in blood were sorted by cellular
locations, based on experimental confirmations or in silico predictions. Predictions of
cellular location were performed using a combination of algorithms: PSORTb, PSL-
pred and bioinformatics tools available at CBS (http://www.cbs.dtu.dk/services),
as described in Section 2.11. All genes that encode a signal peptide (identifying a
protein transported past the inner membrane), or which encode proteins assigned to
a periplasmic or outer membrane location, are listed in Supplementary table C.18.
Genes encoding proteins that previously have been identified in preparations of OMPs
or OMVs, or that have been experimentally confirmed to be located on the surface,
are also included in the table. In total 231 such genes were up-regulated during
meningococcal growth in blood. Of those, 163 encode proteins that may be located
on the surface under some conditions. Genes encoding surface antigens that were
found to be up-regulated in blood included: pilB (NMB0044), mapA (NMB0390),
mntC (NMB0586), potD-2 (NMB0623), purL (NMB1996), NMB0464, NMB0787,
NMB0964, NMB0995, NMB1040, NMB1126/1164, NMB1332, NMB1523, NMB1875,
NMB1882, NMB1961 and NMB2132. NMB0464, also known as pldA or OMP1A,
was found to be up-regulated at 20 to 60 min. NMB0464 encodes a putative outer
membrane located phospholipase A that has been assessed for its vaccine poten-
tial, however, anti-OMP1A serum has not been found to have protective activity
(Bos et al., 2005). NMB0995 encodes a putative macrophage infectivity potentia-
tor (MIP). A gonococcal homologue of the protein has previously been shown to be
a surface exposed lipoprotein with peptidyl-prolyl cis-trans isomerase (PPIase) ac-
tivity that is important for bacterial survival in macrophages (Leuzzi et al., 2005).
NMB2132, encoding a transferrin binding protein-related protein, is one of the com-
ponents of a MenB protein based vaccine currently in clinical trials (Giuliani et al.,
2006). NMB1332, up-regulated at 240 min (also up-regulated between 90 and 240
min), encodes a carboxy-terminal peptidase that has been described as a virulence
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factor (Tettelin et al., 2000). The gene product of NMB1332 has been identified in
protein preparations of both OM (Williams et al., 2007) and OMVs (Ferrari et al.,
2006; Vaughan et al., 2006; Williams et al., 2007), which suggests that the protein may
be accessible on the surface of the bacteria. Two genes, NMB0497 and NMB1779,
both encoding the secreted component (TpsA, hemagglutinin/hemolysin-related pro-
tein) of two-partner secretion (TPS) systems in MC58, were found to be up-regulated
at 240 min. TpsA is known to be transported to the extracellular space by TpsB
(encoded by either NMB1762 or NMB1780). TPS systems have recently been shown
to contribute to N. meningitidis adherence to epithelial cells (Schmitt et al., 2007)
and antibodies reactive to the secreted component have been detected in patient sera
(van Ulsen et al., 2008).
6.2.2.2 Meningococcal adaptation to the blood environment
An initial increase in protein synthesis (at 20, 40 and 60 min), as well as major changes
in metabolism, was observed upon culture of meningococci in blood. The increase
in transcription of genes involved in protein and amino acid synthesis may reflect
environmental adaptation. Blood is relatively rich in carbon and energy sources,
such as carbohydrates and peptides, but contains very limited free amino acids. The
proportion of up-regulated genes that were involved in protein synthesis was reduced
at 90 and 240 min in blood (Table 6.1).
During bacterial growth in the bloodstream, glucose is the most readily available
energy source, whereas lactate has been suggested to be an important energy source
during meningococcal colonisation of the nasopharynx (Exley et al., 2005a). However,
similar levels of lactate and glucose can be found in blood and explants of nasopha-
ryngeal tissue (Exley et al., 2005a). The TCA cycle is generally not active during
meningococcal growth in medium with glucose (Morse & Hebeler, 1978), but is, how-
ever, active when lactate is used for energy. Growth in a combination of lactate and
glucose has been shown to render the meningococcus more resistant to serum, most
likely due to an increase in LOS sialyation and production of the capsular sialic acid
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(Exley et al., 2005b). Besides lactate and glucose, meningococci can utilise pyruvate
(Grossowicz, 1945) and maltose (Bartolini et al., 2006) as energy sources. During
in vitro incubation of human blood, with or without inoculated meningococci, a
decrease in levels of glucose and an increase in levels of lactate (L-lactate) were ob-
served between 0 and 240 min (Chapter 3, Figure 3.3), most likely related to host cell
metabolism. The N. meningitidis gene lctP (NMB0543), encoding a lactate perme-
ase, was not found to be up-regulated in response to the increase in plasma lactate,
but was instead found to be down-regulated at the 20 and 240 min time-points in
blood. The gene expression of lctP did increase slightly at 40 and 60 min in blood in
comparison to 20 min, but the change was not significant (≤1.5-fold, FDR ≥0.01 ).
The gene lldA (NMB1377), encoding a L-lactate dehydrogenase involved in utilisation
of L-lactate, was however found to be up-regulated in blood between 20 and 40 min
(Section 6.2.3.1).
During incubation in blood, an initial up-regulation of mapA, up to 40 min, was
observed. mapA encodes a maltose phosphorylase that catalyses the cleavage of mal-
tose to glucose and β-glucose-1-phosphate (further described on page 110). This gene
was also up-regulated during meningococcal growth in plasma at 240 min (Sections
5.2.1.4 and 5.2.2.1).
Amino acid biosynthesis and acquisition Amino acid biosynthesis is important
for bacterial pathogenesis (described in Section 6.1.2). Five of the eleven genes (aroC,
aroG, gdhA, metF (NMB0943) and metH (NMB0944)) in this category found to be
attenuated by Sun et al. (2000) in an infant rat model of infection, were up-regulated
at least once during the time course in blood.
During growth in blood (at 20 to 60 min) up-regulated genes also included those
encoding an L-glutamate transporter, as well as a NADP-linked glutamate dehy-
drogenase (encoded by gdhA) involved in assimilation of nitrogen and glutamate
metabolism, which is highly active in conditions of poor glutamate-availability. Glu-
tamate is central for bacterial growth as it is required for assimilation of nitrogen
(essential for synthesis of amino acids), involved in defence against osmotic stress
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(that may be of importance in the bloodstream) (Dinnbier et al., 1988) and can
also serve as a carbon source. Blood is poor in amino acids, but contains ammo-
nia which N. meningitidis can also use for assimilation of nitrogen in vitro after
adaption to a glutamate-free medium (Jyssum, 1959). In meningococci gdhA has
been shown to be positively regulated by GdhR (described on page 107), an activa-
tion that can be blocked by binding of 2-oxoglutarate (a TCA cycle intermediate)
to the same site (Pagliarulo et al., 2004). N. meningitidis also expresses a NAD-
linked glutamate dehydrogenase (encoded by gluD (NMB1476)), which functions in
catabolism of L-glutamate to 2-oxoglutarate and NH+4 . Over time gdhA and genes
encoding the glutamate transporter were down-regulated, indicating that intracellu-
lar levels of 2-oxoglutarate increased (which may relate to increasing use of lactate
for energy). Increased expression (significantly up-regulated at 240 min vs. 20 min)
was instead observed for the gene encoding the NAD-linked glutamate dehydrogenase
(active at lower levels of glucose and higher levels of L-glutamate (Pagliarulo et al.,
2004)). At 90 and 240 min during growth in blood, a nitrogen assimilation regula-
tory protein (encoded by ntrX ) was up-regulated. NtrX is part of the NtrX/NtrY
two-component system which regulates nitrogen metabolism in response to nitrogen
limitation (Pawlowski et al., 1991). A way for the bacteria to increase intracellu-
lar nitrogen, which can then be used in other processes in the cell, may be through
catabolism of L-glutamate by NAD-linked glutamate dehydrogenase. It is also possi-
ble that L-glutamate may become increasingly available in the extracellular milieu due
to conversion from L-glutamine by host cells (a reaction catalyzed by a glutaminase
(Kovacevic & McGivan, 1983)).
Degradation of peptides may be one mechanism whereby the organisms acquire
amino acids from blood, besides de novo biosynthesis. In addition to increased ex-
pression of genes associated with amino acid biosynthesis, prlC (NMB0214), encoding
an oligopeptidase, was up-regulated at 40, 60 and 90 min in blood. At 240 min, a pro-
line iminopeptidase (encoded by pip (NMB0927)) was up-regulated, which catalyses
removal of the N-terminal proline from peptides.
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Genes encoding amino acid transporters were also found to be up-regulated during
growth in blood. These included NMB0787–89, an operon encoding a putative ABC
transporter of polar amino acids, which was found to be up-regulated in blood at 20
to 90 min. The operon has previously been shown to be up-regulated in response
to growth in L-glutamine (Friedrich et al., 2007), the most abundant amino acid in
blood (Tsai & Huang, 1999). Additionally, a transporter of L-glutamate, encoded
by gltS (NMB0085), was up-regulated at 20 min. During incubation in blood the
gene hisJ (NMB1612), encoding the periplasmic amino acid-binding protein of a
putative ABC transporter, was found to be up-regulated after 40 min, but was down-
regulated at the 240 min time-point. Upon incubation beyond 90 min in blood,
mtr (NMB2031), encoding a tryptophan transporter, was found to be up-regulated.
A P. multocida tryptophan transporter (Mtr) has previously been found to be up-
regulated in response to growth in the presence of haemoglobin (Paustian et al., 2002).
In relation to time-point 0 min, NMB0177 (at 20 and 60 min) and putP (NMB0402)
(at 40 min) were found to be down-regulated. They encode alanine and proline
symporters, respectively.
Genes involved in sulphur metabolism were found to be up-regulated in response
to human plasma (Chapter 5). A similar transcriptional response was also observed
for meningococci incubated in human blood. Following 240 min incubation in blood,
sbp (NMB1017) and cysW (NMB0880) were found to be up-regulated. They encode
components of a transporter involved in acquisition of sulphate from the extracellular
milieu. Incubation in blood also led to consistent up-regulation of metH and metF,
the gene products of which are involved in methionine biosynthesis.
Nucleotide biosynthesis Genes involved in nucleotide biosynthesis have been
found to be essential for in vitro growth in serum (Samant et al., 2008) and in ani-
mal models of disease (Sun et al., 2000). The function geneSetTest(), available in
the R-package Limma (Smyth, 2004), was used to test if genes involved in de novo
purine or pyrimidine ribonucleotide biosynthesis were also significantly associated
with meningococcal growth in blood. Moderated t-statistics for each gene from the
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Limma statistical analysis were used as input data to the function. Genes involved in
purine biosynthesis were found to have significantly higher expression at 20, 40, and
60 min in blood compared to expression at time-point 0 min (P-value ≤ 0.01). The
enrichment was most significant at early time-points (20 and 40 min) in blood. Like-
wise, genes involved in pyrimidine biosynthesis were up-regulated in blood compared
to growth on solid agar and significantly enriched at time-points 20, 40, 60 and 90
min.
6.2.2.3 Transport systems
In addition to genes encoding amino acid-transporters, incubation in blood induced
differential regulation of several other genes encoding transport machinery. Up-
regulated genes encoded transporters of cations (kefB (NMB0209), NMB1271, trkA
(NMB1614) and mntABC (NMB0588–86)) and anions (NMB0378, cysW, sbp). mntC,
encoding the periplasmic substrate binding component of a putative transporter of
Mn2+ and/or Zn2+, was up-regulated in blood at 40 min. Orthologues of mntABC in
N. gonorrhoeae have previously been shown to encode a transporter that transports
Mn2+ and Zn2+ with equal affinity (Lim et al., 2008). Mutations in mntC have been
shown to result in meningococcal strains with increased sensitivity to O.−2 killing (Seib
et al., 2004). The product of trkA up-regulated during growth in blood at 20 to 90
min (also up-regulated in FFP 2 (page 124)), has been suggested to counteract the
osmotic changes associated with insertion of MAC into the bacterial OM (Chen et al.,
2004).
Genes encoding iron-binding proteins (e.g. tbpA (NMB0461), tbpB (NMB0460)
and hmbR) were not up-regulated during incubation in blood in relation to a time-
point 0 min. However, some of the genes involved in iron uptake were found to be
progressively up-regulated as a response to bacterial growth in blood (Section 6.2.3).
Transcriptional profiles in blood of genes encoding systems required for iron uptake
(and some putative iron uptake systems) are shown in Figure 6.6. During growth in
blood, fetB2 (NMB1880) and NMB1882, encoding two proteins potentially involved
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Figure 6.6: Transcriptional profiles of iron uptake genes (and putative iron uptake genes)
over time. Y-axis shows log2 ratios versus gDNA. In each subfigure (in order as listed in
title): gene (1) is represented by solid lines and filled squares, gene (2) is represented by
dashed lines and empty squares and gene (3) is represented by solid lines and filled red
squares.
in iron uptake, were found to be up-regulated. NMB1882, up-regulated at 90 min,
encodes a putative ferric siderophore receptor protein and fetB2, up-regulated at
240 min, encodes a periplasmic solute-binding protein component of a putative ABC
transporter. NMB1882 has been shown to be required for meningococcal intra-cellular
survival and transcytosis through a cell layer (Quattroni et al., 2007).
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6.2.2.4 Virulence factors
Twenty-five of the genes that were up-regulated at one or several time-points in blood
are listed as virulence factors in Tettelin et al. (2000) (Table 6.3). Two of these genes,
both encoding unrelated opacity proteins (Opa and Opc), will be presented in greater
depth. Stephens & McGee (1983) observed that colonies of clinical isolates from
blood or CSF generally are transparent, which relates to down-regulation of opacity
proteins through phase-variation or other processes. Both opcA (NMB1053), encoding
a surface exposed opacity protein, and NMB0926 (Opa) were up-regulated at early
time-points in blood, but gene expression waned over time. Although NMB0926
is annotated with a frame-shift in the MC58 genome sequence, antibodies to this
protein have been detected in sera from patients (Steller et al., 2005), suggesting
expression of the protein on the surface of at least some meningococcal strains during
invasive infection. Lewis et al. (2008) demonstrated that Opa interacts with C3b and
C4b on the meningococcal surface, and speculate that it is therefore advantageous
for meningococci to down-regulate surface expression of opacity proteins to avoid
complement-mediated killing, which could explain down-regulation of NMB0926 at
later time-points during growth in blood in this study. OpcA is immunogenic in
humans (Rosenqvist et al., 1993), and clinical isolates from the bloodstream have
been found to express lower levels of the protein (Achtman et al., 1991).
Table 6.3: Genes that were differentially expressed during growth in blood at 20, 40, 60,
90 and/or 240 min in comparison to time-point 0 min, which are annotated as virulence
factors in Tettelin et al. (2000). Only genes with an adjusted P-value ≤ 0.01 in the statistical
analysis are listed in the table.
Microarray data (log2 ratio)










NMB0014 kdtA 3-deoxy-D-manno-octulosonic-acid transferase 0.851
NMB0018 pilE pilin 0.837 0.714 0.723




NMB0199 lpxB lipid-A-disaccharide synthase 0.691 0.657
NMB0216 katA catalase 2.656 2.750 3.301 2.483
NMB0393 multidrug resistance protein 0.816
NMB0586 putative adhesin 0.649
NMB0922 lst alpha-2,3-sialyltransferase 1.159 0.809 0.913 0.686
NMB0926 opacity protein (authentic frameshift) 0.673 -0.884
NMB0995 macrophage infectivity potentiator-related pro-
tein
1.337 0.958 0.741 0.734 0.729
NMB1053 opcA class 5 outer membrane protein 1.124 1.068
Continued on next page . . .
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Table 6.3 – continued from previous page
Microarray data (log2 ratios)










NMB1206 bfrB bacterioferritin B 2.482 1.193 0.633 1.001
NMB1207 bfrA bacterioferritin A 2.186 0.969 1.164
NMB1332 prc carboxy-terminal peptidase 1.217
NMB1704 lgtF beta-1,4-glucosyltransferase 0.960 0.844 0.884 0.760 0.806
NMB1705 rfaK alpha-1,2-N-acetylglucosamine transferase 0.654 1.041
NMB1779 hemagglutinin/hemolysin-related protein 1.057
NMB1880 fetB2 putative ABC transporter, periplasmic solute-
binding protein
1.233
NMB1882 TonB-dependent receptor 0.866
NMB1926 lgtE lacto-N-neotetraose biosynthesis glycosyl trans-
ferase
0.725
NMB1928 lgtB lacto-N-neotetraose biosynthesis glycosyl trans-
ferase
0.600
NMB1929 lgtA lacto-N-neotetraose biosynthesis glycosyl trans-
ferase
0.726 0.904 0.779 0.974
NMB1961 VacJ-related protein 0.742 0.691 0.721 0.634
NMB2132 transferrin binding protein-related protein 0.661
6.2.2.5 Stress responses and cell detoxification
Some of the changes in meningococcal gene expression that were observed over the 240
min time course of incubation in blood may be attributed to MenB stress responses.
At the 40 and 60 min time-points, several genes encoding chaperones were found
to be up-regulated: grpE (NMB0561), dnaJ (NMB0059), dnaK (NMB0556), dsbC
(NMB0550), groEL (NMB1972) and groES (NMB1973). Additionally the expression
of katA (NMB0216), encoding catalase, increased greater than 8-fold after 40 min
incubation in blood, and stayed consistently up-regulated until 240 min. This may
reflect the fact that one aspect of host defence to which these organisms are exposed
in this whole blood experimental system is the oxygen free radical burst derived from
specialised phagocytic cells (polymorphonuclear leukocytes; PMNs) (Klebanoff et al.,
1983). Several other genes, the products of which have previously been reported to
protect against oxidative stress, were also found to be up-regulated. One of these,
pilB, encodes a protein with methionine sulfoxide reductase and disulphide reductase
activity. The PilB protein is found both in a secreted form (with three domains)
associated with the outer membrane and a cytoplasmic form (with two domains).
The central and C-terminal domains of the protein have previously been shown to
have methionine sulfoxide reductase (Mrs) A and MrsB activities, respectively, which
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mediate the repair of proteins damaged by sulfoxidation of methionine residues. The
N-terminal domain, specifically expressed in the secreted form, has been shown to
display a disulphide reductase activity that can recycle Msr activities (Wu et al.,
2005). The operon NMB1436–38, the gene products of which have been suggested to
be involved in protection against oxidative stress, was found to be up-regulated at
all time-points between 20 and 90 min. Grifantini et al. (2004) demonstrated that
knocking out the operon resulted in increased sensitivity to killing by PMNs and
impaired growth in the bloodstream of mice compared to wild-type (Grifantini et al.,
2004).
Polyamines are involved in many processes in the cell, including protection against
oxidative damage and responses to nitric oxide-mediated immune functions (Shah &
Swiatlo, 2008). The S. pneumoniae potD gene, encoding the substrate-binding pro-
tein, has previously been found to be highly expressed in a murine model of bacter-
aemia (Shah et al., 2008). During meningococcal growth in blood, four genes - potB
(NMB0611), potC (NMB0612), potD-2 and potD-3 (NMB1594), encoding proteins
involved in transport of polyamines - were found to be up-regulated at 20 to 60 min.
Protection against host antibacterial factors is, in part, mediated through eﬄux
proteins. During meningococcal growth in blood, farA (NMB0318), encoding a com-
ponent of an eﬄux protein (FarAB) mediating resistance to long-chained fatty acids,
was found to be up-regulated after 90 and 240 min. The FarAB complex is located
in the bacterial inner membrane and requires the outer membrane protein MtrE, also
used by the mtrCDE -encoded eﬄux pump (NMB1714–16), for export of fatty acids
from the cell (Lee & Shafer, 1999). An additional two genes encoding multidrug re-
sistance proteins were found to be up-regulated during growth in blood: NMB0393,
up-regulated at 90 min and norM (NMB0812), up-regulated at 240 min. The NorM
eﬄux protein has been shown to be involved in protection against toxic effects of
cationic compounds during in vitro incubation (Rouquette-Loughlin et al., 2003).
The multidrug eﬄux protein NMB0393 was also found to be up-regulated during
growth in FFP 2 (described on page 124).
Chapter 6: Genome-wide transcriptional profiling in blood 166
Another group of genes found to be up-regulated in blood-grown organisms were
those belonging to the category of DNA metabolism. Up-regulation of these genes
was most prominent at the 240 min time-point (6.6%). Genes up-regulated at 240
min included mutY (NMB1396), encoding an A/G-specific adenine glycosylase, and
mutS (NMB2160), encoding a DNA mismatch repair protein. N. meningitidis mutS
mutants have been shown to undergo an increased rate of phase variation (Alexander
et al., 2004). The gene xseB (NMB0262), encoding the small subunit of an exodeoxyri-
bonuclease, was found to be significantly up-regulated at 60 and 240 min. Expression
of xseB was also found to be increased at 20, 40 and 90 min, but, at these time-points
the up-regulation was not significant in the statistical test. xseB has previously been
demonstrated to be up-regulated when meningococci attach to epithelial cells (Gri-
fantini et al., 2002b; Morelle et al., 2003). Morelle et al. (2005) have demonstrated
in a later study that increased expression of xseB (as a result of either host cell con-
tact or IPTG-induced over expression) is associated with increased phase-variation,
which may be advantageous during invasive disease to avoid recognition by the host’s
immune system. At the 240 min time-point, many of the up-regulated genes - for
example, NMB0805, NMB1050 and NMB1251 - encode proteins with transposase
function. Transposase genes NMB1050 and NMB1251 have previously been found
to be up-regulated during N. meningitidis attachment to epithelial cells (Grifantini
et al., 2002b).
6.2.2.6 Transcriptional regulation
Thirty-two genes annotated as regulators were differentially expressed during incuba-
tion in blood (Supplementary table C.14), twelve of which were up-regulated at least
once during the time course in blood. Up-regulated genes included NMB0737 (at 20,
60, 240 min), encoding a putative HPr kinase phosphatase, and NMB1816 (at 60,
90 min), annotated as an NrdR family transcriptional regulator. HPr kinase phos-
phatases have previously been shown to regulate carbohydrate metabolism through
the PTS system in Gram positive bacteria (Warner & Lolkema, 2003). NMB1816 is
homologous to a group of transcriptional regulators, including the E. coli regulator
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YbaD that consists of a Zn-ribbon and ATP-cone domain. This group of regula-
tors has been shown to act as repressors of Nrd operons, encoding ribonucleotide
reductases (Grinberg et al., 2006; Torrents et al., 2007).
Six genes (NMB0398, NMB0573, NMB1007, NMB1249–50 and NMB1303) encod-
ing putative regulators were down-regulated at four or more of the time-points in
blood, in comparison to expression at time-point 0 min. An orthologue of NMB0398,
annotated as a ArsR family regulator, has been demonstrated to act as a repres-
sor of norB in N. gonorrhoeae. This repression can be reversed by binding of the
regulator Fur to the same site (Isabella et al., 2008). During incubation in blood,
norB (NMB1622) was down-regulated at 20, 40 and 60 min, but showed increased
gene expression between 60 and 90 min in blood. NMB0398 has previously been
demonstrated to be induced by exposure to H2O2 (Grifantini et al., 2004). NMB0573
encodes a protein predicted to belong to the AsnC family of regulators (Lrp homo-
logue). NMB0573 has previously been shown to respond to growth under low nutrient
conditions, especially under limited amino acid availability. The octameric assembly
of the protein, essential for DNA binding, has been suggested to be stabilised by L-
methionine and L-leucine, suggesting that it may respond to limitation of these amino
acids (Ren et al., 2007). In E. coli, transcription of asnC, encoding a similar regu-
lator, responds to levels of asparagine and the nitrogen assimilation control protein
(Nac) (Poggio et al., 2002). NMB1249–NMB1250, genes that encode the components
of one of only four of the complete two-component systems in the MC58 genome,
were down-regulated at all time-points (20 to 240 min) during incubation in blood.
NMB1249 encodes a putative nitrate/nitrite sensory protein (NarX) and NMB1250
encodes as a LuxR family regulator. The equivalent two-component system in gono-
cocci has previously been shown to regulate the transition from aerobic to anaerobic
growth (Lissenden et al., 2000). NMB1303, annotated as a MerR family regulator
and 99% identical at the amino acid level to the gonococcal gene nmlR (NGO0602),
was also found to be down-regulated at all time-points. NmlR has been shown to act
as a redox-responsive Zn2+-dependent repressor, regulating the expression of itself
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and three other genes: adhC, encoding a class III alcohol dehydrogenase; copA, en-
coding a Cu2+-exporting ATPase; and trxB, encoding a thioredoxin reductase, which
in strain MC58 are the annotations of genes NMB1304, NMB1325, NMB1324 respec-
tively (Kidd et al., 2005). During incubation in blood, NMB1304 was found to be
down-regulated at all time-points from 20 to 240 min, but differential regulation of
NMB1324 and NMB1325 could not be determined, due to poor quality of data for
these two genes recovered from all microarrays.
6.2.2.7 Putative or unassigned function
The largest proportion of genes differentially expressed in response to incubation in
blood fall into the categories conserved hypothetical or unassigned proteins, a re-
minder that many genes associated with meningococcal biology and virulence are
still poorly characterised. Two of these genes, which either have significant sequence
similarity to proteins with known function or have previously been shown to be differ-
entially expressed in conditions mimicking meningococcal in vivo growth, are briefly
discussed here. NMB0840 of unknown function, has previously been shown to be
required for bacterial growth in an infant rat model of sepsis (Sun et al., 2000), and
was up-regulated at 20 to 60 min during culture in blood. NMB1475 was found to be
highly up-regulated in blood at all time-points after 20 min. Its product has sequence
similarity (44% identity) to universal stress response proteins in other prokaryotes
and also similarity to ABC transporters of Co2+ (44% identity). Transcription of the
gene has previously been shown to be altered during prolonged incubation in NHS
(Dove et al., 2003).
6.2.3 Meningococcal genes progressively up-regulated on in-
cubation in blood
Since a common reference design was used in the microarray study, gene expression
differences between time-points in blood could also be determined. Two different com-
parisons were performed. Firstly, the gene expression changes between consecutive
time-points in blood were determined, to find time-responsive genes (Supplementary
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tables C.19 – C.35). Secondly, the gene expression at 40, 60, 90 and 240 min post-
infection was compared to transcription at 20 min in blood, to account for initial
adjustments to the new environment (Supplementary tables C.37 – C.53). Genes
that were found to be differentially expressed (between time-points or relative to t
= 20 min) will be presented in the following sections. Up-regulated meningococcal
genes encoding known or putative surface exposed proteins will first be described, as
identification of such proteins were the primary aim of the study presented here.
6.2.3.1 Transcriptional changes between time-points in blood
Comparison of the gene expression at adjacent time-points during incubation in blood
showed that major shifts in gene expression occurred between most time-points during
the time course, although, very few genes changed significantly between 40 and 60
min. An overview of the proportion of the up-regulated genes annotated in each
TFRCs is shown in Figure 6.7.
Surface exposed proteins As in Section 6.2.2.1 all up-regulated genes were di-
vided into cellular locations (Supplementary table C.36). Of the up-regulated genes,
74 encode proteins that are either known or predicted to be located in the outer
membrane or for which experimental data suggest a possible surface exposed loca-
tion. Genes up-regulated between 20 and 40 min, encoding putative surface exposed
proteins, included: NMB0035, encoding a lipoprotein (Arenas et al., 2006); NMB0345,
previously found to be essential in an animal model of bacteraemia (Sun et al., 2000);
NMB0946, encoding a peroxiredoxin 2 family protein/glutaredoxin previously found
to contribute to plasminogen binding to the bacterial surface (Knaust et al., 2007);
and NMB0964, encoding a putative TonB-dependent receptor (described on page
172). NMB0345 is most likely co-transcribed with NMB0342–47, of which NMB0346
was also found to be significantly up-regulated at 40 min (as well as at 60 min in com-
parison to 20 min; Section 6.2.3.2). In acute phase sera collected from patients with
meningococcal disease, reactive antibodies were found to, for example, NMB0345 and
mntC (Litt et al., 2004), suggesting that these proteins are expressed on the bacterial
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Figure 6.7: TFRCs represented among genes up-regulated between time-points in blood.
A. 20 → 40 min; B. 60 → 90 min; and C. 90 → 240 min. Numbers in the figure reflect the
number of genes in each category. Data for 60 min in relation to 40 min are not included
as no genes were up-regulated in this comparison. Some of the genes are annotated in more
than one TFRC.
surface during bacterial growth in the host. Proteins involved in iron-transport such
as the surface exposed immunogenic proteins TbpA and TbpB were also found to be
up-regulated between 20 and 40 min.
Genes up-regulated at later time-points, encoding putative surface exposed pro-
teins, included gcp (NMB1802) and secreted components (TpsA) of the TPS system.
A possibly secreted O-sialoglycoprotein endopeptidase, encoded by gcp, was found to
be up-regulated between 60 and 90 min. A similar protein (50% sequence identity) in
Mannheimia haemolytica serotype A is secreted and forms the basis for an experimen-
tal cattle vaccine against infection with M. haemolytica A1 (Pandher & Murphy, 1996;
Shewen et al., 2003). The M. haemolytica protein can interact with leukocyte surface
antigens CD34, CD43, CD44 and CD45 (Abdullah et al., 1992). However, this protein
may not be secreted in other Gram-negative bacteria (Watt et al., 1997). Two tpsA-
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type genes (NMB0497 and NMB1779) were significantly up-regulated between 60 and
90 min. Incubation of bacteria for 240 min resulted in further increase in the level
of expression of genes encoding both the transporter (TpsB) and the secreted part
(TpsA) of a TPS system. Up-regulated genes included the tpsA-type genes NMB0493,
NMB497/NMB1779 and NMB1214 and the tpsB -type genes NMB0496 (truncated)
and NMB1762. The different meningococcal TPS systems have recently been shown
to contribute to bacterial adherence to epithelial cells mediated through the secreted
TpsA, suggesting that the protein may remain surface associated (Schmitt et al.,
2007). van Ulsen et al. (2008) suggested that TPS system II (tpsA genes NMB0493,
NMB1768; tpsB gene NMB1762) and III (tpsA gene NMB1214) are associated with
invasive strains, whereas TPS system I (tpsA genes NMB0497/NMB1779; tpsB genes
NMB0496 and NMB1780) is ubiquitous. They found reactive antibodies to TPS
domains in blood from four out of fourteen meningococcal patients (NMB1768 (1),
NMB0493 (2) and NMB1214 (1)), indicating secretion of the proteins in vivo.
The largest group of genes (N = 13) up-regulated between 20 and 40 min were those
annotated in the TFRC protein fate (Figure 6.7 (A)). MenB gene expression changes
resulting from incubation in blood between 20 and 40 min were analysed using the
GSEA software. In this analysis, genes in the following five TFRCs were significantly
enriched among genes with increased expression at 40 min: protein fate; amino acid
biosynthesis; purines, pyrimidines, nucleosides and nucleotides biosynthesis; cellular
processes; and regulatory functions. Two of the most highly up-regulated (> 3.5-fold)
genes between 20 and 40 min were the catalase gene (katA) and NMB1475, which
may have a role in general stress responses. Incubation in blood between 20 and 40
min also resulted in increased expression of the genes lldA, encoding an L-lactate
dehydrogenase, and ppsA (NMB0618), encoding a phosphoenol pyruvate synthase,
both involved in pyruvate metabolism. L-lactate dehydrogenase catalyses conversion
of L-lactate to pyruvate, which may be further converted by phosphoenol pyruvate
synthase to phosphoenol pyruvate, utilised in the biosynthesis of sialic acid. Increased
expression of these genes may reflect the increased levels of lactate observed over
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time during in vitro incubation in blood (Chapter 3, Figure 3.3). Genes encoding
proteins involved in iron uptake, such as tonB, fbpA (NMB0634) and tbpB, were
among those up-regulated between 20 and 40 min in blood. N. meningitidis growth
in blood may be associated with an increased need for zinc, as four of the up-regulated
genes between 20 and 40 min are associated with either zinc-deficient conditions or
zinc uptake. Expression of rpmJ2 (NMB0941) and rpmE2 (NMB0942), encoding
alternative ribosomal proteins, was elevated between 20 and 40 min. Transcription of
rpmE2 and rpmJ2 has previously been shown to increase under conditions of zinc-
deficiency in other bacteria (Nanamiya et al., 2004; Owen et al., 2007; Shin et al.,
2007). NMB0964, encoding a TonB-dependent receptor, has been shown to be up-
regulated under conditions of low zinc-availability (Stork et al., 2008), and was found
to be up-regulated here. mntC, encoding a putative Zn2+/Mn2+ transporter, was also
found to be up-regulated.
Only three genes were found to be differentially expressed between 40 and 60 min
in blood, all down-regulated. Significant down-regulation was observed for the genes
pgm, encoding phosphoglucomutase involved in biosynthesis and degradation of sur-
face polysaccharides and lipopolysaccharides; xseA (NMB1363), encoding the large
subunit of exodeoxyribonuclease involved in degradation of DNA; and NMB1564,
encoding a protein with a putative redox function. Sequence alignment indicated
similarity between NMB1564 and proteins with an osmotically inducible protein C
(OsmC) domain. Other proteins with this domain have been shown to respond to a
variety of stresses, such as osmotic stress (Gutierrez & Devedjian, 1991) and oxidative
stress (Lesniak et al., 2003). In meningococci, NMB1564 has previously been shown
to be up-regulated in response to a temperature shift (37◦C to 45◦C) (Guckenberger
et al., 2002), as well as being found to be essential for bacteraemia in an infant rat
model (Sun et al., 2000). These studies indicate that the NMB1564 gene product
may be involved in stress responses, although its function is not yet known. The
limited number of significantly differentially regulated genes between 40 and 60 min
suggest that bacteria at these two time-points in the time course were in a stable phase
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of growth (after initial adaptations to the blood environment) in which only minor
changes occurred in the transcription levels of genes. Although there are few signifi-
cantly differentially regulated genes between 40 and 60 min the overall transcriptome
is unlikely to be identical.
In contrast to the limited gene expression changes occurring between 40 and 60
min, more substantial changes were seen between 60 to 90 min, with up-regulation
of 46 genes and down-regulation of 43 genes. The five most common TFRCs among
genes up-regulated between 60 and 90 min were: unassigned; hypothetical proteins;
transport and binding proteins; cell envelope; and energy metabolism (Figure 6.7
(B)). Several of the up-regulated genes encode proteins annotated in the category
biosynthesis and degradation of surface polysaccharides and lipo-polysaccharides, in-
cluding lipA, the gene product of which is required for proper translocation of the
capsular biopolymer to the bacterial surface (Tzeng et al., 2005b). This gene was pre-
viously found to be up-regulated in response to meningococcal intracellular growth
(Spinosa et al., 2007). Genes encoding the proteins involved in biosynthesis of the
capsular polysaccharide were found to be down-regulated, although still expressed at
high absolute levels (Figure 6.5) (discussed on page 155).
At 90 min, two genes encoding regulatory proteins were up-regulated in compari-
son to their respective gene expression at 60 min. These were ntrX (NMB0115), en-
coding a nitrogen assimilation regulatory protein, and NMB1792, encoding a putative
sensor histidine kinase. In Azorhizobium caulinodans, the NtrX/NtrY two-component
system regulates nitrogen metabolism in response to nitrogen limitation (Pawlowski
et al., 1991), so up-regulation of meningococcal NtrX may indicate an increased need
for nitrogen at later time-points in blood. Transcription of ntrY was also increased,
but not significantly (log2 ratio = 0.552; adjusted P-value = 0.0183). Sun et al. (2000)
showed that this transcriptional regulator is essential for sustained bacteraemia in an
infant rat model.
Corresponding to the observed induction of zinc-regulated meningococcal genes
between 20 and 40 min in blood, the putative ZupT low-affinity transporter (NMB0175),
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transporting zinc from the periplasm to the cytoplasm, was up-regulated at 90 versus
60 min. In E. coli, a similar protein has been shown to also transport other metal
cations, such as Fe2+ and Co2+ (Grass et al., 2005).
Two genes associated with cell detoxification, norM and farB (NMB0319), were
found to be up-regulated in response to incubation in blood. Up-regulation of these
genes may be a response to anti-bacterial factors secreted by the human cells in
blood. Time-responsive genes also included some encoding secreted factors as well as
secretion systems, such as hlyB (NMB1400) and hlyD (NMB1738), the gene products
of which have been shown by Wooldridge et al. (2005) to form a secretion system
that translocates cytolysins. Change in transcription of tolC (NMB1737), encoding
the third component of the system, did not reach significance in the statistical test
(adjusted P-value = 0.063) but expression was at a similar level to hlyB and hlyD
(1.8-fold change). The hlyD gene was also found to be progressively up-regulated
during growth in plasma (FFP 1 and FFP 2).
The five most common TFRCs among genes up-regulated between 90 and 240 min
were: unassigned; hypothetical proteins; energy metabolism; cellular processes; and
transport and binding proteins (Figure 6.7 (C)). Up-regulation of genes involved in
cellular processes primarily reflects an increased expression of genes encoding the
NADH dehydrogenase I (nuo genes). Up-regulated genes annotated in the TFRC
cellular processes also included sodB (NMB0884), encoding a [Fe,Mn]-cofactored su-
peroxide dismutase involved in cell detoxification. Significant up-regulation was also
observed for clpP (NMB1312), encoding a protease involved in protein degradation.
Some of the changes in gene expression between the 90 and 240 min time-points
may reflect differences in either the growth phase of the bacteria or the availabil-
ity of nutrients at the later time-point. For example genes involved in glycoly-
sis/glucogenesis and peptidoglycan synthesis were found to be down-regulated at 240
min (compared to 90 min), which may suggest a slowing in bacterial growth, although
this was not reflected in CFUs at 240 min. Down-regulation of genes in these two func-
tional categories was also observed for GAS incubated in blood (Graham et al., 2005).
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A significant down-regulation was also observed for genes associated with synthesis of
pyruvate family amino acids. A regulatory protein encoded by NMB0573 (described
on page 167), that may respond to amino acid availability, was also up-regulated.
6.2.3.2 Comparison of gene expression at later time-points in blood to
the 20 min time-point
Meningococcal gene expression at 40, 60, 90 and 240 min was compared to the gene
expression at the earliest time-point in blood, at 20 min (Supplementary tables C.37
– C.53). As expected, the greatest changes occurred between 20 min and the last
time-points (90 and 240 min) in the time course. Up-regulation in relation to 20 min
was investigated in more detail by determining the proportion of genes belonging to









































Biosynthesis of cofactors, prosthetic groups, and carriers  
Cell envelope
Cellular processes  
Central intermediary metabolism  
DNA metabolism  
Energy metabolism  
Fatty acid and phospholipid metabolism  
Hypothetical proteins  
Mobile and extrachromosomal element functions  
Protein fate  
Protein synthesis  
Purines, pyrimidines, nucleosides, and nucleotides biosynthesis 
Regulatory functions  
Transcription  
Transport and binding proteins  
Unassigned  
Unknown function 
N = 55 
N = 310 
N = 130
Figure 6.8: TFRCs represented among genes up-regulated at 60, 90 and 240 min relative
to 20 min. A 60 vs. 20 min, B 90 vs. 20 min and C 240 vs. 20 min. Numbers in the figure
reflect the number of genes in each category. Observe that some genes may be annotated
in more than one TFRC.
The majority of the up-regulated genes were annotated in TFRCs unassigned
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or hypothetical proteins. TRFC transport and binding proteins were also common
among genes up-regulated at all time-points. Changes relative to 20 min, observed
at all time-points, included up-regulation of genes involved in iron uptake, such as
tbpA, hmbR and NMB0034. Concordantly, NMB1378, encoding a putative DNA
binding protein that has been shown to be regulated by iron depletion as well as
other environmental cues such as hydrogen peroxide and contact with cells (Basler
et al., 2006), was also found to be up-regulated at 40, 60, 90 and 240 min. A larger
proportion of genes with elevated expression was associated with protein fate and
amino acid biosynthesis at 60 min than at 20 min (significantly enriched in GSEA
analysis). At the 90 min time-point, a large proportion of the down-regulated genes
was associated with protein synthesis, indicated by enrichment of this TFRC among
genes up-regulated at 20 min when compared to the 90 min time-point.
Surface exposed proteins and structures As in Section 6.2.2.1, all up-regulated
genes were divided into cellular locations (Supplementary table C.54). Seventy-five
genes (excluding data for 40 vs. 20 min) encoding known or potential surface ex-
posed proteins (identified by in silico predictions or by experimental data), were
up-regulated during the extended time course in blood. These included NMB0035
(up-regulated at 60–240 min), NMB0345–46 (up-regulated at 60 min) and NMB0964
(up-regulated at 60 and 90 min). These were also up-regulated between 20 and 40
min during growth in blood and have already been described in Section 6.2.3.2.
Other genes up-regulated at later time-points in blood included NMB1882, up-
regulated at 90 min (described on page 162) and NMB0655, up-regulated at 240
min. NMB0655, annotated as a hypothetical protein, has been found to be up-
regulated in contact with epithelial cells and identified on the bacterial surface by
flow cytometry (Grifantini et al., 2002b). Genes encoding the secreted part (TpsA)
and the transporter part (TpsB) of a two component system (TPS) were also up-
regulated at 90 and 240 min during incubation in blood. The functions of products of
these genes have already been discussed in Section 6.2.3.1 (page 171). The secreted
part may, in some cases, remain bound to the bacterial surface, where it can act as
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a surface receptor (Schmitt et al., 2007). At the two last time-points in the time
course, the genes of operon NMB2003–2004 with sequence similarity to the lgrAB
operon, encoding membrane proteins involved in control of murein hydrolase activity
and penicillin tolerance (Groicher et al., 2000), were also up-regulated.
However, many genes encoding various meningococcal surface structures and OMPs
were found to be down-regulated at these two time-points. These included genes en-
coding the type IV pilus (e.g. pilE and pilQ), as well as genes encoding OMPs such
as opcA and rmpM (NMB0382). Down-regulation of opcA, encoding the class 5 outer
membrane protein, could reflect a response to human complement (Section 6.2.2.4).
Expression of capsule polysaccharide biosynthesis genes was also down-regulated at
later time-points during incubation in blood (Figure 6.5). In contrast, genes involved
in LOS biosynthesis (e.g. galE, kdtA), as well as lipA and lipB (required for translo-
cation of the capsular polysaccharide), were up-regulated at 90 and 240 min.
Energy metabolism Some of the changes in gene expression after 20 min may
relate to the increase observed in blood lactate. The L-lactate dehydrogenase gene
(lldA) was found to be up-regulated at all time-points after 20 min. As at 40 min (Sec-
tion 6.2.3.1), the phosphoenol pyruvate synthase gene, ppsA, was also up-regulated
at 60 min. The gene products of lldA and ppsA are involved in the conversion of L-
lactate to phosphoenolpyruvate (L-lactate
LldA−→ pyruvate PpsA−→ phosphoenolpyruvate).
Unlike the response to growth in plasma (Section 5.2.3), genes encoding proteins in-
volved in the TCA cycle were down-regulated over time (at 90 and 240 min) during
incubation in blood, rather than up-regulated.
Cell detoxification Besides the up-regulation of katA at all time-points beyond 20
min, arsC (NMB0005) an oxidoreductase (annotated as an arsenate reductase from
sequence similarity) was found to be up-regulated at 240 min. sodC (NMB1398), en-
coding a periplasmic [Cu,Zn]-cofactored superoxide dismutase involved in extracyto-
plasmic protection to oxidative stress, was found to be down-regulated at time-points
90 and 240 min. However, the gene encoding the cytoplasmic [Fe,Mn]-cofactored
superoxide dismutase SodB, was up-regulated between 90 and 240 min.
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Genes encoding various multidrug eﬄux proteins were induced at the later time-
points (90 and 240 min). These included farAB, norM and the mtrCDE -encoded ef-
flux pump. N. gonorroheae FarAB, the fatty acid receptor, similar to FarAB in MenB,
mediates protection against bactericidal long chain fatty acids (Lee & Shafer, 1999).
Responses at the last time-point also included up-regulation of DNA metabolism
genes such as mutT (NMB0453) and mutY.
6.2.4 MC58 gene expression in blood analysed by compara-
tive real-time RT-PCR
Comparative real-time RT-PCR was used to validate a subset of the microarray data
obtained using donor A’s blood (Section 6.2.1), and was used to assess the expres-
sion of a set of meningococcal genes upon incubation in blood from donor B (Section
6.2.4.1). This can provide some information of inter-individual variation. All genes
explored in this analysis were selected because they encode proteins located in the
periplasm or on the surface of the meningococci and may have vaccine potential (dis-
cussed in Section 6.3.2). Comparative real-time RT-PCR experiments were conducted
using the TaqMan platform as described in Section 2.8.2. For each gene-specific primer
and each sample, the TaqMan reaction was performed both with cDNA (reverse tran-
scribed from total RNA) and with total RNA, used to subtract any signal attributable
to contaminating DNA. The data were analysed using the comparative CT (threshold
cycle) method, in which the amount of target normalised to a control (16s rRNA)
and relative to a ‘calibrator’ is given by 2−44CT (Described in Section 2.8.2) (Applied
Biosystems, 1997). Standard deviations were calculated as in Bookout & Mangelsdorf
(2003). As for microarray data, the gene expression at time-points 40, 60, 90 and 240
min in blood were compared to gene expression at both 0 min and 20 min. Data from
TaqMan analysis and microarray analysis for the subset of genes are listed in Table
6.4 (comparison to 0 min) and Table 6.5 (comparison to 20 min). Log2 ratio data
from microarray experiments are included for all time-points, but as before only data
points with an adjusted P-value ≤ 0.01 and a fold change of ≥1.5 are considered to
be significantly differentially expressed. The gene expression of nine of the genes, in
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comparison to 0 min, is shown in Figure 6.9.
Figure 6.9: Gene expression of nine MenB genes in blood in comparison to 0 min, as mea-
sured by TaqMan and microarray technology. For TaqMan analysis each point represents
the average of three biological replicates, with each assay performed four times (technical
replication). Data from donor B for time-point 90 min are only based on an experiment on
one occasion and are only included for illustrative purposes. Data from microarray analysis
that were not found to be significant in the statistical analysis, using Limma, are repre-
sented by open symbols. Symbols falling above or below the red dotted lines (at 0.5 and
1.5) have a 1.5-fold change in expression.
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6.2.4.1 Transcriptional profile in blood from donor B
RNA was isolated from meningococcal strain MC58 after incubation in blood col-
lected from a second donor (B, male). The growth of MC58 in blood from this
individual is shown in Figure 6.1. Although MC58 showed a similar pattern of un-
restricted growth in blood from donors A and B, less RNA could be recovered from
meningococci in blood from donor B. The quality of the meningococcal RNA was
analysed on a Bioanalyzer (Figure 6.2). Expression of eleven genes (pilB, NMB0267,
farA, NMB0345, mapA, apbE (NMB0563), mntC, NMB1040, NMB1164, NMB1882
and NMB1961) was determined using comparative real-time RT-PCR. Gene expres-
sion data for time-points 0, 20, 40 and 240 min were collected from RNA isolated
in three independent experiments (biological replicates), performed on three different
days, with the exception of data included for gene expression at 90 min in donor B’s
blood, which are only based on an experiment on one occasion. As before, the gene
expression changes at 40, 90 and 240 min were determined relative to 0 min (Table
6.4) and 20 min (Table 6.5). TaqMan data collected for strain MC58 incubated in
blood from donor B were compared to data collected for donor A, analysed using
microarrays and comparative real-time RT-PCR.
Expression of most of the genes tested changed at one or more time-points during
incubation in blood from donor B, relative to gene expression at 0 or 20 min. The
expression profile of farA and NMB1164 over time is similar for data from microarray
and TaqMan analysis (donor A) and also similar for the two donors (A and B).
Comparison of data from donor B to data from donor A revealed differences in the
temporal expression of genes. The overall pattern of gene expression in blood from
donor A and B was found to be most different at the 40 min time-point in comparison
to 0 min (Pearson correlation = – 0.2). Genes that were found to have a different
expression pattern (in comparison to 0 min) during MenB incubation in blood from
the two donors (A and B) are listed below:
• The gene expression of pilB was only elevated at 240 min during incubation in
blood from donor B, whereas in blood from donor A the gene was up-regulated
at all time-points beyond 20 min.
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• mntC, encoding a component of a zinc/manganese transporter, was up-regulated
after 20 and 40 min (by TaqMan analysis) during growth in blood from donor
A. In blood from donor B, expression of the gene increased later (at 240 min).
• During incubation in blood from donor A, the genes NMB0267 and NMB1882
were found to be significantly up-regulated from 20 min and 90 min, respectively,
whereas in blood from donor B, expression of the genes transiently increased
after 20 min incubation.
• The initial expression at 20 min of mapA was higher during incubation in blood
from donor B than in blood from donor A.
• NMB1961, up-regulated during incubation in blood from donor A, was only
slightly elevated at one time-point (20 min) during incubation in blood from
donor B.
Potential explanations for these differences are discussed in Section 6.3.3.
6.2.4.2 Validation of microarray data
RNA isolated from meningococci incubated in blood samples from donor A was used
to validate the microarray data. RNA was isolated from independent samples not used
in microarray analysis, and validation was performed using the TaqMan platform. The
results of the TaqMan analysis of individual genes broadly agreed with the findings
based on microarray hybridisations. However, the following discrepancies were found:
• By TaqMan analysis, expression of NMB0345 was increased at 240 min com-
pared to 20 min, while it was not significantly changed as assessed by microarray
analysis.
• By TaqMan analysis, expression of mapA was not increased at 20 min compared
to 0 min, while it was significantly increased as assessed by microarray analysis.
In addition, expression of mapA was increased at 40 min compared to 20 min,
while it was not significantly changed as assessed by microarray analysis.
• By TaqMan analysis, expression of mntC was significantly increased at 20 min
compared to 0 min, while it was reduced as assessed by microarray analysis.
However, at 40 min, the results were concordant.
• By TaqMan analysis, expression of NMB1040 was unchanged at 90 min com-
pared to 0 min, while it was modestly increased as assessed by microarray
analysis.
• By TaqMan analysis, expression of NMB1961 was increased at 240 min com-
pared to 0 min, while it was not significantly changed as assessed by microarray
analysis.
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6.3 Discussion
In this study, N. meningitidis was incubated in anti-coagulated non-bactericidal whole
blood collected from adult donors. Growth of meningococci in this ex vivo model of
septicaemia induced extensive re-modelling of the bacterial transcriptome. In compar-
ison with corresponding time-points for meningococci incubated in plasma (Chapter
5), there was a greater response to growth in blood. An overview of the overlap be-
tween genes differentially expressed in blood and plasma (FFP 2) at corresponding
time-points is shown in Figure 6.10.
89 65 158 99 92147
Blood FFP 2 Blood FFP 2
25 60 392 40 39278
Blood FFP 2 Blood FFP 2
60 min
240 min
Figure 6.10: Venn diagrams showing the overlap of differentially expressed genes at 60
and 240 min during incubation in blood and FFP 2, in relation to 0 min.
First, transcriptional changes relating to meningococcal adaptations to growth
in blood and bacterial responses to host factors will be discussed. In subsequent
sections the focus will be on potential surface exposed proteins, as identification of
such proteins was the main objective of this study.
6.3.1 Global impact of growth in blood on meningococci
During growth in blood, the majority of genes with altered expression levels, at all
time-points/comparisons were annotated in TFRCs hypothetical proteins and unas-
signed, reflecting the large proportion of the meningococcal genome that are still of
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unknown functionality. Many genes involved in key metabolic functions were also
affected by blood exposure, such as those associated with synthesis of amino acids,
uptake of trace elements and energy production. The functional group amino acid
biosynthesis was also significantly enriched in GSEA analysis in comparisons of 20, 40
and 60 min to the 0 min time-point. Up-regulated genes in this TFRC included those
involved in synthesis of glutamate, methionine, and branched chain amino acids. One
of the up-regulated genes gdhA, a NADP-linked glutamate dehydrogenase, has previ-
ously been observed to be up-regulated both during meningococcal growth in plasma
(in this project) and when P. multocida was incubated in blood (Boyce et al., 2002).
In GSEA analysis the TFRCs purines, pyrimidines, nucleosides and nucleotides and
protein synthesis were also significantly enriched at the three first time-points in
blood.
During incubation in blood many genes associated with transport and binding
were observed to be up-regulated. In relation to the 20 min time-point, this reflects
an up-regulation of genes encoding proteins involved in, for example, iron transport.
Other groups of genes progressively up-regulated during the time course in blood (in
relation to the 20 min time-point or between adjacent time-points) included those
responding to conditions of low zinc availability and those involved in protein fate.
In blood, most iron is available bound to transferrin, which can be assimilated
by meningococci through the agency of transferrin binding protein. N. meningitidis
expresses a haemoglobin receptor and may also acquire iron from this source in the
context of haemolysis. At t = 20 min, genes encoding iron uptake proteins were found
to be down-regulated, in comparison to time-point 0 min, a finding which may be
explained by the bacteria having already adapted to an iron-deplete state at the time
of inoculation by expressing these genes at high levels. Results from other studies
in which transcriptional profiling has been used to explore the bacterial responses
during growth in blood has also indicated limited up-regulation of iron-regulated
genes (Boyce et al., 2002; Orihuela et al., 2004). However, previous studies have
shown iron-uptake to be essential in meningococcal invasive disease (Section 6.1.2).
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Over the time course in blood, iron regulated genes were found to be progressively
up-regulated after the 20 min time-point. For example, at 90 min hmbR, encoding
a haemoglobin receptor, was found to be up-regulated in comparison to time-point
20 min. Up-regulation of hmbR may suggest that haemolysis occurred during in
vitro incubation of blood over this period of time. This was not gross, however, as
concentration of potassium, a marker of haemolysis, did not change significantly over
the 240 min time course (Section 3.2.2). However, up-regulation of hmbR may not be
associated with haemolysis, but instead reflect a need by the bacteria to acquire iron,
resulting in up-regulation of genes encoding iron-uptake systems. This highlights one
of the limitations of genome-wide transcriptional profiling, i.e. that it is in most cases
not possible to directly draw conclusions about causal mechanisms from patterns
of differential gene expression. However, microarray experiments are invaluable for
finding genes associated with a certain perturbation or growth condition, and useful
for generating new hypothesis.
Responses to host factors during incubation in blood. In the bloodstream,
meningococci are exposed both to complement (modelled in plasma) and host cells
and factors secreted by such cells. Some transcriptional changes during meningococcal
growth in blood may be responses to anti-bacterial factors secreted by host cells, or
other toxic compounds. For example, during prolonged incubation in blood genes
encoding eﬄux proteins were up-regulated. In addition lipA, up-regulated at later
time-points in blood, has previously been found to up-regulated in response extended
growth in broth with sub-lethal levels of the CAMP protegrin PG-1, as well as to
intracellular growth (Spinosa et al., 2007).
Binding of plasminogen to the bacterial surface and subsequent activation to plas-
min (a serine protease that cleaves host fibrinogen) has been shown to increase inva-
siveness of bacteria (La¨hteenma¨ki et al., 2005; Cole et al., 2006). Activated plasmin
can also degrade complement (Seya et al., 1985) and has been shown to degrade C3b
and immunoglobins when bound to the surface of bacteria (Sodeinde et al., 1992;
Rooijakkers et al., 2005). Plasminogen binds to the surface of meningococci (Ullberg
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et al., 1992), where it is activated by host factors. An increase in formation of plasmin
is observed early in meningococcal invasive infection and in infection models (up to 2
hr). This activation is, however, rapidly decreased due to increased expression of the
plasminogen activation inhibitor pAI-1 (at approximately 3 hr in infection models)
(Brandtzaeg et al., 1990). Three of the genes (eno (NMB1285), dnaK, NMB0946) that
were up-regulated in blood encode proteins that have been demonstrated to interact
with human plasminogen in vitro (Knaust et al., 2007). However, these proteins also
perform important functions in meningococcal metabolism and maintenance, so up-
regulation in blood may not necessarily indicate increased expression of these proteins
on the surface of the bacteria. Curiously, all three proteins are predicted to be located
and to function in processes in the cytoplasm. Other cytoplasmic proteins that have
also been demonstrated to be on the bacterial surface under some conditions include
GroEL chaperonin (Hsp60) (Yamaguchi et al., 1996), and reactive antibodies to this
protein have been identified in convalescent sera from meningococcal patients (Pan-
nekoek et al., 1993). Apparent surface location of these proteins (as well as others
predicted to be cytoplasmic) emphasises the difficulty in accurately predicting the
cellular location of bacterial proteins using in silico methods.
In recent studies, TPS systems have been shown to be involved in interactions
with host cells (Schmitt et al., 2007; Tala` et al., 2008) and to be associated with inva-
sive clinical isolates (van Ulsen et al., 2008). The secreted component of the system
(TpsA; hemagglutinin/hemolysin-related protein) has also been found to be bound to
the meningococcal surface, where the protein can act as an adhesin. During growth
in blood in this study, genes encoding TPS systems were found to be up-regulated.
A similar up-regulation was also observed in an earlier study of meningococcal tran-
scriptional responses to growth in blood (Webb, 2001).
The abundance of some surface exposed meningococcal proteins is governed by
phase-variation (described in Section 1.4.1.2), which may regulate transcription or
translation of the gene. Down-regulation of genes encoding antigenic surface proteins,
or variation of surface epitopes, is used by meningococci as a way of evading the
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host immune system. OpcA, down-regulated over time in blood, has been shown
to be regulated at the transcriptional level by phase-variation (Sarkari et al., 1994).
Down-regulation of opcA may therefore represent a bacterial response to host immune
responses in blood.
6.3.2 Potential surface exposed proteins
The primary aim of this study was to find genes, encoding surface exposed pro-
teins, which were up-regulated in blood, a model of septicaemia, while being down-
regulated or not differentially expressed in contact with epithelial cells, a model of
colonisation. Data were therefore compared to a published data set, reporting the
pattern of MenB gene expression upon extended contact with epithelial cells (Gri-
fantini et al., 2002b). The set of meningococcal genes found to be up-regulated in
response to incubation in human blood was compared to the set of genes differen-
tially expressed in contact with epithelial cells (Supplementary table C.55), particu-
larly focusing on those differentially expressed after 3 hr in the colonisation model.
(Imperfect as it may be, this time-point in Grifantini et al.’s experimental system, is
the one most nearly representing conditions of prolonged meningococcal colonisation
of the nasopharynx). In silico prediction of protein location was used to identify
genes encoding proteins with a putative surface location. Eight genes up-regulated in
blood were down-regulated at 3 hr in contact with epithelial cells. These were rpsO
(NMB0609), rplT (NMB0723), bfrA (NMB1207), bfrB (NMB1206), pilP (NMB1811),
atpD (NMB1934), atpG (NMB1935) and mapA. The mapA gene was selected for fur-
ther studies based on the fact that it was up-regulated at more then one time-point
during growth in blood, as well as that its gene product is predicted to be located in
the outer membrane of the bacteria.
Several genes, encoding (known or putative) surface-exposed proteins, which were
up-regulated during incubation in blood were not reported to be differentially ex-
pressed upon attachment to epithelial cells in the study by Grifantini et al. (2002b)
(Supplementary table C.56). These genes included abpE, mlp, NMB0345, NMB0821,
NMB0866, NMB1040, NMB1882 and NMB1961.
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Based on the putative location of proteins, as well as their expression pattern in
blood and in contact with epithelial cells, seven genes (mapA, NMB0345, NMB0267,
abpE, NMB1040, NMB1882 and NMB1961) were selected for further studies (Chapter
7). The expression of these genes was also measured during growth in blood samples
from a second individual (donor B).
6.3.3 Confirmation of the transcriptional profile in blood us-
ing comparative real-time RT-PCR
Comparative real-time RT-PCR was used to confirm the microarray data in blood
from donor A, as well as to determine the expression of a select set of genes in RNA
isolated from meningococci incubated in blood from a second individual (donor B),
to get a measure of variability in gene expression of these genes during incubation
of meningococci in different individuals’ non-bactericidal blood. In this study the
assumption is made that there is limited variability in meningococcal response to
incubation in ‘non-killer’ blood from healthy adult individuals.
Using comparative real-time RT-PCR, data from microarray analysis (donor A)
could be confirmed for most of the genes tested. Comparison to data collected for
meningococci incubated in blood from donor B indicated that many of the genes
tested were up-regulated, in at least one time-point, during incubation in blood sam-
ples from this donor as well. However, the temporal expression of the genes was not
always identical. Some potential explanations for the observed differences in tran-
scription of the subset of genes during meningococcal growth samples from these
two individuals are discussed below. Firstly, differences in availability of nutrients in
blood samples from donor A and B may result in some of the changes seen, such as
the difference in expression of NMB1961, which is most likely regulated by GdhR, a
glutamate responsive regulator (Monaco et al., 2006). Secondly, even though strain
MC58 can survive in blood samples from these two individuals, which is assumed to
result from an absence of bactericidal antibodies, the individuals could have antibodies
to meningococcal surface structures which although non-bactericidal could through
binding to the surface of the bacterium induce a response resulting in changes in the
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transcriptional profile of the meningococcus. In addition, other immune responses in
blood may differ between the two individuals, which may affect the bacteria. Thirdly,
the transcription profile of a subset of genes, based on a pre-selection criteria (poten-
tial surface exposure), was investigated in meningococci incubated in blood samples
from donor B. In deciding about this group of genes those with more variable expres-
sion may have been selected. It is possible that the results do not reflect the general
response of meningococci in blood, which may be more similar in the two differ-
ent blood samples. Ideally the genome-wide transcriptional profile should have been
explored in meningococci during growth in blood samples from donor B. However,
problems with isolating sufficient amounts of RNA for microarray experiments after
growth in blood samples from this individual meant that this could not be achieved.
It may be that the difference in amount of RNA that could be isolated (even though
similar growth was observed for the bacteria) was a result of alteration in bacterial
metabolism, resulting in less RNA expressed per cell.
6.3.4 Conclusions and future work
Criticisms of the model and the study Bacterial growth rate and nutritional
status of the bacteria initially inoculated into the blood must be anticipated critically
to influence the transcriptional changes that are recorded subsequently. In this study,
gene expression of meningococci in blood was compared to time-point 0 min (start
point), but also between time-points in blood. The selection of the conditions defin-
ing the zero time-point (bacteria being scraped off plates after standardised culture,
re-suspended in RPMI 1640 culture medium, added to fresh blood and immediately
processed for RNA extraction) has been pragmatic, as the most relevant reference
point achievable in practise. The approach is comparable to the experimental de-
sign employed by Graham et al. (2005) in examining the transcriptome of group A
Streptococcus in whole human blood. In addition, meningococci on the nasopharyn-
geal mucosal surface (the condition I ultimately wish to compare to the bacterium in
blood) are almost certainly more similar to meningococci on solid agar than to those
grown in liquid culture. In similar studies others have used as a reference standard
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the no more physiological condition of organisms incubated in rich liquid medium
(Orihuela et al., 2004). Regardless of the conditions chosen for preparing organisms
to start the experiment, the use of a common reference design allows comparisons of
gene transcription not only of later time-points to time zero, but also any other pair
wise comparisons, for example, comparison of gene expression at 90 min in blood to
that at 20 min. Since a comparison to time-point zero or any other control condition
have their respective disadvantages, data have also been presented of gene expres-
sion differences between later time-points and 20 min, as well as the gene expression
between time-points, as a way of detecting genes progressively up-regulated in the
system. An alternative experimental design would be to propagate bacteria in mini-
mal medium designed to mimic the mucosal environment before inoculation in blood.
However there is currently insufficient information on how to develop such a recipe
without extensive further investigation.
Conclusions and future work To this end, DNA microarray analysis was utilised
to quantify transcriptional changes in among all known genes in the genome of N.
meningitidis strain MC58 in response to culturing in whole human non-bactericidal
blood. At all time-points in blood there was an extensive remodelling of the tran-
scriptome compared to the starting point. Genes up-regulated during meningococcal
incubation in blood included those associated with adaptations to the host environ-
ment such as those characterised in functional groups amino acid biosynthesis and
protein synthesis. Up-regulation was also observed for genes involved in cell detoxifi-
cation, expression of surface structures, and those encoding transporters.
Blood used in this study was collected from adult donors. Since meningococcal
disease mostly affects young children and teenagers, it might be suggested that blood
from younger individuals should have been used, but this was not practically possible.
However, this was modelled satisfactorily by identifying healthy adult ‘non-killers’
of the MenB strain under consideration, this phenotype assumed to reflect a lack
of bactericidal antibodies and so to model the na¨ıve, infant, state. It would be of
interest to characterise the meningococcal transcriptome in blood samples collected
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from additional individuals. However, to model the variation in meningococcal gene
expression in response to incubation in blood from different individuals, blood from
an estimated number of at least 10–20 non-killing volunteers1 would be required.
Identifying 20 adults with non-killing capacity would have required screening of blood
from ∼400 individuals assuming ∼5% are ‘non-killers’, as suggested by Ison et al.
(unpublished). This was not within the scope of this project.
I propose that the ex vivo whole blood model can be used to model some responses
of the bacteria during septicaemia, while conceding that that it cannot completely
replicate the complex environment encountered by the bacteria during infections. The
ex vivo whole blood model has been used with the objective to find new antigens -
new targets of interest for vaccines. From this work, seven candidate genes were
selected for further studies, presented in Chapter 7. Identification of targets (for
example metabolic genes) for other therapeutic interventions such as anti-bacterial
drugs could also be envisioned from the work presented here.
1Further transcriptional profiling studies are needed to calculate the exact number of individuals

Chapter 7
Sequence variability of genes encoding
OMPs up-regulated in infection models
Sequence variability among meningococcal strains is an important issue in the assess-
ment of candidate protein vaccine antigens. Our hypothesis is that meningococcal
genes encoding surface expressed proteins which are up-regulated during growth in
blood to a greater extent than during colonisation, may be less variable than those
highly expressed on the epithelial surface, where the bacteria will be subjected to
immune selection pressure (Section 1.5.1). In this chapter a set of genes encoding
proteins of putative or known surface location, which were found to be up-regulated
during incubation of MenB in plasma (Chapter 5) and blood (Chapter 6), are inves-
tigated for sequence variability to test this hypothesis.
7.1 Introduction
The sequence variability of meningococcal genes has proved a major challenge to the
development of universal protein based MenB vaccines. Intense immune-mediated
selection pressure operating at the mucosal surface colonised by meningococci has
led to the evolution of mechanisms of evasion including phase-variation and sequence
plasticity. Antigenic variability intra- or inter-strains occurs through gene sequence
variability, but also through variable expression of gene products, variable abundance
of proteins (Moe et al., 1999), or proteins being poorly accessible on the meningo-
coccal surface (Arenas et al., 2008). Only the sequence variability of genes has been
195
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explored in this project. Meningococcal sequence variability can be exemplified by the
immunodominant meningococcal OMPs PorA and PorB, used in sero and serosubtyp-
ing, which both have been shown to have high sequence variability in surface exposed
loops. Sequencing of the three variable loop regions (VR1, VR2 and VR3) in PorA
have so far yielded 185, 508 and 13 different variants, respectively. Sequence variants
of PorA VR1 and VR2 are stored in a public database that can be assessed and in-
terrogated through a webpage interface (http://neisseria.org/nm/typing/pora)
(Russell et al., 2004), and a limited set of sequence variants found in VR3 are available
at http://www.smprl.scot.nhs.uk/PorA_VR3.htm (Clarke et al., 2003). PorA in-
duces protective antibodies in humans (Peeters et al., 1996), but sequence variability
markedly limits the usefulness of PorA as a cross-protective vaccine (Feavers et al.,
1996).
7.2 Results
7.2.1 Bioinformatic analysis of publically available sequences
of the selected genes
A first indication of potential variability of a gene may be obtained quickly from a
comparison of MenB sequences to homologues in the sequenced Neisserial genomes
of meningococcal strains Z2491 (serogroup A) and FAM18 (serogroup C), as well as
gonococcal strain FA1090. Local sequence alignments were performed, using BLAST,
at both nucleotide (blastn) and protein (blastp) level (Altschul et al., 1990). All of the
MC58 genes listed in Table 7.1 have more than 90% identity (amino acid (aa) level)
to the genes from strains Z2491 and FAM18. No gonococcal strain FA1090 protein
with sequence similarity to mapA (NMB0390) was found in the non-redundant data
base at NCBI.
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Table 7.1: Sequence alignment of seven protein sequences of MenB strain MC58 with
protein sequences of N. meningitidis strains Z2491 and FAM18 and N. gonorrhoeae strain











NMB0345 288 Identical Identical Id. = 284/288,
Pos. = 286/288























NMB1961 275 Identical Identical Id. = 263/277,
Pos = 265/277,
Gaps = 2/277
Id. in the table stands for Identities and Pos. in the table stands for Positives i.e. amino acids
with similar characteristics.
7.2.2 Sequence variability of genes up-regulated in models of
infection
The regions containing the genes listed in Table 7.1 were amplified from genomic DNA
prepared from 23 meningococcal strains: 21 MenB strains, one MenA strain and one
MenC strain (Table 2.1), as described in Section 2.3. The strains used for sequencing
were from a diverse collection of well characterised strains, mainly isolated in Europe.
Figure 7.1 shows the relationship between STs represented in the strain collection.
Any differences in the size of the amplified fragments were observed upon separation in
a 2% agarose gel (Section 2.4) before direct sequencing of the amplicons as described
in Section 2.3.3. Sequence variability was defined as differences in sequence compared
to the gene sequence in MenB reference strain MC58.












































Figure 7.1: Balanced tree of STs constructed of MLST data from the database at http://
pubmlst.org/neisseria using neighbour joining algorithm and edited in MEGA (Tamura
et al., 2007). Names of the meningococcal strains that were used in sequencing are listed
in red next to their respective ST designation (details in Table 2.1).
7.2.2.1 Sequence variability of NMB0345
NMB0345 encodes a putative cell binding factor, possibly a member of the peptidyl-
prolyl isomerase family (30% sequence similarity). Its product has a predicted outer
membrane location and has been found in OMV preparations from meningococci
(Ferrari et al., 2006) and from N. lactamica (Vaughan et al., 2006). NMB0345 has
been shown to be important for survival in the blood stream, at least in an infant
rat model (Sun et al., 2000). The gene was found to be progressively up-regulated
in whole human blood (Chapter 6), with a peak in gene expression at 40 and 60
min. NMB0345 is 100% identical, at the amino acid level, to homologous genes in
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Z2491 and FAM18 genomes and 98% identical to a FA1090 homologue (Table 7.1).
Secondary structures (predicted using Jnet (Cuff & Barton, 2000)) mapped to the
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Figure 7.2: Secondary structure predictions for NMB0345 using Jnet algorithm (Cuff &
Barton, 2000) mapped to the sequence of the gene (produced using TEXshade package
(Beitz, 2000)). Amino acids are coloured by their functional characteristics. Symbols above
the primary sequence show positions of three variable residues (and their frequency) among
strains (see multiple alignment in Figure D.1 for details).
The genomic region containing NMB0345 could be amplified from DNA isolated
from all the strains (Table 2.1), and no difference in the sizes of the amplified frag-
ments could be observed upon separation in an agarose gel. Direct sequencing of
the products revealed limited sequence variability. The amino acid sequences were
deduced from the nucleotide sequences. Multiple sequence alignment of the amino
acid sequences from all strains is shown in Figure 7.3 (detailed alignment in Supple-
mentary figure D.1). Only three non-synonymous variants were found, resulting from
single nucleotide variants at positions 412, 527 and 653. All three variants are located
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Identical residues (comp. MC58)
Conserved residues (comp. MC58)
Non-matching residues (comp. MC58)
Figure 7.3: Alignment fingerprint of the 24 amino acid sequence of NMB0345 produced
using the TEXshadepackage (Beitz, 2000). Residues that are identical, conserved or non-
matching to the MC58 sequence are indicated.
7.2.2.2 Sequence variability of mapA (NMB0390)
The gene mapA encodes a protein annotated as maltose phosphorylase, with a pre-
dicted outer membrane position. It was found to be differentially regulated during















X 13.9 (C); Accessible sidechain area (A˚2)
X 23.0 (I); 23.5 (V); 25.2 (G)
X 28.7 (F); 29.0 (L); 30.5 (M); 31.5 (A)
X 41.7 (W); 44.2 (S); 46.0 (T); 46.7 (H)
X 53.7 (P)
X 59.1 (Y); 60.9 (D); 62.2 (N)
X 72.3 (E); 74.0 (Q)
X 93.8 (R)
X 110.3 (K)
Figure 7.4: Alignment of the central domain of mapA with a maltose phosphorylase from
L. brevis. The catalytic residue (E482) and residues (Y347, S619, S620, H663) in the active
site (in the L. brevis protein) are indicated by a bar and bullets respectively. The figure
was constructed using TEXshade (Beitz, 2000)
incubation in both human blood and plasma (Chapter 5 and Chapter 6). In blood,
mapA was significantly up-regulated at 20 and 40 min in comparison to expression
at time-point 0 min. The expression of mapA was found to be highest at the 40 min
time-point in blood. Sequence alignment of protein sequences from meningococcal
strains MC58 (serogroup B), Z2491 (serogroup A) and FAM18 (Serogroup C) indi-
cate that the protein is fairly conserved in meningococci, but there is no homologue in
gonococcal strain FA1090 (Table 7.1). The protein is similar in sequence (59.2% over
743 aa) to a maltose phosphorylase from Lactobacillus brevis, the three dimensional
structure of which has been determined (PDB identity: 1h54) (Egloff et al., 2001).
The catalytic residue (E482) and residues in contact with phosphate in the active
site (Y347, S619, S620, H663), which are identical in both the proteins are indicated in
protein alignments (Figures 7.4 and 7.8).
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Using primers designed to bind the genomic sequence of MenA, MenB and MenC
sequence strains up and downstream of mapA, the gene could be amplified from
genomic DNA isolated from all but four of the strains (NG 6/88, NG F26, NG H38,
NG H36) listed in Table 2.1. This indicates that genomic region flanking the gene
is the same in most strains. Using primers designed to bind within the mapA orf,
fragments of the same size (1585 bp) as for strain MC58 could be amplified from
genomic DNA isolated from all of these four strains, indicating the presence of mapA
(Figure 7.5). The fragments from these four strains have not yet been sequenced.
Figure 7.5: Agarose gel image of frag-
ments of gene mapA amplified from ge-
nomic meningococcal DNA using primers
NMB0390FInt and NMB0390RInt (Table 2.3)
designed to bind within the gene. Lane 1:
1kb DNA ladder, Lane 2: strain MC58 (posi-
tive control), Lane 3: strain NG 6/88, Lane 4:
strain NG F26, Lane 5: strain NG H38, Lane
6: strain NG H36, Lane 7: no DNA (negative
control).
Multiple sequence alignment of deduced protein sequences from the other 15
meningococcal strains (Figure 7.8) showed that mapA is conserved among most of
the strains. Identical amino acid sequences were found in the majority of the select
meningococcal strains, indicating that in fact it is the MC58 mapA sequence that
is the most dissimilar. Figure 7.7 shows the characteristics of residues, highlight-
ing potential differences arising from sequence variability among strains. One of the
sequence polymorphisms resulting in a amino acid difference in comparison to the
MC58 sequence is shown in Figure 7.6.
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A C A G T C T C T C C T A C A T T G C C G C C C A A A C C G T
580
A C G A C C G C T C C T A C A T T G C C A C C C A A A C C G T
580
Figure 7.6: Sequence traces (nucleotide po-
sition 580 to 588) for strains MC58 (top) and
MO1-240185 (bottom) showing a site of varia-
tion found in five of the meningococcal strains,
which resulted in an amino acid change from
SLS to DRS.
catalytic residue T T
↓





















Figure 7.7: Graphical representation of the multiple alignment of protein sequences of
mapA (constructed using TEXshade (Beitz, 2000)), showing the properties of amino acids
and visualising regions of charged, hydrophobic or hydrophilic nature. Transmembrane he-
lices, indicated by T in the figure, were predicted using TMpred (http://www.ch.embnet.
org/software/TMPRED_form.html). In the consensus line a lighter colour represent similar
residues, whereas a darker colour indicates less conserved residues.
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7.2.2.3 Sequence variability of NMB1040
NMB1040 encodes a hypothetical protein, with similarity to several proteins of un-
known function found in proteobacteria. The first 20 amino acids of NMB1040 encode
a probable signal peptide, but the cellular location of this protein is unclear. Pfam
analysis (Sonnhammer et al., 1997) suggests that the protein contains a domain simi-
lar to the SCP-like extracellular protein domain, which have a putative Ca2+ chelating
function (Milne et al., 2003). NMB1040 was found to be up-regulated upon incuba-
tion in plasma (FFP 2) at 60 and 240 min (Section 5.2.2) and was also found to be
moderately up-regulated in blood (Chapter 6). Sequence alignment of NMB1040 to
the genomic sequences of Neisseria strains FAM18, Z2491 and FA1090 indicate that
the protein is well conserved (Table 7.1).
The genomic region containing NMB1040 could be amplified from all strains (Ta-
ble 2.1), and no size difference of the amplified fragments was observed upon separa-
tion in a 2% agarose gel. Sequencing of the region showed that the gene has limited
sequence variability, at least in the collection of strains used in this study. Amino
acid sequences of the gene NMB1040 in 25 meningococcal strains were aligned us-
ing ClustalW (Larkin et al., 2007). The multiple sequence alignment of the deduced
amino acid sequences (Figure 7.9) indicate that the protein is well conserved. Figure
7.10 shows the characteristics of residues over the full length of the protein, highlight-
ing potential differences arising from sequence variability among strains. The most
common sequence variant found in 17 strains is a change from serine to arginine in
position 76 of the MC58 sequence.
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MC58       --------MK SLFIRLLLLG SAAGVFYHTQ NQSLPAGELV YPSAPQIRDG GDALHYLNRI RAQIGLHKLA HAPVLENSAR RHASYLTLNP EDGHGEHHPD NPHYTAQKLT  102 
NGH36      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
NGH15      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
NGH38      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
BZ133      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
BZ147      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
297-0      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
BZ198      --------.. .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  102 
NG6/88     --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
NGF26      --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
SWZ107     --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
FAM18      LPRREDGI.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  110 
1000       --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
528        --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
NGP165     --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
2996       --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
90/18311   --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
NGE28      --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
MO1-240185 --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
Z2491      --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
F6124      --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
BZ232      --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
BZ169      --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
BZ83       --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
H44/76     --------.. .......... .......... .......... .......... .......... .......... .......... ...R...... .......... ..........  102 
 
MC58       ERTRLAGYLY NGVHENISTE EEAAESSDSD IRTQQRQVDG LMSAIYHRLS LLDRHTDEAG AAFVRENGKT VLVFNQGNGR FERHCAQGRN QPEAGRKYYR NACHNGAVVY  212 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
BZ133      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
BZ198      .H........ .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
FAM18      .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  220 
1000       .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
528        .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
NGP165     .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
2996       .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
90/18311   .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
NGE28      .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... ........S. .......... .......... ..........  212 
Z2491      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
F6124      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
BZ232      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  212 
 
MC58       TDEAMPAQEL LYTAYPVGSG ALPYFHGERP DPVPEYEITG NPASIDFSEA AGKITMKSFK LYQGKNEIRP VRVLTAGNDP NGRLTAYQFA LFPLKPLEYG TLYTAVFDYV  322 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
BZ133      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
FAM18      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  330 
1000       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
528        .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
NGP165     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
2996       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
90/18311   .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
NGE28      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
Z2491      .......... ........N. .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
F6124      .......... ........N. .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
BZ232      .......... ........N. .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
BZ169      .......... ........N. .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
BZ83       .......... ........N. .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
H44/76     .......... ........N. .......... .......... .......... .......... .......... .......... .......... .......... ..........  322 
 
MC58       RNGRRAQAKW QFRTRKPDYP YFEVNGGETL AVRKGEKYFI HWRGRWCLEA CTRYTYRQRP GSRLSIGRHE AGGIVFSVDG MAGSRITLAP EGETERGVTL YLQD 426 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
BZ133      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
FAM18      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 434 
1000       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
528        .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
NGP165     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
2996       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
90/18311   .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
NGE28      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
Z2491      .......... .......... .......... .......... .......... .......... .........K .......... .......... .......... .... 426 
F6124      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
BZ232      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .... 426 
Figure 7.9: Multiple sequence alignment of NMB1040 amino acid sequences in 25 meningo-
coccal strains, including MC58 (labelled in blue), using ClustalW with default settings. The
amino acid sequence in MenB sequence strain (MC58) was used as reference sequence. All
strains used were MenB strains, except F6124 (MenA), 90/18311 (MenC) and NG P165
(NT). Sequences of the homologues genes in serogroup A (Z2491) and serogroup C (FAM18)
sequence strains were also included in the alignment (blue text).
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Signal peptide
MKSLFIRLLLLGSAAGVFYHTQNQSLPAGELVYPSAPQIRDGGDALHYLNRIRAQIGLHKLAHAP 65












o^^ o^ o^ o^ • I • I •I • I
EAAGKITMKSFKLYQGKNEIRPVRVLTAGNDPNGRLTAYQFALFPLKPLEYGTLYTAVFDYVRNG 325
• I o^^ o^•I^o^ • I • I•
RRAQAKWQFRTRKPDYPYFEVNGGETLAVRKGEKYFIHWRGRWCLEACTRYTYRQRPGSRLSIGR 390









Figure 7.10: Secondary structure predictions for NMB1040 using the Jnet algorithm (Cuff
& Barton, 2000) mapped to the sequence of the gene (constructed using TEXshade (Beitz,
2000)). Amino acids are coloured by their functional characteristics. Symbols above the
primary sequence show positions of variable residues (and their frequency) among strains
(see multiple alignment in Figure 7.9 for details).
7.2.2.4 Sequence variability of NMB1882
NMB1882, annotated as a TonB-dependent receptor, was found to be up-regulated
upon growth in blood. The protein is predicted to be located in the outer membrane
(by PSORTb v2.0 (Gardy et al., 2005)) and contains membrane-spanning β-barrels
(PRED-TMBB (Bagos et al., 2004a,b)). The location within the protein of these β-
barrels is shown in Figures 7.11 and 7.12. The corresponding proteins in MenA and
MenC sequence strains (Z2491 and FAM18) are 99% identical to the MC58 protein.
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Figure 7.11: Topology model of membrane protein NMB1882. Representation of putative
membrane spanning β-barrels in NMB1882 predicted using PRED-TMBB. The image rep-
resents the result from the posterior decoding method. Yellow balls indicate residues with
sequence variability (details in Figure 7.13). Positively charged amino acids are coloured
blue and negatively charged are coloured red.
A genomic region containing the gene was sequenced in the collection of meningo-
coccal strains. The gene could be amplified from all strains. A multiple sequence
alignment of the 14 protein sequences 1, deduced from the nucleotide sequence, and
the NMB1882 homologues in MenA strain Z2491 and MenC strain FAM18 is shown
in Figure 7.13. For some of the strains the complete sequence of the full length pro-
tein has not been determined. This was due to undetermined bases in the sequence
trace, even though the sequencing of these amplicons was repeated at least twice.
However, overall only limited sequence variability was found for NMB1882 in this set
of meningococcal strains. Figure 7.12 shows the functional characteristics of amino
1inadequate quality sequence obtained from the remaining five amplified DNA segments
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acids over the full length of the protein, highlighting potential differences arising from
19 sequence variants found. Ten of these variants is located in any of the predicted
surface exposed loops (Figures 7.11 and 7.12), with the eighth loop (residues 544 –
573) being the most variable. This suggests that the eighth loop may be of antigenic
significance.












exposed loop exposed loop exposed loop
DYTRSRFRQPYGVAGVLSIDHNTAATDLIPGYWHADPRTHSASVSLIGKYRLFGREHDLIAGINGYKYASNKYGERSIIP 400
A T
exposed loop exposed loop
NAIPNAYEFSRTGAYPQPASFAQTIPQYGTRRQIGGYLATRFRAADNLSLILGGRYTRYRTGSYDSRTQGMTYVSANRFT 480
S N P S
exposed loop exposed loop
PYTGIVFDLTGNLSLYGSYSSLFVPQSQKDEHGSYLKPVTGNNLEAGIKGEWLEGRLNASAAVYRARKNNLATAAGRDPS 560
A G L
exposed loop exposed loop
GNTYYRAANQAKTHGWEIEVGGRITPEWQIQAGYSQSKTRDQDGSRLNPDSVPERSFKLFTAYHFAPEAPSGWTIGAGVR 640
G K I









Figure 7.12: Secondary structure predictions for NMB1882 using the Jnet algorithm (Cuff
& Barton, 2000) mapped to the sequence of the gene (constructed using TEXshade (Beitz,
2000)). Amino acids are coloured by their functional characteristics. Symbols below the
primary sequence show positions of variable residues (and their frequency) among strains
(see multiple alignment in Figure 7.13 for details).
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7.2.2.5 Sequence variability of NMB1961
NMB1961 was found to be up-regulated in whole human blood at 20, 40, 60 and 90
min post-infection (Chapter 6). NMB1961 was also up-regulated at 60 min during
incubation in plasma (Chapter 5). The gene encodes a 275 amino acids protein
annotated as a VacJ-like lipoprotein through its sequence similarity to a domain
in VacJ, a Shigella flexneri outer membrane lipoprotein required for intercellular
spreading (Suzuki et al., 1994). NMB1961 is predicted to be located in the outer
membrane, and the protein has previously been detected in OMVs isolated from
N. meningitidis (Ferrari et al., 2006). Alignment of the sequence (both nucleotide
and amino acid) from MenB strain MC58 versus the homologues in a MenA strain
(Z2491) and a MenC strain (FAM18) indicated that the gene is highly conserved in
meningococci (Table 7.1). The nucleotide sequence of the Z2491 homologue is 99%
identical over 765 of 768 nucleotides, but is 12 nt longer then the MC58 gene due to a
perfect repeat of the sequence GGAACACAACCT at the extreme 3′ end of the gene.
The protein sequences are identical in MC58 and FAM18 over the whole length of
the protein, and in Z2491 up to position 275 and the FA1090 amino acid sequence is
94% identical to NMB1961 from MC58. Secondary structures (predicted using Jnet
(Cuff & Barton, 2000)) mapped to the protein sequence (with amino acids shaded by
characteristics) is shown in Figure 7.14.
Genomic regions containing the gene were amplified from the whole set of diverse
strains (Table 2.1). The nucleotide sequences and the corresponding deduced amino
acid sequences were aligned using the programme ClustalW (Larkin et al., 2007)
(Supplementary figure D.4), and differences to the MC58 sequence recorded. Ten
different nucleotide polymorphisms were found in NMB1961. The most common
single nucleotide polymorphisms were changes at positions 216 (9 out of 20 strains),
393 (17 out of 20 strains), 570 (5 out of 20 strains) and 591 (10 out of 20 strains).
The nucleotide sequence from the serogroup A strain F6124 was 12 nucleotides longer
than the MC58 sequence due to repeat at the extreme 3′ end of the gene, also found in
serogroup A genome sequence strain Z2491 (Alignment in Supplementary figure D.3).
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Polymorphisms in the coding sequence only contributed to one variant in the amino
acid sequence. The variant at position 8 (F8 to A8) were found in strains 297-0, BZ
232 and F6124. Additionally, the protein is 4 aa longer in strain F6124 (and Z2491)
than the MC58 protein, due to the repeat.
Signal peptide
MKKTAYAFLLLIGFASAPAFAETRPADPYEGYNRAVFKFNDQADRYIFAPAARGYRKVAPKPVRA 65
o^^ o^ o^ o^o^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^ o^^ o^ o^
α-helix α-helix α-helix
↑
F to A in 3 strains
TM
GVSNFFNNLCDVVSFGSNILRLDIKRASEDLVRVGINTTFGLGGLIDIAGAGGIPDNKNTLGDTF 130
o^^ o^ o^ o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^ •
α-helix α-helix β-sheet
ASWGWKNSNYFVLPVLGPSTVRDALGTGITSVYSPKNIVFRTPVGRWGTTAVSAVSTREGLLDLT 195
I • I o^^ o^ o^ o^o^o^o^o^o^ •I o^^ o^ o^ o^o^o^o^o^o^o^o^o^ o^^
β-sheet β-sheet α-helix β-sheet α-helix α-helix
DSLDEAAIDKYSYTRDLYMKVRARQTGATPAEGTEDNIDIDELVESAETGAAETAVQEDSVSETQ 260







Figure 7.14: Secondary structure predictions for NMB1961 using the Jnet algorithm (Cuff
& Barton, 2000) mapped to the sequence of the gene (constructed using TEXshade (Beitz,
2000)). Amino acids are coloured by their functional characteristics.
7.2.2.6 Sequence variability of apbE (NMB0563)
The gene apbE (NMB0563) is annotated as a membrane-associated lipoprotein in-
volved in thiamine biosynthesis. The protein is most likely membrane-anchored, either
in the inner or outer membrane. The gene was found to be consistently up-regulated
during incubation in whole human blood (Chapter 6) and during growth in FFP 1
(Chapter 5). NMB0563 is 99% identical, at the amino acid level, to homologues genes
in Z2491 and FAM18 genomes and 96% identical to a FA1090 homologue (Table 7.1).
Genomic regions containing the gene could be amplified from all meningococcal
strains except NG 6/88, NG F26, SWZ107 and NG H36, using primers designed to
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bind MenB strain MC58, MenA strain Z2491 and MenC strain FAM18. Direct se-
quencing of the gene in 18 meningococcal strains revealed that apbE is well conserved
(Figure 7.15). The most commonly found variant was a change from N269 to S269 in
























Identical residues (comp. MC58)
Similar residues (comp. MC58)
Non-matching residues (comp. MC58)
Figure 7.15: Alignment fingerprint of the 21 amino acid sequence of apbE produced
using the TEXshadepackage (Beitz, 2000). Residues that are identical, similar or non-
matching the MC58 sequence are indicated (based on ClustalW alignment). The position
of a transmembrane helix, indicated by TM in the figure, was predicted using TMpred
(http://www.ch.embnet.org/software/TMPRED_form.html).
Chapter 7: Sequence variability of genes up-regulated in infection models 215
7.2.2.7 Sequence variability of NMB0267
NMB0267 forms part of an operon together with NMB0266 and NMB0268. The gene
was found to be up-regulated at all time-points in blood and plasma. Its product has
sequence similarity to the so-called rare lipoprotein A (RlpA), a member of a family
of lipoproteins that are anchored to the inner membrane facing the periplasm and
which functions in cell membrane biogenesis. NMB0267 is fairly well conserved in
both meningococci and gonococci and is 96% and 95% identical, at the amino acid
level, to homologous genes in the Z2491 and FAM18 genomes and 92% identical to a
FA1090 homologue (Table 7.1).
Direct sequencing of the gene in the collection of meningococcal strains showed
that NMB0267 is well conserved, although four variants were found towards the C-
terminal of the protein (Figure 7.16). Figure 7.17 shows the characteristics of residues
over the full length of the protein, highlighting a difference in hydrophobicity in the C-
terminal of the protein arising as a result of the different sequence variants in fourteen
of the strains in comparison to strain MC58.
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MC58       MTLTRKTLFL LTAAFGTHSL QTASADAVVK AEKLHASANR SYKVAGKRYT PKNQVAEFTQ TGNASWYGGR FHGRKTSGGE RYDMNAFTAA HKTLPIPSYV  100 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
Z2491      .......... ......I..F .........R .......... .......... .......... .......... .......... .......... ..........  100 
F6124      .......... ......I..F .........R .......... .......... .......... .......... .......... .......... ..........  100 
1000       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
528        L......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
FAM18      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGP165     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGE28      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
90/18311   .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
2996       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ232      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
 
MC58       RVTNTKNGKS VIVRVNDRGP FHGNRIIDVS KAAAQKLGFV NQGTAHVKIE QIVPGQSAPV AENKDIFIDL KSFGTEHEAQ AYLNQAAQNF AVSSSGTNLS  200 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
Z2491      .......... .......... .......... .......... .......... .......... .......... .......... .........L .S.A.NP...  200 
F6124      .......... .......... .......... .......... .......... .......... .......... .......... .........L .S.A.NP...  200 
1000       .......... .......... .......... .......... S......... ........L. .......... .......... .........L .S.A.NP...  200 
MO1-240185 .......... .......... .......... .......... S......... ........L. .......... .......... .........L .S.A.NP...  200 
528        .......... .......... .......... .......... S......... ........L. .......... .......... .........L .S.A.NP...  200 
NGH38      .......... .......... .......... .......... S......... ........L. .......... .......... .........L .S.A.NP...  200 
FAM18      .......... .......... .......... .......... S......... .....K.... .......... .......... .......... .A.T.SP..A  200 
NGP165     .......... .......... .......... .......... S......... .....K.... .......... .......... .......... .A.T.SP..A  200 
NGE28      .......... .......... .......... .......... S......... .....K.... .......... .......... .......... .A.T.SP..A  200 
NGH36      .......... .......... .......... .......... S......... .....K.... .......... .......... .......... .A.T.SP..A  200 
90/18311   .......... .......... .......... .......... S......... .....K.... .......... .......... .......... .A.T.SP..A  200 
2996       .......... .......... .......... .......... S......... .....K.... .......... .......... .......... .A.T.SP..A  200 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... .A.A.SP..A  200 
BZ232      .......... .......... .......... .......... .......... .......... .......... .......... .......... .A.A.SP..A  200 
 
MC58       VEKRRYEYVV KMGPFTSQER AAEAEAQARG MVRAVLTAG 239 
BZ83       .......... .......... .......... ......... 239 
H44/76     .......... .......... .......... ......... 239 
SWZ107     .......... .......... .......... ......... 239 
NGF26      .......... .......... .......... ......... 239 
BZ169      .......... .......... .......... ......... 239 
NG6/88     .......... .......... .......... ......... 239 
BZ198      .......... .....A.... .......... ......... 239 
297-0      .......... .....A.... .......... ......... 239 
NGH15      .......... .....A.... .......... ......... 239 
Z2491      .......... .....A.... .......... ......... 239 
F6124      .......... .....A.... .......... ......... 239 
1000       ....H..... .....S.... .......... ......... 239 
MO1-240185 ....H..... .....S.... .......... ......... 239 
528        ....H..... .....S.... .......... ......... 239 
NGH38      ....H..... .....S.... .......... ......P.. 239 
FAM18      I......... .....A.... .......... ..QT..... 239 
NGP165     I......... .....A.... .......... ..QT..... 239 
NGE28      I......... .....A.... .......... ..QT..... 239 
NGH36      I......... .....A.... .......... ..QT..... 239 
90/18311   I......... .....A.... .......... ..QT..... 239 
2996       I......... .....A.... ........H. ..QT..... 239 
BZ147      I......... .....A.... .......... ......... 239 
BZ232      I......... .....A.... .......... ......... 239 
Figure 7.16: Multiple sequence alignment of NMB0267 amino acid sequences in 24
meningococcal strains, including MC58 (labelled in blue), using ClustalW with default
settings. The amino acid sequence in MenB sequence strain (MC58) was used as reference
sequence. All strains used were MenB strains, except F6124 (MenA), 90/18311 (MenC)
and NG P165 (NT). The MenA (strain Z2491) and MenC (strain FAM18) genome sequence
strains were also included for comparison (labelled in blue).































Figure 7.17: Graphical representation of the multiple alignment of protein sequences
of NMB0267 (constructed using TEXshade (Beitz, 2000)), visualising regions of charged,
hydrophobic or hydrophilic nature. In the consensus line a lighter colour represent similar
residues, whereas a darker colour indicates less conserved residues.
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7.3 Discussion
Many surface exposed meningococcal proteins, such as PorA, are highly variable
among strains. The hypothesis I proposed at the start of this project was that proteins
highly expressed during colonisation (modelled by adherence to epithelial cells) may
have relatively more variable sequence than proteins more highly expressed on the
surface of the bacteria in the course of bloodstream spread. Sequence variability in
genes expressed during meningococcal in vivo growth, such as colonisation, is likely
to be the result of immune selection pressure. In this chapter the sequences of a
set of N. meningitidis genes encoding putative surface-exposed proteins differentially
up-regulated in blood revealed limited sequence variability amongst all the selected
strains. Limited sequence variability of these genes may indicate that they are not
expressed on the bacterial surface during infection, that they are under selective
pressure for attaining functionality, or - in support of my hypothesis - that they are
expressed at high levels on the surface only during growth in blood.
Protein NMB1882 is going to be discussed in more detail as it is predicted to
contain surface exposed loops, which may be subjected to immune selection pressure.
Sequencing of the gene revealed that sequence variants were more common in one of its
surface exposed loops, which suggest that it may be of antigenic significance. Sequence
variability of the surface exposed regions was compared to that of surface exposed
loops of the vaccine candidates PorA and NspA. The PorA protein has three highly
variable surface exposed immunogenic regions (VR1, VR2 and VR3). In contrast
NspA has been found to have very limited sequence variability in external loops (Moe
et al., 1999). The limited sequence variability of outer membrane loops of this protein
has been suggested to be due to limited exposure to the environment - the loops
potentially being masked by the exopolysaccharide. In clinical trials recombinant
NspA protein did not induce protective antibodies, which support the hypothesis that
the protein is not accessible to the extracellular milieu, although negative results from
clinical trials could also result from incorrect tertiary structure of antigenic epitopes
in the recombinant proteins used. While sequence variability in the predicted surface
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exposed regions of NMB1882 is limited in comparison to variation of the PorA VR1
and VR2 regions (Supplementary figure D.5), the protein was found to be slightly
more variable than NspA.
Future work Variability of meningococcal surface proteins can also occur due to
other processes (discussed in detail in Section 1.4.1.2), mainly phase variation switch-
ing on or off expression or other processes that regulate protein abundance (such as
different strength promoters or regulatory elements). The influence of these processes
on the expression of the studied proteins will be explored in future experiments. It
would be of value to assess relative protein abundance of these proteins in the 23
strains, and also on their cellular location upon growth in plasma or blood. However,
within the time frame of this project the necessary antibodies were unavailable and
further studies on these proteins will be the aim of a future follow up study. Work will
include assessing both expression of transcripts and proteins among meningococcal
strains. First, potential differences in transcription of the genes among meningococ-
cal strains are going to be analysed using standard RT-PCR or TaqMan analysis.
Second, protein abundance is going to be assessed (using western blotting and flow




General conclusions and future work
Meningococci commonly colonise the nasopharyngeal mucosa, and occasionally in-
vade to cause life-threatening septicaemia and/or meningitis. Many steps in this
disease progression are currently unknown. Greater understanding into pathogenic-
ity of this devastating pathogen is therefore of great importance. Vaccines are the
most effective preventive measure for meningococcal disease. However, currently no
broad-range protective vaccine is available for serogroup B meningococci, the most
common serogroup in Europe.
The work presented here was primarily motivated by the need for new serogroup
B vaccine candidates, focusing on antigenic OMPs. It was the aim of this study
to identify genes up-regulated under bacterial growth in the bloodstream, encoding
surface exposed proteins that may be suitable as vaccine targets. I hypothesized
that their candidacy would be strengthened in the case of genes down-regulated or
expressed at low levels in the nasopharynx. Using a global approach to characterise
changes in the bacterial gene expression in different ex vivo models of septicaemia, I
identified candidates and confirmed relatively reduced variability in genes with this
pattern of expression.
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8.1 Transcriptional profiling of meningococci in ex
vivo models of infection
In order to better understand the genetic response of N. meningitidis during growth
in the bloodstream on a genome-wide scale, DNA microarray analysis was utilised
to quantify transcriptional changes in among all known genes in the genome of N.
meningitidis strain MC58 in response to culturing in whole human non-bactericidal
plasma or blood (Chapters 5 and 6). To my knowledge this is first study to describe
the transcriptional response of meningococci to growth in blood. Expression profiling
of meningococci in blood or plasma showed that growth under these conditions results
in the differential expression of a large proportion of the genome. Growth in blood
to 240 min resulted in a significant shift in transcription of 1135 genes (in relation to
time-point 0 min). Comparing the transcriptional responses for meningococci incu-
bated in plasma and blood at corresponding time-points, there was a greater response
to growth in blood. This likely derives from the more complex environment, as well
as the presence of host cells in blood samples. Similar trends in expression patterns
were, however, observed in these two growth conditions. In both these experiments
a majority of the up-regulated genes encode proteins of unknown function, reflect-
ing the currently limited functional annotation of meningococcal genes. As detailed
in Chapter 5 and 6, incubation of meningococci in human blood or plasma samples
resulted in an up-regulation of genes involved in metabolic adaptations to the host
environment. Transcriptional responses suggested a need for both de novo synthesis,
as well as transport of molecules from the extracellular milieu. I also observed sig-
nificant differential regulation of genes involved in bacterial stress responses and cell
detoxification, such as eﬄux proteins, particularly during growth in blood, indicating
a potential response to innate immune responses and host cell attacks.
The hypothesis defined in Section 1.5.1 were tested by determining the sequence
variability of seven of the genes up-regulated in plasma and/or blood (Chapter 7).
Limited sequence variability of these genes was observed for the tested strains, sug-
gesting that they are indeed comparatively invariant, in support of my hypothesis.
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It is however possible that they may differ in transcript levels or protein abundance
in between meningococcal strains as a result of for example phase-variation. This is
going to be examined in future work.
8.2 Conclusions and improvements to the study
In this thesis I have described methods and results of the meningococcal genome-
wide transcriptional profile in ex vivo models of infection. Some of the transcriptional
responses in blood and plasma were comparable to those previously observed in similar
studies in other pathogens, such as group A Streptococcus and P. multocida. The ex
vivo whole blood or plasma models have here been used with the objective to find new
antigens, and as such should be suitable for studies to find new targets of interest for
vaccines. I propose that the ex vivo whole blood model can be used to model some
responses of the bacteria during septicaemia, although not completely replicating
the complex environment encountered by the bacteria during infections. The work
presented here may, besides being used to find vaccine targets, have implications for
identifying targets for other therapeutic interventions, such as novel anti-bacterial
drugs, and contribute to our basic understanding of behaviour of meningococci in the
bloodstream. As such, results from studies presented here can be built on to study
the importance of specific processes during invasive infection.
For better characterisation of the differences in meningococcal gene expression in
the bloodstream to that during colonisation, some improvements can be made to in
vitro models of both these bacterial growth habitats. Explorations of meningococcal
transcriptional profiles during colonisation have relied on models utilising epithelial
cells, or other cell types. A microarray data set of bacterial gene expression during
attachment to epithelial cells (for up to 3 hr) (Grifantini et al., 2002b) was used to
approximate the transcriptional profile of bacteria during nasopharyngeal colonisa-
tion, and used in all comparisons in this thesis. Attachment of bacteria to epithelial
cells for a limited period of time does not model meningococcal colonisation on the
mucosal membrane, which in the host can last for days or weeks. Furthermore, the
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environment on the nasopharyngeal mucosal surface is inhabited by other species of
bacteria, which is likely to affect growth as well as gene and protein expression of
the meningococci. Such systems of complex microbial ecology would however be ex-
tremely difficult to model in vitro. Better models of meningococcal nasopharyngeal
colonisation, such as organ cultures (using explants), have been used to highlight the
importance of specific genes during colonisation (Exley et al., 2009). The difficulty in
isolating sufficient amounts of RNA from the limited number of bacteria that can be
collected from such models has so far limited the possibility to study the genome-wide
transcriptional response of bacteria to growth in such systems. Other possible models
of colonisation could include longer length incubation of the bacteria with human cells
or biofilm-like growth on an abiotic surface, from which isolation of bacterial RNA
should be less problematic.
Solutions that could be envisioned for the problem of isolating sufficient amounts
of RNA include amplification of the RNA species prior to analysis on microarrays.
This strategy has already been used to explore, for example, the gene expression of
M. tuberculosis in sputum (Garton et al., 2008). During this project I evaluated the
use of RNA amplification (using a poly-A based system developed by Ambion) as
a way of increasing the amount of RNA and found that the method was reliable,
although considerable variability was observed in comparison to unamplified RNA
samples, making amplification a less attractive solution. Bacterial RNA isolated from
a mixture of bacteria and host cells may contain small amounts of eukaryote RNA.
Using a poly-A based system contaminating host RNA may be disproportionally
amplified. Specific priming of bacterial transcripts (in a mixture with host material),
as described by Lawson & Johnston (2006) and Waddell et al. (2008), could be used
to avoid this potential short-coming of the poly-A based system.
During this project I have also considered improvements to the models of blood-
stream infection presented in this thesis. Potential improvements include better con-
trol of nutrients (using for example a flow system), better modelling of the environ-
ment in blood vessels by using a system containing endothelial cells, and lower initial
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loads of bacteria to closer resemble the scenario in early stages of invasive infection.
The use of an animal model could also have been an alternative approach to those
explored here. However, as humans are the only natural host for meningococci many
of the proteins that are important for establishing disease are lacking (or divergent)
in other animals. Therefore, to model meningococcal disease it is advantageous to
use material from humans rather than animals.
Developments of new technologies for exploring the complete RNA profile of an or-
ganism using high-throughput sequencing methods (454 sequencing or Solexa/Illumina
deep sequencing), so-called ‘RNA-Seq’ (Wang et al., 2009) may also lead to significant
improvements to studies of the bacterial transcriptome during infection, although so
far such transcriptome studies have only been performed in eukaryote systems (Mor-
tazavi et al., 2008; Vera et al., 2008). They have however been used for studying the
bacterial metatranscriptome (Gilbert et al., 2008) and for deduction of RNA inter-
actions with protein Hfq in Salmonella (Sittka et al., 2008). Developments of these
methods, as well as improved strategies for RNA isolation and amplification, may
ultimately facilitate studies of meningococcal gene expression in the natural host by
recovery of bacterial RNA from patient material, such as the nasopharynx or blood.
8.3 Future work
Data derived from transcriptional profiling experiments in this work are currently
being used to examine specific genes of interest as vaccine targets. Experiments
following from work in this thesis will primarily focus on answering the following
questions: are the genes expressed (mRNA and protein) in ‘all’ meningococcal strains
(1); does up-regulation of these genes correlate with increased quantities of protein
(2); are these proteins expressed on the surface of meningococci during incubation in
blood or plasma (3); do antibodies to these proteins have bactericidal activity against
meningococci (4); and do these proteins (either recombinant proteins or expressed on
OMVs) protect mice against experimental infection when given as a vaccine (5)?
Potential differences in transcription of the genes among meningococcal strains are
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being analysed using TaqMan analysis and protein abundance assessed (using western
blotting and flow cytometry) under normal culturing conditions in broth and during
growth in plasma and blood. To confirm their cellular location on meningococci under
growth in plasma and blood, flow cytometry will be used.
A subset of the genes identified in this project will be over-expressed in commensal
Neisseria (N. flavescens), using the pMIDG system developed in our laboratory by
O′Dwyer et al. (2004). Surface expression will be confirmed using flow cytometry.
Finally, to test their ability to induce protective bactericidal antibodies OMVs isolated
from such strains or E. coli recombinant proteins will be used to vaccinate mice, to
determine if they protect against experimental meningococcal infection.
In addition, deletion mutants of metabolic genes found to be important for growth
in models used in this work will be used to determine their respective contribution to
bacterial survival and resistance in infection.
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Appendix A
Supplementary data to Chapter 4
Figure A.1: Hierarchical clustering of Hotopp et al., 2006 data and genomotyping data
(strain name in red) from this thesis. The hierarchical clustering was performed using
the hclust function available under R, the distance metric was based on (1–correlation)




Supplementary data to Chapter 5
Table B.1: Genes up-regulated at 60 min during growth in FFP 1 in comparison to
meningococci incubated in medium. Genes are divided into functional categories according
to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0358 aroE shikimate 5-dehydrogenase 0.716 2.24E-02
NMB0763 cysK cysteine synthase 1.306 1.22E-03
NMB1530 dapE succinyl-diaminopimelate desuccinylase 0.888 1.75E-02
Biosynthesis of cofactors, prosthetic groups, and carriers
NMB0392 nadB l-aspartate oxidase 0.877 3.73E-03
NMB0394 nadA quinolinate synthetase A 0.782 6.25E-03
NMB0396 nadC nicotinate-nucleotide pyrophosphorylase 0.876 3.12E-02
NMB0539 hemC porphobilinogen deaminase 0.644 2.13E-02
NMB1156 cysG-1 siroheme synthase 1.580 1.03E-03
NMB1194 cysG-2 siroheme synthase 1.626 2.25E-04
Cell envelope
NMB0285 putative O-antigen acetylase (frameshift) 0.586 4.49E-02
NMB0357 mtgA monofunctional biosynthetic peptidoglycan
transglycosylase
1.164 4.26E-03
NMB1820 pglB pilin glycosylation protein 0.929 4.38E-02
NMA0772 pilin gene inverting protein homolog PivNG 2.273 2.48E-02
Cellular processes
NMB0005 arsC arsenate reductase 0.695 4.58E-02
NMB0277 mviN virulence factor 0.786 4.29E-02
NMB1820 pglB pilin glycosylation protein 0.929 4.38E-02
Central intermediary metabolism
NMB1151 cysI-1 sulphite reductase hemoprotein, β component 1.585 2.83E-03
NMB1152 cysJ-1 sulphite reductase (NADPH) flavoprotein,
α component
1.162 2.20E-02
NMB1153 cysN-1 sulphate adenylyltransferase, subunit 1 1.735 1.49E-03
NMB1154 cysD-1 sulphate adenylyltransferase, subunit 2 1.580 8.65E-04
NMB1155 cysH-1 phosphoadenosine phosphosulphate reductase 1.428 1.22E-03
NMB1189 cysI-2 sulphite reductase hemoprotein, β component 1.686 2.59E-03
NMB1190 cysJ-2 sulphite reductase (NADPH) flavoprotein,
α component
1.398 2.88E-03
NMB1191 cysN-2 sulphate adenylyltransferase, subunit 1 1.745 5.77E-04
NMB1192 cysD-2 sulphate adenylyltransferase, subunit 2 1.653 7.12E-04
NMB1193 cysH-2 phosphoadenosine phosphosulphate reductase 1.404 3.00E-03
Continued on next page . . .
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ID Name Annotation log2 ratio P-value*
DNA metabolism
NMB0533 nth endonuclease III 0.675 7.15E-03
NMB0835 putative type I restriction enzyme EcoR124II R
protein
0.938 2.98E-03
NMB1233 recD exodeoxyribonuclease V, α subunit 0.945 1.22E-03
NMB1673 tag DNA-3-methyladenine glycosylase I 0.855 4.89E-03
Energy metabolism
NMB0530 β-hexosaminidase 0.689 2.60E-02
NMA1934 gcvP glycine dehydrogenase 0.856 4.76E-03
Fatty acid and phospholipid metabolism
NMB1674 GDSL lipase family protein 0.904 4.89E-03
NMB1696 acp-2 acyl carrier protein 0.717 4.95E-02
Hypothetical or unassigned proteins
NMB0108 hypothetical protein 0.598 4.11E-02
NMB0260 hypothetical protein 0.591 4.38E-02
NMB0305 hypothetical protein 0.697 3.02E-02
NMB0395 conserved hypothetical protein 1.191 1.22E-03
NMB0417 hypothetical protein 0.768 2.98E-03
NMB0534 conserved hypothetical protein 0.662 4.95E-02
NMB0793 hypothetical protein 0.939 3.00E-03
NMB0939 conserved hypothetical protein 0.604 3.26E-02
NMB1195 hypothetical protein 0.835 3.77E-02
NMB1316 hypothetical protein 0.671 2.31E-02
NMB1531 conserved hypothetical protein 0.702 3.51E-03
NMB1532 conserved hypothetical protein 0.788 4.36E-03
NMB1672 conserved hypothetical protein 0.655 2.17E-02
NMB1675 hypothetical protein 0.835 1.48E-02
NMB1971 conserved hypothetical protein 0.595 3.30E-02
NMB2099 conserved hypothetical protein 0.588 2.39E-02
NMC0876 hypothetical protein (fragment) 0.604 2.69E-02
Mobile and extrachromosomal element functions
NMC0866 putative phage-related protein 1.295 1.73E-02
NMC0867 putative phage-related protein 1.050 1.34E-02
Protein fate
NMB0836 clpA ATP-dependent Clp protease, ATP-binding sub-
unit
0.673 1.34E-02
NMB1820 pglB pilin glycosylation protein 0.929 4.38E-02
Protein synthesis
NMB0112 rsmB 16S RNA methyltransferase 1.763 4.72E-03
NMB0795 pth peptidyl-tRNA hydrolase 0.689 1.75E-02




NMB0437 nsrR nitric oxide sensitive repressor 0.746 2.59E-02
NMB1792 sensor histidine kinase 0.786 3.46E-02
Transcription
NMB0689 greB transcription elongation factor 0.785 4.28E-03
Transport and binding proteins
NMB0034 high-affinity iron transporter 0.663 3.55E-02
NMB0209 kefB glutathione-regulated potassium-eﬄux system
protein
0.635 3.22E-02
NMB0787 amino acid ABC transporter, periplasmic
substrate-binding protein
1.804 2.25E-04
NMB0788 amino acid ABC transporter, permease protein 1.365 1.03E-03
NMB0789 amino acid ABC transporter, ATP-binding pro-
tein
1.121 1.22E-03
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ID Name Annotation log2 ratio P-value*
NMB1362 putative oxalate/formate antiporter 0.632 4.37E-02
NMB1459 putative drug/metabolite transporter 0.770 2.31E-02
NMB1719 mtrF eﬄux pump component 0.943 3.91E-02
Unknown function
NMB0004 EpiH/GdmH-related protein 0.812 4.37E-02
NMB0994 acyl-CoA dehydrogenase family protein 1.305 1.41E-02
NMB0995 macrophage infectivity potentiator-related pro-
tein
2.094 2.25E-04
NMB1501 HesA/MoeB/ThiF family protein 0.596 2.39E-02
NMB1521 phytoene synthase-related protein 0.619 2.23E-02
NMB1670 PqiA family protein 0.635 6.23E-03
NMB1692 chorismate mutase-related protein 0.686 4.14E-02
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.2: Genes down-regulated at 60 min during growth in FFP 1 in comparison to
meningococci incubated in medium. Genes are divided into functional categories according
to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0678 trpA tryptophan synthase, α subunit -0.610 1.26E-02
NMB1031 leuB 3-isopropylmalate dehydrogenase -0.755 6.25E-03
NMB1576 ilvH acetolactate synthase III, small subunit -1.149 6.88E-03
NMB1577 ilvI acetolactate synthase III, large subunit -1.033 2.04E-02
NMB1579 hisG ATP phosphoribosyltransferase -0.755 4.72E-03
Biosynthesis of cofactors, prosthetic groups, and carriers
NMA1255 ggt γ-glutamyltranspeptidase -0.928 1.33E-02
Cell envelope
NMB0068 siaC polysialic acid capsule biosynthesis protein -1.144 1.29E-02
NMB0069 siaB polysialic acid capsule biosynthesis protein -1.111 3.00E-03
NMB0070 siaA polysialic acid capsule biosynthesis protein -1.058 1.88E-03
NMB0088 putative outer membrane protein P1 -0.638 2.23E-02
NMB0828 rfaD ADP-L-glycero-D-mannoheptose-6-epimerase -0.711 4.95E-02
NMA0319 mafB′ putative MAFB alternative C-terminus -0.964 1.22E-03
NMA0325 mafA adhesin -0.668 2.33E-02
Cellular processes
NMB0170 minC septum site-determining protein -0.893 3.08E-03
NMB0172 minE cell division topological specificity factor -0.760 3.06E-02
NMB0364 FrpC operon protein -0.820 3.65E-03
NMB0584 FrpC operon protein -0.802 8.98E-03
NMB0585 putative iron-regulated protein FrpA -1.066 1.22E-03
NMB0855 putative bacteriocin resistance protein -0.878 5.50E-03
NMB1412 FrpC operon protein -0.833 4.36E-03
NMB1414 FrpC operon protein -0.852 2.83E-03
NMB1985 iga2 adhesion and penetration protein -0.645 3.09E-02
Central intermediary metabolism
NMB1305 esd putative esterase -0.606 3.72E-02
DNA metabolism
NMB0076 methyltransferase HphIm(C) (authentic
frameshift)
-0.729 4.54E-02
NMB0829 hsdM type I restriction enzyme EcoR124II M protein -0.615 1.29E-02
NMB0962 uvrA excinuclease ABC, subunit A -0.927 2.08E-02
NMB1032 nlaIVR type II restriction enzyme NlaIV -1.342 2.25E-04
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ID Name Annotation log2 ratio P-value*
Energy metabolism
NMB0089 pykA pyruvate kinase II -0.858 5.52E-03
NMB0948 sdhC succinate dehydrogenase, cytochrome b556
subunit
-0.655 1.84E-02
NMB0949 sdhD succinate dehydrogenase, hydrophobic mem-
brane anchor protein
-0.744 6.23E-03
NMB0950 sdhA succinate dehydrogenase, flavoprotein subunit -0.714 3.76E-02
NMB0951 sdhB succinate dehydrogenase, iron-sulphur protein -0.798 1.30E-02
NMB1723 fixP cytochrome c oxidase, subunit III -0.736 2.14E-02
NMB1724 fixO cytochrome c oxidase, subunit II -1.057 2.08E-02
NMB1725 fixN cytochrome c oxidase, subunit I -1.299 4.26E-03
NMB2154 etfA electron transfer flavoprotein, α subunit -1.089 9.44E-03
NMB2155 etfB electron transfer flavoprotein, β subunit -1.017 1.37E-02
Hypothetical or unassigned proteins
NMB0065 hypothetical protein -0.813 1.19E-02
NMB0091 hypothetical protein -1.055 3.46E-02
NMB0092 hypothetical protein -0.798 2.08E-02
NMB0119 hypothetical protein -0.973 2.31E-02
NMB0120 hypothetical protein -0.919 7.86E-03
NMB0317 conserved hypothetical protein -0.701 6.54E-03
NMB0366 hypothetical protein -1.000 2.90E-04
NMB0367 hypothetical protein -0.974 2.31E-02
NMB0368 hypothetical protein -0.985 1.96E-02
NMB0370 hypothetical protein -0.958 1.34E-02
NMB0371 hypothetical protein -0.931 2.15E-02
NMB0501 hypothetical protein -0.910 3.28E-02
NMB0507 hypothetical protein -0.723 9.44E-03
NMB0515 hypothetical protein -0.793 2.05E-02
NMB0516 hypothetical protein -0.732 2.08E-02
NMB0555 hypothetical protein -0.762 2.42E-02
NMB0644 hypothetical protein -0.939 1.22E-03
NMB0647 hypothetical protein -0.793 1.10E-02
NMB0650 hypothetical protein -0.883 2.98E-03
NMB0651 hypothetical protein -0.776 5.19E-03
NMB0654 hypothetical protein -0.843 9.81E-03
NMB0660 hypothetical protein -0.673 1.70E-02
NMB0856 hypothetical protein -0.924 3.51E-03
NMB0857 hypothetical protein -0.769 3.46E-02
NMB0859 hypothetical protein -0.836 1.14E-02
NMB0888 putative membrane protein -0.946 4.72E-04
NMB0889 hypothetical protein -0.838 3.76E-02
NMB0945 hypothetical protein -0.947 4.11E-02
NMB1056 hypothetical protein -0.793 4.29E-02
NMB1125 hypothetical protein -0.849 2.31E-02
NMB1345 hypothetical protein -0.764 1.10E-02
NMB1402 hypothetical protein -0.884 1.03E-03
NMB1404 hypothetical protein -0.963 1.49E-03
NMB1406 hypothetical protein -0.626 4.14E-02
NMB1436 conserved hypothetical protein -0.699 3.17E-02
NMB1575 conserved hypothetical protein -1.162 5.50E-03
NMB1578 conserved hypothetical protein -0.784 1.65E-02
NMB1633 hypothetical protein -1.003 4.25E-02
NMB1667 hypothetical protein -0.647 5.19E-03
NMB1784 hypothetical protein -0.830 4.40E-02
NMB2085 hypothetical protein -0.678 4.29E-02
NMB2109 hypothetical protein -0.830 1.84E-02
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ID Name Annotation log2 ratio P-value*
NMB2110 hypothetical protein -0.893 6.46E-03
NMB2112 hypothetical protein -0.990 1.49E-03
NMB2116 hypothetical protein -0.927 6.12E-03
NMB2118 hypothetical protein -1.085 8.83E-04
NMB2123 hypothetical protein -0.866 1.70E-02
NMB2124 hypothetical protein -0.621 4.99E-02
NMB2125 hypothetical protein -0.637 2.39E-02
NMB2146 hypothetical protein -0.739 2.87E-03
NMB2147 hypothetical protein -0.611 1.54E-02
NMB2152 hypothetical protein -0.674 2.54E-02
NMB2153 conserved hypothetical protein -0.864 1.14E-02
NMA0315 mafB′ putative MAFB alternative C-terminus -0.969 1.22E-03
NMA0318 hypothetical protein -0.984 8.65E-04
NMA0426a hypothetical protein -0.710 2.90E-02
NMA0606 hypothetical protein -0.682 9.44E-03
NMA0695 conserved hypothetical protein -1.079 1.62E-03
NMA1288 conserved hypothetical protein -0.735 3.26E-02
NMA1435 conserved hypothetical protein -0.681 3.39E-02
NMA1866 putative integral membrane protein -2.672 4.76E-03
NMA1978 conserved hypothetical protein -1.002 1.84E-02
NMA2123 conserved hypothetical protein -0.912 3.08E-03
NMC0082 conserved hypothetical protein -0.789 1.70E-02
NMC1345 putative iron-regulated protein FrpC outer
membrane (pseudogene)
-1.043 2.87E-03
NMC1797 conserved hypothetical protein -0.990 2.91E-02
NMC2091 hypothetical protein -0.908 3.51E-03
NMC2086 putative adhesin (pseudogene) -0.869 5.19E-03
Mobile and extrachromosomal element functions
NMB0556 putative repressor protein -0.777 3.00E-03
Protein fate
NMB0214 prlC oligopeptidase A -0.915 4.26E-02
NMB0554 dnaK dnaK protein -1.552 4.72E-03
NMB0561 grpE grpE protein -0.824 3.96E-02
Protein synthesis
NMB0854 hisS histidyl-tRNA synthetase -0.847 4.25E-02
NMB0942 rpmE2 putative 50S ribosomal protein L31 -0.947 4.38E-02
Purines, pyrimidines, nucleosides, and nucleotides
NMB2151 purD phosphoribosylamine-glycine ligase -0.647 4.29E-02
Regulatory functions
NMB0173 oxyR transcriptional regulator, LysR family -0.707 2.80E-02
NMB0556 putative repressor protein -0.777 3.00E-03
Transcription
NMB0132 rpoB DNA-directed RNA polymerase, β subunit -0.847 2.17E-02
NMB2144 putative sigma factor -0.642 7.05E-03
Transport and binding proteins
NMB0071 ctrA capsule polysaccharide export, outer mem-
brane protein
-0.791 1.84E-02
NMB0073 ctrC capsule polysaccharide export, inner mem-
brane protein
-0.730 4.91E-02
NMB0098 ABC transporter, ATP-binding protein (au-
thentic frameshift)
-0.719 2.49E-02
NMB0586 putative zinc/manganese transporter -0.858 1.62E-03
NMB1497 TonB-dependent receptor -0.588 4.22E-02
NMB1732 putative transporter -0.788 6.65E-03
NMB1783 putative secretion protein -0.929 3.88E-02
NMC1691 tbpB transferrin-binding protein B -1.097 9.41E-03
Continued on next page . . .
Appendix B: Supplementary data to Chapter 5 268
Table B.2 – continued from previous page
ID Name Annotation log2 ratio P-value*
Unknown function
NMB0827 nmgI type II restriction enzyme-related protein -1.273 2.83E-03
NMB0852 engA essential GTPase -0.852 3.37E-02
NMB1280 very long chain acyl-CoA dehydrogenase-
related protein
-0.590 1.19E-02
NMB1381 HesB/YadR/YfhF family protein -0.712 4.06E-02
NMB1405 FrpA/C-related protein -0.906 4.83E-03
NMB1409 FrpA/C-related protein -0.759 3.39E-02
NMB2105 mafB mafB protein -0.761 6.77E-03
NMB2122 mafB′ MafB-related protein -0.843 8.36E-03
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.3: Genes up-regulated at 240 min during growth in FFP 1 in comparison to
meningococci incubated in medium. Genes are divided into functional categories according
to TIGR designations.





NMB0337 ilvE putative branched-chain amino acid aminotrans-
ferase
1.387 7.36E-07
NMB1036 leuC 3-isopropylmalate dehydratase, large subunit 0.722 3.67E-02
NMB1069 proB glutamate 5-kinase 0.842 4.39E-03
NMB1150 ilvD-1 dihydroxy-acid dehydratase 0.836 5.64E-03
NMB1188 ilvD-2 dihydroxy-acid dehydratase 0.830 5.64E-03




NMB1573 argF ornithine carbamoyltransferase, catabolic 1.052 6.43E-06
NMB1710 gdhA glutamate dehydrogenase, NADP-specific 1.935 1.76E-05
Cell envelope
NMB0663 nspA outer membrane protein 2.234 5.50E-13
NMB1623 aniA nitrite reductase, major anaerobically induced
outer membrane protein
1.107 4.96E-04
NMB1994 nadA putative adhesin/invasin 1.196 7.27E-05
Cellular processes
NMB1994 nadA putative adhesin/invasin 1.196 7.27E-05
Central intermediary metabolism
NMB0031 glmS glucosamine–fructose-6-phosphate aminotrans-
ferase
0.883 1.65E-03
NMB1154 cysD-1 sulphate adenylyltransferase, subunit 2 0.978 1.24E-02
NMB1584 3-hydroxyacid dehydrogenase 0.712 1.42E-02
DNA metabolism
NMB0831 type I restriction enzyme S protein (degenerate) 0.622 2.53E-03
NMB0962 uvrA excinuclease ABC, subunit A 0.883 6.92E-03
Energy metabolism
NMB0241 nuoA NADH dehydrogenase I, chain A 1.281 1.71E-04
NMB0242 nuoB NADH dehydrogenase I, chain B 1.433 8.31E-08
NMB0243 nuoC NADH dehydrogenase I, chain C 1.253 3.36E-06
NMB0244 nuoD NADH dehydrogenase I, chain D 1.478 9.95E-08
NMB0245 nuoE NADH dehydrogenase I, chain E 1.286 2.74E-05
NMB0246 nuoF NADH dehydrogenase I, chain F 0.965 8.49E-04
NMB0249 nuoG NADH dehydrogenase I, chain G 1.133 1.73E-04
NMB0250 nuoH NADH dehydrogenase I, chain H 1.083 5.17E-05
Continued on next page . . .
Appendix B: Supplementary data to Chapter 5 269
Table B.3 – continued from previous page
ID Name Annotation log2 ratio P-value*
NMB0251 nuoI NADH dehydrogenase I, chain I 1.377 1.03E-06
NMB0253 nuoJ NADH dehydrogenase I, chain J 0.866 2.33E-02
NMB0254 nuoK NADH dehydrogenase I, chain K 0.946 8.97E-03
NMB0257 nuoL NADH dehydrogenase I, chain L 0.882 3.05E-03
NMB0258 nuoM NADH dehydrogenase I, chain M 0.809 1.64E-02
NMB0340 gloA lactoylglutathione lyase 1.537 6.25E-08
NMB0390 mapA maltose phosphorylase 0.599 1.64E-02
NMB0401 putA proline dehydrogenase 0.958 7.47E-03
NMB0433 acnA aconitate hydratase 1 1.813 8.58E-04
NMB0631 putative phosphate acyltransferase 1.052 8.54E-03
NMB0920 icd isocitrate dehydrogenase 1.192 8.78E-05
NMB0923 cytochrome c 0.754 3.65E-04
NMB0948 sdhC succinate dehydrogenase, cytochrome b556 sub-
unit
0.639 1.44E-02
NMB0949 sdhD succinate dehydrogenase, hydrophobic mem-
brane anchor protein
0.737 4.04E-03
NMB0950 sdhA succinate dehydrogenase, flavoprotein subunit 0.752 8.76E-03
NMB0951 sdhB succinate dehydrogenase, iron-sulphur protein 0.860 1.29E-03
NMB0954 gltA citrate synthase 0.983 3.12E-03
NMB0980 pntA NAD(P) transhydrogenase, α subunit 0.808 1.38E-02
NMB1244 rpe ribulose-phosphate 3-epimerase 0.607 2.31E-02
NMB1388 pgi-1 glucose-6-phosphate isomerase 0.598 3.41E-02
NMB1393 edd phosphogluconate dehydratase 0.886 8.16E-03
NMB1474 putative 4-oxalocrotonate tautomerase 0.718 7.45E-03
NMB1572 acnB aconitate hydratase 2 2.493 5.64E-12
NMB1613 fumA fumarate hydratase, class I 1.534 2.31E-09




NMB1723 fixP cytochrome c oxidase, subunit III 1.471 4.22E-07
NMB1724 fixO cytochrome c oxidase, subunit II 1.097 1.00E-02
NMB1805 cyc cytochrome c4 0.662 2.31E-02
NMB2051 petC ubiquinol–cytochrome c reductase,
cytochrome c1
0.936 2.20E-03
NMB2052 petB ubiquinol–cytochrome c reductase,
cytochrome b
0.768 1.08E-02
NMB2053 petA ubiquinol–cytochrome c reductase,
iron-sulphur subunit
0.963 1.57E-03
NMB2096 mqo malate:quinone oxidoreductase 1.306 6.25E-08




NMB1573 argF ornithine carbamoyltransferase, catabolic 1.052 6.43E-06
NMA2094 mapA′ putative maltose phosphorylase (fragment) 0.943 8.44E-04
Hypothetical or unassigned proteins
NMB0100 hypothetical protein (frameshift) 0.819 5.58E-03
NMB0228 conserved hypothetical protein 1.093 1.82E-03
NMB0230 conserved hypothetical protein 1.012 3.88E-04
NMB0252 hypothetical protein 1.014 1.08E-03
NMB0311 hypothetical protein 0.979 4.79E-03
NMB0500 hypothetical protein 0.912 4.27E-02
NMB0516 hypothetical protein 0.637 3.79E-02
NMB0709 putative membrane protein 1.706 2.24E-08
NMB0710 putative membrane protein 0.888 5.58E-03
NMB0711 conserved hypothetical protein 0.643 2.41E-03
NMB0776 putative secreted protein 0.785 3.04E-02
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NMB0921 hypothetical protein 0.737 7.68E-03
NMB0952 conserved hypothetical protein 0.861 1.39E-02
NMB0968 hypothetical protein 1.071 2.10E-03
NMB1035 putative lipoprotein 0.735 4.29E-03
NMB1064 conserved hypothetical protein 0.695 1.96E-03
NMB1144 putative periplasmic protein 0.816 2.74E-03
NMB1365 dnrN conserved hypothetical protein 0.898 2.11E-05
NMB1427 hypothetical protein 0.786 3.81E-02
NMB1431 hypothetical protein 2.983 2.17E-04
NMB1436 conserved hypothetical protein 0.940 1.54E-03
NMB1437 conserved hypothetical protein 1.153 2.80E-03
NMB1438 conserved hypothetical iron-sulphur protein 1.178 1.34E-04
NMB1456 hypothetical protein 0.840 1.67E-03
NMB1571 conserved hypothetical (integral membrane pro-
tein)
0.790 5.20E-03
NMB1590 conserved hypothetical protein 0.719 2.63E-04
NMB1598 hypothetical protein 0.746 7.68E-03
NMB1620 conserved hypothetical protein 0.913 3.87E-03
NMB1624 hypothetical protein 1.060 1.73E-04
NMB1656 hypothetical protein 0.998 2.10E-04
NMB1667 hypothetical protein 0.661 2.34E-03
NMB1718 hypothetical protein 0.970 3.17E-03
NMB1824 conserved hypothetical protein 0.993 6.58E-04
NMB2050 putative periplasmic protein 0.594 3.97E-02
NMB2064 conserved hypothetical protein 1.000 7.97E-03
NMB2089 conserved hypothetical protein 0.759 6.00E-03
NMB2097 hypothetical protein 1.346 9.90E-04
NMA0041 conserved hypothetical protein 0.829 6.32E-03
NMA1157 conserved hypothetical protein 2.927 2.63E-03
NMA1214 conserved hypothetical protein 1.561 4.40E-02
NMA1220 conserved hypothetical protein 0.627 2.26E-02
NMA1290 conserved hypothetical protein 4.896 1.84E-07
NMA1293 putative phage anti-repressor protein; AntB 4.558 3.96E-06
NMA1298 conserved hypothetical protein 2.331 6.07E-03
NMA1311 conserved hypothetical protein 3.041 2.24E-05
NMA1461 putative dnaJ-family protein 0.629 1.01E-02
NMA1976 putative cytochrome (pseudogene) 1.265 3.40E-04
NMA1978 conserved hypothetical protein 1.039 8.60E-03
Mobile and extrachromosomal element functions
NMA1851 Mu-like phage gp29 0.925 4.03E-04
Protein fate
NMB1649 dsbB disulfide bond formation protein B 0.730 4.18E-03
NMB1998 mspA serine-type peptidase 0.831 1.44E-02
Purines, pyrimidines, nucleosides, and nucleotides
NMB1849 carA carbamoyl phosphate synthase, small subunit 0.762 3.47E-02
Regulatory functions
NMB1711 gdhR GntR-family transcriptional regulator 0.655 1.76E-02
Transcription
NMC0940 putative ATP-dependent helicase 2.017 1.39E-02
Transport and binding proteins
NMB0041 putative thiamin-binding periplasmic protein 0.757 2.54E-02
NMB0085 gltS sodium/glutamate symport carrier protein 0.674 1.76E-02
NMB0318 farA fatty acid eﬄux system protein 0.719 4.36E-02
NMB0402 putP sodium/proline symporter 1.320 5.90E-05
NMB0615 amtB putative ammonium transporter 1.413 1.38E-05
NMB1207 bfrA bacterioferritin A 0.759 4.04E-02
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NMB1719 mtrF eﬄux pump component 0.967 2.56E-02
Unknown function
NMB0255 cell filamentation protein Fic-related protein 1.224 7.37E-04
NMB1220 stomatin/Mec-2 family protein 0.598 3.92E-02
NMB1891 helix-turn-helix family protein 0.696 1.61E-02
NMB1924 inositol monophosphatase family protein 0.931 9.64E-03
NMA0029 urea amidolyase-related protein 1.242 3.88E-04
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.4: Genes down-regulated at 240 min during growth in FFP 1 in comparison to
meningococci incubated in medium. Genes are divided into functional categories according
to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0637 argH argininosuccinate lyase -0.701 3.04E-02
NMB1228 metM homoserine dehydrogenase -0.604 4.02E-02
Biosynthesis of cofactors, prosthetic groups, and carriers





NMB0038 glmU UDP-N-acetylglucosamine pyrophosphorylase -0.682 1.97E-04
NMB0088 putative outer membrane protein P1 -0.979 1.10E-04




NMB0790 pgm phosphoglucomutase -0.625 2.34E-03
NMB1279 mltB putative membrane-bound lytic murein transgly-
cosylase B
-1.095 2.11E-05
NMB1716 mtrC membrane fusion protein -0.731 5.86E-03
Cellular processes
NMB0364 FrpC operon protein -1.513 2.04E-08
NMB0584 FrpC operon protein -1.563 6.25E-08
NMB0585 putative iron-regulated protein FrpA -1.187 6.67E-05
NMB0799 ftsJ cell division protein -0.608 3.12E-03
NMB0855 putative bacteriocin resistance protein -0.623 4.89E-02
NMB1412 FrpC operon protein -1.557 2.24E-08
NMB1414 FrpC operon protein -1.525 1.59E-08
NMB1714 mtrE multidrug eﬄux pump channel protein -0.916 2.11E-04
Central intermediary metabolism
NMB0641 ppa inorganic pyrophosphatase -0.825 4.16E-02
NMB0804 putative NAD(P)H nitroreductase -0.598 3.75E-02
NMB1799 metK S-adenosylmethionine synthetase -0.746 3.79E-03
DNA metabolism
NMB1322 priB putative primosomal replication protein N -1.374 2.17E-02




NMB0010 pgk phosphoglycerate kinase -0.890 1.20E-03
NMB0671 maeA malate oxidoreductase (NAD) -1.142 2.11E-05
NMB0790 pgm phosphoglucomutase -0.625 2.34E-03
NMB0947 lpdA2 putative lipoamide dehydrogenase -0.779 3.46E-02
NMB1044 fpr-1 ferredoxin–NADP reductase -0.781 1.76E-02
NMB1377 lldA L-lactate dehydrogenase -2.176 2.72E-07
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NMB1934 atpD ATP synthase F1, β subunit -1.134 4.14E-02
NMB1935 atpG ATP synthase F1, γ subunit -1.323 1.30E-02
NMB1936 atpA ATP synthase F1, α subunit -1.211 3.72E-02
NMB2154 etfA electron transfer flavoprotein, α subunit -0.985 1.40E-02
NMB2155 etfB electron transfer flavoprotein, β subunit -0.962 1.40E-02
NMA1688 phosphoglycolate phosphatase -0.902 4.73E-03
NMA1934 gcvP glycine dehydrogenase -0.655 2.73E-02
Fatty acid and phospholipid metabolism
NMB0179 fabZ (3R)-hydroxymyristoyl-(acyl carrier protein) de-
hydratase
-0.609 1.19E-02
NMB0180 lpxD UDP-3-O-(3-hydroxymyristoyl)-glucosamine N-
acyltransferase
-0.664 2.95E-02
NMB0219 fabF 3-oxoacyl-(acyl-carrier-protein) synthase II -1.396 2.47E-05
Hypothetical or unassigned proteins
NMB0035 putative lipoprotein -1.622 1.52E-06
NMB0036 possible periplasmic protein -1.161 1.86E-04
NMB0313 conserved hypothetical protein -0.730 2.54E-03
NMB0347 conserved hypothetical protein -0.837 1.44E-02
NMB0593 conserved hypothetical protein -0.814 3.22E-05
NMB0596 possible integral membrane protein -0.692 2.11E-05
NMB0597 hypothetical protein -0.700 1.03E-03
NMB0730 putative membrane protein -0.920 1.73E-04
NMB0744 hypothetical protein -1.959 4.01E-05
NMB0803 conserved hypothetical protein -0.642 3.32E-04
NMB0847 hypothetical protein -0.632 7.79E-04
NMB0850 putative periplasmic protein -1.470 6.44E-04
NMB0856 hypothetical protein -0.689 2.49E-02
NMB0864 hypothetical protein -1.068 8.32E-03
NMB0866 putative periplasmic protein -0.641 1.48E-02
NMB0905 hypothetical protein -0.938 4.51E-04
NMB1327 conserved hypothetical protein -0.664 7.84E-04
NMB1336 conserved hypothetical protein -0.619 1.44E-02
NMB1564 conserved hypothetical protein -0.832 3.96E-03
NMB1565 hypothetical protein -0.719 4.29E-03
NMB1648 conserved hypothetical protein -0.658 1.69E-02
NMB1959 conserved hypothetical protein -0.717 3.14E-02
NMB2085 putative ATP-binding protein -0.738 1.86E-02
NMB2147 putative lipoprotein -0.614 9.09E-03
NMB2153 conserved hypothetical protein -0.861 7.17E-03
NMC0806 putative integral membrane protein -1.155 2.80E-03
NMC1345 pseudogene -1.632 3.39E-08
NMA2123 conserved hypothetical protein -1.199 2.24E-05
Protein fate
NMA1758 pepA aminopeptidase A -1.004 1.82E-03
NMB0059 dnaJ DnaJ protein -0.727 2.34E-03
NMB0214 prlC oligopeptidase A -1.448 3.57E-04
NMB0294 dsbA-2 thiol:disulfide interchange protein -0.858 4.29E-03
NMB0550 dsbC thiol:disulfide interchange protein -1.137 5.02E-04
NMB0554 dnaK putative chaperone protein -1.473 4.29E-03
NMB0561 grpE probable heat shock protein -1.523 2.24E-05
NMB0700 iga IgA-specific serine endopeptidase -1.132 8.04E-03
NMB0791 ppiB peptidyl-prolyl cis-trans isomerase B -1.471 9.37E-04
NMB1231 lon ATP-dependent protease La -0.704 4.29E-02
NMB1519 dsbD thiol:disulfide interchange protein -0.595 4.21E-02
NMB1664 putative protease -0.620 4.33E-03
NMB1972 groEL chaperonin, 60 kDa -1.409 2.95E-02
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NMB1973 groES chaperonin, 10 kDa -1.866 6.06E-04
Protein synthesis
NMB0128 rplA 50S ribosomal protein L1 -1.329 1.47E-02
NMB0145 rplB 50S ribosomal protein L2 -1.257 4.72E-02
NMB0146 rpsS 30S ribosomal protein S19 -1.320 4.77E-02
NMB0147 rplV 50S ribosomal protein L22 -1.479 3.75E-02
NMB0152 rplN 50S ribosomal protein L14 -1.508 3.34E-02
NMB0154 rplE 50S ribosomal protein L5 -1.868 7.69E-03
NMB0155 rpsN 30S ribosomal protein S14 -1.602 2.50E-02
NMB0156 rpsH 30S ribosomal protein S8 -1.531 3.32E-02
NMB0169 rplQ 50S ribosomal protein L17 -1.237 2.49E-02
NMB0174 valS valyl-tRNA synthetase -0.673 1.58E-02
NMB0626 prfC peptide chain release factor 3 -0.742 3.96E-06
NMB0721 infC translation initiation factor 3 -1.017 2.57E-02
NMB1301 rpsA 30S ribosomal protein S1 -1.112 4.26E-02
NMB1321 rpsR 30S ribosomal protein S18 -1.314 4.33E-02
NMB1323 rpsF 30S ribosomal protein S6 -1.254 4.49E-02
NMB1358 gatB Glu-tRNA(Gln) amidotransferase, subunit B -0.910 1.27E-04
NMB1425 lysS lysyl-tRNA synthetase, heat inducible -0.743 8.17E-03
NMB1911 rpmF 50S ribosomal protein L32 -1.145 5.02E-04
Purines, pyrimidines, nucleosides, and nucleotides
NMB0849 putative deoxycytidine triphosphate deaminase -1.168 1.97E-04
NMB1252 purM putative phosphoribosylformylglycinamidine
cyclo-ligase
-0.835 4.85E-03
NMB1566 purN phosphoribosylglycinamide formyltransferase -0.687 2.92E-03
Transcription
NMB0132 rpoB DNA-directed RNA polymerase, β subunit -0.983 1.23E-03
NMB0133 rpoC DNA-directed RNA polymerase, β ′ subunit -0.816 8.45E-03
NMB0168 rpoA DNA-directed RNA polymerase, α subunit -1.251 4.29E-02
NMB0617 rho transcription termination factor Rho -0.814 5.12E-03
NMB0683 nusB N utilization substance protein B -0.758 4.73E-03
NMB1538 rpoD RNA polymerase sigma factor RpoD -0.717 2.46E-02
Transport and binding proteins
NMB0034 high-affinity iron transporter -1.129 7.09E-05
NMB0293 putative TonB-dependent receptor -1.424 8.81E-08
NMB0378 putative phosphate permease -1.262 1.21E-03
NMB0460 tbpB transferrin-binding protein 2 -2.071 1.03E-08
NMB0461 tbpA transferrin-binding protein 1 -2.271 1.83E-12
NMB1497 TonB-dependent receptor -0.810 2.03E-03
NMB1540 lbpA lactoferrin-binding protein A -1.376 1.71E-04
NMB1541 lbpB lactoferrin-binding protein B -1.325 1.34E-04
NMB1714 mtrE multidrug eﬄux pump channel protein -0.916 2.11E-04
NMB1715 mtrD multiple transferable resistance system protein -0.926 1.66E-04
NMB1716 mtrC membrane fusion protein -0.731 5.86E-03
NMB1728 exbD biopolymer transport protein -1.412 2.03E-03
NMB1729 exbB biopolymer transport protein -1.150 7.18E-03
NMB1730 tonB TonB protein -0.925 1.16E-02
NMB1988 fetA iron-regulated outer membrane protein FrpB -2.518 2.31E-09
NMB1989 fetB iron(III) ABC transporter, periplasmic
substrate-binding protein
-0.987 2.19E-06
NMA1740 lbpB lactoferrin-binding protein B -1.520 1.08E-05
NMA2025 tbpB transferrin-binding protein 2 -2.371 8.31E-08
NMC1469 lbpB lactoferrin-binding protein B -0.941 2.24E-02
NMC1690 tbpA transferrin-binding protein 1 -1.060 1.86E-03
NMC1691 tbpB transferrin-binding protein B -0.700 4.00E-02
NMC1946 hpuA haemoglobin-haptoglobin-utilization protein -1.872 2.34E-03
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Unknown function
NMB0598 Maf/YceF/YhdE family protein -0.641 1.57E-03
NMB0766 lepA GTP-binding protein -0.675 8.32E-03
NMB0852 essential GTPase -0.816 3.47E-02
NMB1199 typA GTP-binding protein -0.981 5.28E-03
NMB1280 very long chain acyl-CoA dehydrogenase-related
protein
-1.060 8.18E-07
NMB1638 YhbX/YhjW/YijP/YjdB family protein -1.115 7.72E-07
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.5: Genes down-regulated at both 60 and 240 min during growth in FFP 1 in
comparison to meningococci incubated in medium.
60 min 240 min
ID Name Annotation log2 ratio log2 ratio
NMB0088 putative outer membrane protein P1 -0.638 -0.979
NMB0132 rpoB DNA-directed RNA polymerase, subunit β -0.847 -0.983
NMB0214 prlC oligopeptidase A -0.915 -1.448
NMB0554 dnaK molecular chaperone -1.552 -1.473
NMB0561 grpE -0.824 -1.523
NMB0584 FrpC operon protein -0.802 -1.563
NMB0585 putative iron-regulated protein FrpA -1.066 -1.187
NMB0852 engA GTP-binding protein -0.852 -0.816
NMB0855 putative bacteriocin resistance protein -0.878 -0.623
NMB0856 hypothetical protein -0.924 -0.689
NMB1280 very long chain acyl-CoA dehydrogenase-related
protein
-0.590 -1.060
NMB1412 FrpC operon protein -0.833 -1.557
NMB1414 FrpC operon protein -0.852 -1.525
NMB1497 TonB-dependent receptor -0.588 -0.810
NMB2085 hypothetical protein -0.678 -0.738
NMB2147 hypothetical protein -0.611 -0.614
NMB2153 hypothetical protein -0.864 -0.861
NMB2154 etfA electron transfer flavoprotein, α subunit -1.089 -0.985
NMB2155 etfB electron transfer flavoprotein, β subunit -1.017 -0.962
NMA2123 hypothetical protein -0.912 -1.199
NMC1345 pseudogene -1.043 -1.632
NMC1691 tbpB transferrin-binding protein B -1.097 -0.700
Table B.6: Genes up-regulated at 60 min during growth in FFP 2 in comparison to t =
0 min (meningococci on solid agar medium). Genes are divided into functional categories
according to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0760 dapF diaminopimelate epimerase 0.688 1.05E-02
NMB0802 metB cystathionine γ-synthase 0.633 1.28E-02
NMB0943 metF 5,10-methylenetetrahydrofolate reductase 0.740 3.53E-03
NMB0981 serB phosphoserine phosphatase 0.759 4.39E-03
NMB1021 trpE anthranilate synthase, component I 0.857 3.10E-03
NMB1031 leuB 3-isopropylmalate dehydrogenase 0.750 7.82E-03
NMB1034 leuD isopropylmalate isomerase, small subunit 1.604 8.86E-10
NMB1036 leuC isopropylmalate isomerase, large subunit 2.168 3.49E-09
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NMB1070 leuA 2-isopropylmalate synthase 1.378 1.06E-06
NMB1150 ilvD-1 dihydroxy-acid dehydratase 0.749 2.55E-02
NMB1188 ilvD-2 dihydroxy-acid dehydratase 0.747 2.48E-02
NMB1446 aroD 3-dehydroquinate dehydratase 0.669 1.85E-02
NMB1498 lysC aspartate kinase 0.929 2.94E-03
NMB1680 aroC chorismate synthase 0.742 1.01E-03
Biosynthesis of cofactors, prosthetic groups, and carriers
NMB0392 nadB L-aspartate oxidase 1.117 2.04E-04
NMB0394 nadA quinolinate synthetase 1.141 6.97E-05
NMB0396 nadC nicotinate-nucleotide pyrophosphorylase 1.159 3.89E-03
NMB0527 putative 6-pyruvoyl tetrahydrobiopterin syn-
thase
0.713 1.40E-02
NMB0539 hemC porphobilinogen deaminase 0.752 2.00E-03
NMB0563 apbE thiamine biosynthesis lipoprotein 0.642 1.39E-02
NMB0777 hemD uroporphyrinogen-III synthase 0.706 2.05E-02
NMB1037 gshA glutamate–cysteine ligase 0.975 2.12E-04
NMB1130 putative phytoene synthase 1.275 2.16E-08
NMB1156 cysG-1 siroheme synthase 1.212 1.04E-02
NMB1168 putative phytoene synthase 1.486 1.64E-10
NMB1194 cysG-2 siroheme synthase 1.438 5.80E-04





NMB1273 putative alginate O-acetylation protein AlgI 0.715 1.93E-02
NMB1297 mltD membrane-bound lytic murein transglycosylase
D
0.708 3.70E-02
NMB1533 H.8 outer membrane protein 0.845 1.76E-02
NMB1704 lgtF β-1,4-glucosyltransferase 1.036 1.35E-04
NMB1705 rfaK α-1,2-N-acetylglucosamine transferase 0.790 1.91E-03




NMB0191 ParA family protein 0.602 9.50E-03
NMB0525 putative aluminum resistance protein 1.192 1.67E-03
NMB0582 putative bacteriocin resistance protein 1.803 3.54E-06
NMB1621 gpxA glutathione peroxidase 0.590 3.65E-02
NMA0860 apaH bis(5-nucleosyl)-tetraphosphatase (symmetrical) 0.804 1.01E-03
Central intermediary metabolism
NMB0468 speA arginine decarboxylase 0.730 2.97E-04
NMB0998 putative oxidoreductase 1.308 2.57E-06
NMB1151 cysI-1 sulphite reductase hemoprotein, β component 1.341 1.24E-02
NMB1152 cysJ-1 sulphite reductase (NADPH) flavoprotein,
α component
1.176 2.34E-02
NMB1153 cysN-1 sulphate adenylyltransferase, subunit 1 1.421 1.00E-02
NMB1154 cysD-1 sulphate adenylyltransferase subunit 2 1.315 3.95E-03
NMB1189 cysI-2 sulphite reductase hemoprotein, β component 1.405 1.28E-02
NMB1190 cysJ-2 sulphite reductase (NADPH) flavoprotein,
α component
1.393 2.71E-03
NMB1191 cysN-2 sulphate adenylyltransferase, subunit 1 1.636 6.46E-04
NMB1192 cysD-2 sulphate adenylyltransferase, subunit 2 1.447 1.80E-03
NMB1338 putative isomerase 0.627 1.23E-03
NMB1799 metK S-adenosylmethionine synthetase 1.174 1.67E-05
DNA metabolism
NMB0533 nth endonuclease III 0.599 2.29E-02
NMB1982 polA DNA polymerase I 0.870 1.42E-03
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NMA0059 pseudogene (modification methylase) 0.826 8.33E-03
Energy metabolism
NMB0010 pgk phosphoglycerate kinase 0.790 8.71E-03
NMB1044 fpr-1 ferredoxin–NADP reductase 0.792 6.79E-03
NMB1613 fumA fumarate hydratase, class I, anaerobic 0.726 3.96E-03
NMB2053 petA ubiquinol–cytochrome c reductase, iron-sulphur
subunit
0.924 1.28E-02
Fatty acid and phospholipid metabolism
NMB1913 plsX fatty acid/phospholipid synthesis protein 0.723 3.01E-02
Hypothetical or unassigned proteins
NMB0263 putative ribosome-associated GTPase 0.770 1.94E-02
NMB0266 hypothetical protein 0.914 1.58E-03
NMB0267 putative rare lipoprotein A 1.616 1.44E-06
NMB0292 hypothetical protein 0.715 2.97E-04
NMB0316 hypothetical protein 1.232 1.79E-07
NMB0317 putative 7-cyano-7-deazaguanine reductase 1.152 8.12E-06
NMB0320 hypothetical protein 1.225 6.79E-03
NMB0395 hypothetical protein 1.829 3.63E-07
NMB0438 hypothetical protein 0.986 8.61E-04
NMB0531 hypothetical protein 0.749 7.76E-05
NMB0545 hypothetical protein 0.591 2.89E-02
NMB0596 hypothetical protein 0.587 8.38E-04
NMB0597 hypothetical protein 0.688 2.89E-03
NMB0742 hypothetical protein 1.000 1.48E-03
NMB0762 hypothetical protein 0.692 2.56E-02
NMB0775 hypothetical protein 0.608 1.94E-02
NMB0819 hypothetical protein 0.805 1.67E-05
NMB0820 hypothetical protein 0.634 1.04E-02
NMB0821 hypothetical protein 1.115 3.03E-07
NMB0840 hypothetical protein 0.831 5.94E-03
NMB0861 hypothetical protein 0.949 4.08E-04
NMB0862 hypothetical protein 0.696 1.14E-02
NMB0865 hypothetical protein 0.869 3.82E-04
NMB0866 hypothetical protein 0.675 1.81E-02
NMB0872 hypothetical protein 0.618 3.89E-03
NMB1018 hypothetical protein 0.625 2.89E-02
NMB1020 hypothetical protein 0.649 9.35E-03
NMB1035 hypothetical protein 1.000 7.68E-03
NMB1040 hypothetical protein 0.713 6.79E-03
NMB1073 hypothetical protein 0.780 1.04E-02
NMB1142 hypothetical protein 0.681 1.41E-02
NMB1180 hypothetical protein 0.665 2.22E-02
NMB1253 hypothetical protein 0.666 1.66E-02
NMB1270 hypothetical protein 0.903 2.22E-06
NMB1286 hypothetical protein 0.962 4.19E-03
NMB1308 hypothetical protein 0.630 2.09E-02
NMB1336 hypothetical protein 0.897 6.69E-04
NMB1337 Holliday junction resolvase-like protein 0.750 9.40E-04
NMB1349 hypothetical protein 0.874 1.86E-04
NMB1426 hypothetical protein 0.778 3.87E-03
NMB1427 hypothetical protein 1.268 2.05E-04
NMB1531 hypothetical protein 0.669 5.93E-03
NMB1534 hypothetical protein 0.621 1.38E-02
NMB1565 hypothetical protein 0.747 5.90E-03
NMB1641 hypothetical protein 1.030 4.67E-05
NMB1800 hypothetical protein 1.139 2.56E-05
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NMB1866 hypothetical protein 0.895 3.42E-02
NMB1906 hypothetical protein 0.978 1.65E-04
NMB1912 hypothetical protein 0.985 1.16E-03
NMB1977 hypothetical protein 0.854 9.73E-04
NMA0380 hypothetical protein 0.833 2.76E-04
NMA2069 pseudogene 0.889 4.85E-04
Protein fate
NMB0059 dnaJ molecular chaperone DnaJ 1.435 4.15E-08
NMB0214 prlC oligopeptidase A 0.936 4.60E-02
NMB0554 dnaK molecular chaperone DnaK 1.221 3.55E-02
NMB0561 grpE molecular chaperone GrpE 1.201 2.09E-03
NMB0822 htpX heat shock protein HtpX 0.787 3.89E-03
NMB0922 lst α-2,3-sialyltransferase 1.101 1.28E-03
NMB1231 lon ATP-dependent Lon protease 1.226 1.59E-03
NMB1372 clpX ATP-dependent protease, ATP-binding subunit 0.816 2.17E-03
NMB2000 hslO Hsp33-like chaperonin 0.809 7.09E-03
Protein synthesis
NMB0142 rplC 50S ribosomal protein L3 1.503 1.70E-02
NMB0174 valS valyl-tRNA synthetase 0.743 1.30E-02
NMB0268 RNA methyltransferase, TrmH family 1.355 4.89E-07
NMB0626 prfC peptide chain release factor 3 1.041 7.65E-09
NMB0719 tgt queuine tRNA-ribosyltransferase 0.819 3.34E-07
NMB0720 thrS threonyl-tRNA synthetase 0.755 1.39E-02
NMB1348 putative RNA methylase 1.050 6.46E-04
NMB1425 lysS lysyl-tRNA synthetase 0.878 4.15E-04
NMB1643 infB translation initiation factor IF-2 0.825 2.71E-03
NMB1679 trmA tRNA (uracil-5-)-methyltransferase 1.096 3.92E-07
NMA1588 truB tRNA pseudouridine synthase B 1.239 1.44E-06
Purines, pyrimidines, nucleosides, and nucleotides
NMB0774 upp uracil phosphoribosyltransferase 1.000 1.18E-03
NMB0815 purA adenylosuccinate synthetase 0.954 1.59E-03
NMB1019 purK phosphoribosylaminoimidazole carboxylase,
ATPase subunit
0.815 1.28E-02
NMB1252 purM phosphoribosylaminoimidazole synthetase 0.866 6.93E-03
NMB1709 thyA thymidylate synthase 0.664 1.01E-03
Regulatory functions
NMB0594 sensor histidine kinase 0.651 1.27E-04
NMB1561 glpR transcriptional regulator, DeoR family 0.740 2.00E-03
NMB2055 metR transcriptional regulator, LysR family 0.796 1.91E-02
Transcription
NMB0075 putative transcriptional accessory protein Tex 0.795 2.74E-02
NMB1373 rbfA ribosome-binding factor A 0.875 5.09E-05
NMB1538 rpoD RNA polymerase sigma factor RpoD 0.798 1.91E-02
NMB1642 nusA transcription elongation factor NusA 1.078 7.65E-03
NMB1905 rnpA ribonuclease P 0.816 4.10E-03
Transport and binding proteins
NMB0098 ABC transporter, ATP-binding protein (authen-
tic frameshift)
0.882 5.90E-03
NMB0393 multidrug resistance protein 0.790 4.46E-02
NMB0611 potB spermidine/putrescine ABC transporter, perme-
ase protein
0.786 7.11E-04
NMB0612 potC spermidine/putrescine ABC transporter, perme-
ase protein
0.774 3.65E-02
NMB0787 amino acid ABC transporter, periplasmic
substrate-binding protein
1.547 4.08E-04
NMB0788 amino acid ABC transporter, permease protein 1.751 1.21E-05
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NMB0789 amino acid ABC transporter, ATP-binding pro-
tein
1.576 2.50E-06
NMB1614 trkA potassium transporter, peripheral membrane
component
0.763 2.17E-03
NMB1962 L-glutamate ABC transporter, putative NTP-
binding protein
0.679 4.78E-03




NMB0282 ribonuclease II-related protein 0.727 4.38E-04
NMB0995 macrophage infectivity potentiator-related pro-
tein
1.466 1.86E-03
NMB1335 creA creA protein 0.643 2.28E-03
NMB1347 suhB extragenic suppressor protein 1.172 7.59E-04
NMB1421 nifR3 protein 0.667 1.31E-02
NMB1961 VacJ-related protein 0.798 6.38E-04
NMA0271 pilS7 truncated pilin, pseudogene 0.698 4.08E-04
NMA0971 lipoprotein 0.749 4.34E-04
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.7: Genes down-regulated at 60 min during growth in FFP 2 in comparison to t =
0 min (meningococci on solid agar medium). Genes are divided into functional categories
according to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0878 ilvA threonine dehydratase -1.092 2.09E-07
NMB1046 thrC threonine synthase -0.670 4.33E-02
NMB1055 glyA serine hydroxymethyltransferase -0.756 4.46E-02
NMB1476 gluD glutamate dehydrogenase, NAD-specific -1.716 6.40E-09
NMB1579 hisG ATP phosphoribosyltransferase, catalytic sub-
unit
-1.036 9.78E-05
NMB1581 hisD histidinol dehydrogenase -0.920 4.95E-03
NMB2005 argJ bifunctional ornithine acetyltransferase/N-
acetylglutamate synthase protein
-1.369 7.53E-04
Biosynthesis of cofactors, prosthetic groups, and carriers
NMB1055 glyA serine hydroxymethyltransferase -0.756 4.46E-02
NMB1364 nadE putative NH(3)-dependent NAD+ synthetase -0.769 3.65E-02
Cell envelope
NMB0756 rfbD putative dTDP-L-rhamnose synthase -0.778 1.01E-05
NMB1279 mltB putative membrane-bound lytic murein transgly-
cosylase B
-1.093 8.13E-05
NMB1716 mtrC membrane fusion protein -1.340 1.98E-06
NMB1994 nadA putative adhesin/invasin -0.974 2.29E-02
NMB2019 kdtB phosphopantetheine adenylyltransferase -0.675 7.69E-05
NMA0325 mafA adhesin -0.686 2.34E-02
NMC1731 ddpX putative D-alanyl-D-alanine dipeptidase -3.104 1.13E-10
Cellular processes
NMB0216 katA catalase -1.904 2.80E-03
NMB0585 putative iron-regulated protein FrpA -0.856 9.41E-03
NMB0712 rpoH RNA polymerase factor sigma-32 -1.054 1.75E-02
NMB0768 pilT-2 twitching motility protein -0.597 5.93E-03
NMB0784 putative phage shock protein E precursor -0.975 7.93E-05
NMB0851 rdgC recombination associated protein -1.809 2.93E-02
NMB0855 putative bacteriocin resistance protein -1.302 3.92E-05
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NMB0977 putative modulator of drug activity B -2.535 1.36E-12
NMB1398 sodC Cu-Zn-superoxide dismutase -0.896 1.50E-02
NMB1646 putative hemolysin -0.775 1.66E-02
NMB1714 mtrE multidrug eﬄux pump channel protein -1.621 6.09E-09
NMB1791 cytoplasmic axial filament protein -0.687 1.13E-02
NMB1857 mdaB modulator of drug activity B -2.464 4.64E-05
NMB1994 nadA putative adhesin/invasin -0.974 2.29E-02
Central intermediary metabolism
NMB1305 esd putative esterase -0.726 1.28E-02
NMB1584 3-hydroxyacid dehydrogenase -1.824 6.40E-09
DNA metabolism





NMB0089 pykA pyruvate kinase II -0.880 5.13E-03
NMB0176 dadA D-amino acid dehydrogenase, small subunit -1.764 1.32E-04
NMB0207 gapA glyceraldehyde-3-phosphate dehydrogenase -1.071 5.05E-03
NMB0334 pgi-1 glucose-6-phosphate isomerase -0.919 9.32E-03
NMB0401 putA bifunctional proline dehydrogenase/pyrroline-5-
carboxylate dehydrogenase
-1.121 3.26E-03
NMB0431 prpC methylcitrate synthase -5.745 8.54E-14
NMB0433 acnA aconitate hydratase -2.146 7.76E-03
NMB0434 putative AcnD-accessory protein PrpF -2.515 4.17E-06
NMB0435 ackA-2 acetate kinase -1.693 2.36E-07
NMB0546 adhA alcohol dehydrogenase -1.507 1.86E-03
NMB0574 gcvT glycine cleavage system aminomethyltransferase
T
-3.552 3.95E-24
NMB0575 gcvH glycine cleavage system protein H -2.338 1.91E-06
NMB0618 ppsA phosphoenolpyruvate synthase -1.076 7.69E-05
NMB0631 putative phosphate acetyltransferase Pta -1.535 2.76E-04
NMB0920 icd isocitrate dehydrogenase, NADP-dependent,
monomeric type
-1.318 2.89E-04
NMB0948 sdhC succinate dehydrogenase, cytochrome b556 sub-
unit
-0.996 2.60E-04
NMB0949 sdhD succinate dehydrogenase, hydrophobic mem-
brane anchor protein
-1.060 9.70E-05
NMB0950 sdhA succinate dehydrogenase, flavoprotein subunit -1.430 1.80E-05
NMB0951 sdhB succinate dehydrogenase, iron-sulphur subunit -1.361 1.68E-05
NMB0954 gltA type II citrate synthase -2.525 6.86E-11
NMB0955 sucA α-ketoglutarate decarboxylase -1.517 6.34E-06
NMB0956 sucB dihydrolipoamide acetyltransferase -1.175 2.10E-04
NMB0957 lpdA3 dihydrolipoamide dehydrogenase -0.772 4.59E-02
NMB0959 sucC succinyl-CoA synthetase, subunit β -1.808 3.94E-04
NMB0960 sucD succinyl-CoA synthetase, subunit α -1.887 7.98E-08
NMB0978 pntB pyridine nucleotide transhydrogenase -0.789 2.09E-02
NMB1244 rpe ribulose-phosphate 3-epimerase -1.064 1.08E-04
NMB1304 adhC alcohol dehydrogenase, class III -0.975 7.87E-03
NMB1353 aldehyde dehydrogenase family protein -0.868 2.09E-03
NMB1393 edd phosphogluconate dehydratase -0.935 9.77E-03
NMB1395 alcohol dehydrogenase, zinc-containing -2.252 1.55E-11
NMB1493 cstA carbon starvation protein A -2.650 2.91E-12
NMB1572 acnB bifunctional aconitate hydratase 2/2-methyl-
isocitrate dehydratase
-1.345 1.53E-04
NMB1604 gpm phosphoglyceromutase -0.877 2.28E-03
NMB1609 metZ trans-sulphuration enzyme family protein -0.946 1.53E-03
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NMB1734 grxB glutaredoxin 2 -0.889 1.44E-03
NMB1842 putative 4-hydroxyphenylacetate 3-hydroxylase,
small subunit
-0.711 4.29E-02
NMB1968 aldA aldehyde dehydrogenase A -2.076 3.49E-09
NMB2096 mqo malate:quinone oxidoreductase -1.803 8.29E-11
Fatty acid and phospholipid metabolism
NMB0679 accD acetyl-CoA carboxylase, subunit β -0.645 2.88E-02
Hypothetical or unassigned proteins
NMB0035 hypothetical protein -1.365 2.40E-05
NMB0036 hypothetical protein -1.319 8.64E-05
NMB0039 hypothetical protein -0.596 2.10E-02
NMB0042 hypothetical protein -0.811 7.74E-04
NMB0060 hypothetical protein -1.605 4.08E-08
NMB0183 hypothetical protein -0.765 1.44E-03
NMB0227 hypothetical protein -1.839 5.90E-08
NMB0228 hypothetical protein -1.487 7.42E-05
NMB0286 hypothetical protein -0.654 1.63E-03
NMB0366 hypothetical protein -0.940 1.23E-03
NMB0377 anmK putative anhydro-N-acetylmuramic acid kinase -0.724 1.26E-02
NMB0429 hypothetical protein -2.440 4.00E-09
NMB0507 hypothetical protein -0.608 3.93E-02
NMB0514 hypothetical protein -0.841 1.66E-02
NMB0515 hypothetical protein -1.044 1.80E-03
NMB0516 hypothetical protein -1.273 3.92E-05
NMB0542 hypothetical protein -0.740 1.59E-02
NMB0572 hypothetical protein -0.879 5.09E-04
NMB0619 hypothetical protein -0.705 3.69E-03
NMB0625 hypothetical protein -0.652 1.81E-02
NMB0650 hypothetical protein -0.674 2.89E-02
NMB0651 hypothetical protein -0.674 1.97E-02
NMB0706 hypothetical protein -2.273 2.55E-02
NMB0711 hypothetical protein -1.210 1.65E-07
NMB0753 hypothetical protein -0.797 1.31E-02
NMB0754 hypothetical protein -1.133 7.12E-04
NMB0755 hypothetical protein -0.752 1.94E-02
NMB0783 hypothetical protein -0.629 2.87E-02
NMB0793 hypothetical protein -1.203 1.01E-03
NMB0850 hypothetical protein -1.193 1.27E-02
NMB0853 hypothetical protein -1.778 3.63E-07
NMB0856 hypothetical protein -1.017 1.23E-03
NMB0864 hypothetical protein -1.648 4.78E-04
NMB0915 hypothetical protein -0.855 2.55E-02
NMB0952 hypothetical protein -1.951 1.61E-07
NMB0953 hypothetical protein -1.706 1.43E-07
NMB0958 hypothetical protein -1.298 8.72E-04
NMB1047 hypothetical protein -0.832 9.31E-04
NMB1048 hypothetical protein -2.708 6.94E-09
NMB1064 hypothetical protein -0.839 1.58E-03
NMB1124 hypothetical protein -1.724 1.32E-05
NMB1125 hypothetical protein -1.415 4.82E-04
NMB1162 hypothetical protein -1.733 1.01E-05
NMB1163 hypothetical protein -1.402 3.14E-04
NMB1221 hypothetical protein -0.892 9.08E-03
NMB1245 hypothetical protein -0.906 3.60E-03
NMB1354 hypothetical protein -0.851 6.30E-04
NMB1361 hypothetical protein -0.616 3.60E-03
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NMB1402 hypothetical protein -0.872 7.42E-04
NMB1404 hypothetical protein -0.944 1.63E-03
NMB1452 hypothetical protein -2.230 4.98E-10
NMB1453 hypothetical protein -0.728 5.82E-03
NMB1469 hypothetical protein -1.185 2.62E-02
NMB1477 hypothetical protein -0.747 1.81E-02
NMB1485 hypothetical protein -0.744 2.29E-02
NMB1490 hypothetical protein -0.831 1.70E-02
NMB1491 hypothetical protein -1.955 2.77E-10
NMB1492 hypothetical protein -1.906 4.98E-10
NMB1494 hypothetical protein -2.107 4.75E-10
NMB1495 hypothetical protein -0.637 4.16E-02
NMB1500 hypothetical protein -1.310 1.84E-04
NMB1557 hypothetical protein -0.624 2.10E-02
NMB1578 hypothetical protein -1.147 3.46E-04
NMB1580 hypothetical protein -1.548 6.81E-07
NMB1590 hypothetical protein -0.764 3.40E-04
NMB1631 hypothetical protein -0.775 4.49E-02
NMB1667 hypothetical protein -1.013 1.23E-05
NMB1695 hypothetical protein -0.965 9.34E-04
NMB1784 hypothetical protein -1.260 1.78E-03
NMB1806 putative GTPase EngB -0.758 1.28E-02
NMB1840 hypothetical protein -0.731 2.91E-02
NMB1858 hypothetical protein -0.773 7.03E-03
NMB1983 hypothetical protein -0.625 1.18E-02
NMB2004 hypothetical protein -0.990 8.43E-03
NMB2018 hypothetical protein -0.834 6.79E-03
NMB2050 hypothetical protein -0.705 2.00E-02
NMB2064 hypothetical protein -0.894 3.37E-02
NMB2097 hypothetical protein -1.105 1.08E-04
NMA0131 conserved hypothetical protein -4.154 2.26E-21
NMA0607 hypothetical protein -0.985 1.94E-02
NMA0695 conserved hypothetical protein -0.810 4.29E-02
NMA1078 conserved hypothetical protein -1.802 1.43E-04
NMA1194 hypothetical protein -1.724 4.55E-06
NMA1220 conserved hypothetical protein -1.715 6.09E-09
NMA1227 conserved hypothetical protein -0.785 3.17E-02
NMA1291 gam host-nuclease inhibitor protein -0.737 2.68E-02
NMA1613 dehydrogenase fragment -1.477 4.96E-07
NMA1645 NLP/P60 family domain protein -0.763 6.38E-04
NMA1858 hypothetical protein -1.874 1.98E-06
NMA1987 hypothetical protein -0.751 1.02E-04
NMA2123 conserved hypothetical protein -0.763 1.66E-02
NMC0806 putative integral membrane protein -1.998 1.44E-06
NMC0893 putative ParB protein -0.926 3.27E-02
NMC1053 hypothetical protein -0.948 2.94E-04
NMC1345 pseudogene -0.988 4.41E-03
NMC1730 putative integral membrane protein -2.634 2.08E-08
Mobile and extrachromosomal element functions
NMB0583 IS1016C2 transposase -0.869 3.64E-04
NMB0917 death-on-curing protein -0.585 3.65E-02
NMB1401 IS1016C2 transposase -0.829 4.85E-04
NMB1411 IS1016C2 transposase -0.642 3.98E-02
Protein fate
NMB0027 fbp FKBP-type peptidyl-prolyl cis-trans isomerase -0.668 2.09E-03
NMB0281 peptidyl-prolyl cis-trans isomerase -0.730 7.09E-03
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NMB1428 putative aminopeptidase -0.909 4.66E-02
NMB1519 dsbD thiol:disulfide interchange protein precursor -0.779 9.92E-03
NMB1737 tolC putative secretion protein -0.834 2.72E-02
Protein synthesis
NMB0111 fmt methionyl-tRNA formyltransferase -0.728 2.27E-02
NMB0854 hisS histidyl-tRNA synthetase -1.489 2.37E-04
Purines, pyrimidines, nucleosides, and nucleotides
NMB0849 deoxycytidine triphosphate deaminase -0.786 2.78E-02
Regulatory functions
NMB1049 putative transcriptional regulator -0.749 7.03E-03
NMB1303 transcriptional regulator, MerR family -0.592 3.23E-02
NMB1843 transcriptional regulator, MarR family -0.852 2.43E-02
Transcription
NMB1368 putative ATP-dependent RNA helicase -3.255 2.16E-06
NMB0712 rpoH RNA polymerase factor sigma-32 -1.054 1.75E-02
Transport and binding proteins
NMB0034 high-affinity iron transporter -0.903 3.66E-03
NMB0177 putative sodium/alanine symporter -1.905 3.63E-07
NMB0194 putative amino acid symporter -0.791 3.96E-02
NMB0378 putative phosphate permease -1.806 1.55E-05
NMB0402 putP sodium/proline symporter -2.275 1.40E-09
NMB0543 lctP putative L-lactate permease -1.713 4.96E-07
NMB0610 potA-1 spermidine/putrescine ABC transporter, ATP-
binding protein
-1.660 5.47E-04
NMB0615 amtB putative ammonium transporter AmtB -1.333 1.42E-04
NMB0792 transporter, NadC family -2.430 1.35E-13
NMB0879 cysA sulphate ABC transporter, ATP-binding protein -0.796 1.35E-04
NMB1277 transporter, BCCT family -0.782 1.31E-03
NMB1400 ABC transporter family protein -1.091 7.59E-03
NMB1540 lbpA lactoferrin-binding protein A -2.601 5.78E-10
NMB1541 lbpB lactoferrin-binding protein B -2.307 4.00E-09
NMB1668 hmbR hemoglobin receptor -1.277 8.41E-07
NMB1714 mtrE multidrug eﬄux pump channel protein -1.621 6.09E-09
NMB1715 mtrD multiple transferable resistance system protein
MtrD
-1.389 2.53E-07
NMB1716 mtrC membrane fusion protein -1.340 1.98E-06
NMB1732 putative transporter -0.949 1.10E-03
NMB1738 hlyD putative secretion protein -0.727 4.46E-02
NMB1988 fetA iron-regulated outer membrane protein FrpB -1.137 2.21E-02
NMA1083 periplasmic protein -1.528 2.80E-03
NMA1740 lbpB lactoferrin binding protein B -2.280 4.83E-09
NMC1469 lbpB lactoferrin binding protein B -2.404 3.92E-07
NMC1691 tbpB transferrin binding protein B -1.735 4.89E-07
Unknown function
NMB0006 thioredoxin-related protein -1.143 4.14E-06
NMB0852 GTP-binding protein EngA -1.797 4.42E-06
NMB1220 stomatin/Mec-2 family protein -1.339 4.56E-06
NMB1280 very long chain acyl-CoA dehydrogenase-related
protein
-1.120 1.54E-06
NMB1403 FrpA/C-related protein -1.016 1.32E-05
NMB1405 FrpA/C-related protein -0.915 4.97E-03
NMB1526 smpB SsrA-binding protein -0.756 4.12E-02
NMB1669 hemO iron-starvation protein PigA -2.178 2.44E-08
NMA0029 urea amidolyase-related protein -1.337 4.08E-04
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
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Table B.8: Genes up-regulated at 240 min during growth in FFP 2 in comparison to t =
0 min (meningococci on solid agar medium). Genes are divided into functional categories
according to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0337 ilvE branched-chain amino acid aminotransferase 0.783 2.11E-02
NMB0540 aspC aromatic amino acid aminotransferase 0.904 1.32E-03
NMB0678 trpA tryptophan synthase, subunit α 0.624 3.35E-02
NMB0763 cysK cysteine synthase 1.480 4.64E-04
NMB0802 cystathionine γ-synthase 0.844 1.43E-03
NMB1034 leuD isopropylmalate isomerase, small subunit 0.612 3.13E-02
NMB1036 leuC isopropylmalate isomerase, large subunit 1.227 9.56E-04
NMB1069 proB γ-glutamyl kinase 0.929 1.68E-02
NMB1074 argB acetylglutamate kinase 0.715 5.12E-03




NMB1678 tyrB aromatic amino acid aminotransferase 0.588 3.74E-02
NMB2129 argG argininosuccinate synthase 0.801 2.15E-03
Biosynthesis of cofactors, prosthetic groups, and carriers
NMB0394 nadA quinolinate synthetase 0.845 7.39E-03
NMB1037 gshA glutamate–cysteine ligase 0.725 1.33E-02
NMB1156 cysG-1 siroheme synthase 2.168 7.25E-06
NMB1168 putative phytoene synthase 0.650 6.00E-03
NMB1194 cysG-2 siroheme synthase 2.526 1.47E-08
NMB2040 thiC thiamine biosynthesis protein 1.879 2.00E-06
NMB2067 cytX putative hydroxymethylpyrimidine trans-
porter
2.396 1.99E-07
NMB2068 thiO glycine oxidase 2.397 5.61E-04
NMB2069 thiE thiamin-phosphate pyrophosphorylase 1.978 2.52E-06
NMB2071 thiG thiazole synthase 0.871 6.00E-03
Cell envelope
NMB0749 penicillin-binding protein 4 1.059 1.45E-06
NMB0790 pgm phosphoglucomutase 0.717 2.50E-03
NMB1297 mltD membrane-bound lytic murein transglycosy-
lase D
1.066 1.98E-03
NMB1898 mlp lipoprotein 0.929 8.32E-03
Cellular processes
NMB0191 ParA family protein 0.655 8.81E-03
NMB1067 ftsK-1 cell division protein 0.629 1.68E-02
Central intermediary metabolism
NMB0031 glmS D-fructose-6-phosphate amidotransferase 0.965 3.08E-03
NMB0468 speA arginine decarboxylase 0.637 3.75E-03
NMB1151 cysI-1 sulphite reductase hemoprotein, β compo-
nent
2.237 4.49E-05
NMB1152 cysJ-1 sulphite reductase (NADPH) flavoprotein,
α component
1.996 1.43E-04
NMB1153 cysN-1 sulphate adenylyltransferase, subunit 1 2.629 3.03E-06
NMB1154 cysD-1 sulphate adenylyltransferase, subunit 2 2.338 8.78E-07
NMB1155 cysH-1 phosphoadenosine phosphosulphate reduc-
tase
1.201 1.29E-02
NMB1189 cysI-2 sulphite reductase hemoprotein, β compo-
nent
2.301 6.26E-05
NMB1190 cysJ-2 sulphite reductase (NADPH) flavoprotein,
α component
2.367 1.08E-06
NMB1191 cysN-2 sulphate adenylyltransferase, subunit 1 2.793 4.41E-08
NMB1192 cysD-2 sulphate adenylyltransferase, subunit 2 2.514 2.60E-07
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NMB1193 cysH-2 phosphoadenosine phosphosulphate reduc-
tase
1.473 4.02E-03
NMB1799 metK S-adenosylmethionine synthetase 0.758 4.22E-03
DNA metabolism
NMB0835 putative type I restriction enzyme EcoR124II
R protein
0.841 1.56E-02
NMB1442 mutL DNA mismatch repair protein 0.612 2.57E-02
Energy metabolism
NMB0010 pgk phosphoglycerate kinase 0.685 4.91E-02
NMB0389 galM aldose 1-epimerase 0.746 1.50E-02
NMB0390 mapA maltose phosphorylase 1.127 3.78E-05
NMB0391 pgmB β-phosphoglucomutase 1.104 4.75E-05
NMB0790 pgm phosphoglucomutase 0.717 2.50E-03




NMB1390 glk glucokinase 1.122 1.90E-02
NMB2053 petA ubiquinol–cytochrome c reductase, iron-
sulphur subunit
1.309 6.47E-04
NMA2094 mapA′ possible maltose phosphorylase (fragment) 0.982 8.09E-03
Hypothetical or unassigned proteins
NMB0086 hypothetical protein 0.635 3.71E-02
NMB0213 hypothetical protein 0.707 9.96E-03
NMB0438 hypothetical protein 1.138 2.81E-04
NMB0762 hypothetical protein 1.085 5.61E-04
NMB0786 hypothetical protein 0.713 6.80E-03
NMB0821 hypothetical protein 0.748 1.05E-03
NMB1024 hypothetical protein 0.703 4.02E-03
NMB1040 hypothetical protein 0.687 1.75E-02
NMB1073 hypothetical protein 0.975 2.41E-03
NMB1270 hypothetical protein 0.831 3.55E-05
NMB1286 hypothetical protein 0.797 3.93E-02
NMB1365 dnrN hypothetical protein 0.884 2.54E-04
NMB1436 hypothetical protein 0.801 2.66E-02
NMB1437 hypothetical protein 1.138 1.29E-02
NMB1438 hypothetical protein 1.065 3.29E-03
NMB1531 hypothetical protein 0.722 6.00E-03
NMB1800 hypothetical protein 0.820 5.93E-03
NMB1886 hypothetical protein 0.631 1.40E-02
NMB2072 hypothetical protein 1.050 1.62E-02
Protein fate
NMB1969 aspA/nalP putative serotype-1-specific antigen 0.876 3.71E-02
Protein synthesis
NMB0268 RNA methyltransferase, TrmH family 0.715 1.68E-02
NMB0876 50S ribosomal protein L25/general stress pro-
tein Ctc
0.611 1.29E-02
Purines, pyrimidines, nucleosides, and nucleotides
NMB0284 purB adenylosuccinate lyase 0.591 3.71E-02
Regulatory functions
NMB1735 relA GTP pyrophosphokinase 0.972 2.54E-04
Transport and binding proteins
NMB0085 gltS sodium/glutamate symporter 0.717 3.56E-02
NMB0098 ABC transporter, ATP-binding protein (au-
thentic frameshift)
0.932 7.10E-03
NMB0293 putative TonB-dependent receptor 0.823 8.32E-03
NMB0388 putative sugar transporter 1.050 7.13E-04
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NMB0470 C4-dicarboxylate transporter 0.807 1.11E-05
NMB0535 gluP glucose/galactose transporter 1.072 2.37E-04
NMB0787 amino acid ABC transporter, periplasmic
substrate-binding protein
1.279 8.09E-03
NMB0788 amino acid ABC transporter, permease pro-
tein
1.126 1.10E-02
NMB0789 amino acid ABC transporter, ATP-binding
protein
1.066 3.31E-03
NMB1017 sbp sulphate ABC transporter, periplasmic
substrate-binding protein
1.491 1.45E-02




NMB0995 macrophage infectivity potentiator-related
protein
1.869 9.04E-04
NMB1389 RpiR/YebK/YfhH family protein 0.915 2.25E-02
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.9: Genes down-regulated at 240 min during growth in FFP 2 in comparison to t
= 0 min (meningococci on solid agar medium). Genes are divided into functional categories
according to TIGR designations.
ID Name Annotation log2 ratio P-value*
Amino acid biosynthesis
NMB0878 ilvA threonine dehydratase -0.685 2.12E-03
NMC0399a pglB-2 carbamoyl-phosphate synthase -1.317 1.95E-02
Cell envelope
NMB0178 lpxA UDP-N-acetylglucosamine acyltransferase -0.601 2.42E-02
NMB1279 mltB putative membrane-bound lytic murein transg-
lycosylase B
-2.055 2.12E-11
NMB2019 kdtB phosphopantetheine adenylyltransferase -0.723 5.62E-05
Cellular processes
NMB0216 katA catalase -1.625 2.33E-02
NMB0585 putative iron-regulated protein FrpA -0.770 3.97E-02
NMB0851 rdgC recombination associated protein -1.226 2.10E-06
NMB0855 putative bacteriocin resistance protein -0.756 4.02E-02
NMB0977 putative modulator of drug activity B -2.851 2.55E-14
NMB1857 mdaB modulator of drug activity B -2.750 1.48E-05
NMB1714 mtrE multidrug eﬄux pump channel protein -1.128 6.20E-05
NMA0688 Possible hemagglutinin (DUF637) family -1.626 3.31E-03
Central intermediary metabolism
NMB1305 esd putative esterase -1.053 4.64E-04
DNA metabolism




NMB0851 rdgC recombination associated protein -1.226 2.10E-06
NMB0831 type I restriction enzyme S protein (degenerate) -0.615 1.14E-02
Energy metabolism
NMB0207 gapA glyceraldehyde-3-phosphate dehydrogenase -1.108 7.62E-03
NMB0431 prpC methylcitrate synthase -5.724 9.96E-14
NMB0434 putative AcnD-accessory protein PrpF -2.174 1.71E-04
NMB0435 ackA-2 acetate kinase -1.317 1.04E-04
NMB0567 nqrC Na(+)-translocating NADH-quinone reductase,
subunit C
-0.709 1.50E-02
Continued on next page . . .
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Table B.9 – continued from previous page
ID Name Annotation log2 ratio P-value*
NMB0574 gcvT glycine cleavage system aminomethyltrans-
ferase T
-1.885 4.91E-12
NMB0955 sucA α-ketoglutarate decarboxylase -0.808 3.84E-02
NMB0960 sucD succinyl-CoA synthetase, subunit α -1.257 5.62E-04
NMB1304 adhC alcohol dehydrogenase, class III -1.284 7.98E-04
NMB1393 edd phosphogluconate dehydratase -1.252 8.62E-04




NMB1968 aldA aldehyde dehydrogenase A -0.958 9.31E-03
NMB2096 mqo malate:quinone oxidoreductase -0.738 8.49E-03
Fatty acid and phospholipid metabolism
NMC0398 putative hydrolase, haloacid dehalogenase-like
hydrolase
-0.928 1.75E-02
Hypothetical or unassigned proteins
NMB0183 conserved hypothetical protein -0.865 6.93E-04
NMB0226 conserved hypothetical protein -0.666 1.14E-02
NMB0227 conserved hypothetical protein -1.052 3.42E-03
NMB0272 hypothetical protein -0.705 2.44E-02
NMB0366 hypothetical protein -0.897 4.76E-03
NMB0429 hypothetical protein -2.118 3.70E-07
NMB0572 hypothetical protein -0.981 2.54E-04
NMB0741 conserved hypothetical protein -0.699 4.97E-02
NMB0753 conserved hypothetical protein -1.059 1.57E-03
NMB0754 hypothetical protein -1.193 8.13E-04
NMB0755 hypothetical protein -0.818 1.80E-02
NMB0853 conserved hypothetical protein -1.034 6.30E-03
NMB0864 hypothetical protein -1.059 1.70E-02
NMB0915 hypothetical protein -0.931 2.42E-02
NMB0953 hypothetical protein -0.974 8.32E-03
NMB1048 hypothetical protein -1.539 1.43E-03
NMB1345 hypothetical protein -0.728 3.36E-02
NMB1361 conserved hypothetical protein -0.748 7.98E-04
NMB1452 conserved hypothetical protein -2.257 7.46E-09
NMB1485 conserved hypothetical protein -1.332 5.18E-05
NMB1580 hypothetical protein -0.927 6.30E-03
NMB1773 hypothetical protein -1.397 4.97E-02
NMB1858 hypothetical protein -0.882 4.02E-03
NMB2018 conserved hypothetical protein -0.959 3.43E-03
NMA0131 conserved hypothetical protein -3.822 2.92E-19
NMA0432 conserved hypothetical protein -1.744 3.36E-02
NMA0607 hypothetical protein -1.157 9.43E-03
NMA0779 integral membrane protein -0.753 2.04E-02
NMA1194 hypothetical protein -1.354 7.13E-04
NMA1227 conserved hypothetical protein -1.027 2.02E-03
NMA1725 virulence associated protein -1.141 3.19E-02
NMA1858 hypothetical protein -1.485 3.63E-04
NMA2123 conserved hypothetical protein -0.727 4.23E-02
NMC0876 hypothetical protein (fragment) -0.778 3.97E-02
NMC0209 conserved hypothetical protein -1.344 9.31E-03
NMC0806 putative integral membrane protein -1.069 2.14E-02
NMC1053 hypothetical protein -0.909 5.93E-03
NMC1345 putative iron-regulated protein FrpC outer
membrane (pseudogene)
-0.957 1.18E-02
NMC1730 putative integral membrane protein -2.994 1.03E-09
Continued on next page . . .
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Table B.9 – continued from previous page
ID Name Annotation log2 ratio P-value*
Mobile and extrachromosomal element functions
NMB0583 IS1016C2 transposase -0.601 3.19E-02
NMB1401 IS1016C2 transposase -0.608 2.40E-02
Protein fate
NMB1519 dsbD thiol:disulfide interchange protein precursor -0.747 2.58E-02
NMB1587 predicted inner membrane peptidase -1.140 8.32E-03
Protein synthesis
NMB0721 infC translation initiation factor IF-3 -1.816 2.54E-04
NMB0937 efp elongation factor P -1.419 1.27E-02
NMB0942 rpmE2 50S ribosomal protein L31 type B -1.493 2.60E-03
NMB2102 tsf elongation factor Ts -1.176 4.44E-02
Purines, pyrimidines, nucleosides, and nucleotides
NMB2151 purD phosphoribosylamine–glycine ligase -1.200 2.54E-04
Regulatory functions
NMB0398 transcriptional regulator, ArsR family -1.626 7.76E-03
NMB1650 lrp leucine-responsive regulatory protein -0.827 3.14E-02
Transcription
NMB0617 rho transcription termination factor Rho -1.174 3.14E-04
NMB0683 nusB transcription antitermination protein -0.757 1.75E-02
NMB0758 pnp polynucleotide phosphorylase/polyadenylase -0.899 3.14E-02
NMB1368 putative ATP-dependent RNA helicase -5.538 3.71E-11
NMB1863 orn oligoribonuclease -0.878 9.96E-03
Transport and binding proteins
NMB0177 putative sodium/alanine symporter -0.969 1.95E-02
NMB0402 putP sodium/proline symporter -0.883 3.08E-02
NMB0610 potA-1 spermidine/putrescine ABC transporter, ATP-
binding protein
-1.557 2.82E-03
NMB0792 transporter, NadC family -1.051 5.28E-04
NMB1714 mtrE multidrug eﬄux pump channel protein -1.128 6.20E-05
NMB1715 mtrD multiple transferable resistance system protein
MtrD
-0.788 6.80E-03
NMB1732 putative transporter -0.855 7.62E-03
NMC1690 tbpA transferrin-binding protein 1 -1.050 6.93E-05
NMC1691 tbpB transferrin-binding protein B -2.501 1.85E-10
Unknown function
NMB0006 thioredoxin-related protein -0.698 1.10E-02
NMB0643 mafB3 MafB-related protein -1.087 9.01E-03
NMB0852 engA GTP-binding protein EngA -1.136 8.32E-03
NMB1280 very long chain acyl-CoA dehydrogenase-
related protein
-1.811 3.85E-12
NMB1638 YhbX/YhjW/YijP/YjdB family protein -0.793 2.59E-03
NMB1669 hemO iron-starvation protein PigA -1.228 2.80E-03
NMB2063 slyX hypothetical protein -0.769 6.38E-03
NMC1731 ddpX putative D-alanyl-D-alanine dipeptidase -3.487 3.85E-12
* P-value adjusted for multiple testing using Benjamini and Hochberg step down correction
Table B.10: Differentially expressed genes at both 60 and 240 min during growth in FFP
2 in comparison to t = 0 min (meningococci on solid agar medium).
60 min 240 min
ID Name Annotation log2 ratio log2 ratio
Up-regulated genes
NMB0010 pgk phosphoglycerate kinase 0.790 0.685
NMB0098 ABC transporter, ATP-binding protein (au-
thentic frameshift)
0.882 0.932
NMB0191 ParA family protein 0.602 0.655
Continued on next page . . .
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Table B.10 – continued from previous page
60 min 240 min
ID Name Annotation log2 ratio log2 ratio
NMB0268 RNA methyltransferase, TrmH family 1.355 0.715
NMB0292 hypothetical protein 0.715 0.823
NMB0394 nadA quinolinate synthetase 1.141 0.845
NMB0438 hypothetical protein 0.986 1.138
NMB0468 speA arginine decarboxylase 0.730 0.637
NMB0762 hypothetical protein 0.692 1.085
NMB0787 amino acid ABC transporter, periplasmic
substrate-binding protein
1.547 1.279
NMB0788 amino acid ABC transporter, permease protein 1.751 1.126
NMB0789 amino acid ABC transporter, ATP-binding pro-
tein
1.576 1.066
NMB0802 metB cystathionine γ-synthase 0.633 0.844
NMB0821 hypothetical protein 1.115 0.748
NMB0995 macrophage infectivity potentiator-related pro-
tein
1.466 1.869
NMB1034 leuD isopropylmalate isomerase, small subunit 1.604 0.612
NMB1036 leuC isopropylmalate isomerase, large subunit 2.168 1.227
NMB1037 gshA glutamate–cysteine ligase 0.975 0.725
NMB1040 hypothetical protein 0.713 0.687
NMB1073 hypothetical protein 0.780 0.975
NMB1151 cysI-1 sulphite reductase hemoprotein, β component 1.341 2.237
NMB1152 cysJ-1 sulphite reductase (NADPH) flavoprotein,
α component
1.176 1.996
NMB1153 cysN-1 sulphate adenylyltransferase, subunit 1 1.421 2.629
NMB1154 cysD-1 sulphate adenylyltransferase, subunit 2 1.315 2.338
NMB1156 cysG-1 siroheme synthase 1.212 2.168
NMB1168 putative phytoene synthase 1.486 0.650
NMB1189 cysI-2 sulphite reductase hemoprotein, β component 1.405 2.301
NMB1190 cysJ-2 sulphite reductase (NADPH) flavoprotein,
α component
1.393 2.367
NMB1191 cysN-2 sulphate adenylyltransferase, subunit 1 1.636 2.793
NMB1192 cysD-2 sulphate adenylyltransferase, subunit 2 1.447 2.514
NMB1194 cysG-2 siroheme synthase 1.438 2.526
NMB1270 hypothetical protein 0.903 0.831
NMB1286 hypothetical protein 0.962 0.797
NMB1297 mltD membrane-bound lytic murein transglycosylase
D
0.708 1.066
NMB1531 hypothetical protein 0.669 0.722
NMB1799 metK S-adenosylmethionine synthetase 1.174 0.758
NMB1800 hypothetical protein 1.139 0.820
NMB1866 hypothetical protein 0.895 0.631




NMB0006 thioredoxin-related protein -1.143 -0.698
NMB0177 putative sodium/alanine symporter -1.905 -0.969
NMB0183 hypothetical protein -0.765 -0.865
NMB0207 gapA glyceraldehyde-3-phosphate dehydrogenase -1.071 -1.108
NMB0216 katA catalase -1.904 -1.625
NMB0227 hypothetical protein -1.839 -1.052
NMB0366 hypothetical protein -0.940 -0.897
NMB0402 putP sodium/proline symporter -2.275 -0.883
NMB0429 hypothetical protein -2.440 -2.118
NMB0431 prpC methylcitrate synthase -5.745 -5.724
NMB0434 putative AcnD-accessory protein PrpF -2.515 -2.174
Continued on next page . . .
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Table B.10 – continued from previous page
60 min 240 min
ID Name Annotation log2 ratio log2 ratio
NMB0435 ackA2 acetate kinase -1.693 -1.317
NMB0572 hypothetical protein -0.879 -0.981
NMB0574 gcvT glycine cleavage system aminomethyltrans-
ferase T
-3.552 -1.885
NMB0583 IS1016C2 transposase -0.869 -0.601
NMB0585 putative iron-regulated protein FrpA -0.856 -0.770
NMB0610 potA-1 spermidine/putrescine ABC transporter, ATP-
binding protein
-1.660 -1.557
NMB0753 hypothetical protein -0.797 -1.059
NMB0754 hypothetical protein -1.133 -1.193
NMB0755 hypothetical protein -0.752 -0.818
NMB0792 transporter, NadC family -2.430 -1.051
NMB0851 rdgC recombination associated protein -1.809 -1.226
NMB0852 GTP-binding protein EngA -1.797 -1.136
NMB0853 hypothetical protein -1.778 -1.034
NMB0855 putative bacteriocin resistance protein -1.302 -0.756
NMB0864 hypothetical protein -1.648 -1.059
NMB0878 ilvA threonine dehydratase -1.092 -0.685
NMB0915 hypothetical protein -0.855 -0.931
NMB0953 hypothetical protein -1.706 -0.974
NMB0955 sucA α-ketoglutarate decarboxylase -1.517 -0.808
NMB0960 sucD succinyl-CoA synthetase, subunit α -1.887 -1.257
NMB0977 putative modulator of drug activity B -2.535 -2.851
NMB1048 hypothetical protein -2.708 -1.539
NMB1279 mltB putative membrane-bound lytic murein transg-
lycosylase B
-1.093 -2.055
NMB1280 very long chain acyl-CoA dehydrogenase-
related protein
-1.120 -1.811
NMB1304 adhC alcohol dehydrogenase, class III -0.975 -1.284
NMB1305 esd putative esterase -0.726 -1.053
NMB1361 hypothetical protein -0.616 -0.748
NMB1368 putative ATP-dependent RNA helicase -3.255 -5.538
NMB1393 edd phosphogluconate dehydratase -0.935 -1.252
NMB1395 alcohol dehydrogenase, zinc-containing -2.252 -0.801
NMB1401 IS1016C2 transposase -0.829 -0.608
NMB1452 hypothetical protein -2.230 -2.257
NMB1485 hypothetical protein -0.744 -1.332
NMB1519 dsbD thiol:disulfide interchange protein precursor -0.779 -0.747




NMB1669 hemO iron-starvation protein -2.178 -1.228
NMB1714 mtrE multidrug eﬄux pump channel protein -1.621 -1.128
NMB1715 mtrD multiple transferable resistance system protein
MtrD
-1.389 -0.788
NMB1732 putative transporter -0.949 -0.855
NMB1857 mdaB modulator of drug activity B -2.464 -2.750
NMB1858 hypothetical protein -0.773 -0.882
NMB1968 aldA aldehyde dehydrogenase A -2.076 -0.958
NMB2018 hypothetical protein -0.834 -0.959
NMB2019 kdtB phosphopantetheine adenylyltransferase -0.675 -0.723
NMB2096 mqo malate:quinone oxidoreductase -1.803 -0.738
NMA0131 conserved hypothetical protein -4.154 -3.822
NMA0607 hypothetical protein -0.985 -1.157
NMA1194 hypothetical protein -1.724 -1.354
Continued on next page . . .
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Table B.10 – continued from previous page
60 min 240 min
ID Name Annotation log2 ratio log2 ratio
NMA1227 conserved hypothetical protein -0.785 -1.027
NMA1858 hypothetical protein -1.874 -1.485
NMA2123 conserved hypothetical protein -0.763 -0.727
NMC0806 putative integral membrane protein -1.998 -1.069
NMC1053 hypothetical protein -0.948 -0.909
NMC1345 pseudogene -0.988 -0.957
NMC1691 tbpB transferrin binding protein B -1.735 -2.501
NMC1730 putative integral membrane protein -2.634 -2.994
NMC1731 ddpX putative D-alanyl-D-alanine dipeptidase -3.104 -3.487
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BZ232      .......... .......... .......... .......... .......... .......... .......... .......... ........ 288 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... ........ 288 
2996       .......... .......... .......... .......... .......... .......... .......... .......... ........ 288 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... ........ 288 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... ........ 288 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... ........ 288 
NGH15      .......... .......R.. .......... .......... .......... .......... .......... .......... ........ 288 
Figure D.1: Multiple sequence alignment of NMB0345 amino acid sequences from 24
meningococcal strains, including MC58 (labelled in blue), using ClustalW with default
settings. The amino acid sequences were compared to the sequence from strain MC58. All
strains used were MenB strains, except F6124 (MenA), 90/18311 (MenC) and NG P165
(NT). The MenA (strain Z2491) and MenC (strain FAM18) genome sequence strains were
also included for comparison (labelled in blue).
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MC58       -------MPS ETRLPNFIRV LIFALGFIFL NACSEQTAQT VTLQGETMGT TYTVKYLSNN RDKLPSPAEI QKRIDDALKE VNRQMSTYQP DSEISRFNQH  93 
BZ169      -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
NGH38      -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
BZ83       -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
H44/76     -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
BZ198      -------... .........A .......... .......... .......... .......... .G........ .......... .......... ..........  93 
297-0      -------... .........A .......... .......... .......... .......... .G........ .......... .......... ..........  93 
BZ133      -------... .........T .....S.... .......... .......... .......... .......... .......... .......... N........T  93 
NGE28      -------... .........T .....S.... .......... .......... .......... .......... .......... .......... ..........  93 
2996       -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
NGH15      -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
F6124      -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
MO1-240185 -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
NGP165     -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
FAM18      LPKPSNT... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
Z2491      -------... .........T .....S.... .......... .......... .......... .......... .......... .......... ..........  93 
90/18311   -------... .........T .....S.... .......... .......... .......... .......... .......... .......... ..........  93 
BZ147      -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
BZ232      -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
1000       -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
528        -------... .......... .......... .......... .......... .......... .......... .......... .......... ..........  93 
 
MC58       TAGKPLRISS DFAHVTAEAV RLNRLTHGAL DVTVGPLVNL WGFGPDKSVT REPSPEQIKQ AASYTGIDKI ILKQGKDYAS LSKTHPKAYL DLSSIAKGFG  193 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
BZ198      .......... ...Y...... .......... .......... .......... .......... .......... .......... .......... ..........  193 
297-0      .......... ...Y...... .......... .......... .......... .......... .......... .......... .......... ..........  193 
BZ133      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
NGE28      .......... ...Y...... .......... .......... .......... .......... .......... .......... .......... ..........  193 
2996       .......... ...Y...... .......... .......... .....G.... .......... .......... .......... .......... ..........  193 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
F6124      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
NGP165     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
FAM18      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
Z2491      .......... .......... H......... .......... .......... .......... .......... .......... .......... ..........  193 
90/18311   .......... .......... H......... .......... .......... .......... .......... .......... .......... ..........  193 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
BZ232      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
1000       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
528        .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  193 
 
MC58       VDKVAGELEK YGIQNYLVEI GGELHGKGKN ARGEPWRIGI EQPNIVQGGN TQIIVPLNNR SLATSGDYRI FHVDKNGKRL SHIINPNNKR PISHNLASIS  293 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
BZ133      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
NGE28      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  293 
2996       .......... .......... .......... .......... .....I.... .......... .......... .....S.... .......... ..........  293 
NGH15      .......... .......... .......... V......... .......... .......... .......... .....S.... .......... ..........  293 
F6124      .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
NGP165     .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
FAM18      .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  300 
Z2491      .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
90/18311   .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
BZ147      .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
BZ232      .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
1000       .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
528        .......... .......... .......... .......... .......... .......... .......... .....S.... .......... ..........  293 
 
MC58       VVADSAMTAD GLSTGLFVLG ETEALKLAER EKLAVFLIVR DKGGYRTAMS SEFEKLLR 351 
BZ169      .......... .......... .......... .......... .......... ........ 351 
NGH38      .......... .......... .......... .......... .......... ........ 351 
BZ83       .......... .......... .......... .......... .......... ........ 351 
H44/76     .......... .......... .......... .......... .......... ........ 351 
BZ198      .......... .......... .......... .......... .......... ........ 351 
297-0      .......... .......... .......... .......... .......... ........ 351 
BZ133      .......... .......... .......... .......... .....HA... ........ 351 
NGE28      .......... .......... ..K....... .......... .......... ........ 351 
2996       .......... .......... .......... .......... .......... ........ 351 
NGH15      .......... .......... .......... .......... .......... ........ 351 
F6124      .......... .......... .......... .......... .T........ ........ 351 
MO1-240185 .......... .......... .......... .......... .T........ ........ 351 
NGP165     .......... .......... .......... .......... .T........ ........ 351 
FAM18      .......... .......... .......... .......... .T........ ........ 358 
Z2491      .......... .......... .......... .......... .......... ........ 351 
90/18311   .......... .......... .......... .......... .......... ........ 351 
BZ147      .......... .......... .......... .......... .......... ........ 351 
BZ232      .......... .......... .......... .......... .......... ........ 351 
1000       .......... .......... .........Q ...S...... .T........ ...A.... 351 
528        .......... .......... .........Q ...S...... .T........ ...A.... 351 
Figure D.2: Multiple sequence alignment of apbE amino acid sequences from 21 meningo-
coccal strains, including MC58 (labelled in blue), using ClustalW with default settings.
The amino acid sequences were compared to the sequence from strain MC58. All strains
used were MenB strains, except F6124 (MenA), 90/18311 (MenC) and NG P165 (NT).
The MenA (strain Z2491) and MenC (strain FAM18) genome sequence strains were also
included for comparison (labelled in blue).
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MC58            781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
BZ169           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
BZ83            781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
H44/76          781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
BZ198           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
1000            781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
BZ147           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
528             781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
NGH15           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
90/18311        781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
MO1-240185      781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
2996            781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
SWZ107          781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
NGH38           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
NGF26           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
NGP165          781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
NG6/88          781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
FAM18           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
NGH36           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
Z2491           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTGGAACACAACCTTAA 840 
297-0           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
BZ232           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTTAA------------ 828 
F6124           781 GCAGAAGCAGCAGGGGAAGCCGAAACGCAACCTGGAACACAACCTGGAACACAACCTTAA 840 
                    *********************************************  *             
 
Figure D.3: Multiple alignment, using ClustalW, of the nucleotide sequences of the gene
NMB1961 in 23 meningococcal strains. All strains used were MenB strains, except F6124
(MenA), 90/18311 (MenC), NG P165 (NT). The amino acid sequences were compared to
the sequence in strain MC58. Sequences of orthologues genes in serogroup A (Z2491) and
serogroup C (FAM18) sequence strains were also included in the alignment. Only the last
60 nt of the alignment is shown, to highlight the repetitive element in the end of the gene
in strains F6124 and Z2491; both serogroup A strains.
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MC58       MKKTAYAFLL LIGFASAPAF AETRPADPYE GYNRAVFKFN DQADRYIFAP AARGYRKVAP KPVRAGVSNF FNNLCDVVSF GSNILRLDIK RASEDLVRVG  100 
FAM18      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
90/18311   .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
2996       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NGP165     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
528        .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
1000       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
Z2491      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
297-0      .......A.. .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
BZ232      .......A.. .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
F6124      .......A.. .......... .......... .......... .......... .......... .......... .......... .......... ..........  100 
 
MC58       INTTFGLGGL IDIAGAGGIP DNKNTLGDTF ASWGWKNSNY FVLPVLGPST VRDALGTGIT SVYSPKNIVF RTPVGRWGTT AVSAVSTREG LLDLTDSLDE  200 
FAM18      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
90/18311   .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
2996       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
H44/76     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ83       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGH36      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGH15      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGH38      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGF26      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NGP165     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
528        .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ169      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ147      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
1000       .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ198      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
Z2491      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
297-0      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
BZ232      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
F6124      .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........  200 
 
MC58       AAIDKYSYTR DLYMKVRARQ TGATPAEGTE DNIDIDELVE SAETGAAETA VQEDSVSETQ AEAAGEAETQ PGTQP---- 275 
FAM18      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
90/18311   .......... .......... .......... .......... .......... .......... .......... .....---- 275 
MO1-240185 .......... .......... .......... .......... .......... .......... .......... .....---- 275 
2996       .......... .......... .......... .......... .......... .......... .......... .....---- 275 
H44/76     .......... .......... .......... .......... .......... .......... .......... .....---- 275 
BZ83       .......... .......... .......... .......... .......... .......... .......... .....---- 275 
NGH36      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
NGH15      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
SWZ107     .......... .......... .......... .......... .......... .......... .......... .....---- 275 
NGH38      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
NGF26      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
NGP165     .......... .......... .......... .......... .......... .......... .......... .....---- 275 
528        .......... .......... .......... .......... .......... .......... .......... .....---- 275 
BZ169      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
BZ147      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
1000       .......... .......... .......... .......... .......... .......... .......... .....---- 275 
BZ198      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
NG6/88     .......... .......... .......... .......... .......... .......... .......... .....---- 275 
Z2491      .......... .......... .......... .......... .......... .......... .......... .....GTQP 279 
297-0      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
BZ232      .......... .......... .......... .......... .......... .......... .......... .....---- 275 
F6124      .......... .......... .......... .......... .......... .......... .......... .....GTQP 279 
Figure D.4: Multiple sequence alignment, using ClustalW, of the amino acid sequences
of the gene NMB1961 in 23 meningococcal strains. All strains used were MenB strains,
except F6124 (MenA), 90/18311 (MenC), NG P165 (NT). The amino acid sequences were
compared to the sequence in strain MC58. Sequences of the homologues genes in serogroup
A (Z2491) and serogroup C (FAM18) sequence strains were also included in the alignment
(Blue text).
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MC58     MRKKLTALVL SALPLAAVAD VSLYGEIKAG VEGRNYQLQL TEAQAANGGA S--GQVKVTK VTKAKSRIRT KISDFGSFIG FKGSEDLGDG LKAVWQLEQD VSVAGGGATQ WGNRESFIGL  120 
NG6/88   .......... .......... .......... .......... .......... GAS....... .......... .......... ........E. .......... .......... ..........  120 
BZ169    .......... .......... .......... .......... .......... .--......- --........ .......... .......... .......... .......... ..........  120 
H44/76   .......... .......... .......... .......... .......... .--......- --........ .......... .......... .......... .......... ..........  120 
BZ198    .......... .......... .......... .......... .......... .--......- --........ .......... ........E. .......... .......... ..........  120 
297-0    .......... .......... .......... .......... .......... .--......- --........ .......... ........E. .......... .......... ..........  120 
NGF26    .......... .......... .......... .....F.... ..PPSS.Q.K N--QAQTGNT .......... .......... ........E. .......... .......... ..........  120 
FAM18    .......... .......... .......... .....I.... ..PLQ----- ---NIQ--PQ ...R...... .......... ........E. .......... .......... ..........  120 
NGP165   .......... .......... .......... .....I.... ..PLQ----- ---NIQ--PQ ...R...... .......... ........E. .......... .......... ..........  120 
90/18311 .......... .......... .......... .....I.... ..PLQ----- ---NIQ--PQ ...R...... .......... ........E. .......... .......... ..........  120 
NGH36    .......... .......... .......... .....I.... ..PLQ----- ---NIQQ-PQ ...R...... .......... ........E. .......... .........R .......V..  120 
2996     .......... .......... .......... .....I.... ..PLQ----- ---NIQQ-PQ ...R...... .......... ........E. .......... .........R .......V..  120 
BZ232    .......... .......... .......... ...N.I.... ..PLP----- ---NIQ--PQ ...R...... .......... ........E. .......... ........S. ..........  120 
1000     .......... .......... .......... .....I.... ..PLQ----- ---NIQQ-PQ ...R...... .......... ........E. .......... ........S. ..........  120 
BZ83     .......... .......... .......... .....I.... ..PLP----- ---NIQ--PQ ...R...... .......... ........E. .......... ........S. ..........  120 
BZ133    .......... .......... .......... ...N.I.... ..PPS----- ---QGQTGN. ...G...... .......... .R......E. .......... .......... ..........  120 
NGH38    .......... .......... .......... ...N.I.... ..PPS----- ---QGQTGN. ...G...... .......... .R......E. .......... .......... ..........  120 
BZ147    .......... .......... .......... ...N.I.... ..PPSKSQTG --------N. ...G...... ..N....... ........E. .......... .......... ..........  120 
NGH15    .......... .......... .......... .....F.... ..PPS----K .--QPQVK-- .......... .......... ........E. .......... .......... .......V..  120 
NGE28    .......... .......... .......... .......... ..QPSRTQ.- ---QTSNQV. .......... .......... ........E. .......... .........R .......V..  120 
SWZ107   .......... .......... .......... .......... ..QPSRTQ.- ---QTSNQV. .......... .......... ........E. .......... .........R .......V..  120 
528      .......... .......... .......... .....I.... ..QPSKAQ.- ---QTNNQV. .......... .......... .........E .......... .........R .......V..  120 
F6124    .......... .......... .......... .....F.... ..QPQTANT- ---Q.GGKV. .......... .......... ........E. .......... .........R .......V..  120 
 
MC58     AGEFGTLRAG RVANQFDDAS QAIDPWDSNN DVASQLGIFK RHDDMPVSVR YDSPEFSGFS GSVQFVPIQN SKSAYTPAYY TKNTNN---- NLTLVPAVVG KPGSDVYYAG LNYKNGGFAG  240 
NG6/88   .......... .......... .......... .......... .......... ....D..... .......A.. .........V AVE-.G---- VAKK.A.... .......... ..........  240 
BZ169    .......... .......... .......... .......... .......... .......... .......... .......... ..D...---- .......... .......... ..........  240 
H44/76   .......... .......... .......... .......... .......... .......... .......... .......... ..D...---- .......... .......... ..........  240 
BZ198    .......... .......... .......... .......... .......... ....D..... .......... ........HV VV.-.K---- VA.H...... .......... ..........  240 
297-0    .......... .......... .......... .......... .......... ....D..... .......... ........HV VV.-.K---- VA.H...... .......... ..........  240 
NGF26    .......... .......... .......... .......... .......... .......... .......A.. .....K.... ..D...N--- -......... .......... ..........  240 
FAM18    .......... .......... .......... .......... .......... .......... .......A.. ........HF VQQ.PK---S QP........ .......... ..........  240 
NGP165   .......... .......... .......... .......... .......... .......... .......A.. ........HF VQQ.PK---S QP........ .......... ..........  240 
90/18311 .......... .......... .......... .......... .......... .......... .......A.. ........HF VQQPPK---S QP........ .......... ..........  240 
NGH36    .......... .......... K......... V......... .......... .......... .......A.. ........HF VQQ.PQ---S QP........ .......... ..........  240 
2996     .......... .......... K......... V......... .......... .......... .......A.. ........HF VQQ.PE---S QP........ .......... ..........  240 
BZ232    .......... .......... .......... .......... .......... .....V.... .......A.. ........HF VQQ.PQ---S QP........ .......... ..........  240 
1000     .......... .......... .......... .......... .....S.... .......... .......A.. ........HF VQ.KQ.KQNQ PP........ .......... ..........  240 
BZ83     .......... .......... .......... .......... .....S.... .......... .......A.. ........HF VQ.KQ.---Q RP........ .......... ..........  240 
BZ133    .......... .......... .......... .......... .......... .......... .......A.. ........TL ANGA..---- TIIR...... .......... ..........  240 
NGH38    .......... .......... .......... .......... .......... .......... .......A.. ........TL ANGA..---- TIIR...... .......... ..........  240 
BZ147    .......... .......... .......... .......... .......... ....D..... .......A.. .........V AVE-.G---- VVKK.A.... .......... ..........  240 
NGH15    .......... .......... .......... .......... .......... ....D..... .......... ........H. .RQN..NT-- -DVF...... .......... ..........  240 
NGE28    .......... .......... K......... V......... .......... ....D..... .......A.. .....K...V DEK------- -KMVHA.... .......... ..........  240 
SWZ107   .......... .......... K......... V......... .......... ....D..... .......A.. .....K...V DEK------- -KMVHA.... .......... ..........  240 
528      .......... .......... .......... .......... .......... ....D..... .......... .....K...V DEK------- -KMVHA.... .......... ..........  240 
F6124    ........T. .......... .......... .......... .......... ....D..... .......A.. .........V DEQ------- -SKYHA.... .......... ..........  240 
 
MC58     NYAFKYARHA NVGRNAFELF LIGSG--SDQ AKGTDPLKNH QVHRLTGGYE EGGLNLALAA QLDLSENGD- -KTKNSTTEI AATASYRFGN AVPRISYAHG FDFIERGKKG ENTSYDQIIA  360 
NG6/88   .......K.. ....D..... .L...--... .......... .......... .......... .......A.- -......... .......... .......... ..L....... ..........  360 
BZ169    .......... .......... .....--... .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
H44/76   .......... .......... .....--... .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
BZ198    .......... .......... ....AT-... .......... .......... .......... .......A.- -......... .......... .......... ..L....... ..........  360 
297-0    .......... .......... ....AT-... .......... .......... .......... .......A.- -......... .......... .......... ..L....... ..........  360 
NGF26    .......... .......... ....AT-..E .......... .......... .......... .........K A......... .......... .......... ..L....... ..........  360 
FAM18    .......K.. ....D..... .L...--..E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
NGP165   .......K.. ....D..... .L...--..E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
90/18311 .......K.. ....D..... .L...--..E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
NGH36    .......K.. ....D..... .L...--..E .......... .......... .......... .......A.- -......... .......... .......... .......... ..........  360 
2996     .......K.. ....D..... .L...--..E .......... .......... .......... .......A.- -......... .......... .......... .......... ..........  360 
BZ232    .......K.. ....D..... .L...--..E .......... .......... .......... .......A.- -......... .......... .......... .......... ..........  360 
1000     .......K.. ....D..... .L...--..E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
BZ83     .......K.. ....D..... ....AT-..E .......... .......... .......... .........K A......... .......... .......... ..L....... ..........  360 
BZ133    .......... ....D..N.. .L.RIGDD.E .......... ......S... .......... .........- -......... .......... .......... .......... ..........  360 
NGH38    .......... ....D..N.. .L.RIGDD.E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
BZ147    .......K.. ....D..... .L...--... .......... .......... .......... .......A.- -......... .......... .......... ..L....... ..........  360 
NGH15    S......... ....D..... .L.-ST-..E .......... .......... .......... .........K A......... .......... .......... ..L....... ..........  360 
NGE28    .......K.. ....D..N.. .L.RIGDD.E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
SWZ107   .......K.. ....D..N.. .L.RIGDD.E .......... .......... .......... .........- -......... .......... .......... .......... ..........  360 
528      S......... ....D..... .L.--ST..E .......... .......... .......... .......A.- -......... .......... .......... .......... ..........  360 
F6124    .......... ....D..... .L.--SG... .......... .......... .......... .......A.- -......... .......... .......... .......... ..........  360 
 
MC58     GVDYDFSKRT SAIVSGAWLK RNTGIGNYTQ INAASVGLRH KF 402 
NG6/88   .......... .......... .......... .......... .. 402 
BZ169    .......... .......... .......... .......... .. 402 
H44/76   .......... .......... .......... .......... .. 402 
BZ198    .......... .......... .......... .......... .. 402 
297-0    .......... .......... .......... .......... .. 402 
NGF26    .......... .......... .......... .......... .. 402 
FAM18    .......... .......... .......... .......... .. 402 
NGP165   .......... .......... .......... .......... .. 402 
90/18311 .......... .......... .......... .......... .. 402 
NGH36    .......... .......... .......... .......... .. 402 
2996     .......... .......... .......... .......... .. 402 
BZ232    .......... .......... .......... .......... .. 402 
1000     .......... .......... .......... .......... .. 402 
BZ83     .......... .......... .......... .......... .. 402 
BZ133    .......... .......... .......... .......... .. 402 
NGH38    .......... .......... .......... .......... .. 402 
BZ147    .......... .......... .......... .......... .. 402 
NGH15    .......... .......... .......... .......... .. 402 
NGE28    .......... .......... .......... .......... .. 402 
SWZ107   .......... .......... .......... .......... .. 402 
528      .......... .......... .......... .......... .. 402 
F6124    .......... .......... .......... .......... .. 402 
Figure D.5: Multiple sequence alignmentof PorA amino acid sequences available in the
NCBI database for 24 of the meningococcal strains used in sequencing (using ClustalW
with default settings). Regions corresponding to the variable surface exposed loops (VR1
and VR2) are indicated in the alignment
